0000064803-16-000097.txt : 20161108 0000064803-16-000097.hdr.sgml : 20161108 20161108070002 ACCESSION NUMBER: 0000064803-16-000097 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 63 CONFORMED PERIOD OF REPORT: 20160930 FILED AS OF DATE: 20161108 DATE AS OF CHANGE: 20161108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CVS HEALTH Corp CENTRAL INDEX KEY: 0000064803 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-DRUG STORES AND PROPRIETARY STORES [5912] IRS NUMBER: 050494040 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-01011 FILM NUMBER: 161979928 BUSINESS ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 BUSINESS PHONE: 4017651500 MAIL ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 FORMER COMPANY: FORMER CONFORMED NAME: CVS CAREMARK CORP DATE OF NAME CHANGE: 20070509 FORMER COMPANY: FORMER CONFORMED NAME: CVS/CAREMARK CORP DATE OF NAME CHANGE: 20070322 FORMER COMPANY: FORMER CONFORMED NAME: CVS CORP DATE OF NAME CHANGE: 19970128 10-Q 1 cvs20160930-10q.htm 10-Q Document


 
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C.  20549
 
FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended September 30, 2016
 
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from __________ to _________.

Commission File Number 001-01011  
a1282016cvslogoa02.gif
CVS HEALTH CORPORATION
(Exact name of registrant as specified in its charter)   
Delaware
 
 
 
05-0494040
(State of Incorporation)
 
 
 
(I.R.S. Employer Identification Number)
 
One CVS Drive, Woonsocket, Rhode Island 02895
(Address of principal executive offices)
 
Registrant's telephone number, including area code:  (401) 765-1500
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes[X] No [   ]
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [   ]
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer [X]
 
Accelerated filer [   ]
Non-accelerated filer [   ] (Do not check if a smaller reporting company)
 
Smaller reporting company [   ]
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [  ] No [X]
 Common Stock, $0.01 par value, issued and outstanding at November 1, 2016:
 
1,066,439,174 shares
 



INDEX
 
 
Page
 
 
 
Item 1.
Financial Statements
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 




Part I
 
Item 1

 
CVS Health Corporation
Condensed Consolidated Statements of Income
(Unaudited)
 
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
In millions, except per share amounts
2016
 
2015
 
2016
 
2015
 
 
 
 
 
 
 
 
Net revenues
$
44,615

 
$
38,644

 
$
131,555

 
$
112,144

Cost of revenues
37,123

 
31,983

 
110,304

 
92,917

Gross profit
7,492

 
6,661

 
21,251

 
19,227

Operating expenses
4,675

 
4,330

 
13,908

 
12,502

Operating profit
2,817

 
2,331

 
7,343

 
6,725

Interest expense, net
253

 
261

 
816

 
562

Loss on early extinguishment of debt
101

 
—

 
643

 
—

Income before income tax provision
2,463

 
2,070

 
5,884

 
6,163

Income tax provision
921

 
833

 
2,271

 
2,433

Income from continuing operations
1,542

 
1,237

 
3,613

 
3,730

Income (loss) from discontinued operations, net of tax
(1
)
 
10

 
(1
)
 
10

Net income
1,541

 
1,247

 
3,612

 
3,740

Net income attributable to noncontrolling interest
(1
)
 
(1
)
 
(2
)
 
(1
)
Net income attributable to CVS Health
$
1,540

 
$
1,246

 
$
3,610

 
$
3,739

 
 
 
 
 
 
 
 
Basic earnings per share:
 


 


 


 

Income from continuing operations attributable to CVS Health
$
1.44


$
1.10


$
3.34


$
3.31

Income from discontinued operations attributable to CVS Health
$
—


$
0.01


$
—


$
0.01

Net income attributable to CVS Health
$
1.44


$
1.11


$
3.34


$
3.32

Weighted average basic shares outstanding
1,068


1,114


1,076


1,122













Diluted earnings per share:











Income from continuing operations attributable to CVS Health
$
1.43


$
1.10


$
3.32


$
3.28

Income from discontinued operations attributable to CVS Health
$
—


$
0.01


$
—


$
0.01

Net income attributable to CVS Health
$
1.43


$
1.11


$
3.32


$
3.29

Weighted average diluted shares outstanding
1,073


1,121


1,082


1,130

Dividends declared per share
$
0.425


$
0.350


$
1.275


$
1.050

  
See accompanying notes to condensed consolidated financial statements.


3


CVS Health Corporation
Condensed Consolidated Statements of Comprehensive Income
(Unaudited)
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
In millions
2016
 
2015
 
2016
 
2015
 
 
 
 
 
 
 
 
Net income
$
1,541

 
$
1,247

 
$
3,612

 
$
3,740

Other comprehensive income (loss):
 

 
 

 
 

 
 

Foreign currency translation adjustments, net of tax
(3
)
 
(61
)
 
37

 
(100
)
Cash flow hedges, net of tax
1

 
—

 
2

 
1

Total other comprehensive income (loss)
(2
)
 
(61
)
 
39

 
(99
)
Comprehensive income
1,539

 
1,186

 
3,651

 
3,641

Comprehensive income attributable to noncontrolling interest
(1
)
 
(1
)
 
(2
)
 
(1
)
Comprehensive income attributable to CVS Health
$
1,538

 
$
1,185

 
$
3,649

 
$
3,640

 
 
See accompanying notes to condensed consolidated financial statements.


4


CVS Health Corporation
Condensed Consolidated Balance Sheets
(Unaudited)
 
In millions, except per share amounts
September 30,
2016
 
December 31,
2015
 
 
 
 
Assets:
 
 
 
Cash and cash equivalents
$
2,189

 
$
2,459

Short-term investments
74

 
88

Accounts receivable, net
13,625

 
11,888

Inventories
14,348

 
14,001

Other current assets
703

 
722

Total current assets
30,939

 
29,158

Property and equipment, net
9,901

 
9,855

Goodwill
38,214

 
38,106

Intangible assets, net
13,567

 
13,878

Other assets
1,535

 
1,440

Total assets
$
94,156

 
$
92,437

 
 
 
 
Liabilities:
 

 
 

Accounts payable
$
7,584

 
$
7,490

Claims and discounts payable
9,178

 
7,653

Accrued expenses
8,856

 
6,829

Short-term debt
340

 
—

Current portion of long-term debt
783

 
1,197

Total current liabilities
26,741

 
23,169

Long-term debt
25,610

 
26,267

Deferred income taxes
4,254

 
4,217

Other long-term liabilities
1,597

 
1,542

Commitments and contingencies (Note 12)
—

 
—

Redeemable noncontrolling interest
—

 
39

 
 
 
 
Shareholders’ equity:
 

 
 

CVS Health shareholders’ equity:
 
 
 
Preferred stock, par value $0.01: 0.1 share authorized; none issued or outstanding
—

 
—

Common stock, par value $0.01: 3,200 shares authorized; 1,705 shares issued and 1,066
 
 
 
shares outstanding at September 30, 2016 and 1,699 shares issued and 1,101 shares
 
 
 
outstanding at December 31, 2015
17

 
17

Treasury stock, at cost: 638 shares at September 30, 2016 and 597 shares at December 31,
 
 
 
2015
(32,991
)
 
(28,886
)
Shares held in trust: 1 share at September 30, 2016 and December 31, 2015
(31
)
 
(31
)
Capital surplus
31,541

 
30,948

Retained earnings
37,732

 
35,506

Accumulated other comprehensive income (loss)
(319
)
 
(358
)
Total CVS Health shareholders’ equity
35,949

 
37,196

Noncontrolling interest
5

 
7

Total shareholders’ equity
35,954

 
37,203

Total liabilities and shareholders’ equity
$
94,156

 
$
92,437

 
See accompanying notes to condensed consolidated financial statements.


5


CVS Health Corporation
Condensed Consolidated Statements of Cash Flows
(Unaudited)
 
Nine Months Ended September 30,
In millions
2016
 
2015
Cash flows from operating activities:
 
 
 
Cash receipts from customers
$
128,545

 
$
108,324

Cash paid for inventory and prescriptions dispensed by retail network pharmacies
(106,371
)
 
(89,530
)
Cash paid to other suppliers and employees
(11,092
)
 
(11,240
)
Interest received
14

 
15

Interest paid
(954
)
 
(423
)
Income taxes paid
(2,194
)
 
(2,305
)
Net cash provided by operating activities
7,948

 
4,841

 
 
 
 
Cash flows from investing activities:
 

 
 

Purchases of property and equipment
(1,607
)
 
(1,490
)
Proceeds from sale-leaseback transactions
230

 
34

Proceeds from sale of property and equipment and other assets
22

 
28

Acquisitions (net of cash acquired) and other investments
(333
)
 
(9,503
)
Purchase of available-for-sale investments
(40
)
 
(184
)
Sales/maturities of available-for-sale investments
76

 
115

Net cash used in investing activities
(1,652
)
 
(11,000
)
 
 
 
 
Cash flows from financing activities:
 

 
 

Increase in short-term debt
340

 
(685
)
Proceeds from issuance of long-term debt
3,455

 
14,808

Repayments of long-term debt
(5,185
)
 
(2,898
)
Purchase of noncontrolling interest in subsidiary
(39
)
 
—

Payment of contingent consideration
(26
)
 
—

Dividends paid
(1,384
)
 
(1,185
)
Proceeds from exercise of stock options
205

 
277

Excess tax benefits from stock-based compensation
72

 
132

Repurchase of common stock
(4,000
)
 
(3,871
)
Other
(6
)
 
(2
)
Net cash provided by (used in) financing activities
(6,568
)
 
6,576

Effect of exchange rate changes on cash and cash equivalents
2

 
(8
)
Net increase (decrease) in cash and cash equivalents
(270
)
 
409

Cash and cash equivalents at beginning of period
2,459

 
2,481

Cash and cash equivalents at end of period
$
2,189

 
$
2,890

 
 
 
 
Reconciliation of net income to net cash provided by operating activities:
 

 
 

Net income
$
3,612

 
$
3,740

Adjustments to reconcile net income to net cash provided by operating activities:
 

 
 

Depreciation and amortization
1,847

 
1,510

Stock-based compensation
166

 
175

Loss on early extinguishment of debt
643

 
—

Deferred income taxes and other noncash items
119

 
(184
)
Change in operating assets and liabilities, net of effects from acquisitions:
 

 
 

Accounts receivable, net
(1,714
)
 
(2,530
)
Inventories
(337
)
 
(893
)
Other current assets
2

 
591

Other assets
(86
)
 
(13
)
Accounts payable and claims and discounts payable
1,570

 
2,038

Accrued expenses
2,077

 
523

Other long-term liabilities
49

 
(116
)
Net cash provided by operating activities
$
7,948

 
$
4,841

 
See accompanying notes to condensed consolidated financial statements.

6


CVS Health Corporation
Notes to Condensed Consolidated Financial Statements
(Unaudited)
 
Note 1 – Accounting Policies
 
Basis of Presentation
 
The accompanying unaudited condensed consolidated financial statements of CVS Health Corporation and its subsidiaries (collectively, “CVS Health” or the “Company”) have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. In accordance with such rules and regulations, certain information and accompanying note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted, although the Company believes the disclosures included herein are adequate to make the information presented not misleading. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto, which are included in Exhibit 13 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 (“2015 Form 10-K”).

In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods presented. Because of the influence of various factors on the Company’s operations, including business combinations, certain holidays and other seasonal influences, net income for any interim period may not be comparable to the same interim period in previous years or necessarily indicative of income for the full year.

Principles of Consolidation
 
The condensed consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries and variable interest entities (“VIEs”) for which the Company is the primary beneficiary. All material intercompany balances and transactions have been eliminated.

The Company continually evaluates its investments to determine if they represent variable interests in a VIE. If the Company determines that it has a variable interest in a VIE, the Company then evaluates if it is the primary beneficiary of the VIE. The evaluation is a qualitative assessment as to whether the Company has the ability to direct the activities of a VIE that most significantly impact the entity’s economic performance. The Company consolidates a VIE if it is considered to be the primary beneficiary.

Assets and liabilities of VIEs for which the Company is the primary beneficiary were not significant to the Company’s condensed consolidated financial statements. VIE creditors do not have recourse against the general credit of the Company.
 
Fair Value of Financial Instruments
 
The Company utilizes the three-level valuation hierarchy for the recognition and disclosure of fair value measurements. The categorization of assets and liabilities within this hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy consist of the following:
 
•
Level 1 – Inputs to the valuation methodology are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
 
•
Level 2 – Inputs to the valuation methodology are quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active or inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the instrument.

•
Level 3 – Inputs to the valuation methodology are unobservable inputs based upon management’s best estimate of inputs market participants could use in pricing the asset or liability at the measurement date, including assumptions about risk.
 


7


As of September 30, 2016, the carrying value of cash and cash equivalents, short-term investments, accounts receivable and accounts payable approximated their fair value due to the nature of these financial instruments. The Company invests in money market funds, commercial paper and time deposits that are classified as cash and cash equivalents within the accompanying condensed consolidated balance sheets, as these funds are highly liquid and readily convertible to known amounts of cash. These investments are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. The Company’s short-term investments of $74 million at September 30, 2016 consist of certificates of deposit with initial maturities of greater than three months when purchased that mature within one year from the balance sheet date. These investments, which are classified within Level 1 of the fair value hierarchy, are carried at fair value, which approximated historical cost at September 30, 2016. The carrying amount and estimated fair value of the Company’s total long-term debt was $26.4 billion and $28.7 billion, respectively, as of September 30, 2016. The fair value of the Company’s long-term debt was estimated based on quoted prices currently offered in active markets for the Company’s debt, which is considered Level 1 of the fair value hierarchy.

Redeemable Noncontrolling Interest

As a result of the acquisition of Omnicare, Inc. (“Omnicare”) in August 2015, the Company obtained a 73% ownership interest in a limited liability company (“LLC”). Due to the change in control in Omnicare, the noncontrolling member of the LLC had the contractual right to put its membership interest to the Company at fair value. Consequently, the noncontrolling interest in the LLC was recorded as a redeemable noncontrolling interest at fair value. During the first quarter of 2016, the noncontrolling shareholder of the LLC exercised its option to sell its ownership interest and the Company purchased the noncontrolling interest in the LLC for approximately $39 million.

Below is a summary of the changes in the redeemable noncontrolling interest for the nine months ended September 30, 2016:
In millions
 
 
Beginning balance
$
39

 
Net income attributable to noncontrolling interest
1

 
Distributions
(2
)
 
Purchase of noncontrolling interest
(39
)
 
Reclassification to capital surplus in connection with purchase of noncontrolling interest
1

 
Ending balance
$
—

 

Related Party Transactions

The Company has an equity method investment in SureScripts, LLC (“SureScripts”), which operates a clinical health information network. The Pharmacy Services and Retail/LTC segments utilize this clinical health information network in providing services to its client plan members and retail customers. The Company expensed fees for the use of this network of approximately $7 million and $16 million in the three months ended September 30, 2016 and 2015, respectively, and expensed fees of $29 million and $37 million in the nine months ended September 30, 2016 and 2015, respectively. The Company’s investment in and equity in earnings of SureScripts for all periods presented is immaterial.

In connection with the acquisition of Omnicare in August 2015, the Company obtained an equity method investment in Heartland Healthcare Services, LLC (“Heartland”). Heartland operates several long-term care pharmacies in four states. Heartland paid the Company approximately $46 million and $116 million for pharmaceutical inventory purchases during the three and nine months ended September 30, 2016, respectively. Additionally, the Company performs certain collection functions for Heartland and then passes those customer cash collections to Heartland. The Company’s investment in Heartland as of December 31, 2015 and September 30, 2016 and equity in earnings of Heartland for the three and nine months ended September 30, 2016 is immaterial.

In April 2016, the Company made a charitable contribution of $32 million to the CVS Foundation (the “Foundation”) to fund future giving. The Foundation is a non-profit entity that focuses on health, education and community involvement programs. The charitable contribution was recorded as an operating expense in the condensed consolidated statement of income for the nine months ended September 30, 2016.





8


New Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 outlines a single comprehensive model for companies to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. In March 2016, the FASB issued ASU 2016-08, “Principal Versus Agent Considerations (Reporting Revenue Gross Versus Net),” which amends the principal-versus-agent implementation guidance and in April 2016 the FASB issued ASU 2016-10, "Identifying Performance Obligations and Licensing," which amends the guidance in those areas in the new revenue recognition standard. Both ASU's were issued in response to feedback received from the FASB-International Accounting Standards Board joint revenue recognition transition resource group. This new revenue standard is effective for annual reporting periods (including interim reporting periods within those periods) beginning January 1, 2018; early adoption in 2017 is permitted. Companies have the option of using either a full retrospective or a modified retrospective approach to adopt the guidance. This standard could impact the timing and amounts of revenue recognized. The Company is currently evaluating the effect that implementation of this standard will have on its consolidated financial position and results of operations upon adoption, as well as the method of transition and required disclosures.
In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740). The new guidance simplifies the presentation of deferred income taxes by requiring that deferred tax assets and liabilities be classified as noncurrent in a classified statement of financial position. The updated standard is effective for the Company beginning on January 1, 2017 with early application permitted as of the beginning of any interim or annual reporting period. The Company elected to early adopt this standard as of January 1, 2016 and has, accordingly, reclassified the current deferred tax assets to noncurrent deferred tax liabilities for all periods presented. The following is a reconciliation of the effect of the reclassification on the Company's condensed consolidated balance sheet as of December 31, 2015:
In millions
 
As Previously Reported
 
Adjustments
 
As Revised
Deferred tax assets - current
 
$
1,220

 
$
(1,220
)
 
$
—

Total current assets
 
30,378

 
(1,220
)
 
29,158

Total assets
 
93,657

 
(1,220
)
 
92,437

Deferred tax liabilities - noncurrent
 
5,437

 
(1,220
)
 
4,217

Total liabilities and shareholders’ equity
 
93,657

 
(1,220
)
 
92,437


In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). Lessees will be required to recognize a right-of-use asset and a lease liability for virtually all of their leases (other than leases that meet the definition of a short-term lease). The liability will be equal to the present value of lease payments. The asset will be based on the liability, subject to adjustment, such as for initial direct costs. For income statement purposes, a dual model was retained, requiring leases to be classified as either operating or finance leases. Operating leases will result in straight-line expense (similar to current operating leases) while finance leases will result in a front-loaded expense pattern (similar to current capital leases). Lessor accounting is similar to the current model, but updated to align with certain changes to the lessee model (e.g., certain definitions, such as initial direct costs, have been updated) and the new revenue recognition standard. The standard is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The Company believes that the new standard will have a material impact on its consolidated balance sheet but it will not have a material impact on its liquidity. The Company is currently evaluating the effect that implementation of this standard will have on its consolidated results of operations upon adoption.

In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting, which amends Accounting Standard Codification Topic 718, Compensation - Stock Compensation, in three areas. (1) The new guidance eliminates accounting for tax benefits and deficiencies through equity to the extent of previous windfalls, and then to the income statement. The new requirement is to record all tax benefits and deficiencies through the income statement. This amendment is required to be applied prospectively. The amendment also requires the presentation of excess tax benefits on the statements of cash flows as operating activities, a change which may be applied prospectively or retrospectively at the election of the Company. The amendment requires the presentation of employee taxes paid on the statement of cash flows when an employer withholds shares for tax withholding purposes as financing activities, a change which must be applied retrospectively. (2) The new guidance also permits companies to withhold an amount up to the employees' maximum individual tax rate in the relevant jurisdiction without resulting in liability classification of the award. (3) Finally, the new guidance provides companies with an accounting policy election for the impact of forfeitures on the recognition of expense for share-based payment awards.

9


Forfeitures can be estimated, as required today, or recognized when they occur. If elected, the change to recognize forfeitures when they occur needs to be adopted using a modified retrospective approach, with a cumulative effect adjustment recorded to beginning retained earnings. The ASU is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that annual reporting period. The Company is currently evaluating the effect of adopting this new accounting guidance.

In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 is intended to add or clarify guidance on the classification of certain cash receipts and payments in the statement of cash flows and to eliminate the diversity in practice related to such classifications. The guidance in ASU 2016-15 is required for annual reporting periods beginning after December 15, 2017, with early adoption permitted. The Company is currently evaluating the effect on its consolidated statement of cash flows of adopting this new accounting guidance.

Note 2 – Acquisition

On August 18, 2015, the Company acquired 100% of the outstanding common shares and voting interests of Omnicare for $98 per share, for a total of $9.6 billion and assumed long-term debt with a fair value of approximately $3.1 billion. Omnicare is a leading health care services company that specializes in the management of complex pharmaceutical care. Omnicare’s long-term care (“LTC”) business is the nation’s largest provider of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings. In addition, Omnicare has a specialty pharmacy business operating primarily under the name of Advanced Care ScriptsTM, and provides commercialization services under the name of RxCrossroads®. The Company acquired Omnicare to expand its operations in dispensing prescription drugs to assisted-living and long-term care facilities, and to broaden its presence in the specialty pharmacy business as the Company seeks to serve a greater percentage of the growing senior patient population in the United States.

The following unaudited pro forma information presents a summary of the Company’s combined results of operations for the three and nine months ended September 30, 2015 as if the Omnicare acquisition and the related financing transactions had occurred on January 1, 2014. The following pro forma financial information is not necessarily indicative of the results of operations as they would have been had the transactions been effected on the assumed date, nor is it necessarily an indication of trends in future results for a number of reasons, including, but not limited to, differences between the assumptions used to prepare the pro forma information, basic shares outstanding and dilutive equivalents, cost savings from operating efficiencies, potential synergies, and the impact of incremental costs incurred in integrating the businesses.
In millions, except per share data
Three
Months Ended
September 30,
2015
 
Nine
Months Ended
September 30,
2015
Total revenues
$
39,374

 
$
115,652

Income from continuing operations
1,318

 
3,774

Earnings per share from continuing operations:
 
 
 
Basic
$
1.18

 
$
3.35

Diluted
$
1.17

 
$
3.32


Note 3 – Goodwill and Intangible Assets

Goodwill and indefinitely-lived trade names are not amortized, but are subject to annual impairment reviews, or more frequent reviews if events or circumstances indicate there may be impairment. During the three months ended September 30, 2016, the Company performed its required annual impairment tests and concluded there was no impairment of goodwill or trade names.

The Company's total goodwill was $38.2 billion and $38.1 billion as of September 30, 2016 and December 31, 2015, respectively.








10



The following is a summary of the Company's intangible assets as of September 30, 2016 and December 31, 2015:

 
September 30, 2016
 
December 31, 2015
In millions
Gross
Carrying Amount
 
Accumulated Amortization
 
Net Carrying Amount
 
Gross
Carrying Amount
 
Accumulated Amortization
 
Net Carrying Amount
Trademarks (indefinitely-lived)
$
6,398

 
$
—

 
$
6,398

 
$
6,398

 
$
—

 
$
6,398

Customer contracts and
  relationships and covenants not
  to compete
11,340

 
(4,624
)
 
6,716

 
10,594

 
(4,092
)
 
6,502

Favorable leases and other
1,132

 
(679
)
 
453

 
1,595

 
(617
)
 
978

 
$
18,870

 
$
(5,303
)
 
$
13,567

 
$
18,587

 
$
(4,709
)
 
$
13,878


Note 4 – Share Repurchase Program
 
During the nine months ended September 30, 2016, the Company had the following outstanding share repurchase program that was authorized by the Company’s Board of Directors:
In billions
 
 
 
 
 
 
Authorization Date
Authorized
Remaining
December 15, 2014 (“2014 Repurchase Program”)
 
$
10.0

 
 
$
3.7

 

On November 2, 2016, the Company's Board of Directors authorized a new share repurchase program for up to $15 billion of outstanding common stock (the “2016 Repurchase Program”). The 2014 and 2016 Repurchase Programs, which were effective immediately, permit the Company to effect repurchases from time to time through a combination of open market repurchases, privately negotiated transactions, accelerated share repurchase transactions, and/or other derivative transactions. The repurchase programs may be modified or terminated by the Board of Directors at any time.

During the three months ended September 30, 2016, the Company repurchased an aggregate of approximately 0.4 million shares of common stock for approximately $40.0 million pursuant to the 2014 Repurchase Program. During the nine months ended September 30, 2016, the Company repurchased an aggregate of approximately 41.4 million shares of common stock for approximately $4.0 billion pursuant to the 2014 Repurchase Program. This activity includes the accelerated share repurchase agreement (“ASR”) described below.

Pursuant to the authorization under the 2014 Repurchase Program, effective December 11, 2015, the Company entered into a $725 million fixed dollar ASR with Barclays Bank PLC (“Barclays”). Upon payment of the $725 million purchase price on December 14, 2015, the Company received a number of shares of its common stock equal to 80% of the $725 million notional amount of the ASR or approximately 6.2 million shares. The initial 6.2 million shares of common stock delivered to the Company by Barclays were placed into treasury stock in December 2015. The ASR was accounted for as an initial treasury stock transaction for $580 million and a forward contract for $145 million. The forward contract was classified as an equity instrument and was recorded within capital surplus on the condensed consolidated balance sheet as of December 31, 2015. On January 28, 2016, the Company received 1.4 million shares of common stock, representing the remaining 20% of the $725 million notional amount of the ASR, thereby concluding the ASR. The remaining 1.4 million shares of common stock delivered to the Company by Barclays were placed into treasury stock and the forward contract was reclassified from capital surplus to treasury stock in January 2016.

At the time they were received, the initial and final receipt of shares resulted in an immediate reduction of the outstanding shares used to calculate the weighted average common shares outstanding for basic and diluted net income per share.

Note 5 – Accumulated Other Comprehensive Income

Accumulated other comprehensive income consists of foreign currency translation adjustments, unrealized losses on cash flow hedges executed in previous years associated with the issuance of long-term debt, and changes in the net actuarial gains and losses associated with pension and other postretirement benefit plans. The following table summarizes the activity within the components of accumulated other comprehensive income.

11


Changes in accumulated other comprehensive income (loss) by component is shown on the below:
 
Three Months Ended September 30, 2016(1)
In millions
Foreign Currency
 
Losses on Cash Flow Hedges
 
Pension and Other Postretirement Benefits
 
Total
Balance, June 30, 2016
$
(125
)
 
$
(6
)
 
$
(186
)
 
$
(317
)
     Other comprehensive income (loss) before
reclassifications
(3
)
 
—

 
—

 
(3
)
     Amounts reclassified from accumulated
other comprehensive income(2)
—

 
1

 
—

 
1

Net other comprehensive income (loss)
(3
)
 
1

 
—

 
(2
)
Balance, September 30, 2016
$
(128
)
 
$
(5
)
 
$
(186
)
 
$
(319
)
 
 
 
 
 
 
 
 
 
Three Months Ended September 30, 2015(1)
 
Foreign Currency
 
Losses on Cash Flow Hedges
 
Pension and Other Postretirement Benefits
 
Total
Balance, June 30, 2015
$
(104
)
 
$
(8
)
 
$
(143
)
 
$
(255
)
     Other comprehensive income (loss) before
reclassifications
(61
)
 
—

 
—

 
(61
)
     Amounts reclassified from accumulated
other comprehensive income(2)
—

 
—

 
—

 
—

Net other comprehensive (loss)
(61
)
 
—

 
—

 
(61
)
Balance, September 30, 2015
$
(165
)
 
$
(8
)
 
$
(143
)
 
$
(316
)
 
 
 
 
 
 
 
 
 
Nine Months Ended September 30, 2016(1)
 
Foreign Currency
 
Losses on Cash Flow Hedges
 
Pension and Other Postretirement Benefits
 
Total
Balance, December 31, 2015
$
(165
)
 
$
(7
)
 
$
(186
)
 
$
(358
)
     Other comprehensive income (loss) before
reclassifications
37

 
—

 
—

 
37

     Amounts reclassified from accumulated
other comprehensive income (2)
—

 
2

 
—

 
2

Net other comprehensive income
37

 
2

 
—

 
39

Balance, September 30, 2016
$
(128
)
 
$
(5
)
 
$
(186
)
 
$
(319
)
 
 
 
 
 
 
 
 
 
Nine Months Ended September 30, 2015(1)
 
Foreign Currency
 
Losses on Cash Flow Hedges
 
Pension and Other Postretirement Benefits
 
Total
Balance, December 31, 2014
$
(65
)
 
$
(9
)
 
$
(143
)
 
$
(217
)
     Other comprehensive income (loss) before
reclassifications
(100
)
 
1

 
—

 
(99
)
     Amounts reclassified from accumulated
other comprehensive income (2)
—

 
—

 
—

 
—

Net other comprehensive income (loss)
(100
)
 
1

 
—

 
(99
)
Balance, September 30, 2015
$
(165
)
 
$
(8
)
 
$
(143
)
 
$
(316
)

(1)
All amounts are net of tax.
(2)
The amounts reclassified from accumulated other comprehensive income for losses on cash flow hedges are recorded within interest expense, net on the condensed consolidated statement of income. The amounts reclassified from accumulated other comprehensive income for pension and other postretirement benefits are included in operating expenses on the condensed consolidated statement of income.

12


Note 6 – Borrowings

On May 16, 2016, the Company issued $1.75 billion aggregate principal amount of 2.125% unsecured senior notes due June 1, 2021 and $1.75 billion aggregate principal amount of 2.875% unsecured senior notes due June 1, 2026 (collectively, the "2016 Notes") for total proceeds of approximately $3.5 billion, net of discounts and underwriting fees. The 2016 Notes pay interest semi-annually and may be redeemed, in whole at any time, or in part from time to time, at the Company's option at a defined redemption price plus accrued and unpaid interest to the redemption date. The net proceeds of the 2016 Notes were used for general corporate purposes and to repay certain corporate debt.

On May 16, 2016, the Company announced tender offers for (1) any and all of its 5.75% Senior Notes due 2017, its 6.60% Senior Notes due 2019 and its 4.75% Senior Notes due 2020 (collectively, the “Any and All Notes”) and (2) up to $1.5 billion aggregate principal amount of its 6.25% Senior Notes due 2027, its 6.125% Senior Notes due 2039, its 5.75% Senior Notes due 2041, the 5.00% Senior Notes due 2024 issued by its wholly-owned subsidiary, Omnicare, Inc. (“Omnicare”), the 4.75% Senior Notes due 2022 issued by Omnicare, its 4.875% Senior Notes due 2035 and its 3.875% Senior Notes due 2025 (collectively, the “Maximum Tender Offer Notes” and together with the Any and All Notes, the “Notes”). On May 31, 2016, the Company increased the aggregate principal amount of the tender offers for the Maximum Tender Offer Notes to $2.25 billion. The Company purchased approximately $835 million aggregate principal amount of the Any and All Notes and $2.25 billion aggregate principal amount of the Maximum Tender Offer Notes pursuant to the tender offers, which expired on June 13, 2016. The Company paid a premium of $486 million in excess of the debt principal in connection with the purchase of the Notes, wrote off $50 million of unamortized deferred financing costs and incurred $6 million in fees, for a total loss on the early extinguishment of debt of $542 million which was recorded in income from continuing operations in the condensed consolidated statements of income for the nine months ended September 30, 2016.

On June 27, 2016, the Company notified the holders of the remaining Any and All Notes that the Company was exercising its option to redeem the outstanding Any and All Notes pursuant to the terms of the Any and All Notes and the Indenture dated as of August 15, 2006, between the Company and The Bank of New York Mellon Trust Company, N.A. Approximately $1.1 billion aggregate principal amount of Any and All Notes was redeemed on July 27, 2016. The Company paid a premium of $97 million in excess of the debt principal and wrote off $4.0 million of unamortized deferred financing costs, for a total loss on early extinguishment of debt of $101 million during the three months ended September 30, 2016.

The Company recorded a total loss on the early extinguishment of debt of $643 million which was recorded in the income from continuing operations in the condensed statements of income for the nine months ended September 30, 2016.

Note 7 – Stock-Based Compensation
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
In millions
2016
 
2015
 
2016
 
2015
Stock-based compensation:
 
 
 
 
 
 
 
Stock options
$
20

 
$
22

 
$
60

 
$
67

Restricted stock units
38

 
65

 
106

 
108

Total stock-based compensation
$
58

 
$
87

 
$
166

 
$
175


During the nine months ended September 30, 2016, the Company granted 4 million stock options with a weighted average fair value of $13.02 and a weighted average fair value exercise price of $104.75. The Company had 24 million stock options outstanding as of September 30, 2016 with a weighted average exercise price of $68.31 and a weighted average remaining contractual term of 3.94 years. During the nine months ended September 30, 2016, the Company granted 2 million restricted stock units with a weighted average fair value of $103.47. The Company had 5 million unvested restricted stock units as of September 30, 2016 with a weighted average grant date fair value of $56.20.


13


Note 8 – Sale-Leaseback Transactions

The Company finances a portion of its store development program through sale-leaseback transactions. The properties are
generally sold at net book value, which approximates fair value, and the resulting leases typically qualify and are accounted for
as operating leases. The Company does not have any retained or contingent interests in the stores and does not provide any
guarantees, other than a guarantee of lease payments, in connection with the sale-leaseback transactions. Proceeds from sale-leaseback transactions totaled $230 million and $34 million for the nine months ended September 30, 2016 and 2015,
respectively.

Note 9 – Interest Expense
 
The following are the components of net interest expense: 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
In millions
2016
 
2015
 
2016
 
2015
Interest expense
$
258

 
$
268

 
$
830

 
$
577

Interest income
(5
)
 
(7
)
 
(14
)
 
(15
)
Interest expense, net
$
253

 
$
261

 
$
816

 
$
562


Note 10 – Earnings Per Share
 
Earnings per share is computed using the two-class method. Options to purchase 7.7 million and 6.4 million shares of common stock were outstanding, but were not included in the calculation of diluted earnings per share, for the three and nine months ended September 30, 2016, respectively, because the options’ exercise prices were greater than the average market price of the common shares and, therefore, the effect would be antidilutive. For the same reason, options to purchase approximately 3.5 million and 2.4 million shares of common stock were outstanding, but were not included in the calculation of diluted earnings per share for the three and nine months ended September 30, 2015, respectively.

The following is a reconciliation of basic and diluted net income per share from continuing operations for the respective periods:
 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
In millions, except per share amounts
2016
 
2015
 
2016
 
2015
Numerator for earnings per share calculations:
 
 
 
 
 
 
 
Income from continuing operations
$
1,542

 
$
1,237

 
$
3,613

 
$
3,730

Income allocated to participating securities
(7
)
 
(6
)
 
(18
)
 
(18
)
Net income attributable to noncontrolling interest
(1
)
 
(1
)
 
(2
)
 
(1
)
Income from continuing operations attributable to CVS Health
$
1,534

 
$
1,230

 
$
3,593

 
$
3,711

 
 
 
 
 
 
 
 
Denominators for earnings per share calculations:
 

 
 

 
 

 
 
Weighted average shares, basic
1,068

 
1,114

 
1,076

 
1,122

Effect of dilutive securities
5

 
7

 
6

 
8

Weighted average shares, diluted
1,073

 
1,121

 
1,082

 
1,130

 
 
 
 
 
 
 
 
Earnings per share from continuing operations:
 

 
 

 
 

 
 

Basic
$
1.44

 
$
1.10

 
$
3.34

 
$
3.31

Diluted
$
1.43

 
$
1.10

 
$
3.32

 
$
3.28


Note 11 – Segment Reporting
 
The Company has three reportable segments: Pharmacy Services, Retail/LTC and Corporate. The Retail/LTC Segment includes the operating results of the Company's Retail Pharmacy and LTC/RxCrossroads operating segments as the operations and economic characteristics are similar. The Company’s three reportable segments maintain separate financial information by

14


which operating results are evaluated on a regular basis by the Company’s chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company evaluates its Pharmacy Services and Retail/LTC segments’ performance based on net revenue, gross profit and operating profit before the effect of nonrecurring charges and gains and certain intersegment activities. The Company evaluates the performance of its Corporate Segment based on operating expenses before the effect of nonrecurring charges and gains and certain intersegment activities. The chief operating decision maker does not use total assets by segment to make decisions regarding resources, therefore the total asset disclosure by segment has not been included.
 
The Pharmacy Services Segment provides a full range of pharmacy benefit management (“PBM”) services including plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management services and medical spend management. The Company’s clients are primarily employers, insurance companies, unions, government employee groups, health plans, Managed Medicaid plans and other sponsors of health benefit plans, and individuals throughout the United States. A portion of covered lives primarily within the Managed Medicaid, health plan and employer markets have access to our services through public and private exchanges. Through the Company’s SilverScript Insurance Company subsidiary, the Company is a national provider of drug benefits to eligible beneficiaries under the federal government’s Medicare Part D program. The Pharmacy Services Segment operates under the CVS CaremarkTM Pharmacy Services, Caremark®, CVS CaremarkTM, CarePlus CVS Pharmacy®, CVS SpecialtyTM, RxAmerica®, Accordant®, SilverScript®, NovoLogix®, Coram®, Navarro® Health Services and Advanced Care ScriptsTM names. As of September 30, 2016, the Pharmacy Services Segment operated 23 retail specialty pharmacy stores, 13 specialty mail order pharmacies, four mail service dispensing pharmacies, and 85 branches for infusion and enteral services, including approximately 74 ambulatory infusion suites and five centers of excellence, located in 41 states, Puerto Rico and the District of Columbia.

The Retail/LTC Segment sells prescription drugs and a wide assortment of general merchandise, including over-the-counter drugs, beauty products and cosmetics, personal care products, convenience foods, photo finishing, seasonal merchandise and greeting cards. With the acquisition of Omnicare, the Retail/LTC Segment now includes LTC operations, which is comprised of providing the distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings, as well as commercialization services which are provided under the name RxCrossroads®. We added approximately 1,670 pharmacies through the acquisition of the pharmacies of Target Corporation ("Target") in December 2015, thereby expanding our presence in new and existing markets. The stores within Target sell only prescription drugs and over-the-counter drugs that are required to be behind the pharmacy counter. The Retail/LTC Segment also operates retail medical clinics under the MinuteClinic® name. MinuteClinics utilize nationally-recognized medical protocols to diagnose and treat minor health conditions, perform health screenings, monitor chronic conditions and deliver vaccinations. The clinics are staffed by board-certified nurse practitioners and physician assistants who provide access to affordable care without appointment. As of September 30, 2016, our Retail/LTC Segment included 9,694 retail stores (of which 9,638 were either the Company's retail stores that operated a pharmacy, or pharmacies located within Target stores) located in 49 states, the District of Columbia, Puerto Rico and Brazil operating primarily under the CVS Pharmacy®, CVS®, Longs Drugs®, Navarro Discount Pharmacy® and Drogaria OnofreTM names, 34 onsite pharmacies primarily operating under the CarePlus CVS Pharmacy®, CarePlus® and CVS Pharmacy® names, 1,136 retail health care clinics operating under the MinuteClinic® name (of which 1,129 were located in CVS Pharmacy and Target stores), and our online retail websites, CVS.com®, Navarro.comTM and Onofre.com.brTM. LTC operations are comprised of 151 spoke pharmacies that primarily handle new prescription orders, of which 32 are also hub pharmacies that use proprietary automation to support spoke pharmacies with refill prescriptions. LTC operates primarily under the Omnicare® and NeighborCare® names.

The Corporate Segment provides management and administrative services to support the Company. The Corporate Segment consists of certain aspects of executive management, corporate relations, legal, compliance, human resources, information technology and finance departments.


15


In millions
Pharmacy
Services
Segment(1)
 
Retail/LTC
Segment
 
Corporate
Segment
 
Intersegment
Eliminations(2)
 
Consolidated
Totals
Three Months Ended
 
 
 
 
 
 
 
 
 
September 30, 2016:
 
 
 
 
 
 
 
 
 
Net revenues
$
30,429

 
$
20,143

 
$
—

 
$
(5,957
)
 
$
44,615

Gross profit(3)
1,797

 
5,893

 
—

 
(198
)
 
7,492

Operating profit (loss)(4)(5)
1,458

 
1,773

 
(229
)
 
(185
)
 
2,817

September 30, 2015:
 

 
 

 
 

 
 

 
 

Net revenues
25,528

 
17,912

 
—

 
(4,796
)
 
38,644

Gross profit
1,468

 
5,373

 
—

 
(180
)
 
6,661

Operating profit (loss)(4)(5)
1,162

 
1,643

 
(309
)
 
(165
)
 
2,331

Nine Months Ended
 

 
 

 
 

 
 

 
 

September 30, 2016:
 

 
 

 
 

 
 

 
 

Net revenues
88,704

 
60,253

 
—

 
(17,402
)
 
131,555

Gross profit(3)
4,266

 
17,560

 
—

 
(575
)
 
21,251

Operating profit (loss)(4)(5)
3,278

 
5,255

 
(661
)
 
(529
)
 
7,343

September 30, 2015:
 

 
 

 
 

 
 

 
 

Net revenues
73,849

 
52,105

 
—

 
(13,810
)
 
112,144

Gross profit
3,735

 
15,990

 
—

 
(498
)
 
19,227

Operating profit (loss)(4)(5)
2,837

 
5,050

 
(712
)
 
(450
)
 
6,725


(1) 
Net revenues of the Pharmacy Services Segment include approximately $2.5 billion and $2.1 billion of retail co-payments for the three months ended September 30, 2016 and 2015, respectively, as well as $8.1 billion and $6.8 billion of retail co-payments for the nine months ended September 30, 2016 and 2015, respectively.
(2)
Intersegment eliminations relate to intersegment revenue generating activities that occur between the Pharmacy Services Segment and the Retail/LTC Segment. These occur in the following ways: when members of Pharmacy Services Segment clients (“members”) fill prescriptions at the Company's retail stores to purchase covered products, when members enrolled in programs such as Maintenance Choice ® elect to pick up maintenance prescriptions at one of the Company's retail stores instead of receiving them through the mail, or when members have prescriptions filled at the Company's long-term care pharmacies. When these occur, both the Pharmacy Services and Retail/LTC segments record the revenues, gross profit and operating profit on a standalone basis.
(3)
The Retail/LTC Segment gross profit for the three and nine months ended September 30, 2016 includes $5 million and $15 million, respectively, of acquisition-related integration costs. The integration costs are related to the acquisitions of Omnicare and the pharmacies and clinics of Target.
(4)
The Retail/LTC Segment operating profit for the three and nine months ended September 30, 2016 includes $52 million and $194 million, respectively, of acquisition-related integration costs. The Retail/LTC Segment operating profit for the three and nine months ended September 30, 2015 includes $12 million of acquisition-related integration costs. The integration costs are related to the acquisitions of Omnicare and the pharmacies and clinics of Target.
(5)
The Corporate Segment operating loss for the three and nine months ended September 30, 2016 includes $13 million of integration costs. The Corporate Segment operating loss for the three and nine months ended September 30, 2015 includes $115 million and $135 million, respectively, of acquisition-related transaction and integration costs.

Note 12 – Commitments and Contingencies
 
Lease Guarantees
 
Between 1991 and 1997, the Company sold or spun off a number of subsidiaries, including Bob’s Stores, Linens ‘n Things, Marshalls, Kay-Bee Toys, Wilsons, This End Up and Footstar. In many cases, when a former subsidiary leased a store, the Company provided a guarantee of the store’s lease obligations. When the subsidiaries were disposed of, the Company’s guarantees remained in place, although each initial purchaser has agreed to indemnify the Company for any lease obligations the Company was required to satisfy. If any of the purchasers or any of the former subsidiaries were to become insolvent and failed to make the required payments under a store lease, the Company could be required to satisfy these obligations. As of September 30, 2016, the Company guaranteed approximately 87 such store leases (excluding the lease guarantees related to Linens ‘n Things, which have been recorded as a liability on the condensed consolidated balance sheet), with the maximum remaining lease term extending through 2047.



16


In April 2016, the parent entity of Bob’s Stores filed for Chapter 11 bankruptcy protection. As described above, the Company, through one or more of its affiliates, is alleged to have guaranteed certain of the Bob’s Stores’ leases (the “Bob’s Leases”). On June 20, 2016, the bankruptcy court approved the sale of substantially all of the assets of Bob’s Stores and certain other assets to a new entity (“Buyer”), which designated Buyer’s affiliate Bob’s Stores, LLC, a Delaware limited liability company (“New Bob’s”), to acquire substantially all of the assets of Bob’s Stores.

The Company, through its subsidiary, CVS Pharmacy, Inc., and New Bob’s have entered into an agreement dated October 14, 2016, pursuant to which, in exchange for an immaterial payment to be made by CVS Pharmacy, Inc., New Bob’s has agreed to accept the assignment of the Bob’s Leases and to be bound by certain restrictions regarding renewals, extensions and modifications to the Bob’s Leases. The Company believes these restrictions will potentially reduce the Company's exposure to liability under guarantees of the Bob's leases in the future. The assignment of the Bob’s Leases to New Bob’s will be subject to bankruptcy court approval. The Company will continue to monitor the bankruptcy proceedings.

Legal Matters
 
The Company is a party to legal proceedings, investigations and claims in the ordinary course of its business, including the matters described below. The Company records accruals for outstanding legal matters when it believes it is probable that a loss will be incurred and the amount can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in legal matters that could affect the amount of any accrual and developments that would make a loss contingency both probable and reasonably estimable. If a loss contingency is not both probable and estimable, the Company does not establish an accrued liability. None of the Company’s accruals for outstanding legal matters are material individually or in the aggregate to the Company’s financial position.

The Company’s contingencies are subject to significant uncertainties, including, among other factors: (i) the procedural status of pending matters; (ii) whether class action status is sought and certified; (iii) whether asserted claims or allegations will survive dispositive motion practice; (iv) the extent of potential damages, fines or penalties, which are often unspecified or indeterminate; (v) the impact of discovery on the legal process; (vi) whether novel or unsettled legal theories are at issue; (vii) the settlement posture of the parties, and/or (viii) in the case of certain government agency investigations, whether a sealed qui tam lawsuit (“whistleblower” action) has been filed and whether the government agency makes a decision to intervene in the lawsuit following investigation.

Except as otherwise noted, the Company cannot predict with certainty the timing or outcome of the legal matters described below, and is unable to reasonably estimate a possible loss or range of possible loss in excess of amounts already accrued for these matters.

•
Caremark (the term “Caremark” being used herein to generally refer to any one or more PBM subsidiaries of the Company, as applicable) was named in a putative class action lawsuit filed in October 2003 in Alabama state court by John Lauriello, purportedly on behalf of participants in the 1999 settlement of various securities class action and derivative lawsuits against Caremark and others. Other defendants include insurance companies that provided coverage to Caremark with respect to the settled lawsuits. A similar lawsuit was filed in November 2003 by Frank McArthur, also in Alabama state court, naming as defendants, among others, Caremark and several insurance companies involved in the 1999 settlement. This lawsuit was stayed as a later-filed class action, but McArthur was subsequently allowed to intervene in the Lauriello action. The parties have entered into an agreement to resolve the matter. In connection with this agreement, the Company contributed a total of $80 million to the settlement fund and agreed to forego its right to have its insurer continue to reimburse its related legal fees. The Company had established reserves related to this matter to fully cover such payments and the payment was made in the three months ended September 30, 2016. In August 2016, the court entered final judgment dismissing the matter and approving the settlement. The Company denies any wrongdoing, and agreed to a settlement to avoid the burden, uncertainty and distraction of litigation.

•
Beginning in August 2003, various lawsuits were filed by pharmacies alleging that various PBMs were violating certain antitrust laws. In October 2003, two independent pharmacies, North Jackson Pharmacy, Inc. and C&C, Inc. d/b/a Big C Discount Drugs, Inc., filed three separate putative class action complaints in the United States District Court for the Northern District of Alabama, all seeking treble damages and injunctive relief. One complaint named three Caremark entities as defendants, and the other two complaints named PBM competitors. The North Jackson Pharmacy case against two of the Caremark entities was transferred to the United States District Court for the Northern District of Illinois; the case against the third Caremark entity was sent to arbitration based on contract terms between the pharmacies and that entity. The arbitration was stayed at the parties’ request and later closed by the American

17


Arbitration Association. In August 2006, the Judicial Panel on Multidistrict Litigation issued an order transferring all related PBM antitrust cases, including the North Jackson Pharmacy cases, to the United States District Court for the Eastern District of Pennsylvania for coordinated and consolidated proceedings with the cases originally filed in that court. The consolidated action is now known as In re Pharmacy Benefit Managers Antitrust Litigation. A motion for class certification filed by the North Jackson Pharmacy plaintiffs against the Caremark defendants in August 2015 is currently pending.

•
In February 2006, two substantially similar putative class action lawsuits were filed in the U.S. District Court for the Eastern District of Kentucky, and were consolidated and entitled Indiana State Dist. Council of Laborers & HOD Carriers Pension & Welfare Fund v. Omnicare, Inc. The consolidated complaint was filed against Omnicare, three of its officers and two of its directors and purported to be brought on behalf of all open-market purchasers of Omnicare common stock from August 3, 2005 through July 27, 2006, as well as all purchasers who bought shares of Omnicare common stock in Omnicare’s public offering in December 2005. The complaint alleged violations of the Securities Exchange Act of 1934 and Section 11 of the Securities Act of 1933 and sought, among other things, compensatory damages and injunctive relief. After dismissals and appeals to the United States Court of Appeals for the Sixth Circuit, the United States Supreme Court remanded the case to the district court. In October 2016, Omnicare filed an answer to plaintiffs’ third amended complaint, and discovery commenced.

•
In December 2007, the Company received a document subpoena from the Office of Inspector General (“OIG”) within the U.S. Department of Health and Human Services, requesting information relating to the processing of Medicaid and certain other government agency claims on behalf of its clients (which allegedly resulted in underpayments from our pharmacy benefit management clients to the applicable government agencies) on one of the Company’s adjudication platforms. In September 2014, the Company settled the OIG’s claims, as well as related claims by the Department of Justice and private plaintiffs, without any admission of liability. The Company is in discussions with the OIG concerning other claim processing issues.

•
In December 2009, a shareholder derivative lawsuit was filed by Mark Wuotila in the United States District Court for the District of Rhode Island against the directors and certain officers of the Company. The lawsuit includes allegations of, among other things, securities fraud, insider trading and breach of fiduciary duties and further alleges that the Company was damaged by the purchase of stock at allegedly inflated prices under its share repurchase program. The Company entered into an agreement to settle the matter, pursuant to which the Company agreed to maintain or implement certain corporate governance measures and pay the plaintiff’s legal fees of $270,000. In August 2016, the court entered final judgment dismissing the matter and approving the settlement. The Company denies any wrongdoing, and agreed to settle these matters to avoid the burden, uncertainty and distraction of litigation. The settlement was funded by insurance proceeds.

•
In March 2010, the Company learned that various State Attorneys General offices and certain other government agencies were conducting a multi-state investigation of certain of the Company’s business practices similar to those being investigated at that time by the U.S. Federal Trade Commission (“FTC”). Twenty-eight states, the District of Columbia and the County of Los Angeles are known to be participating in this investigation. The prior FTC investigation, which commenced in August 2009, was officially concluded in May 2012 when the consent order entered into between the FTC and the Company became final. The Company has cooperated with the multi-state investigation.

•
In March 2010, the Company received a subpoena from the OIG requesting information about programs under which the Company has offered customers remuneration conditioned upon the transfer of prescriptions for drugs or medications to the Company’s pharmacies in the form of gift cards, cash, non-prescription merchandise or discounts or coupons for non-prescription merchandise. In October 2016, the U.S. District Court for the Central District of California unsealed a qui tam complaint, filed in April 2009 against CVS Pharmacy and other retail pharmacies, alleging that the Company violated the federal False Claims Act, and the false claims acts of several states, by offering such programs. The federal government has declined intervention in the case.

•
On October 29, 2010, a qui tam complaint entitled United States et al., ex rel. Banigan and Templin v. Organon USA, Inc., Omnicare, Inc. and PharMerica Corporation that had been filed under seal with the U.S. District Court for the District of Massachusetts, was ordered unsealed by the court. The complaint was brought by two former employees of Organon, as private party qui tam relators on behalf of the federal government and several state and local governments. The action alleges civil violations of the federal False Claims Act based on allegations that Organon and its affiliates paid Omnicare and several other long-term care pharmacies rebates, post-purchase discounts and other forms of

18


remuneration in return for purchasing pharmaceuticals from Organon and taking steps to increase the purchase of Organon’s drugs in violation of the Anti-Kickback Statute. The U.S. Department of Justice declined to intervene in this action. Discovery is closed in this matter. In August 2016, the Court granted in part and denied in part Omnicare’s motion for summary judgment. The Company has tentatively agreed with the Department of Justice to resolve this matter for $23 million plus interest. These financial terms are contingent on approval by authorized officials at the Department of Justice, negotiation of terms of a settlement agreement, approval and releases from the OIG, the National Association of Medicaid Fraud Control Units, and the Department of Justice. While the Company believes that a final settlement will be reached, there can be no assurance that any final settlement agreement will be reached or as to the final terms of such settlement.

•
In January 2012, the United States District Court for the Eastern District of Pennsylvania unsealed a first amended qui tam complaint filed in August 2011 by an individual relator, Anthony Spay, who is described in the complaint as having once been employed by a firm providing pharmacy prescription benefit audit and recovery services. The complaint seeks monetary damages and alleges that Caremark’s processing of Medicare claims on behalf of one of its clients violated the federal False Claims Act. The United States declined to intervene in the lawsuit. In September 2015, the Court granted Caremark's motion for summary judgment in its entirety, and entered judgment in favor of Caremark and against Spay. In October 2015, Spay filed a notice of appeal in the United States Court of Appeals for the Third Circuit.

•
In February 2012, the Attorney General of the State of Texas issued Civil Investigative Demands and other requests, and has issued a series of subsequent requests for documents and information in connection with its investigation concerning the Health Savings Pass program and other pricing practices with respect to claims for reimbursement from the Texas Medicaid program.

•
In November 2012, the Company received a subpoena from the OIG requesting information concerning automatic refill programs used by pharmacies to refill prescriptions for customers. The Company cooperated and provided documents and other information in response to this request for information.

•
In 2013, Omnicare received subpoenas seeking information regarding Omnicare’s nationwide billing practices with regard to National Drug Code overrides and Omnicare’s May 2008 acquisition of Pure Service Pharmacy. In 2014, Omnicare received subpoenas seeking information regarding Omnicare’s Auto Label Verification system and Omnicare’s per diem arrangements. Omnicare has produced documents and provided information in response to these subpoenas and continues to cooperate in the investigations. In October 2016, the Department of Justice intervened for purposes of settling a qui tam complaint Ervin v. Omnicare which related to the subpoena seeking information with regard to National Drug Code overrides. In October 2016, the Company, the Department of Justice, OIG, and National Association of Medicaid Fraud Control Units finalized and signed settlement agreements for approximately $2.2 million plus interest. The Court unsealed and dismissed the False Claim Act claims of the complaint.

Omnicare reached an agreement regarding financial terms to resolve, for $1.5 million plus interest, the subpoena regarding the acquisition of Pure Service Pharmacy. These financial terms are contingent on approval by authorized officials at the Department of Justice, negotiation of terms of a settlement agreement, approval and releases from the OIG, the National Association of Medicaid Fraud Control Units, and the Department of Justice. While the Company believes that a final settlement will be reached, there can be no assurance that any final settlement agreement will be reached or as to the final terms of such settlement.
Omnicare reached an agreement regarding financial terms to resolve, for $8 million plus interest, the subpoena regarding Omnicare’s Auto Label Verification system. These financial terms are contingent on approval by authorized officials at the Department of Justice, negotiation of terms of a settlement agreement, approval and releases from the OIG, the National Association of Medicaid Fraud Control Units, and the Department of Justice. While the Company believes that a final settlement will be reached, there can be no assurance that any final settlement agreement will be reached or as to the final terms of such settlement.
•
On March 22, 2013, a qui tam complaint entitled United States et al., ex rel. Susan Ruscher v. Omnicare, Inc., et al., which had been filed under seal in the U.S. District Court for the Southern District of Texas, was unsealed by the court. The complaint was brought by Susan Ruscher as a private party qui tam relator on behalf of the federal government and several state governments alleging violations of the federal False Claims Act and analogous state laws based upon allegations that Omnicare’s practices relating to customer collections violated the Anti-Kickback Statute. In September 2015, the court granted summary judgment dismissing all claims against Omnicare and denied relator’s motion for summary judgment related to Omnicare’s counterclaims and thereafter, in October 2015, the court entered a

19


final judgment for Omnicare and stayed trial on the counterclaims pending an appeal from the relator. In October 2015, plaintiffs filed a notice of appeal in the United States Court of Appeals for the Fifth Circuit. In October 2016, the appellate court affirmed the district court’s grant of summary judgment dismissing all claims against Omnicare.

•
In March 2014, the Company received a subpoena from the United States Attorney’s Office for the District of Rhode Island, requesting documents and information concerning bona fide service fees and rebates received from pharmaceutical manufacturers in connection with certain drugs utilized under Part D of the Medicare Program, as well as the reporting of those fees and rebates to Part D plan sponsors. The Company has been cooperating with the government and providing documents and information in response to the subpoena.

•
The U.S. Department of Justice, through the U.S. Attorney’s Office for the Western District of Virginia, investigated whether Omnicare’s activities in connection with the agreements it had with the manufacturer of the pharmaceutical Depakote violated the False Claims Act or the Anti-Kickback Statute. Omnicare cooperated with this investigation and believes that it has complied with applicable laws and regulations with respect to this matter. In connection with this matter, on December 22, 2014, the U.S. Department of Justice filed a civil complaint-in-intervention in two qui tam complaints, entitled United States, et al., ex rel. Spetter v. Abbott Laboratories, Inc., Omnicare, Inc., and PharMerica Corp., and United States, et al., ex rel. McCoyd v. Abbott Laboratories, Omnicare, Inc., PharMerica Corp., and Miles White, alleging civil violations of the False Claims Act in connection with the manufacturer agreements described above. In July 2015, the parties filed a Joint Motion to Stay the Litigation stating that the parties have reached a proposed resolution of the monetary terms of a potential settlement agreement. In October 2016, the Company, the Department of Justice, OIG, and National Association of Medicaid Fraud Control Units finalized and signed a settlement agreement for approximately $28.1 million plus interest.

As part of Omnicare’s settlements with the Department of Justice, the Company entered into a corporate integrity agreement (“CIA”) with the OIG. The CIA has a term of five years commencing on October 11, 2016. The CIA imposes various compliance requirements relating to the provision of institutional pharmacy services. As part of entering into the CIA, OIG provided the Company with a release related to the previously described subpoena regarding Omnicare’s per diem arrangements. That release is more fully described in the CIA.
•
In May 2015, the Company received a subpoena from the OIG requesting information and documents concerning the Company’s automatic refill programs, adherence outreach programs, and pharmacy customer incentives, particularly in connection with claims for reimbursement made to the Minnesota Medicaid program. The Company has been cooperating with the investigation and providing information in response to the subpoena.

•
In July and September 2015, two related putative class actions, Corcoran, et al. v. CVS Health Corp., and Podgorny, et al. v. CVS Health Corp., were filed against the Company in the United States District Court in the Northern District of California and the Northern District of Illinois, respectively. The two cases have been consolidated in United States District Court in the Northern District of California. In March 2016, the Court granted in part and denied in part the Company’s first motion to dismiss. In July 2016, the Court granted in part and denied in part the Company's partial motion to dismiss the third amended complaint. Discovery is proceeding on the remaining allegations in the third amended complaint, which alleges that the plaintiffs overpaid for prescriptions for generic drugs filled at CVS pharmacies. The plaintiffs seek damages and injunctive relief under the consumer protection statutes and common laws of certain states and in October 2016 Plaintiffs moved for the certification of a class involving CVS customers from 11 states. In February 2016, two third-party payors filed a similar putative class action, Sheet Metal Workers Local No. 20 Welfare and Benefit Fund v. CVS Health Corp., against the Company in the United States District Court for the District of Rhode Island. The Company’s motion to dismiss remains pending. In August 2016, a similar complaint was filed by another third-party payor, Plumbers Welfare Fund, Local 130 v. CVS Health Corp., also in the United States District Court for the District of Rhode Island. The Company likewise intends to defend this action.

•
In September 2015, Omnicare was served with an administrative subpoena by the U.S. Drug Enforcement Agency (“DEA”). The subpoena seeks documents related to controlled substance policies, procedures, and practices at eight pharmacy locations from May 2012 to the present. The Company has been cooperating and providing documents in response to this administrative subpoena.

•
In October 2015, Omnicare received a Civil Investigative Demand from the United States Attorney’s Office for the Southern District of New York requesting information and documents concerning Omnicare’s cycle fill process for assisted living facilities. The Company has been cooperating with the government and providing documents and information in response to the Civil Investigative Demand.

20


•
In October 2015, the Company received from the U.S. Department of Justice a Civil Investigative Demand requesting documents and information in connection with a False Claims Act investigation concerning allegations that the Company submitted, or caused to be submitted, to the Medicare Part D program prescription drug event data that misrepresented true prices paid by the Company's PBM to pharmacies for drugs dispensed to Part D beneficiaries with prescription benefits administered by the Company’s PBM. The Company has been cooperating with the government and providing documents and information in response to the Civil Investigative Demand.

•
In November 2015, the United States District Court for the Eastern District of Pennsylvania unsealed a second amended qui tam complaint filed in September 2015, in an action captioned United States, et al., ex rel. Sally Schimelpfeinig and John Segura v. Dr. Reddy’s Laboratories Limited, et al. The U.S. Department of Justice declined to intervene in this action. The relators allege that the Company, Walgreens, Wal-Mart, and Dr. Reddy’s Laboratories violated the federal and various state False Claims Acts by dispensing prescriptions in unit dose packaging supplied by Dr. Reddy’s that was not compliant with the Consumer Product Safety Improvement Act and the Poison Preventive Packaging Act and thereby allegedly rendering the drugs misbranded under the Food, Drug & Cosmetic Act. The Company's motion to dismiss remains pending.

•
In February 2016, an ERISA class action lawsuit was filed against the Company, the Benefit Plans Committee of the Company, and Galliard Capital Management, Inc., in the United States District Court for the District of Rhode Island by Mary Barchock, Thomas Wasecko, and Stacy Weller, purportedly on behalf of the 401(k) Plan and the Employee Stock Ownership Plan of the Company (the “Plan”), and participants in the Plan. The complaint alleges that the defendants breached fiduciary duties owed to the plaintiffs and the Plan by investing too much of the Plan’s Stable Value Fund in short-term money market funds and cash management accounts. The Company has moved to dismiss the plaintiffs' amended complaint.

•
In April 2016, the Superior Court of the State of California (Sacramento) unsealed a first amended qui tam complaint filed in July 2013, in an action captioned State of California ex rel. Matthew Omlansky v. CVS Caremark Corporation, et al. The government has declined intervention in this case. The relator alleged that the Company submitted false claims for payment to California Medicaid in connection with reimbursement for drugs available through the Health Savings Pass program as well as certain other generic drugs. The Company's motion to dismiss the complaint was denied.

•
In June 2016, the Company entered into a settlement agreement with the U.S. Attorney’s Office for the District of Massachusetts, resolving alleged violations of the Controlled Substances Act (“CSA”). The Company paid a fine of $3.5 million in connection with the settlement in July 2016 which was previously fully reserved in the Company's financial statements. The Company is also undergoing several audits by the DEA Administrator and is in discussions with the DEA and the U.S. Attorney’s Office in several locations concerning allegations that the Company has violated certain requirements of the CSA.

•
In July 2016, the Company was served with a complaint filed on behalf of the State of Mississippi, in the Chancery Court of DeSoto County, Third Judicial District, alleging that CVS retail pharmacies in Mississippi submitted false claims for reimbursement to Mississippi Medicaid by not submitting as the pharmacy’s usual and customary price the price available to members of the CVS Health Savings Pass program. The Company has responded to the complaint, filed a counterclaim, and moved to transfer the case to circuit court.

The Company is also a party to other legal proceedings, government investigations, inquiries and audits, and has received and is cooperating with subpoenas or similar process from various governmental agencies requesting information, all arising in the normal course of its business, none of which is expected to be material to the Company. The Company can give no assurance, however, that its business, financial condition and results of operations will not be materially adversely affected, or that the Company will not be required to materially change its business practices, based on: (i) future enactment of new health care or other laws or regulations; (ii) the interpretation or application of existing laws or regulations as they may relate to the Company’s business, the pharmacy services, specialty pharmacy, retail pharmacy, long-term care pharmacy or retail clinic industries or to the health care industry generally; (iii) pending or future federal or state governmental investigations of the Company’s business or the pharmacy services, specialty pharmacy, retail pharmacy, long-term care pharmacy or retail clinic industry or of the health care industry generally; (iv) pending or future government enforcement actions against the Company; (v) adverse developments in any pending qui tam lawsuit against the Company, whether sealed or unsealed, or in any future qui tam lawsuit that may be filed against the Company; or (vi) adverse developments in pending or future legal proceedings against the Company or affecting the pharmacy services, specialty pharmacy, retail pharmacy, long-term care pharmacy or retail clinic industry or the health care industry generally.

21


Report of Independent Registered Public Accounting Firm
 
The Board of Directors and Shareholders
CVS Health Corporation:

We have reviewed the condensed consolidated balance sheet of CVS Health Corporation (the Company) as of September 30, 2016, the related condensed consolidated statements of income and comprehensive income for the three-month and nine-month periods ended September 30, 2016 and 2015, and the condensed consolidated statements of cash flows for the nine-month periods ended September 30, 2016 and 2015. These financial statements are the responsibility of the Company’s management.

We conducted our review in accordance with the standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the Public Company Accounting Oversight Board (United States), the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our review, we are not aware of any material modifications that should be made to the condensed consolidated financial statements referred to above for them to be in conformity with U.S. generally accepted accounting principles.

We have previously audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheet of CVS Health Corporation as of December 31, 2015, and the related consolidated statements of income, comprehensive income, shareholders’ equity, and cash flows for the year then ended not presented herein, and we expressed an unqualified opinion on those consolidated financial statements in our report dated February 9, 2016. In our opinion, the information set forth in the accompanying condensed consolidated balance sheet as of December 31, 2015, is fairly stated, in all material respects, in relation to the consolidated balance sheet from which it has been derived.


 
 
 
/s/ Ernst & Young LLP
 
 
November 8, 2016
 
Boston, Massachusetts
 


22


Part I
 
Item 2
 
Management’s Discussion and Analysis of Financial Condition and Results of Operations
 
Overview of Our Business
 
CVS Health Corporation, together with its subsidiaries (collectively, “CVS Health,” the “Company,” “we,” “our” or “us”), is a pharmacy innovation company helping people on their path to better health. At the forefront of a changing health care landscape, the Company has an unmatched suite of capabilities and the expertise needed to drive innovations that will help shape the future of health.

We are currently the only integrated pharmacy health care company with the ability to impact consumers, payors, and providers with innovative, channel-agnostic solutions to complex challenges managing costs and care. We have a deep understanding of their diverse needs through our unique integrated model, and we are bringing them innovative solutions that help increase access to quality care, deliver better health outcomes and lower overall health care costs.

Through our more than 9,600 retail pharmacies, more than 1,100 walk-in medical clinics, a leading pharmacy benefits manager with more than 80 million plan members, a dedicated senior pharmacy care business serving more than one million patients per year, and expanding specialty pharmacy services, we enable people, businesses and communities to manage health in more affordable, effective ways. We are delivering break-through products and services, from advising patients on their medications at our CVS Pharmacy® locations, to introducing unique programs to help control costs for our clients at CVS Caremark®, to innovating how care is delivered to our patients with complex conditions through CVS SpecialtyTM, to improving pharmacy care for the senior community through Omnicare®, or by expanding access to high-quality, low-cost care at CVS MinuteClinicTM.

We have three reportable segments: Pharmacy Services, Retail/LTC and Corporate.
 
Pharmacy Services Segment
 
Our Pharmacy Services business generates revenue from a full range of pharmacy benefit management (“PBM”) solutions, including plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management services and medical spend management. Our clients are primarily employers, insurance companies, unions, government employee groups, health plans, Managed Medicaid plans and other sponsors of health benefit plans and individuals throughout the United States. A portion of covered lives primarily within the Managed Medicaid, health plan and employer markets have access to our services through public and private exchanges. As a pharmacy benefits manager, we manage the dispensing of prescription drugs through our mail order pharmacies, specialty pharmacies, long-term care pharmacies and a national network of more than 68,000 retail pharmacies, consisting of approximately 41,000 chain pharmacies (which includes our CVS Pharmacy® stores) and 27,000 independent pharmacies, to eligible members in the benefit plans maintained by our clients and utilize our information systems to perform, among other things, safety checks, drug interaction screenings and brand to generic substitutions.

Our specialty pharmacies support individuals who require complex and expensive drug therapies. Our specialty pharmacy business includes mail order and retail specialty pharmacies that operate under the CVS Caremark®, CarePlus CVS Pharmacy®, Navarro® Health Services and Advanced Care ScriptsTM names. The Pharmacy Services Segment also provides health management programs, which include integrated disease management for 17 conditions, through our Accordant® rare disease management offering. In addition, through our SilverScript Insurance Company subsidiary, we are a national provider of drug benefits to eligible beneficiaries under the federal government’s Medicare Part D program. The Pharmacy Services Segment operates under the CVS Caremark® Pharmacy Services, Caremark®, CVS Caremark®, CarePlus CVS Pharmacy®, Accordant®, SilverScript®, Coram®, CVS SpecialtyTM, NovoLogix®, Navarro® Health Services and Advanced Care ScriptsTM names. As of September 30, 2016, the Pharmacy Services Segment operated 23 retail specialty pharmacy stores, 13 specialty mail order pharmacies, four mail order dispensing pharmacies, and 85 branches for infusion and enteral services, including approximately 74 ambulatory infusion suites and five centers of excellence, located in 41 states, Puerto Rico and the District of Columbia.
 





23


Retail/LTC Segment
 
Our Retail/LTC Segment sells prescription drugs and a wide assortment of general merchandise, including over-the-counter drugs, beauty products and cosmetics, personal care products, convenience foods, photo finishing, seasonal merchandise and greeting cards through our CVS Pharmacy ®, CVS ®, Longs Drugs ®, Navarro Discount Pharmacy ® and Drogaria Onofre TM retail stores and online through CVS.com®, Navarro.comTM and Onofre.com.brTM. The Retail/LTC Segment also includes providing the distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings, as well as commercialization services which are provided under the name RxCrossroads ®. Our Retail/LTC Segment derives the majority of its revenues through the sale of prescription drugs, which are dispensed by our more than 30,000 pharmacists. Our Retail/LTC Segment also provides health care services through our CVS MinuteClinic offering. MinuteClinics are staffed by nurse practitioners and physician assistants who utilize nationally recognized protocols to diagnose and treat minor health conditions, perform health screenings, monitor chronic conditions and deliver vaccinations. As of September 30, 2016, our Retail/LTC Segment included 9,694 retail stores (of which 9,638 were either the Company's retail stores that operated a pharmacy, or pharmacies located within Target stores) located in 49 states, the District of Columbia, Puerto Rico and Brazil operating primarily under the CVS Pharmacy®, CVS®, Longs Drugs®, Navarro Discount Pharmacy® and Drogaria OnofreTM names, 34 onsite pharmacies primarily operating under the CarePlus CVS Pharmacy®, CarePlus® and CVS Pharmacy® names, and 1,136 retail health care clinics operating under the MinuteClinic® name (of which 1,129 were located in CVS Pharmacy and Target stores), and our online retail websites, CVS.com®, Navarro.comTM and Onofre.com.brTM. LTC operations are comprised of 151 spoke pharmacies that primarily handle new prescription orders, of which 32 are also hub pharmacies that use proprietary automation to support spoke pharmacies with refill prescriptions. LTC operates primarily under the Omnicare® and NeighborCare® names.

Corporate Segment
 
The Corporate Segment provides management and administrative services to support the Company. The Corporate Segment consists of certain aspects of our executive management, corporate relations, legal, compliance, human resources, information technology and finance departments.

Results of Operations
 
The following discussion explains the material changes in our results of operations for the three and nine months ended September 30, 2016 and 2015, and the significant developments affecting our financial condition since December 31, 2015. We strongly recommend that you read our audited consolidated financial statements and notes thereto and Management’s Discussion and Analysis of Financial Condition and Results of Operations included as Exhibit 13 to our 2015 Form 10-K along with this report.


24


Summary of the Condensed Consolidated Financial Results:
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
In millions
2016
 
2015
 
2016
 
2015
 
 
 
 
 
 
 
 
Net revenues
$
44,615

 
$
38,644

 
$
131,555

 
$
112,144

Cost of revenues
37,123

 
31,983

 
110,304

 
92,917

Gross profit
7,492

 
6,661

 
21,251

 
19,227

Operating expenses
4,675

 
4,330

 
13,908

 
12,502

Operating profit
2,817

 
2,331

 
7,343

 
6,725

Interest expense, net
253

 
261

 
816

 
562

Loss on early extinguishment of debt
101

 
—

 
643

 
—

Income before income tax provision
2,463

 
2,070

 
5,884

 
6,163

Income tax provision
921

 
833

 
2,271

 
2,433

Income from continuing operations
1,542

 
1,237

 
3,613

 
3,730

Income (loss) from discontinued operations, net of tax
(1
)
 
10

 
(1
)
 
10

Net income
1,541

 
1,247

 
3,612

 
3,740

Net income attributable to noncontrolling interest
(1
)
 
(1
)
 
(2
)
 
(1
)
Net income attributable to CVS Health
$
1,540

 
$
1,246

 
$
3,610

 
$
3,739

 
Net Revenues
 
Net revenues increased approximately $6.0 billion, or 15.5%, and $19.4 billion, or 17.3%, in the three and nine months ended September 30, 2016, as compared to the prior year. Part of the increase was driven by the acquisition of Omnicare in August 2015, which positively affected both segments, and the pharmacies and clinics of Target in December 2015, which positively affected the Retail/LTC Segment. The increase in the Pharmacy Services Segment was also driven by pharmacy network claim volume growth primarily attributable to net new business and growth in specialty pharmacy. The increase in the Retail/LTC Segment was also driven by increased pharmacy same store sales. Net revenues in both segments were negatively impacted by an increase in generic dispensing rates, as well as continued price compression in the Pharmacy Services Segment and reimbursement pressure in the Retail/LTC Segment. Generic prescription drugs typically have a lower selling price than brand name prescription drugs.
 
Please see the section entitled “Segment Analysis” below for additional information regarding net revenues.
 
Gross Profit
 
Gross profit dollars increased $831 million, or 12.5%, and $2.0 billion, or 10.5% in the three and nine months ended September 30, 2016 as compared to the prior year. Gross profit as a percentage of net revenues decreased approximately 45 basis points in the three months ended September 30, 2016 to 16.8%, as compared to the prior year. Gross profit as a percentage of net revenues decreased approximately 100 basis points in the nine months ended September 30, 2016 to 16.2%, as compared to the prior year. The decrease in gross profit as a percentage of net revenues was driven by a change in the mix of business within both segments, as well as continued price compression in the Pharmacy Services Segment and reimbursement pressure in the Retail/LTC Segment. Gross profit dollars for the three and nine months ended September 30, 2016, were positively affected by an increase in generic dispensing rates, an increase in pharmacy network claims and specialty growth in the Pharmacy Services Segment compared to the prior year, as well as volume from the acquisitions of Omnicare and the pharmacies and clinics of Target.
 
Please see the section entitled “Segment Analysis” below for additional information regarding gross profit.







25


Operating Expenses
 
Operating expenses increased $345 million, or 8.0%, and $1.4 billion, or 11.3%, in the three and nine months ended September 30, 2016, respectively, as compared to the prior year. Operating expenses as a percentage of net revenues decreased approximately 75 basis points to 10.5% and 60 basis points to 10.6% in the three and nine months ended September 30, 2016, respectively, as compared to 11.2% and 11.1% in the three and nine months ended September 30, 2015, respectively. The increase in operating expense dollars in the three and nine months ended September 30, 2016, was primarily due to the addition of Omnicare, as well as incremental store operating costs associated with operating more stores, including the pharmacies and clinics of Target, in our Retail/LTC Segment. The improvement in operating expenses as a percentage of net revenues for the three and nine months ended September 30, 2016 was primarily due to expense leverage from net revenue growth.

Please see the section entitled “Segment Analysis” below for additional information regarding operating expenses.

Interest Expense, net
 
Interest expense, net, decreased $8 million and increased $254 million in the three and nine months ended September 30, 2016, respectively, as compared to the prior year. The decrease in the three months ended was primarily due to the amortization of bridge facility fees in the three months ended September 30, 2015. The increase in the nine months ended September 30, 2016, was primarily due to the $15 billion debt issuance in July 2015, the proceeds of which were used to fund the acquisitions of Omnicare and the pharmacies and clinics of Target, and the debt assumed through the Omnicare acquisition.
 
For additional information on our financing activities, please see the “Liquidity and Capital Resources” section below.

Loss on Early Extinguishment of Debt
 
During the three months ended September 30, 2016, the Company exercised its option to redeem outstanding senior notes of approximately $1.1 billion aggregate principal amount (see Note 6 to the condensed consolidated financial statements). The Company paid a premium of $97 million in excess of the debt principal in connection with the purchase of the senior notes and wrote off $4 million of unamortized deferred financing costs, for a total loss on the early extinguishment of debt of $101 million.

During the nine months ended September 30, 2016, the Company purchased approximately $4.2 billion aggregate principal amount of certain of its senior notes pursuant to its tender offer for such senior notes and option to redeem the outstanding senior notes (see Note 6 to the condensed consolidated financial statements). The Company paid a premium of $583 million in excess of the debt principal, wrote off $54 million of unamortized deferred financing costs and incurred $6 million in fees, for a total loss on the early extinguishment of debt of $643 million.

Income Tax Provision
 
Our effective income tax rate was 37.4% and 38.6% for the three and nine months ended September 30, 2016, compared to 40.2% and 39.5% for the three and nine months ended September 30, 2015. The difference in the effective income tax rate for the three and nine months ended September 30, 2016 was primarily due to the resolution for $49 million of income tax matters in open tax years through 2012, as well as other permanent items.

Income (Loss) from Discontinued Operations

The income from discontinued operations for the three and nine months ended September 30, 2015 of $10 million was primarily due to a change in the estimated lease obligation associated with guarantees of store lease obligations of Linens ‘n Things, a former subsidiary of the Company that became insolvent subsequent to its disposition. The $1 million loss from discontinued operations for the three and nine months ended September 30, 2016 primarily relates to the accretion of interest on the Linens ‘n Things store lease obligations.


26


Segment Analysis
 
We evaluate the performance of our Pharmacy Services and Retail/LTC segments based on net revenue, gross profit and operating profit before the effect of nonrecurring charges and gains and certain intersegment activities. We evaluate the performance of our Corporate Segment based on operating expenses before the effect of nonrecurring charges and gains and certain intersegment activities. The following is a reconciliation of our segments to the condensed consolidated financial statements:
In millions
Pharmacy
Services
Segment(1)
 
Retail/LTC
Segment
 
Corporate
Segment
 
Intersegment
Eliminations(2)
 
Consolidated
Totals
Three Months Ended
 
 
 
 
 
 
 
 
 
September 30, 2016:
 
 
 
 
 
 
 
 
 
Net revenues
$
30,429

 
$
20,143

 
$
—

 
$
(5,957
)
 
$
44,615

Gross profit(3)
1,797

 
5,893

 
—

 
(198
)
 
7,492

Operating profit (loss)(4)(5)
1,458

 
1,773

 
(229
)
 
(185
)
 
2,817

September 30, 2015:
 

 
 

 
 

 
 

 
 

Net revenues
25,528

 
17,912

 
—

 
(4,796
)
 
38,644

Gross profit
1,468

 
5,373

 
—

 
(180
)
 
6,661

Operating profit (loss)(4)(5)
1,162

 
1,643

 
(309
)
 
(165
)
 
2,331

Nine Months Ended
 

 
 

 
 

 
 

 
 

September 30, 2016:
 

 
 

 
 

 
 

 
 

Net revenues
88,704

 
60,253

 
—

 
(17,402
)
 
131,555

Gross profit(3)
4,266

 
17,560

 
—

 
(575
)
 
21,251

Operating profit (loss)(4)(5)
3,278

 
5,255

 
(661
)
 
(529
)
 
7,343

September 30, 2015:
 

 
 

 
 

 
 

 
 

Net revenues
73,849

 
52,105

 
—

 
(13,810
)
 
112,144

Gross profit
3,735

 
15,990

 
—

 
(498
)
 
19,227

Operating profit (loss)(4)(5)
2,837

 
5,050

 
(712
)
 
(450
)
 
6,725

 
(1) 
Net revenues of the Pharmacy Services Segment include approximately $2.5 billion and $2.1 billion of retail co-payments for the three months ended September 30, 2016 and 2015, respectively, as well as $8.1 billion and $6.8 billion of retail co-payments for the nine months ended September 30, 2016 and 2015, respectively.
(2)
Intersegment eliminations relate to intersegment revenue generating activities that occur between the Pharmacy Services Segment and the Retail/LTC Segment. These occur in the following ways: when members of Pharmacy Services Segment clients (“members”) fill prescriptions at our retail stores to purchase covered products, when members enrolled in programs such as Maintenance Choice ® elect to pick up maintenance prescriptions at one of our retail stores instead of receiving them through the mail, or when members have prescriptions filled at our long-term care pharmacies. When these occur, both the Pharmacy Services and Retail/LTC segments record the revenues, gross profit and operating profit on a standalone basis.
(3)
The Retail/LTC Segment gross profit for the three and nine months ended September 30, 2016 includes $5 million and $15 million, respectively, of acquisition-related integration costs. The integration costs are related to the acquisitions of Omnicare and the pharmacies and clinics of Target.
(4)
The Retail/LTC Segment operating profit for the three and nine months ended September 30, 2016 includes $52 million and $194 million, respectively, of acquisition-related integration costs. The Retail/LTC Segment operating profit for the three and nine months ended September 30, 2015 includes $12 million of acquisition-related integration costs. The integration costs are related to the acquisitions of Omnicare and the pharmacies and clinics of Target.
(5)
The Corporate Segment operating loss for the three and nine months ended September 30, 2016 includes $13 million of integration costs. The Corporate Segment operating loss for the three and nine months ended September 30, 2015 includes $115 million and $135 million, respectively, of acquisition-related transaction and integration costs.



27


Pharmacy Services Segment
 
The following table summarizes our Pharmacy Services Segment’s performance for the respective periods:
 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
In millions
2016
 
2015
 
2016
 
2015
 
 
 
 
 
 
 
 
Net revenues
$
30,429

 
$
25,528

 
$
88,704

 
$
73,849

Gross profit
1,797

 
1,468

 
4,266

 
3,735

Gross profit % of net revenues
5.9
%
 
5.8
%
 
4.8
%
 
5.1
%
Operating expenses
339

 
306

 
988

 
898

Operating expense % of net revenues
1.1
%
 
1.2
%
 
1.1
%
 
1.2
%
Operating profit
1,458

 
1,162

 
3,278

 
2,837

Operating profit % of net revenues
4.8
%
 
4.6
%
 
3.7
%
 
3.8
%
Net revenues:
 

 
 

 
 

 
 

Mail choice(1)
$
10,872

 
$
9,735

 
$
31,668

 
$
27,592

Pharmacy network(2)
19,469

 
15,716

 
56,783

 
46,043

Other
88

 
77

 
253

 
214

Pharmacy claims processed:
 

 
 

 


 
 
Total
305.0

 
251.0

 
912.5

 
752.3

Mail choice(1)
22.4

 
21.9

 
66.3

 
63.5

Pharmacy network(2)
282.6

 
229.1

 
846.2

 
688.8

Generic dispensing rate:
 
 
 
 
 

 
 

Total
85.4
%
 
83.8
%
 
85.4
%
 
83.7
%
Mail choice(1)
78.5
%
 
76.5
%
 
78.0
%
 
76.3
%
Pharmacy network(2)
86.0
%
 
84.5
%
 
85.9
%
 
84.4
%
Mail choice penetration rate
18.1
%
 
21.1
%
 
18.0
%
 
20.5
%
 
(1) 
Mail choice is defined as claims filled at a Pharmacy Services mail facility, which includes specialty mail claims inclusive of Specialty Connect® claims filled at retail, as well as prescriptions filled at our retail stores under the Maintenance Choice® program.
(2)
Pharmacy network net revenues, claims processed and generic dispensing rates do not include Maintenance Choice, which are included within the mail choice category. Pharmacy network is defined as claims filled at retail and specialty retail pharmacies, including our retail stores and long-term care pharmacies, but excluding Maintenance Choice activity.

Net Revenues
 
Net revenues in our Pharmacy Services Segment increased $4.9 billion, or 19.2%, to $30.4 billion in the three months ended September 30, 2016, as compared to the prior year. Net revenues increased approximately $14.9 billion, or 20.1%, to $88.7 billion in the nine months ended September 30, 2016, as compared to the prior year. The increase is primarily due to increased pharmacy network claims, growth in specialty pharmacy, including the addition of Advanced Care Scripts ("ACS") through the acquisition of Omnicare, and inflation, partially offset by increased generic dispensing and price compression. As you review our Pharmacy Services Segment’s performance in this area, we believe you should consider the following important information about the business for the three and nine months ended September 30, 2016:
 
•
In the three months ended September 30, 2016, our mail choice claims processed increased 2.5% to 22.4 million claims compared to 21.9 million claims in the prior year. In the nine months ended September 30, 2016, our mail choice claims processed increased 4.3% to 66.3 million claims compared to 63.5 million claims in the prior year. The increase in mail choice claims was primarily driven by the continuing adoption of our Maintenance Choice offerings.
 
•
Our average revenue per mail choice claim increased by 8.9% and 10.0% in the three and nine months ended September 30, 2016, respectively, compared to the prior year. This increase was primarily due to growth in specialty pharmacy.
 


28


•
In the three months ended September 30, 2016, our pharmacy network claims processed increased 23.3% to 282.6 million claims compared to 229.1 million claims in the prior year. In the nine months ended September 30, 2016, our pharmacy network claims processed increased 22.9% to 846.2 million claims compared to 688.8 million claims in the prior year. The increase in the pharmacy network claim volume was primarily due to net new business.

•
Our average revenue per pharmacy network claim processed in both the three and nine months ended September 30, 2016 remained relatively flat compared to the prior year.

•
For the three months ended September 30, 2016, our mail choice generic dispensing rate increased to 78.5%, compared to 76.5% in the prior year. Our pharmacy network generic dispensing rate increased to 86.0%, compared to 84.5% in the prior year. For the nine months ended September 30, 2016, our mail choice generic dispensing rate increased to 78.0% in the nine months ended September 30, 2016, compared to 76.3% in the prior year. Our pharmacy network generic dispensing rate increased to 85.9%, compared to 84.4% in the prior year. These continued increases in mail choice and pharmacy network generic dispensing rates were primarily due to the impact of new generic drug introductions, and our continuous efforts to encourage plan members to use generic drugs when they are available and clinically appropriate. We believe our generic dispensing rates will continue to increase in future periods, albeit at a slower pace. This increase will be affected by, among other things, the number of new brand and generic drug introductions and our success at encouraging plan members to utilize generic drugs when they are available and clinically appropriate.

Gross Profit
 
Gross profit in our Pharmacy Services Segment includes net revenues less cost of revenues. Cost of revenues includes (i) the cost of pharmaceuticals dispensed, either directly through our mail service, specialty mail and specialty retail pharmacies or indirectly through our retail pharmacy networks, (ii) shipping and handling costs and (iii) the operating costs of our mail service dispensing pharmacies, customer service operations and related information technology support.
 
Gross profit increased $329 million, or 22.4%, to approximately $1.8 billion in the three months ended September 30, 2016, as compared to the prior year. Gross profit increased $531 million, or 14.2%, to approximately $4.3 billion in the nine months ended September 30, 2016, as compared to the prior year. The increase in gross profit dollars was primarily due to growth in specialty pharmacy, growth in Medicare Part D lives, higher generic dispensing and favorable purchasing economics, partially offset by price compression. Gross profit as a percentage of net revenues increased slightly to 5.9% in the three months ended September 30, 2016, compared to 5.8% in the prior year. The slight increase in gross profit as a percentage of net revenues for the three months ended September 30, 2016 was primarily due to favorable generic dispensing. Gross profit as a percentage of net revenues decreased to 4.8% in the nine months ended September 30, 2016, compared to 5.1% in the prior year. The decrease in gross profit as a percentage of net revenues was primarily due to changes in the mix of our business and continued price compression, partially offset by favorable generic dispensing and purchasing economics.

As you review our Pharmacy Services Segment’s performance in this area, we believe you should consider the following important information about the business for the three and nine months ended September 30, 2016:
 
•
Our efforts to (i) retain existing clients, (ii) obtain new business and (iii) maintain or improve the rebates and/or discounts we received from manufacturers, wholesalers and retail pharmacies continue to have an impact on our gross profit dollars and gross profit as a percentage of net revenues. In particular, competitive pressures in the PBM industry have caused us and other PBMs to continue to share a larger portion of rebates and/or discounts received from pharmaceutical manufacturers with clients. In addition, market dynamics and regulatory changes have limited our ability to offer plan sponsors pricing that includes retail network “differential” or “spread,” and we expect these trends to continue. The “differential” or “spread” is any difference between the drug price charged to plan sponsors, including Medicare Part D plan sponsors, by a PBM and the price paid for the drug by the PBM to the dispensing provider. The increased use by patients of generic drugs has generally improved our gross profit margins but has also resulted in third party payors augmenting their efforts to reduce reimbursement payments for prescriptions. This trend, which we expect to continue, reduces the benefit we realize from brand to generic product conversions.

•
Our gross profit as a percentage of revenues benefited from the increase in our total generic dispensing rate, which increased to 85.4% in both the three and nine months ended September 30, 2016 compared to our generic dispensing rate of 83.8% and 83.7% in the three and nine months ended September 30, 2015, respectively. This increase was primarily due to new generic drug introductions and our continual efforts to encourage plan members to use clinically

29


appropriate generic drugs when they are available. We expect the trend in generic introductions to continue, albeit at a slower pace.

Operating Expenses
 
Operating expenses in our Pharmacy Services Segment include selling, general and administrative expenses; depreciation and amortization related to selling, general and administrative activities; and expenses related to specialty retail pharmacies, which include store and administrative payroll, employee benefits and occupancy costs.
 
Operating expenses increased $33 million to $339 million, or 1.1% as a percentage of net revenues, in the three months ended September 30, 2016, compared to $306 million, or 1.2% as a percentage of net revenues, in the prior year. Operating expenses increased $90 million to $988 million, or 1.1% as a percentage of revenues, in the nine months ended September 30, 2016, compared to $898 million, or 1.2% as a percentage of net revenues, in the prior year. The improvement in operating expenses as a percentage of net revenues for the three and nine months ended September 30, 2016 was primarily driven by expense leverage from our revenue growth. The increase in operating expense dollars for the three and nine months ended September 30, 2016 was primarily due to the addition of ACS and increased costs associated with the growth of our business.

Retail/LTC Segment
 
The following table summarizes our Retail/LTC Segment’s performance for the respective periods:

 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
In millions
2016
 
2015
 
2016
 
2015
 
 
 
 
 
 
 
 
Net revenues
$
20,143

 
$
17,912

 
$
60,253

 
$
52,105

Gross profit(1)
5,893

 
5,373

 
17,560

 
15,990

Gross profit % of net revenues
29.3
 %
 
30.0
 %
 
29.1
 %
 
30.7
 %
Operating expenses(2)
4,120

 
3,730

 
12,305

 
10,940

Operating expense % of net revenues
20.5
 %
 
20.8
 %
 
20.4
 %
 
21.0
 %
Operating profit
1,773

 
1,643

 
5,255

 
5,050

Operating profit % of net revenues
8.8
 %
 
9.2
 %
 
8.7
 %

9.7
 %
Prescriptions filled (90 Day = 3 Rx)(3)
302.9

 
258.7

 
908.9

 
744.1

Net revenue increase (decrease):
 
 
 

 
 
 
 

Total
12.5
 %
 
6.9
 %
 
15.6
 %
 
4.0
 %
Pharmacy
15.3
 %
 
10.4
 %
 
19.9
 %
 
7.0
 %
Front store
0.8
 %
 
(2.4
)%
 
0.9
 %
 
(3.7
)%
Total prescription volume (90 Day = 3 Rx)(3)
17.1
 %
 
10.7
 %
 
22.1
 %
 
7.7
 %
Same store increase (decrease)(4):
 
 
 

 
 
 
 
Total sales
2.3
 %
 
1.7
 %
 
2.8
 %
 
1.1
 %
Pharmacy sales
3.4
 %
 
4.6
 %
 
4.3
 %
 
4.3
 %
Front store sales
(1.0
)%
 
(5.8
)%
 
(1.0
)%
 
(6.6
)%
Prescription volume (90 Day = 3 Rx)(3)
3.0
 %
 
4.4
 %
 
4.1
 %
 
4.8
 %
Generic dispensing rate
85.8
 %
 
84.8
 %
 
85.8
 %
 
84.7
 %
Pharmacy % of total revenues
76.0
 %
 
74.1
 %
 
75.2
 %
 
72.5
 %
 
(1)
Gross profit for the three and nine months ended September 30, 2016 includes $5 million and $15 million, respectively, of acquisition-related integration costs related to the acquisitions of Omnicare and the pharmacies and clinics of Target.
(2)
Operating expenses for the three and nine months ended September 30, 2016 includes $47 million and $179 million, respectively, of acquisition-related integration costs related to the acquisitions of Omnicare and the pharmacies and clinics of Target. Operating expenses for the three and nine months ended September 30, 2015 includes $12 million of acquisition-related integration costs related to the acquisitions of Omnicare and the pharmacies and clinics of Target.
(3)
Includes the adjustment to convert 90-day, non-specialty prescriptions to the equivalent of three 30-day prescriptions. This adjustment reflects the fact that these prescriptions include approximately three times the amount of product days supplied compared to a normal prescription.
(4)
Same store sales and prescriptions exclude revenues from MinuteClinic, and revenue and prescriptions from stores in Brazil, LTC operations and from commercialization services.


30


As of September 30, 2016, we operated 9,694 retail stores, compared to 7,911 retail drugstores as of September 30, 2015. The increase in the number of retail stores is due to the acquisition of the pharmacies of Target, as well as growth of our stand-alone retail stores.

Net Revenues
 
Net revenues in our Retail/LTC Segment increased $2.2 billion, or 12.5%, to approximately $20.1 billion in the three months ended September 30, 2016, as compared to the prior year. Net revenues increased $8.2 billion, or 15.6%, to approximately $60.3 billion in the nine months ended September 30, 2016, as compared to the year. As you review our Retail/LTC Segment’s performance in this area, we believe you should consider the following important information about the business for the three and nine months ended September 30, 2016:
 
•
Net revenues were positively affected by the addition of LTC which was acquired in August 2015. Net revenues from new stores, including the locations within Target stores, acquired in December 2015, accounted for approximately 680 and 690 basis points of the increase in our total net revenues for the three and nine months ended September 30, 2016, respectively.

•
Pharmacy same store prescription volumes and revenues were negatively affected in the three and nine months ended September 30, 2016 by slowing prescription growth in the overall market, partially driven by a soft seasonal business during the three months ended September 30, 2016.
.
•
Front store same store sales decreased by 1.0% for both the three and nine months ended September 30, 2016, compared to the prior year as the result of continued softer customer traffic, partially offset by an increase in basket size. For the nine months ended September 30, 2016, front store same store sales increased by approximately 40 basis points due to an additional day in 2016 related to leap year.

•
Pharmacy same store sales increased 3.4% and 4.3% for the three and nine months ended September 30, 2016, respectively, as compared to the prior year. The increase in pharmacy same store sales was primarily due to the increase in same store script growth of 3.0% and 4.1% for the three and nine months ended September 30, 2016, respectively, as well as approximately 40 basis points due to an additional day in 2016 related to leap year for the nine months ended September 30, 2016. We expect script growth to be negatively impacted for the next several quarters by recently announced restricted network relationships that exclude CVS Pharmacy.

•
Pharmacy revenues continue to be negatively impacted by the conversion of brand name drugs to equivalent generic drugs, which typically have a lower selling price. Pharmacy same store sales declined by approximately 340 and 350 basis points for the three and nine months ended September 30, 2016, respectively, due to recent generic introductions. The generic dispensing rate grew to 85.8% for both the three and nine months ended September 30, 2016, compared to 84.8% and 84.7%, respectively, in the prior year. In addition, our pharmacy revenue growth has also been affected by the mix of drugs sold, continued reimbursement pressure and the lack of significant new brand name drug introductions.

•
Pharmacy revenue continued to benefit from the increased utilization by Medicare Part D beneficiaries, our ability to attract and retain managed care customers and favorable industry trends. These trends include an aging American population as “baby boomers” are now in their fifties and sixties and are consuming a greater number of prescription drugs, as well as expanded coverage from the Patient Protection and Affordable Care Act (“ACA”). In addition, the increased use of pharmaceuticals as the first line of defense for individual health care contributed to the growing demand for pharmacy services.

Gross Profit
 
Gross profit in our Retail/LTC Segment includes net revenues less the cost of merchandise sold in the period and the related purchasing costs, warehousing costs, delivery costs and actual and estimated inventory losses.

31



Gross profit increased $521 million, or 9.7%, to $5.9 billion in the three months ended September 30, 2016, as compared to the prior year. Gross profit increased $1.6 billion or 9.8%, to $17.6 billion in the nine months ended September 30, 2016, as compared to the prior year. Gross profit as a percentage of net revenues decreased to 29.3% and 29.1% in the three and nine months ended September 30, 2016, respectively, compared to 30.0% and 30.7% in the three and nine months ended September 30, 2015, respectively.

The increase in gross profit dollars was primarily driven by the addition of the pharmacies and clinics of Target and LTC, as well as same store sales, partially offset by continued reimbursement pressure. The decrease in gross profit as a percentage of net revenues was primarily driven by a decline in pharmacy margins due to continued reimbursement pressure and the mix effect of the acquisitions of the pharmacies and clinics of Target and Omnicare, partially offset by increased front store margins. Front store margins increased due to changes in the mix of products sold and efforts to rationalize promotional strategies.
 
As you review our Retail/LTC Segment’s performance in this area, we believe you should consider the following important information about the business for the three and nine months ended September 30, 2016:
  
•
Front store revenues as a percentage of net revenues for the three and nine months ended September 30, 2016 was 22.7% and 23.5%, respectively, compared to 25.3% and 26.9% in the prior year, respectively. On average, our gross profit on front store revenues is higher than our gross profit on pharmacy revenues. Pharmacy revenues as a percentage of total revenues increased approximately 190 and 270 basis points in the three and nine months ended September 30, 2016, compared to the prior year. This was due to pharmacy revenues growing faster than front store revenues because of the addition of the pharmacies of Target and LTC as well as a shift in the base business. The mix effect from a higher proportion of pharmacy sales had a negative effect on our overall gross profit as a percentage of net revenues for the three and nine months ended September 30, 2016, compared to the prior year. This negative effect was partially offset by an increase in generic drugs dispensed, an improved front store gross margin rate, which includes efforts to rationalize promotional strategies.

•
During the three and nine months ended September 30, 2016, our front store gross profit as a percentage of net revenues increased compared to the same period in the prior year. The increase is primarily related to a change in the mix of products sold, including store brand products, as well as efforts to rationalize promotional strategies.

•
Our pharmacy gross profit rates have been adversely affected by the efforts of managed care organizations, PBMs and governmental and other third-party payors to reduce their prescription drug costs, including the use of restrictive networks, as well as changes in the mix of our business within the pharmacy portion of the Retail/LTC Segment. In the event the reimbursement pressure accelerates, we may not be able to sustain our current rate of revenue growth and gross profit dollars could be adversely impacted. The increased use of generic drugs has positively impacted our gross profit but has resulted in third-party payors augmenting their efforts to reduce reimbursement payments to retail pharmacies for prescriptions. This trend, which we expect to continue, reduces the benefit we realize from brand to generic product conversions.

Operating Expenses
 
Operating expenses in our Retail/LTC Segment include payroll and employee benefits, occupancy costs, selling expenses, advertising expenses, depreciation and amortization expense and certain administrative expenses.
 
Operating expenses increased $391 million to $4.1 billion, or 20.5% as a percentage of net revenues, in the three months ended September 30, 2016, as compared to $3.7 billion, or 20.8% as a percentage of net revenues, in the prior year. Operating expenses increased $1.4 billion to $12.3 billion, or 20.4% as a percentage of net revenues, in the nine months ended September 30, 2016, as compared to $10.9 billion, or 21.0% as a percentage of net revenues, in the prior year. The increase in operating expense dollars for the three and nine months ended September 30, 2016, was primarily due to the addition of the pharmacies and clinics within Target stores and LTC, including acquisition-related integration costs of $47 million and $179 million, respectively, and incremental store operating costs associated with operating more stores. Operating expenses as a percentage of net revenues for the three and nine months ended September 30, 2016 improved primarily due to expense leverage from net revenue growth.




32


Operating expenses for the nine months ended September 30, 2016, includes a gain from a legal settlement with certain credit card companies of $32 million. In April 2016, the Retail/LTC Segment made a charitable contribution of $32 million to the CVS Foundation to fund future giving. The CVS Foundation is a non-profit entity that focuses on health, education and community involvement programs. The charitable contribution was recorded as an operating expense in the nine months ended September 30, 2016.
 
Corporate Segment
 
Operating Expenses
 
Operating expenses in our Corporate Segment include expenses from the Company’s executive management, corporate relations, legal, compliance, human resources, information technology and finance departments. Operating expenses decreased $80 million, or 26.0%, to $229 million and decreased $51 million, or 7.3%, to $661 million in the three months and nine months ended September 30, 2016, respectively, as compared to the prior year. The decrease in operating expenses for the three months and nine months ended September 30, 2016 was primarily due to acquisition-related transaction and integration costs associated with the acquisition of Omnicare that occurred in August 2015, and the acquisition of the pharmacies and clinics of Target that occurred in December 2015.

Liquidity and Capital Resources
 
We maintain a level of liquidity sufficient to allow us to cover our cash needs in the short-term. Over the long-term, we manage our cash and capital structure to maximize shareholder return, maintain our financial position and maintain flexibility for future strategic initiatives. We continuously assess our working capital needs, debt and leverage levels, capital expenditure requirements, dividend payouts, potential share repurchases and future investments or acquisitions. We believe our operating cash flows, commercial paper program, sale-leaseback program, as well as any potential future borrowings, will be sufficient to fund these future payments and long-term initiatives.
 
The change in cash and cash equivalents is as follows:
 
 
Nine Months Ended September 30,
In millions
 
2016
 
2015
Net cash provided by operating activities
 
$
7,948

 
$
4,841

Net cash used in investing activities
 
(1,652
)
 
(11,000
)
Net cash provided by (used in) financing activities
 
(6,568
)
 
6,576

Effect of exchange rate changes on cash and cash equivalents
 
2

 
(8
)
Net increase (decrease) in cash and cash equivalents
 
$
(270
)
 
$
409


Net cash provided by operating activities was approximately $7.9 billion in the nine months ended September 30, 2016, compared to $4.8 billion in the nine months ended September 30, 2015. The $3.1 billion increase in cash provided by operating activities is primarily due to the timing of payments for our Medicare Part D operations.
 
Net cash used in investing activities was approximately $1.7 billion in the nine months ended September 30, 2016, compared to $11.0 billion in the nine months ended September 30, 2015. The decrease in cash used in investing activities is primarily due to the $9.6 billion in cash consideration paid for the acquisition of Omnicare in August 2015.
 
Net cash used in financing activities was $6.6 billion in the nine months ended September 30, 2016, compared to net cash provided by financing activities of $6.6 billion in the nine months ended September 30, 2015. The cash used in financing activities increased $13.1 billion primarily due to lower long-term borrowings and higher net repayments of short and long-term debt in 2016.

As of September 30, 2016, the Company had the following outstanding share repurchase program that was authorized by the Company’s Board of Directors:

33


In billions
 
 
 
 
 
 
Authorization Date
Authorized
Remaining
December 15, 2014 (“2014 Repurchase Program”)
 
$
10.0

 
 
$
3.7

 

On November 2, 2016, the Company's Board of Directors authorized a new share repurchase program for up to $15 billion of outstanding common stock (the “2016 Repurchase Program”). The 2014 and 2016 Repurchase Programs, which were effective immediately, permit the Company to effect repurchases from time to time through a combination of open market repurchases, privately negotiated transactions, accelerated share repurchase transactions, and/or other derivative transactions. The repurchase programs may be modified or terminated by the Board of Directors at any time.

During the nine months ended September 30, 2016, the Company repurchased an aggregate of approximately 41.4 million shares of common stock for approximately $4 billion pursuant to the 2014 Repurchase Program which includes the accelerated share repurchase agreement (“ASR”) described below.

Pursuant to the authorization under the 2014 Repurchase Program, effective December 11, 2015, the Company entered into a $725 million fixed dollar ASR with Barclays Bank PLC (“Barclays”). Upon payment of the $725 million purchase price on December 14, 2015, the Company received a number of shares of its common stock equal to 80% of the $725 million notional amount of the ASR or approximately 6.2 million shares. The initial 6.2 million shares of common stock delivered to the Company by Barclays were placed into treasury stock in December 2015. The ASR was accounted for as an initial treasury stock transaction for $580 million and a forward contract for $145 million. The forward contract was classified as an equity instrument and was recorded within capital surplus on the consolidated balance sheet. On January 28, 2016, the Company received 1.4 million shares of common stock, representing the remaining 20% of the $725 million notional amount of the ASR, thereby concluding the ASR. The remaining 1.4 million shares of common stock delivered to the Company by Barclays were placed into treasury stock in January 2016 and the forward contract was reclassified from capital surplus to treasury stock.

At the time they were received, the initial and final receipt of shares resulted in an immediate reduction of the outstanding shares used to calculate the weighted average common shares outstanding for basic and diluted net earnings per share.

We had $340 million of commercial paper outstanding at a weighted average interest rate of 0.62% as of September 30, 2016. In connection with our commercial paper program, we maintain a $1.0 billion, five-year unsecured back-up credit facility that expires on May 23, 2018, a $1.25 billion, five-year unsecured back-up credit facility that expires on July 24, 2019, and a $1.25 billion, five-year unsecured back-up credit facility that expires on July 1, 2020. The credit facilities allow for borrowings at various rates that are dependent, in part, on the Company’s public debt ratings and require the Company to pay a weighted average quarterly facility fee of approximately 0.03%, regardless of usage. As of September 30, 2016, there were no borrowings outstanding under the back-up credit facilities.

Our back-up credit facilities and unsecured senior notes contain customary restrictive financial and operating covenants. These covenants do not include a requirement for the acceleration of our debt maturities in the event of a downgrade in our credit rating. We do not believe the restrictions contained in these covenants materially affect our financial or operating flexibility.

On May 16, 2016, the Company issued $1.75 billion aggregate principal amount of 2.125% unsecured senior notes due June 1, 2021 and $1.75 billion aggregate principal amount of 2.875% unsecured senior notes due June 1, 2026 (collectively, the "2016 Notes") for total proceeds of approximately $3.5 billion, net of discounts and underwriting fees. The 2016 Notes pay interest semi-annually and may be redeemed, in whole at any time, or in part from time to time, at the Company's option at a defined redemption price plus accrued and unpaid interest to the redemption date. The net proceeds of the 2016 Notes were used for general corporate purposes and to repay certain corporate debt.

On May 16, 2016, the Company announced tender offers for (1) any and all of its 5.75% Senior Notes due 2017, its 6.60% Senior Notes due 2019 and its 4.75% Senior Notes due 2020 (collectively, the “Any and All Notes”) and (2) up to $1.5 billion aggregate principal amount of its 6.25% Senior Notes due 2027, its 6.125% Senior Notes due 2039, its 5.75% Senior Notes due 2041, the 5.00% Senior Notes due 2024 issued by its wholly-owned subsidiary, Omnicare, Inc. (“Omnicare”), the 4.75% Senior Notes due 2022 issued by Omnicare, its 4.875% Senior Notes due 2035 and its 3.875% Senior Notes due 2025 (collectively, the “Maximum Tender Offer Notes” and together with the Any and All Notes, the “Notes”). On May 31, 2016, the Company increased the aggregate principal amount of the tender offers for the Maximum Tender Offer Notes to $2.25 billion. The Company purchased approximately $835 million aggregate principal amount of the Any and All Notes and $2.25 billion aggregate principal amount of the Maximum Tender Offer Notes pursuant to the tender offers, which expired on June 13, 2016. The Company paid a premium of $486 million in excess of the debt principal in connection with the purchase of the Notes,

34


wrote off $50 million of unamortized deferred financing costs and incurred $6 million in fees, for a total loss on the early extinguishment of debt of $542 million which was recorded in income from continuing operations in the condensed consolidated statement of income for the nine months ended September 30, 2016.

On June 27, 2016, the Company notified the holders of the remaining Any and All Notes that the Company was exercising its option to redeem the outstanding Any and All Notes pursuant to the terms of the Any and All Notes and the Indenture dated as of August 15, 2006, between the Company and The Bank of New York Mellon Trust Company, N.A. Approximately $1.1 billion aggregate principal amount of Any and All Notes was redeemed on July 27, 2016. The Company paid a premium of $97 million in excess of the debt principal and wrote off $4.0 million of unamortized deferred financing costs, for a total loss on early extinguishment of debt of $101 million during the three months ended September 30, 2016.

As of September 30, 2016, our long-term debt was rated by Moody’s as “Baa1” with a stable outlook and by Standard & Poor’s as “BBB+” with a stable outlook, and our commercial paper program was rated “P-2” by Moody’s and “A-2” by Standard & Poor’s. In assessing our credit strength, we believe that both Moody’s and Standard & Poor’s considered, among other things, our capital structure and financial policies as well as our consolidated balance sheet, our historical acquisition activity and other financial information. Although we currently believe our long-term debt ratings will remain investment grade, we cannot guarantee the future actions of Moody’s and/or Standard & Poor’s. Our debt ratings have a direct impact on our future borrowing costs, access to capital markets and new store operating lease costs.


35


Off-Balance Sheet Arrangements
 
In connection with executing operating leases, we provide a guarantee of the lease payments. We also finance a portion of our new store development through sale-leaseback transactions, which involve selling stores to unrelated parties and then leasing the stores back under leases that generally qualify and are accounted for as operating leases. We do not have any retained or contingent interests in the stores, and we do not provide any guarantees, other than a guarantee of the lease payments, in connection with the transactions. In accordance with GAAP, such operating leases are not reflected in our condensed consolidated balance sheet. See Note 12 to our condensed consolidated financial statements for a detailed discussion of these guarantees.

Critical Accounting Policies
 
We prepare our consolidated financial statements in conformity with GAAP, which requires management to make certain estimates and apply judgment. We base our estimates and judgments on historical experience, current trends and other factors that management believes to be important at the time the condensed consolidated financial statements are prepared. On a regular basis, we review our accounting policies and how they are applied and disclosed in our condensed consolidated financial statements.
 
While we believe that the historical experience, current trends and other factors considered support the preparation of our condensed consolidated financial statements in conformity with GAAP, actual results could differ from our estimates and such differences could be material.

During the three months ended September 30, 2016, we performed our required annual impairment tests of goodwill. The results of the impairment tests indicated that there was no impairment of goodwill. The goodwill impairment tests resulted in the fair values of our Pharmacy Services and Retail Pharmacy reporting units exceeding their carrying values by significant margins. The fair values of our LTC and RxCrossroads reporting units exceeded their carrying values by 7% and 12%, respectively. The balance of goodwill for our LTC and RxCrossroads reporting units at September 30, 2016 was approximately $6.3 billion and $0.6 billion, respectively.

The determination of the fair value of our reporting units requires the Company to make significant assumptions and estimates. These assumptions and estimates primarily include, but are not limited to, the selection of appropriate peer group companies; control premiums and valuation multiples appropriate for acquisitions in the industries in which the Company competes; discount rates, terminal growth rates; and forecasts of revenue, operating profit, depreciation and amortization, capital expenditures and future working capital requirements. When determining these assumptions and preparing these estimates, we consider each reporting unit’s historical results and current operating trends and our consolidated revenues, profitability and cash flow results, forecasts and industry trends. Our estimates can be affected by a number of factors including, but not limited to, general economic and regulatory conditions, our market capitalization, efforts of customers and payers to reduce costs including their prescription drug costs and/or increase member co-payments, the continued efforts of competitors to gain market share and consumer spending patterns.

For a full description of our other critical accounting policies, please refer to Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2015 Form 10-K.




36


Cautionary Statement Concerning Forward-Looking Statements
 
This quarterly report contains forward-looking statements within the meaning of the federal securities laws. In addition, the Company and its representatives may, from time to time, make written or verbal forward-looking statements, including statements contained in the Company’s filings with the U.S. Securities and Exchange Commission (“SEC”) and in its reports to stockholders, press releases, webcasts, conference calls, meetings and other communications. Generally, the inclusion of the words “believe,” “expect,” “intend,” “estimate,” “project,” “anticipate,” “will,” “should” and similar expressions identify statements that constitute forward-looking statements. All statements addressing operating performance of CVS Health Corporation or any subsidiary, events or developments that the Company expects or anticipates will occur in the future, including statements relating to corporate strategy; revenue growth; earnings or earnings per common share growth; adjusted earnings or adjusted earnings per common share growth; free cash flow; debt ratings; inventory levels; inventory turn and loss rates; store development; relocations and new market entries; retail pharmacy business, sales trends and operations; PBM business, sales trends and operations; specialty pharmacy business, sales trends and operations; LTC pharmacy business, sales trends and operations; the Company’s ability to attract or retain customers and clients; Medicare Part D competitive bidding, enrollment and operations; new product development; and the impact of industry and regulatory developments, as well as statements expressing optimism or pessimism about future operating results or events, are forward-looking statements within the meaning of the federal securities laws.

The forward-looking statements are and will be based upon management’s then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

By their nature, all forward-looking statements involve risks and uncertainties. Actual results may differ materially from those contemplated by the forward-looking statements for a number of reasons as described in our SEC filings, including those set forth in the Risk Factors section within the 2015 Annual Report on Form 10-K, and including, but not limited to:

•
Risks relating to the health of the economy in general and in the markets we serve, which could impact consumer purchasing power, preferences and/or spending patterns, drug utilization trends, the financial health of our PBM and LTC clients, retail and specialty pharmacy payors or other payors doing business with the Company and our ability to secure necessary financing, suitable store locations and sale-leaseback transactions on acceptable terms.

•
Efforts to reduce reimbursement levels and alter health care financing practices, including pressure to reduce reimbursement levels for generic drugs.

•
The possibility of PBM and LTC client loss and/or the failure to win new PBM and LTC business, including as a result of failure to win renewal of expiring contracts, contract termination rights that may permit clients to terminate a contract prior to expiration and early or periodic renegotiation of pricing by clients prior to expiration of a contract.

•
The possibility of loss of Medicare Part D business and/or failure to obtain new Medicare Part D business, whether as a result of the annual Medicare Part D competitive bidding process, a sanction or otherwise.

•
Risks related to the frequency and rate of the introduction of generic drugs and brand name prescription products.

•
Risks of declining gross margins attributable to increased competitive pressures, increased client demand for lower prices, enhanced service offerings and/or higher service levels and market dynamics and, with respect to the PBM industry, regulatory changes that impact our ability to offer plan sponsors pricing that includes the use of retail “differential” or “spread” or the use of maximum allowable cost pricing.

•
Regulatory changes, business changes and compliance requirements and restrictions that may be imposed by Centers for Medicare and Medicaid Services (“CMS”), Office of Inspector General or other government agencies relating to the Company’s participation in Medicare, Medicaid and other federal and state government-funded programs, including sanctions and remedial actions that may be imposed by CMS on our Medicare Part D business.

•
Risks and uncertainties related to the timing and scope of reimbursement from Medicare, Medicaid and other government-funded programs, including the possible impact of sequestration, the impact of other federal budget, debt and deficit negotiations and legislation that could delay or reduce reimbursement from such programs and the impact of any closure, suspension or other changes affecting federal or state government funding or operations.

37



•
Possible changes in industry pricing benchmarks used to establish pricing in many of our PBM and LTC client contracts, pharmaceutical purchasing arrangements, retail network contracts, specialty payor agreements and other third party payor contracts.

•
A highly competitive business environment, including the uncertain impact of increased consolidation in the PBM industry, uncertainty concerning the ability of our retail and specialty pharmacy businesses to secure and maintain contractual relationships with PBMs and other payors on acceptable terms, uncertainty concerning the ability of our PBM business to secure and maintain competitive access, pricing and other contract terms from retail network pharmacies in an environment where some PBM clients are willing to consider adopting narrow or more restricted retail pharmacy networks.

•
The Company’s ability to timely identify or effectively respond to changing consumer preferences and spending patterns, an inability to expand the products being purchased by our customers, or the failure or inability to obtain or offer particular categories of products.

•
Risks relating to our ability to secure timely and sufficient access to the products we sell from our domestic and/or international suppliers.

•
Reform of the U.S. health care system, including ongoing implementation of ACA, continuing legislative efforts, regulatory changes and judicial interpretations impacting our health care system and the possibility of shifting political and legislative priorities related to reform of the health care system in the future.

•
Risks relating to any failure to properly maintain our information technology systems, our information security systems and our infrastructure to support our business and to protect the privacy and security of sensitive customer and business information.

•
Risks related to compliance with a broad and complex regulatory framework, including compliance with new and existing federal, state and local laws and regulations relating to health care, accounting standards, corporate securities, tax, environmental and other laws and regulations affecting our business.

•
Risks related to litigation, government investigations and other legal proceedings as they relate to our business, the pharmacy services, retail pharmacy, LTC pharmacy or retail clinic industries or to the health care industry generally.

•
The risk that any condition related to the closing of any proposed acquisition may not be satisfied on a timely basis or at all, including the inability to obtain required regulatory approvals of any proposed acquisition, or on the terms desired or anticipated; the risk that such approvals may result in the imposition of conditions that could adversely affect the resulting combined company or the expected benefits of any proposed transaction; and the risk that the proposed transactions fail to close for any other reason.

•
The possibility that the anticipated synergies and other benefits from any acquisition by us will not be realized, or will not be realized within the expected time periods.

•
The risks and uncertainties related to our ability to integrate the operations, products, services and employees of any entities acquired by us and the effect of the potential disruption of management’s attention from ongoing business operations due to any pending acquisitions.

•
The accessibility or availability of adequate financing on a timely basis and on reasonable terms in connection with any proposed acquisition.

•
Risks related to the outcome of any legal proceedings related to, or involving any entity that is a part of, any proposed acquisition contemplated by us.

•
Other risks and uncertainties detailed from time to time in our filings with the SEC.

The foregoing list is not exhaustive. There can be no assurance that the Company has correctly identified and appropriately assessed all factors affecting its business. Additional risks and uncertainties not presently known to the Company or that it currently believes to be immaterial also may adversely impact the Company. Should any risks and uncertainties develop into

38


actual events, these developments could have a material adverse effect on the Company’s business, financial condition and results of operations. For these reasons, you are cautioned not to place undue reliance on the Company’s forward-looking statements.

Item 3.    Quantitative and Qualitative Disclosures About Market Risk
 
As of September 30, 2016, the Company did not have any interest rate, foreign currency exchange rate or commodity derivative instruments in place and believes that as of September 30, 2016 its exposure to interest rate risk (inherent in the Company’s debt portfolio), foreign currency exchange rate risk and commodity price risk is not material.
 
Item 4.    Controls and Procedures
 
Evaluation of disclosure controls and procedures: The Company’s Chief Executive Officer and Chief Financial Officer, after evaluating the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Securities Exchange Act Rules 13a-15(f) and 15d-15(f)) as of September 30, 2016, have concluded that as of such date the Company’s disclosure controls and procedures were adequate and effective and designed to provide reasonable assurance that material information relating to the Company and its subsidiaries would be made known to such officers on a timely basis.
 
Changes in internal control over financial reporting: On August 18, 2015, the Company completed its acquisition of Omnicare and on December 16, 2015, the Company completed its acquisition of the pharmacies and clinics of Target. As a result, the Company is in the process of integrating the applicable internal controls for each business into its internal control over financial reporting for the rest of the Company. Other than the foregoing, there have been no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Securities Exchange Act Rule 13a-15 or Rule 15d-15 that occurred in the three months ended September 30, 2016 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.


39


Part II
Item 1. Legal Proceedings
 
I. Legal Proceedings

We refer you to Note 12 - “Commitments and Contingencies - Legal Matters” contained in the “Notes to the Condensed Consolidated Financial Statements” of our Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2016 for a description of our legal proceedings.
 
 
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
 
(c) Stock Repurchases
 
The following table presents the total number of shares purchased in the three months ended September 30, 2016, the average price paid per share and the approximate dollar value of shares that still could have been purchased at the end of the applicable fiscal period, pursuant to the 2014 Repurchase Program. See Note 4 - “Share Repurchase Program” contained in the “Notes to the Condensed Consolidated Financial Statements” of our Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2016.
 
Fiscal Period
Total Number
of Shares
Purchased
 
Average
Price Paid
per Share
 
Total Number of
Shares
Purchased as Part of
Publicly Announced
Plans or Programs
 
Approximate Dollar
Value of Shares that
May Yet Be
Purchased Under the
Plans or Programs
July 2016
—

 
$
—

 
—

 
$
3,731,002,281

August 2016
410,500

 
$
97.44

 
410,500

 
$
3,691,002,299

September 2016
—

 
$
—

 
—

 
$
3,691,002,299

Totals
410,500

 
 

 
410,500

 
 



40


Item 6.    Exhibits
 
Exhibits:
 
Exhibits marked with an asterisk (*) are hereby incorporated by reference to exhibits or appendices previously filed by the Registrant as indicated in brackets following the description of the exhibit.
 
3.1*
Amended and Restated Certificate of Incorporation of the Registrant [incorporated by reference to Exhibit 3.1 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 1996 (Commission File No. 001-01011)].
 
3.1A*
Certificate of Amendment to the Amended and Restated Certificate of Incorporation, effective May 13, 1998 [incorporated by reference to Exhibit 4.1A to the Registrant’s Registration Statement No. 333-52055 on Form S-3/A dated May 18, 1998 (Commission File No. 001-01001)].
 
3.1B*
Certificate of Amendment to the Amended and Restated Certificate of Incorporation [incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K dated March 22, 2007 (Commission File No. 001-01011)].
 
3.1C*
Certificate of Merger dated May 9, 2007 [incorporated by reference to Exhibit 3.1C to the Registrant’s Quarterly Report on Form 10-Q dated November 1, 2007 (Commission File No. 001-01011)].
 
3.1D*
Certificate of Amendment to the Amended and Restated Certificate of Incorporation [incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K dated May 13, 2010 (Commission File No. 001-01011)].
 
3.1E*
Certificate of Amendment to the Amended and Restated Certificate of Incorporation [incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K dated May 10, 2012 (Commission File No. 001-01011)].

3.1F*
Certificate of Amendment to the Amended and Restated Certificate of Incorporation [incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K dated May 13, 2013 (Commission File No. 001-01011)].

3.1G*
Certificate of Amendment to the Amended and Restated Certificate of Incorporation [incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K dated September 3, 2014 (Commission File No. 001-01011)].
 
3.2*
By-laws of Registrant, as amended and restated [incorporated by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K dated January 26, 2016 (Commission File No. 001-01011)].

15.1
Letter re: Unaudited Interim Financial Information.

31.1
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 
31.2
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 
32.1
Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
 
32.2
Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101
The following materials from the CVS Health Corporation Quarterly Report on Form 10-Q for the three months ended September 30, 2016 formatted in Extensible Business Reporting Language (XBRL): (i) the Condensed Consolidated Statements of Income, (ii) the Condensed Consolidated Statements of Comprehensive Income, (iii) the Condensed Consolidated Balance Sheets, (iv) the Condensed Consolidated Statements of Cash Flows and (v) related Footnotes to the Condensed Consolidated Financial Statements.


41


Signatures:
 
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized.
 
CVS Health Corporation
 
(Registrant)
 
 
 
/s/ David M. Denton
 
 
 
David M. Denton
 
Executive Vice President and
 
Chief Financial Officer
 
November 8, 2016
 
 
 


42
 EX-15.1 2 exhibit151q316eyconsent.htm EXHIBIT 15.1 Exhibit


Part II
 
 
 
Exhibit 15.1
Letter re: Unaudited Interim Financial Information


November 8, 2016

The Board of Directors and Shareholders:
CVS Health Corporation

We are aware of the incorporation by reference in the Registration Statements (Nos. 333-49407, 333-34927, 333-28043, 333-91253, 333-63664, 333-139470, 333-141481, 333-167746 and 333-208805 on Form S-8, Nos. 333-187440 and 333-200217 on Form S-3ASR, Nos. 333-205156 and 333-210872 on Form S-3 and No. 333-210873 on Form S-4) of CVS Health Corporation of our reports dated May 3, 2016, August 2, 2016 and November 8, 2016 relating to the unaudited condensed consolidated interim financial statements of CVS Health Corporation that are included in its Form 10-Q for the quarters ended March 31, 2016, June 30, 2016 and September 30, 2016.    

        

/s/ Ernst & Young LLP
                        
Boston, Massachusetts



 EX-31.1 3 cvs20160930ex311.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
I, Larry J. Merlo, President and Chief Executive Officer of CVS Health Corporation, certify that:
 
1.
I have reviewed this quarterly report on Form 10-Q of CVS Health Corporation;
 
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
(a)
Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
(c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5.
The registrant’s other certifying officer and I have disclosed based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors:
 
(a) 
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: November 8, 2016
By:
/s/ Larry J. Merlo
 
 
Larry J. Merlo
 
 
President and Chief Executive Officer



 EX-31.2 4 cvs20160930ex312.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2
Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
I, David M. Denton, Executive Vice President and Chief Financial Officer of CVS Health Corporation, certify that:
 
1.
I have reviewed this quarterly report on Form 10-Q of CVS Health Corporation;
 
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
(a)  
Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
(c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5. 
The registrant’s other certifying officer and I have disclosed based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors:
 
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: November 8, 2016
By:
/s/ David M. Denton
 
 
David M. Denton
 
 
Executive Vice President and
 
 
Chief Financial Officer



 EX-32.1 5 cvs20160930ex321.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
 
The certification set forth below is being submitted in connection with the Quarterly Report of CVS Health Corporation (the “Company”) on Form 10-Q for the period ended September 30, 2016 (the “Report”), for the purpose of complying with Rule 13(a)-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code.
 
I, Larry J. Merlo, President and Chief Executive Officer of the Company, certify that, to the best of my knowledge:
 
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and
 
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
 
Date: November 8, 2016
/s/ Larry J. Merlo
 
Larry J. Merlo
 
President and Chief Executive Officer



 EX-32.2 6 cvs20160930ex322.htm EXHIBIT 32.2 Exhibit


Exhibit 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
 
The certification set forth below is being submitted in connection with the Quarterly Report of CVS Health Corporation (the “Company”) on Form 10-Q for the period ended September 30, 2016 (the “Report”), for the purpose of complying with Rule 13(a)-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code.
 
I, David M. Denton, Executive Vice President and Chief Financial Officer of the Company, certify that, to the best of my knowledge:
 
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and
 
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
 
Date: November 8, 2016
 
/s/ David M. Denton
 
 
David M. Denton
 
 
Executive Vice President and
 
 
Chief Financial Officer


 EX-101.INS 7 cvs-20160930.xml XBRL INSTANCE DOCUMENT 0000064803 2016-01-01 2016-09-30 0000064803 cvs:OmnicareInc.Member 2016-01-01 2016-09-30 0000064803 2016-11-01 0000064803 2015-07-01 2015-09-30 0000064803 2016-07-01 2016-09-30 0000064803 2015-01-01 2015-09-30 0000064803 2015-12-31 0000064803 2016-09-30 0000064803 2014-12-31 0000064803 2015-09-30 0000064803 cvs:NCRXMember 2016-01-01 2016-09-30 0000064803 cvs:NCRXMember 2015-12-31 0000064803 cvs:NCRXMember 2016-09-30 0000064803 us-gaap:EquityMethodInvesteeMember 2016-01-01 2016-09-30 0000064803 cvs:NCRXMember 2015-08-31 0000064803 cvs:NCRXMember 2016-01-01 2016-03-31 0000064803 us-gaap:EquityMethodInvesteeMember 2016-07-01 2016-09-30 0000064803 cvs:HeartlandHealthcareServicesMember 2016-09-30 0000064803 2016-04-01 2016-04-30 0000064803 us-gaap:AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember 2015-12-31 0000064803 us-gaap:AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember us-gaap:RestatementAdjustmentMember 2015-12-31 0000064803 us-gaap:AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember us-gaap:ScenarioPreviouslyReportedMember 2015-12-31 0000064803 cvs:OmnicareInc.Member 2015-07-01 2015-09-30 0000064803 cvs:OmnicareInc.Member 2015-01-01 2015-09-30 0000064803 cvs:OmnicareInc.Member 2015-08-18 2015-08-18 0000064803 cvs:OmnicareInc.Member 2015-08-18 0000064803 cvs:CustomerContractsRelationshipsAndCovenantsNotToCompeteMember 2015-12-31 0000064803 cvs:FavorableLeasesAndOtherMember 2016-09-30 0000064803 cvs:FavorableLeasesAndOtherMember 2015-12-31 0000064803 cvs:CustomerContractsRelationshipsAndCovenantsNotToCompeteMember 2016-09-30 0000064803 cvs:RepurchaseProgram2013Member 2016-07-01 2016-09-30 0000064803 cvs:December112015Member 2016-01-28 0000064803 cvs:December112015Member 2015-12-11 0000064803 cvs:RepurchaseProgram2014Member 2016-01-01 2016-09-30 0000064803 cvs:December112015Member 2015-12-31 0000064803 cvs:RepurchaseProgram2016Member us-gaap:SubsequentEventMember 2016-11-02 0000064803 cvs:RepurchaseProgram2014Member 2016-09-30 0000064803 cvs:RepurchaseProgram2014Member 2014-12-15 0000064803 us-gaap:AccumulatedTranslationAdjustmentMember 2015-09-30 0000064803 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2016-07-01 2016-09-30 0000064803 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2016-06-30 0000064803 us-gaap:AccumulatedTranslationAdjustmentMember 2015-06-30 0000064803 us-gaap:AccumulatedTranslationAdjustmentMember 2015-01-01 2015-09-30 0000064803 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-12-31 0000064803 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-06-30 0000064803 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-07-01 2016-09-30 0000064803 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2015-07-01 2015-09-30 0000064803 us-gaap:AccumulatedTranslationAdjustmentMember 2016-01-01 2016-09-30 0000064803 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-09-30 0000064803 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-09-30 0000064803 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2016-01-01 2016-09-30 0000064803 us-gaap:AccumulatedTranslationAdjustmentMember 2015-07-01 2015-09-30 0000064803 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2015-09-30 0000064803 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2015-12-31 0000064803 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-01-01 2016-09-30 0000064803 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2015-01-01 2015-09-30 0000064803 us-gaap:AccumulatedTranslationAdjustmentMember 2016-07-01 2016-09-30 0000064803 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2015-09-30 0000064803 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-09-30 0000064803 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2015-01-01 2015-09-30 0000064803 us-gaap:AccumulatedTranslationAdjustmentMember 2016-09-30 0000064803 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2016-09-30 0000064803 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2015-07-01 2015-09-30 0000064803 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2015-06-30 0000064803 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2015-06-30 0000064803 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-06-30 0000064803 us-gaap:AccumulatedTranslationAdjustmentMember 2015-12-31 0000064803 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2015-12-31 0000064803 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2014-12-31 0000064803 us-gaap:AccumulatedTranslationAdjustmentMember 2014-12-31 0000064803 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2014-12-31 0000064803 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0000064803 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-06-30 0000064803 us-gaap:AccumulatedTranslationAdjustmentMember 2016-06-30 0000064803 cvs:UnsecuredSeniorNotes6.6PercentDueIn2019Member us-gaap:SeniorNotesMember 2016-05-16 0000064803 cvs:UnsecuredSeniorNotes3.875Duein2025Member us-gaap:SeniorNotesMember 2016-05-16 0000064803 cvs:MaximumTenderOfferNotesMember us-gaap:SeniorNotesMember 2016-05-31 0000064803 cvs:UnsecuredSeniorNotes2.875Duein2026Member us-gaap:UnsecuredDebtMember 2016-05-16 0000064803 cvs:UnsecuredSeniorNotes4.75PercentDueIn2020Member us-gaap:SeniorNotesMember 2016-05-16 0000064803 2016-05-16 2016-05-16 0000064803 cvs:UnsecuredSeniorNotes2.125Duein2021Member us-gaap:UnsecuredDebtMember 2016-05-16 0000064803 cvs:UnsecuredSeniorNotes4.75Duein2022Member us-gaap:SeniorNotesMember 2016-05-16 0000064803 cvs:AnyandAllNotesMember us-gaap:SeniorNotesMember 2016-05-31 0000064803 cvs:TheNotesMember 2016-01-01 2016-09-30 0000064803 2016-07-27 2016-07-27 0000064803 cvs:UnsecuredSeniorNotes4.875Duein2035Member us-gaap:SeniorNotesMember 2016-05-16 0000064803 cvs:MaximumTenderOfferNotesMember us-gaap:SeniorNotesMember 2016-05-31 2016-05-31 0000064803 cvs:UnsecuredSeniorNotes6.125PercentDueIn2039Member us-gaap:SeniorNotesMember 2016-05-16 0000064803 cvs:UnsecuredSeniorNotes6.25PercentDueIn2027Member us-gaap:SeniorNotesMember 2016-05-16 0000064803 cvs:AnyandAllNotesMember us-gaap:SeniorNotesMember 2016-07-27 0000064803 cvs:A2016NotesMember us-gaap:UnsecuredDebtMember 2016-05-16 2016-05-16 0000064803 cvs:UnsecuredSeniorNotes5.75PercentDueIn2041Member us-gaap:SeniorNotesMember 2016-05-16 0000064803 cvs:UnsecuredSeniorNotes5.00PercentDuein2024Member us-gaap:SeniorNotesMember 2016-05-16 0000064803 cvs:MaximumTenderOfferNotesMember us-gaap:SeniorNotesMember 2016-05-16 2016-05-16 0000064803 cvs:UnsecuredSeniorNotes5.75PercentDueIn2017Member us-gaap:SeniorNotesMember 2016-05-16 0000064803 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-09-30 0000064803 us-gaap:EmployeeStockOptionMember 2016-07-01 2016-09-30 0000064803 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-09-30 0000064803 us-gaap:RestrictedStockUnitsRSUMember 2016-07-01 2016-09-30 0000064803 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-09-30 0000064803 us-gaap:RestrictedStockUnitsRSUMember 2015-01-01 2015-09-30 0000064803 us-gaap:RestrictedStockUnitsRSUMember 2015-07-01 2015-09-30 0000064803 us-gaap:EmployeeStockOptionMember 2015-07-01 2015-09-30 0000064803 us-gaap:RestrictedStockUnitsRSUMember 2016-09-30 0000064803 cvs:RetailLTCSegmentMember 2016-09-30 0000064803 cvs:SpecialtyStoresMember cvs:PharmacyServicesSegmentMember 2016-09-30 0000064803 cvs:PharmacyServicesSegmentMember 2015-07-01 2015-09-30 0000064803 cvs:MinuteClinicMember cvs:RetailLTCSegmentMember 2016-09-30 0000064803 us-gaap:OperatingIncomeLossMember cvs:RetailLTCSegmentMember 2015-07-01 2015-09-30 0000064803 cvs:GrossProfitMember cvs:RetailLTCSegmentMember 2016-07-01 2016-09-30 0000064803 us-gaap:OperatingIncomeLossMember cvs:RetailLTCSegmentMember 2016-07-01 2016-09-30 0000064803 cvs:PharmacyServicesSegmentMember 2016-09-30 0000064803 cvs:MinuteClinicWithinCVSPharmacyStoresMember cvs:RetailLTCSegmentMember 2016-09-30 0000064803 cvs:PharmacyServicesSegmentMember 2015-01-01 2015-09-30 0000064803 us-gaap:OperatingIncomeLossMember us-gaap:CorporateMember 2016-07-01 2016-09-30 0000064803 cvs:TargetPharmacyAcquisitionMember cvs:RetailLTCSegmentMember 2015-12-01 2015-12-31 0000064803 cvs:GrossProfitMember cvs:RetailLTCSegmentMember 2016-01-01 2016-09-30 0000064803 cvs:CarePlusandCVSPharmacyMember cvs:RetailLTCSegmentMember 2016-09-30 0000064803 cvs:MailServiceMember cvs:PharmacyServicesSegmentMember 2016-09-30 0000064803 us-gaap:OperatingIncomeLossMember us-gaap:CorporateMember 2015-01-01 2015-09-30 0000064803 cvs:InfusionandEnteralBranchesMember cvs:PharmacyServicesSegmentMember 2016-09-30 0000064803 cvs:AmbulatoryinfusionsuitesMember cvs:PharmacyServicesSegmentMember 2016-09-30 0000064803 cvs:SpecialtyMailOrderMember cvs:PharmacyServicesSegmentMember 2016-09-30 0000064803 cvs:PharmacyServicesSegmentMember 2016-07-01 2016-09-30 0000064803 us-gaap:OperatingIncomeLossMember cvs:RetailLTCSegmentMember 2016-01-01 2016-09-30 0000064803 us-gaap:OperatingIncomeLossMember us-gaap:CorporateMember 2015-07-01 2015-09-30 0000064803 cvs:PharmacyServicesSegmentMember 2016-01-01 2016-09-30 0000064803 us-gaap:OperatingSegmentsMember us-gaap:CorporateMember 2015-07-01 2015-09-30 0000064803 us-gaap:OperatingSegmentsMember cvs:RetailLTCSegmentMember 2016-01-01 2016-09-30 0000064803 us-gaap:IntersegmentEliminationMember 2015-07-01 2015-09-30 0000064803 us-gaap:OperatingSegmentsMember us-gaap:CorporateMember 2016-01-01 2016-09-30 0000064803 us-gaap:IntersegmentEliminationMember 2015-01-01 2015-09-30 0000064803 us-gaap:OperatingSegmentsMember cvs:PharmacyServicesSegmentMember 2016-01-01 2016-09-30 0000064803 us-gaap:OperatingSegmentsMember cvs:PharmacyServicesSegmentMember 2016-07-01 2016-09-30 0000064803 us-gaap:OperatingSegmentsMember cvs:PharmacyServicesSegmentMember 2015-01-01 2015-09-30 0000064803 us-gaap:IntersegmentEliminationMember 2016-01-01 2016-09-30 0000064803 us-gaap:OperatingSegmentsMember us-gaap:CorporateMember 2015-01-01 2015-09-30 0000064803 us-gaap:OperatingSegmentsMember cvs:RetailLTCSegmentMember 2016-07-01 2016-09-30 0000064803 us-gaap:IntersegmentEliminationMember 2016-07-01 2016-09-30 0000064803 us-gaap:OperatingSegmentsMember cvs:RetailLTCSegmentMember 2015-01-01 2015-09-30 0000064803 us-gaap:OperatingSegmentsMember us-gaap:CorporateMember 2016-07-01 2016-09-30 0000064803 us-gaap:OperatingSegmentsMember cvs:PharmacyServicesSegmentMember 2015-07-01 2015-09-30 0000064803 us-gaap:OperatingSegmentsMember cvs:RetailLTCSegmentMember 2015-07-01 2015-09-30 0000064803 us-gaap:OperatingIncomeLossMember us-gaap:CorporateMember 2016-01-01 2016-09-30 0000064803 us-gaap:OperatingIncomeLossMember cvs:RetailLTCSegmentMember 2015-01-01 2015-09-30 0000064803 2016-07-01 2016-07-31 0000064803 cvs:OmnicareInc.Member cvs:Spetterv.AbbottLaboratoriesInc.OmnicareInc.andPharMericaCorp.Member us-gaap:SubsequentEventMember 2016-10-01 2016-10-31 0000064803 cvs:OmnicareAutoLabelVerificationSystemMember 2016-01-01 2016-09-30 0000064803 cvs:BaniganandTemplinv.OrganonUSAInc.OmnicareInc.andPharMericaCorporationMember 2010-10-29 2010-10-29 0000064803 cvs:WuotilaDerivativeMatterMember 2009-12-01 2009-12-31 0000064803 us-gaap:SubsequentEventMember 2016-10-11 2016-10-11 0000064803 cvs:OmnicareInc.Member 2015-09-01 2015-09-30 0000064803 cvs:PureServicePharmacyAcquisitionMember 2016-01-01 2016-09-30 0000064803 cvs:DarleneErvinv.OmnicareInc.Member us-gaap:SubsequentEventMember 2016-10-01 2016-10-31 0000064803 cvs:NorthJacksonPharmacyInc.andCCInc.dbaBigCDiscountDrugsInc.vsCaremarkCaseMember 2003-10-01 2003-10-31 0000064803 2003-10-01 2003-10-31 0000064803 2010-03-01 2010-03-31 0000064803 cvs:OmnicareInc.Member 2006-02-01 2006-02-28 0000064803 cvs:LaurielloLawsuitMember 2016-01-01 2016-09-30 0000064803 us-gaap:SubsequentEventMember 2016-10-01 2016-10-31 0000064803 cvs:SheetMetalWorkersLocalNo.20WelfareandBenefitFundv.CVSHealthCorp.Member 2016-02-01 2016-02-29 0000064803 cvs:OmnicareInc.Member 2014-12-22 2014-12-22 0000064803 cvs:BaniganandTemplinv.OrganonUSAInc.OmnicareInc.andPharMericaCorporationMember 2016-08-01 2016-08-31 cvs:qui_tam_complaint iso4217:USD cvs:Mail_Service_Pharmacy cvs:class_action_complaint xbrli:pure cvs:state xbrli:shares cvs:Center cvs:competitor cvs:employee cvs:segment cvs:officer cvs:drugstore cvs:director cvs:store_lease iso4217:USD xbrli:shares cvs:plaintiff cvs:defendant cvs:pharmacy 725000000.0 6200000 1400000 0.8 0.2 5 32000000 7653000000 9178000000 2100000000 6800000000 2500000000 8100000000 1500000000.0 2250000000 486000000 97000000 -184000000 119000000 87 2 1197000000 783000000 26267000000 25610000000 2 P5Y 2 3 8 11 1000000 2 4 13 23 34 2 28 74 85 32 151 1670 9694 1136 1129 9638 0 26000000 28000000 22000000 0 39000000 2047 false --12-31 Q3 2016 2016-09-30 10-Q 0000064803 1066439174 Large Accelerated Filer CVS HEALTH CORPORATION -580000000 -145000000 7490000000 7584000000 11888000000 13625000000 6829000000 8856000000 -358000000 -319000000 30948000000 31541000000 87000000 22000000 65000000 175000000 67000000 108000000 58000000 20000000 38000000 166000000 60000000 106000000 3500000 2400000 7700000 6400000 92437000000 92437000000 -1220000000 93657000000 94156000000 29158000000 29158000000 -1220000000 30378000000 30939000000 0.73 1 1.18 3.35 1.17 3.32 98.00 1318000000 3774000000 39374000000 115652000000 115000000 135000000 5000000 52000000 15000000 194000000 9600000000 3100000000 12000000 12000000 13000000 13000000 2481000000 2890000000 2459000000 2189000000 409000000 -270000000 0 0 0.350 1.050 0.425 1.275 0.01 0.01 3200000000 3200000000 31000000 31000000 1000000 1000000 1699000000 1705000000 1101000000 1066000000 17000000 17000000 1185000000 3640000000 1538000000 3649000000 1000000 1000000 1000000 2000000 1186000000 3641000000 1539000000 3651000000 31983000000 92917000000 37123000000 110304000000 26400000000 1750000000.00 1750000000.00 0.02125 0.02875 0.03875 0.0475 0.0475 0.04875 0.05 0.0575 0.0575 0.06125 0.0625 0.066 835000000 2250000000 1100000000 0 -1220000000 1220000000 4217000000 4217000000 -1220000000 5437000000 4254000000 1510000000 1847000000 1.11 3.32 1.44 3.34 1.11 3.29 1.43 3.32 -8000000 2000000 132000000 72000000 4709000000 4092000000 617000000 5303000000 4624000000 679000000 0 0 -101000000 -643000000 -542000000 38106000000 38214000000 6661000000 -180000000 1468000000 5373000000 0 19227000000 -498000000 3735000000 15990000000 0 7492000000 -198000000 1797000000 5893000000 0 21251000000 -575000000 4266000000 17560000000 0 1230000000 3711000000 1534000000 3593000000 2070000000 6163000000 2463000000 5884000000 1237000000 3730000000 1542000000 3613000000 1.10 3.31 1.44 3.34 1.10 3.28 1.43 3.32 10000000 10000000 -1000000 -1000000 0.01 0.01 0.00 0.00 0.01 0.01 0.00 0.00 833000000 2433000000 921000000 2271000000 2305000000 2194000000 2038000000 1570000000 2530000000 1714000000 523000000 2077000000 893000000 337000000 -591000000 -2000000 13000000 86000000 -116000000 49000000 7000000 8000000 5000000 6000000 6398000000 6398000000 18587000000 10594000000 1595000000 18870000000 11340000000 1132000000 13878000000 6502000000 978000000 13567000000 6716000000 453000000 268000000 577000000 258000000 830000000 -261000000 -562000000 -253000000 -816000000 423000000 954000000 14001000000 14348000000 7000000 15000000 5000000 14000000 92437000000 92437000000 -1220000000 93657000000 94156000000 23169000000 26741000000 -270000 -23000000 -28100000 -2200000.0 -80000000 -8000000 -1500000.0 3500000 28700000000 3 1 2 2 2 2 3 2 7000000 39000000 5000000 0 2000000 39000000 39000000 6576000000 -6568000000 -11000000000 -1652000000 4841000000 7948000000 1000000 1000000 1000000 2000000 1000000 1246000000 3739000000 1540000000 3610000000 3 4 41 49 4330000000 12502000000 4675000000 13908000000 2331000000 -165000000 1162000000 1643000000 -309000000 6725000000 -450000000 2837000000 5050000000 -712000000 2817000000 -185000000 1458000000 1773000000 -229000000 7343000000 -529000000 3278000000 5255000000 -661000000 722000000 703000000 1440000000 1535000000 -61000000 0 0 -61000000 -99000000 0 1000000 -100000000 -3000000 0 0 -3000000 37000000 0 0 37000000 -61000000 -100000000 -3000000 37000000 -61000000 0 0 -61000000 -99000000 0 1000000 -100000000 -2000000 0 1000000 -3000000 39000000 0 2000000 37000000 0 1000000 1000000 2000000 1542000000 1597000000 3871000000 4000000000 6000000 1185000000 1384000000 184000000 40000000 9503000000 333000000 1490000000 1607000000 89530000000 106371000000 11240000000 11092000000 0.01 0.01 100000.0 100000.0 0 0 0 0 0 0 108324000000 128545000000 15000000 14000000 3500000000 14808000000 3455000000 -2000000 -6000000 -685000000 340000000 115000000 76000000 277000000 205000000 1247000000 3740000000 1541000000 3612000000 9855000000 9901000000 0 0 0 0 0 0 0 0 -1000000 0 -1000000 0 -2000000 0 -2000000 0 39000000 0 16000000 37000000 7000000 29000000 46000000 116000000 2898000000 5185000000 35506000000 37732000000 38644000000 -4796000000 25528000000 17912000000 0 112144000000 -13810000000 73849000000 52105000000 0 44615000000 -5957000000 30429000000 20143000000 0 131555000000 -17402000000 88704000000 60253000000 0 34000000 230000000 175000000 166000000 2000000 103.47 5000000 56.20 4000000 13.02 24000000 68.31 104.75 P3Y11M9D 0 340000000 88000000 74000000 10000000000 15000000000 3700000000 400000 41400000 40000000 4000000000 37196000000 35949000000 -143000000 -9000000 -217000000 -65000000 -143000000 -8000000 -255000000 -104000000 -143000000 -8000000 -316000000 -165000000 37203000000 -186000000 -7000000 -358000000 -165000000 -186000000 -6000000 -317000000 -125000000 35954000000 -186000000 -5000000 -319000000 -128000000 597000000 638000000 28886000000 32991000000 6000000 18000000 7000000 18000000 1121000000 1130000000 1073000000 1082000000 1114000000 1122000000 1068000000 1076000000 50000000 4000000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Due to the change in control in Omnicare, the noncontrolling member of the LLC had the contractual right to put its membership interest to the Company at fair value. Consequently, the noncontrolling interest in the LLC was recorded as a redeemable noncontrolling interest at fair value.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30,</font><font style="font-family:inherit;font-size:10pt;"> 2016, the Company had the following outstanding share repurchase program that was authorized by the Company&#8217;s Board of Directors:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:69.78557504873294%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;text-decoration:underline;">In billions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-decoration:underline;">Authorization Date</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-decoration:underline;">Authorized</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-decoration:underline;">Remaining</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 15, 2014 (&#8220;2014 Repurchase Program&#8221;)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following pro forma financial information is not necessarily indicative of the results of operations as they would have been had the transactions been effected on the assumed date, nor is it necessarily an indication of trends in future results for a number of reasons, including, but not limited to, differences between the assumptions used to prepare the pro forma information, basic shares outstanding and dilutive equivalents, cost savings from operating efficiencies, potential synergies, and the impact of incremental costs incurred in integrating the businesses.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:79.53216374269006%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;text-decoration:underline;">In millions, except per share data</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Three </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Months Ended</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">September 30, </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Nine</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Months Ended</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">September 30, </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,374</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115,652</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income from continuing operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,318</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,774</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Earnings per share from continuing operations:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.18</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.35</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.17</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.32</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Acquisition</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On </font><font style="font-family:inherit;font-size:10pt;">August&#160;18, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company acquired </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> of the outstanding common shares and voting interests of Omnicare for </font><font style="font-family:inherit;font-size:10pt;">$98</font><font style="font-family:inherit;font-size:10pt;"> per share, for a total of </font><font style="font-family:inherit;font-size:10pt;">$9.6 billion</font><font style="font-family:inherit;font-size:10pt;"> and assumed long-term debt with a fair value of approximately </font><font style="font-family:inherit;font-size:10pt;">$3.1 billion</font><font style="font-family:inherit;font-size:10pt;">. Omnicare is a leading health care services company that specializes in the management of complex pharmaceutical care. Omnicare&#8217;s long-term care (&#8220;LTC&#8221;) business is the nation&#8217;s largest provider of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings. In addition, Omnicare has a specialty pharmacy business operating primarily under the name of Advanced Care Scripts</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">TM</sup></font><font style="font-family:inherit;font-size:10pt;">, and provides commercialization services under the name of RxCrossroads</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">. The Company acquired Omnicare to expand its operations in dispensing prescription drugs to assisted-living and long-term care facilities, and to broaden its presence in the specialty pharmacy business as the Company seeks to serve a greater percentage of the growing senior patient population in the United States.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following unaudited pro forma information presents a summary of the Company&#8217;s combined results of operations for the three and nine months ended September 30, 2015 as if the Omnicare acquisition and the related financing transactions had occurred on January 1, 2014. The following pro forma financial information is not necessarily indicative of the results of operations as they would have been had the transactions been effected on the assumed date, nor is it necessarily an indication of trends in future results for a number of reasons, including, but not limited to, differences between the assumptions used to prepare the pro forma information, basic shares outstanding and dilutive equivalents, cost savings from operating efficiencies, potential synergies, and the impact of incremental costs incurred in integrating the businesses.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:79.53216374269006%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;text-decoration:underline;">In millions, except per share data</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Three </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Months Ended</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">September 30, </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Nine</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Months Ended</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">September 30, </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,374</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115,652</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income from continuing operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,318</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,774</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Earnings per share from continuing operations:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.18</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.35</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.17</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.32</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Commitments and Contingencies</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Lease Guarantees</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Between 1991 and 1997, the Company sold or spun off a number of subsidiaries, including Bob&#8217;s Stores, Linens &#8216;n Things, Marshalls, Kay-Bee Toys, Wilsons, This End Up and Footstar. In many cases, when a former subsidiary leased a store, the Company provided a guarantee of the store&#8217;s lease obligations. When the subsidiaries were disposed of, the Company&#8217;s guarantees remained in place, although each initial purchaser has agreed to indemnify the Company for any lease obligations the Company was required to satisfy. If any of the purchasers or any of the former subsidiaries were to become insolvent and failed to make the required payments under a store lease, the Company could be required to satisfy these obligations. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company guaranteed approximately </font><font style="font-family:inherit;font-size:10pt;">87</font><font style="font-family:inherit;font-size:10pt;"> such store leases (excluding the lease guarantees related to Linens &#8216;n Things, which have been recorded as a liability on the condensed consolidated balance sheet), with the maximum remaining lease term extending through </font><font style="font-family:inherit;font-size:10pt;">2047</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2016, the parent entity of Bob&#8217;s Stores filed for Chapter 11 bankruptcy protection. As described above, the Company, through one or more of its affiliates, is alleged to have guaranteed certain of the Bob&#8217;s Stores&#8217; leases (the &#8220;Bob&#8217;s Leases&#8221;). On June 20, 2016, the bankruptcy court approved the sale of substantially all of the assets of Bob&#8217;s Stores and certain other assets to a new entity (&#8220;Buyer&#8221;), which designated Buyer&#8217;s affiliate Bob&#8217;s Stores, LLC, a Delaware limited liability company (&#8220;New Bob&#8217;s&#8221;), to acquire substantially all of the assets of Bob&#8217;s Stores.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company, through its subsidiary, CVS Pharmacy, Inc., and New Bob&#8217;s have entered into an agreement dated October 14, 2016, pursuant to which, in exchange for an immaterial payment to be made by CVS Pharmacy, Inc., New Bob&#8217;s has agreed to accept the assignment of the Bob&#8217;s Leases and to be bound by certain restrictions regarding renewals, extensions and modifications to the Bob&#8217;s Leases. The Company believes these restrictions will potentially reduce the Company's exposure to liability under guarantees of the Bob's leases in the future. The assignment of the Bob&#8217;s Leases to New Bob&#8217;s will be subject to bankruptcy court approval. The Company will continue to monitor the bankruptcy proceedings.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Legal Matters</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is a party to legal proceedings, investigations and claims in the ordinary course of its business, including the matters described below. The Company records accruals for outstanding legal matters when it believes it is probable that a loss will be incurred and the amount can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in legal matters that could affect the amount of any accrual and developments that would make a loss contingency both probable and reasonably estimable. If a loss contingency is not both probable and estimable, the Company does not establish an accrued liability. None of the Company&#8217;s accruals for outstanding legal matters are material individually or in the aggregate to the Company&#8217;s financial position.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s contingencies are subject to significant uncertainties, including, among other factors: (i)&#160;the procedural status of pending matters; (ii)&#160;whether class action status is sought and certified; (iii)&#160;whether asserted claims or allegations will survive dispositive motion practice; (iv)&#160;the extent of potential damages, fines or penalties, which are often unspecified or indeterminate; (v)&#160;the impact of discovery on the legal process; (vi)&#160;whether novel or unsettled legal theories are at issue; (vii)&#160;the settlement posture of the parties, and/or (viii)&#160;in the case of certain government agency investigations, whether a sealed </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> lawsuit (&#8220;whistleblower&#8221; action) has been filed and whether the government agency makes a decision to intervene in the lawsuit following investigation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Except as otherwise noted, the Company cannot predict with certainty the timing or outcome of the legal matters described below, and is unable to reasonably estimate a possible loss or range of possible loss in excess of amounts already accrued for these matters.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Caremark (the term &#8220;Caremark&#8221; being used herein to generally refer to any one or more PBM subsidiaries of the Company, as applicable) was named in a putative class action lawsuit filed in October&#160;2003 in Alabama state court by John Lauriello, purportedly on behalf of participants in the 1999 settlement of various securities class action and derivative lawsuits against Caremark and others. Other defendants include insurance companies that provided coverage to Caremark with respect to the settled lawsuits. A similar lawsuit was filed in November&#160;2003 by Frank McArthur, also in Alabama state court, naming as defendants, among others, Caremark and several insurance companies involved in the 1999 settlement. This lawsuit was stayed as a later-filed class action, but McArthur was subsequently allowed to intervene in the Lauriello action. The parties have entered into an agreement to resolve the matter. In connection with this agreement, the Company contributed a total of </font><font style="font-family:inherit;font-size:10pt;">$80 million</font><font style="font-family:inherit;font-size:10pt;"> to the settlement fund and agreed to forego its right to have its insurer continue to reimburse its related legal fees. The Company had established reserves related to this matter to fully cover such payments and the payment was made in the three months ended September 30, 2016. In August 2016, the court entered final judgment dismissing the matter and approving the settlement. The Company denies any wrongdoing, and agreed to a settlement to avoid the burden, uncertainty and distraction of litigation. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning in August 2003, various lawsuits were filed by pharmacies alleging that various PBMs were violating certain antitrust laws. In October&#160;2003, </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> independent pharmacies, North Jackson Pharmacy,&#160;Inc. and C&amp;C,&#160;Inc. d/b/a Big C Discount Drugs,&#160;Inc., filed </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> separate putative class action complaints in the United States District Court for the Northern District of Alabama, all seeking treble damages and injunctive relief. </font><font style="font-family:inherit;font-size:10pt;">One</font><font style="font-family:inherit;font-size:10pt;"> complaint named </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> Caremark entities as defendants, and the other </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> complaints named PBM competitors. The North Jackson Pharmacy case against </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> of the Caremark entities was transferred to the United States District Court for the Northern District of Illinois; the case against the third Caremark entity was sent to arbitration based on contract terms between the pharmacies and that entity. The arbitration was stayed at the parties&#8217; request and later closed by the American Arbitration Association. In August&#160;2006, the Judicial Panel on Multidistrict Litigation issued an order transferring all related PBM antitrust cases, including the North Jackson Pharmacy cases, to the United States District Court for the Eastern District of Pennsylvania for coordinated and consolidated proceedings with the cases originally filed in that court.&#160;The consolidated action is now known as </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">In re Pharmacy Benefit Managers Antitrust Litigation</font><font style="font-family:inherit;font-size:10pt;">. A motion for class certification filed by the North Jackson Pharmacy plaintiffs against the Caremark defendants in August 2015 is currently pending. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2006, </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> substantially similar putative class action lawsuits were filed in the U.S. District Court for the Eastern District of Kentucky, and were consolidated and entitled Indiana State Dist. Council of Laborers &amp; HOD Carriers Pension &amp; Welfare Fund v. Omnicare, Inc. The consolidated complaint was filed against Omnicare, </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> of its officers and </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> of its directors and purported to be brought on behalf of all open-market purchasers of Omnicare common stock from August 3, 2005 through July 27, 2006, as well as all purchasers who bought shares of Omnicare common stock in Omnicare&#8217;s public offering in December 2005. The complaint alleged violations of the Securities Exchange Act of 1934 and Section 11 of the Securities Act of 1933 and sought, among other things, compensatory damages and injunctive relief. After dismissals and appeals to the United States Court of Appeals for the Sixth Circuit, the United States Supreme Court remanded the case to the district court. In October 2016, Omnicare filed an answer to plaintiffs&#8217; third amended complaint, and discovery commenced. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December&#160;2007, the Company received a document subpoena from the Office of Inspector General (&#8220;OIG&#8221;) within the U.S. Department of Health and Human Services, requesting information relating to the processing of Medicaid and certain other government agency claims on behalf of its clients (which allegedly resulted in underpayments from our pharmacy benefit management clients to the applicable government agencies) on one of the Company&#8217;s adjudication platforms. In September 2014, the Company settled the OIG&#8217;s claims, as well as related claims by the Department of Justice and private plaintiffs, without any admission of liability.&#160;The Company is in discussions with the OIG concerning other claim processing issues.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2009, a shareholder derivative lawsuit was filed by Mark Wuotila in the United States District Court for the District of Rhode Island against the directors and certain officers of the Company. The lawsuit includes allegations of, among other things, securities fraud, insider trading and breach of fiduciary duties and further alleges that the Company was damaged by the purchase of stock at allegedly inflated prices under its share repurchase program. The Company entered into an agreement to settle the matter, pursuant to which the Company agreed to maintain or implement certain corporate governance measures and pay the plaintiff&#8217;s legal fees of </font><font style="font-family:inherit;font-size:10pt;">$270,000</font><font style="font-family:inherit;font-size:10pt;">. In August 2016, the court entered final judgment dismissing the matter and approving the settlement. The Company denies any wrongdoing, and agreed to settle these matters to avoid the burden, uncertainty and distraction of litigation. The settlement was funded by insurance proceeds.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2010, the Company learned that various State Attorneys General offices and certain other government agencies were conducting a multi-state investigation of certain of the Company&#8217;s business practices similar to those being investigated at that time by the U.S. Federal Trade Commission (&#8220;FTC&#8221;). </font><font style="font-family:inherit;font-size:10pt;">Twenty-eight</font><font style="font-family:inherit;font-size:10pt;"> states, the District of Columbia and the County of Los Angeles are known to be participating in this investigation. The prior FTC investigation, which commenced in August 2009, was officially concluded in May 2012 when the consent order entered into between the FTC and the Company became final. The Company has cooperated with the multi-state investigation.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March&#160;2010, the Company received a subpoena from the OIG requesting information about programs under which the Company has offered customers remuneration conditioned upon the transfer of prescriptions for drugs or medications to the Company&#8217;s pharmacies in the form of gift cards, cash, non-prescription merchandise or discounts or coupons for non-prescription merchandise. In October 2016, the U.S. District Court for the Central District of California unsealed a </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> complaint, filed in April 2009 against CVS Pharmacy and other retail pharmacies, alleging that the Company violated the federal False Claims Act, and the false claims acts of several states, by offering such programs. The federal government has declined intervention in the case.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 29, 2010, a </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> complaint entitled United States </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">et al., ex rel.</font><font style="font-family:inherit;font-size:10pt;"> Banigan and Templin v. Organon USA, Inc., Omnicare, Inc. and PharMerica Corporation that had been filed under seal with the U.S. District Court for the District of Massachusetts, was ordered unsealed by the court. The complaint was brought by </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> former employees of Organon, as private party </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> relators on behalf of the federal government and several state and local governments. The action alleges civil violations of the federal False Claims Act based on allegations that Organon and its affiliates paid Omnicare and several other long-term care pharmacies rebates, post-purchase discounts and other forms of remuneration in return for purchasing pharmaceuticals from Organon and taking steps to increase the purchase of Organon&#8217;s drugs in violation of the Anti-Kickback Statute. The U.S. Department of Justice declined to intervene in this action. Discovery is closed in this matter. In August 2016, the Court granted in part and denied in part Omnicare&#8217;s motion for summary judgment. The Company has tentatively agreed with the Department of Justice to resolve this matter for </font><font style="font-family:inherit;font-size:10pt;">$23 million</font><font style="font-family:inherit;font-size:10pt;"> plus interest. These financial terms are contingent on approval by authorized officials at the Department of Justice, negotiation of terms of a settlement agreement, approval and releases from the OIG, the National Association of Medicaid Fraud Control Units, and the Department of Justice. While the Company believes that a final settlement will be reached, there can be no assurance that any final settlement agreement will be reached or as to the final terms of such settlement. </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2012, the United States District Court for the Eastern District of Pennsylvania unsealed a first amended </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> complaint filed in August 2011 by an individual relator, Anthony Spay, who is described in the complaint as having once been employed by a firm providing pharmacy prescription benefit audit and recovery services. The complaint seeks monetary damages and alleges that Caremark&#8217;s processing of Medicare claims on behalf of one of its clients violated the federal False Claims Act. The United States declined to intervene in the lawsuit. In September 2015, the Court granted Caremark's motion for summary judgment in its entirety, and entered judgment in favor of Caremark and against Spay. In October 2015, Spay filed a notice of appeal in the United States Court of Appeals for the Third Circuit.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2012, the Attorney General of the State of Texas issued Civil Investigative Demands and other requests, and has issued a series of subsequent requests for documents and information in connection with its investigation concerning the Health Savings Pass program and other pricing practices with respect to claims for reimbursement from the Texas Medicaid program.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2012, the Company received a subpoena from the OIG requesting information concerning automatic refill programs used by pharmacies to refill prescriptions for customers. The Company cooperated and provided documents and other information in response to this request for information.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2013, Omnicare received subpoenas seeking information regarding Omnicare&#8217;s nationwide billing practices with regard to National Drug Code overrides and Omnicare&#8217;s May 2008 acquisition of Pure Service Pharmacy. In 2014, Omnicare received subpoenas seeking information regarding Omnicare&#8217;s Auto Label Verification system and Omnicare&#8217;s per diem arrangements. Omnicare has produced documents and provided information in response to these subpoenas and continues to cooperate in the investigations. In October 2016, the Department of Justice intervened for purposes of settling a </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> complaint Ervin v. Omnicare which related to the subpoena seeking information with regard to National Drug Code overrides. In October 2016, the Company, the Department of Justice, OIG, and National Association of Medicaid Fraud Control Units finalized and signed settlement agreements for approximately </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;"> plus interest. The Court unsealed and dismissed the False Claim Act claims of the complaint. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Omnicare reached an agreement regarding financial terms to resolve, for </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> plus interest, the subpoena regarding the acquisition of Pure Service Pharmacy. These financial terms are contingent on approval by authorized officials at the Department of Justice, negotiation of terms of a settlement agreement, approval and releases from the OIG, the National Association of Medicaid Fraud Control Units, and the Department of Justice. While the Company believes that a final settlement will be reached, there can be no assurance that any final settlement agreement will be reached or as to the final terms of such settlement.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Omnicare reached an agreement regarding financial terms to resolve, for </font><font style="font-family:inherit;font-size:10pt;">$8 million</font><font style="font-family:inherit;font-size:10pt;"> plus interest, the subpoena regarding Omnicare&#8217;s Auto Label Verification system. These financial terms are contingent on approval by authorized officials at the Department of Justice, negotiation of terms of a settlement agreement, approval and releases from the OIG, the National Association of Medicaid Fraud Control Units, and the Department of Justice. While the Company believes that a final settlement will be reached, there can be no assurance that any final settlement agreement will be reached or as to the final terms of such settlement.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 22, 2013, a </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> complaint entitled United States </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">et al., ex rel.</font><font style="font-family:inherit;font-size:10pt;"> Susan Ruscher v. Omnicare, Inc., </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">et al.</font><font style="font-family:inherit;font-size:10pt;">, which had been filed under seal in the U.S. District Court for the Southern District of Texas, was unsealed by the court. The complaint was brought by Susan Ruscher as a private party </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> relator on behalf of the federal government and several state governments alleging violations of the federal False Claims Act and analogous state laws based upon allegations that Omnicare&#8217;s practices relating to customer collections violated the Anti-Kickback Statute. In September 2015, the court granted summary judgment dismissing all claims against Omnicare and denied relator&#8217;s motion for summary judgment related to Omnicare&#8217;s counterclaims and thereafter, in October 2015, the court entered a final judgment for Omnicare and stayed trial on the counterclaims pending an appeal from the relator. In October 2015, plaintiffs filed a notice of appeal in the United States Court of Appeals for the Fifth Circuit. In October 2016, the appellate court affirmed the district court&#8217;s grant of summary judgment dismissing all claims against Omnicare.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2014, the Company received a subpoena from the United States Attorney&#8217;s Office for the</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">District of Rhode Island, requesting documents and information concerning bona fide service fees and rebates received from pharmaceutical manufacturers in connection with certain drugs utilized under Part D of the Medicare Program, as well as the reporting of those fees and rebates to Part D plan sponsors.&#160;The Company has been cooperating with the government and providing documents and information in response to the subpoena.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The U.S. Department of Justice, through the U.S. Attorney&#8217;s Office for the Western District of Virginia, investigated whether Omnicare&#8217;s activities in connection with the agreements it had with the manufacturer of the pharmaceutical Depakote violated the False Claims Act or the Anti-Kickback Statute. Omnicare cooperated with this investigation and believes that it has complied with applicable laws and regulations with respect to this matter. In connection with this matter, on December 22, 2014, the U.S. Department of Justice filed a civil complaint-in-intervention in </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> complaints, entitled United States, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">et al., ex rel. </font><font style="font-family:inherit;font-size:10pt;">Spetter v. Abbott Laboratories, Inc., Omnicare, Inc., and PharMerica Corp., and United States, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">et al., ex rel. </font><font style="font-family:inherit;font-size:10pt;">McCoyd v. Abbott Laboratories, Omnicare, Inc., PharMerica Corp., and Miles White, alleging civil violations of the False Claims Act in connection with the manufacturer agreements described above. In July 2015, the parties filed a Joint Motion to Stay the Litigation stating that the parties have reached a proposed resolution of the monetary terms of a potential settlement agreement. In October 2016, the Company, the Department of Justice, OIG, and National Association of Medicaid Fraud Control Units finalized and signed a settlement agreement for approximately </font><font style="font-family:inherit;font-size:10pt;">$28.1</font><font style="font-family:inherit;font-size:10pt;"> million plus interest. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of Omnicare&#8217;s settlements with the Department of Justice</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, </font><font style="font-family:inherit;font-size:10pt;">the Company entered into a corporate integrity agreement (&#8220;CIA&#8221;) with the OIG. The CIA has a term of </font><font style="font-family:inherit;font-size:10pt;">five years</font><font style="font-family:inherit;font-size:10pt;"> commencing on October 11, 2016. The CIA imposes various compliance requirements relating to the provision of institutional pharmacy services. As part of entering into the CIA, OIG provided the Company with a release related to the previously described subpoena regarding Omnicare&#8217;s per diem arrangements. That release is more fully described in the CIA.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2015, the Company received a subpoena from the OIG requesting information and documents concerning the Company&#8217;s automatic refill programs, adherence outreach programs, and pharmacy customer incentives, particularly in connection with claims for reimbursement made to the Minnesota Medicaid program. The Company has been cooperating with the investigation and providing information in response to the subpoena.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July and September 2015, </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> related putative class actions, Corcoran,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> et al. </font><font style="font-family:inherit;font-size:10pt;">v. CVS Health Corp., and Podgorny, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">et al</font><font style="font-family:inherit;font-size:10pt;">. v. CVS Health Corp., were filed against the Company in the United States District Court in the Northern District of California and the Northern District of Illinois, respectively. The </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> cases have been consolidated in United States District Court in the Northern District of California. In March 2016, the Court granted in part and denied in part the Company&#8217;s first motion to dismiss. In July 2016, the Court granted in part and denied in part the Company's partial motion to dismiss the third amended complaint. Discovery is proceeding on the remaining allegations in the third amended complaint, which alleges that the plaintiffs overpaid for prescriptions for generic drugs filled at CVS pharmacies. The plaintiffs seek damages and injunctive relief under the consumer protection statutes and common laws of certain states and in October 2016 Plaintiffs moved for the certification of a class involving CVS customers from </font><font style="font-family:inherit;font-size:10pt;">11</font><font style="font-family:inherit;font-size:10pt;"> states. In February 2016, </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> third-party payors filed a similar putative class action, Sheet Metal Workers Local No. 20 Welfare and Benefit Fund v. CVS Health Corp., against the Company in the United States District Court for the District of Rhode Island. The Company&#8217;s motion to dismiss remains pending. In August 2016, a similar complaint was filed by another third-party payor, Plumbers Welfare Fund, Local 130 v. CVS Health Corp., also in the United States District Court for the District of Rhode Island. The Company likewise intends to defend this action.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2015, Omnicare was served with an administrative subpoena by the U.S. Drug Enforcement Agency (&#8220;DEA&#8221;). The subpoena seeks documents related to controlled substance policies, procedures, and practices at </font><font style="font-family:inherit;font-size:10pt;">eight</font><font style="font-family:inherit;font-size:10pt;"> pharmacy locations from May 2012 to the present. The Company has been cooperating and providing documents in response to this administrative subpoena.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2015, Omnicare received a Civil Investigative Demand from the United States Attorney&#8217;s Office for the Southern District of New York requesting information and documents concerning Omnicare&#8217;s cycle fill process for assisted living facilities. The Company has been cooperating with the government and providing documents and information in response to the Civil Investigative Demand.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2015, the Company received from the U.S. Department of Justice a Civil Investigative Demand requesting documents and information in connection with a False Claims Act investigation concerning allegations that the Company submitted, or caused to be submitted, to the Medicare Part D program prescription drug event data that misrepresented true prices paid by the Company's PBM to pharmacies for drugs dispensed to Part D beneficiaries with prescription benefits administered by the Company&#8217;s PBM. The Company has been cooperating with the government and providing documents and information in response to the Civil Investigative Demand.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2015, the United States District Court for the Eastern District of Pennsylvania unsealed a second amended </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> complaint filed in September 2015, in an action captioned United States, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">et al., ex rel.</font><font style="font-family:inherit;font-size:10pt;"> Sally Schimelpfeinig and John Segura v. Dr. Reddy&#8217;s Laboratories Limited,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> et al</font><font style="font-family:inherit;font-size:10pt;">. The U.S. Department of Justice declined to intervene in this action. The relators allege that the Company, Walgreens, Wal-Mart, and Dr. Reddy&#8217;s Laboratories violated the federal and various state False Claims Acts by dispensing prescriptions in unit dose packaging supplied by Dr. Reddy&#8217;s that was not compliant with the Consumer Product Safety Improvement Act and the Poison Preventive Packaging Act and thereby allegedly rendering the drugs misbranded under the Food, Drug &amp; Cosmetic Act. The Company's motion to dismiss remains pending.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, an ERISA class action lawsuit was filed against the Company, the Benefit Plans Committee of the Company, and Galliard Capital Management, Inc., in the United States District Court for the District of Rhode Island by Mary Barchock, Thomas Wasecko, and Stacy Weller, purportedly on behalf of the 401(k) Plan and the Employee Stock Ownership Plan of the Company (the &#8220;Plan&#8221;), and participants in the Plan. The complaint alleges that the defendants breached fiduciary duties owed to the plaintiffs and the Plan by investing too much of the Plan&#8217;s Stable Value Fund in short-term money market funds and cash management accounts. The Company has moved to dismiss the plaintiffs' amended complaint.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2016, the Superior Court of the State of California (Sacramento) unsealed a first amended </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> complaint filed in July 2013, in an action captioned State of California </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">ex rel. </font><font style="font-family:inherit;font-size:10pt;">Matthew Omlansky v. CVS Caremark Corporation, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">et al</font><font style="font-family:inherit;font-size:10pt;">. The government has declined intervention in this case. The relator alleged that the Company submitted false claims for payment to California Medicaid in connection with reimbursement for drugs available through the Health Savings Pass program as well as certain other generic drugs. The Company's motion to dismiss the complaint was denied.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the Company entered into a settlement agreement with the U.S. Attorney&#8217;s Office for the District of Massachusetts, resolving alleged violations of the Controlled Substances Act (&#8220;CSA&#8221;). The Company paid a fine of </font><font style="font-family:inherit;font-size:10pt;">$3.5 million</font><font style="font-family:inherit;font-size:10pt;"> in connection with the settlement in July 2016 which was previously fully reserved in the Company's financial statements.&#160;The Company is also undergoing several audits by the DEA Administrator and is in discussions with the DEA and the U.S. Attorney&#8217;s Office in several locations concerning allegations that the Company has violated certain requirements of the CSA.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2016, the Company was served with a complaint filed on behalf of the State of Mississippi, in the Chancery Court of DeSoto County, Third Judicial District, alleging that CVS retail pharmacies in Mississippi submitted false claims for reimbursement to Mississippi Medicaid by not submitting as the pharmacy&#8217;s usual and customary price the price available to members of the CVS Health Savings Pass program. The Company has responded to the complaint, filed a counterclaim, and moved to transfer the case to circuit court.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is also a party to other legal proceedings, government investigations, inquiries and audits, and has received and is cooperating with subpoenas or similar process from various governmental agencies requesting information, all arising in the normal course of its business, none of which is expected to be material to the Company. The Company can give no assurance, however, that its business, financial condition and results of operations will not be materially adversely affected, or that the Company will not be required to materially change its business practices, based on: (i)&#160;future enactment of new health care or other laws or regulations; (ii)&#160;the interpretation or application of existing laws or regulations as they may relate to the Company&#8217;s business, the pharmacy services, specialty pharmacy, retail pharmacy, long-term care pharmacy or retail clinic industries or to the health care industry generally; (iii)&#160;pending or future federal or state governmental investigations of the Company&#8217;s business or the pharmacy services, specialty pharmacy, retail pharmacy, long-term care pharmacy or retail clinic industry or of the health care industry generally; (iv)&#160;pending or future government enforcement actions against the Company; (v)&#160;adverse developments in any pending </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> lawsuit against the Company, whether sealed or unsealed, or in any future </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> lawsuit that may be filed against the Company; or (vi)&#160;adverse developments in pending or future legal proceedings against the Company or affecting the pharmacy services, specialty pharmacy, retail pharmacy, long-term care pharmacy or retail clinic industry or the health care industry generally.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Principles of Consolidation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries and variable interest entities (&#8220;VIEs&#8221;) for which the Company is the primary beneficiary. All material intercompany balances and transactions have been eliminated.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company continually evaluates its investments to determine if they represent variable interests in a VIE. If the Company determines that it has a variable interest in a VIE, the Company then evaluates if it is the primary beneficiary of the VIE. The evaluation is a qualitative assessment as to whether the Company has the ability to direct the activities of a VIE that most significantly impact the entity&#8217;s economic performance. The Company consolidates a VIE if it is considered to be the primary beneficiary.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets and liabilities of VIEs for which the Company is the primary beneficiary were not significant to the Company&#8217;s condensed consolidated financial statements. VIE creditors do not have recourse against the general credit of the Company.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Borrowings</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 16, 2016, the Company issued </font><font style="font-family:inherit;font-size:10pt;">$1.75 billion</font><font style="font-family:inherit;font-size:10pt;"> aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">2.125%</font><font style="font-family:inherit;font-size:10pt;"> unsecured senior notes due June 1, 2021 and </font><font style="font-family:inherit;font-size:10pt;">$1.75 billion</font><font style="font-family:inherit;font-size:10pt;"> aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">2.875%</font><font style="font-family:inherit;font-size:10pt;"> unsecured senior notes due June 1, 2026 (collectively, the "2016 Notes") for total proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">$3.5 billion</font><font style="font-family:inherit;font-size:10pt;">, net of discounts and underwriting fees. The 2016 Notes pay interest semi-annually and may be redeemed, in whole at any time, or in part from time to time, at the Company's option at a defined redemption price plus accrued and unpaid interest to the redemption date. The net proceeds of the 2016 Notes were used for general corporate purposes and to repay certain corporate debt.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 16, 2016, the Company announced tender offers for (1)&#160;any and all of its </font><font style="font-family:inherit;font-size:10pt;">5.75%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes due 2017, its </font><font style="font-family:inherit;font-size:10pt;">6.60%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes due 2019 and its </font><font style="font-family:inherit;font-size:10pt;">4.75%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes due 2020 (collectively, the &#8220;Any and All Notes&#8221;) and (2)&#160;up to </font><font style="font-family:inherit;font-size:10pt;">$1.5 billion</font><font style="font-family:inherit;font-size:10pt;"> aggregate principal amount of its </font><font style="font-family:inherit;font-size:10pt;">6.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes due 2027, its </font><font style="font-family:inherit;font-size:10pt;">6.125%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes due 2039, its </font><font style="font-family:inherit;font-size:10pt;">5.75%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes due 2041, the </font><font style="font-family:inherit;font-size:10pt;">5.00%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes due 2024 issued by its wholly-owned subsidiary, Omnicare, Inc. (&#8220;Omnicare&#8221;), the </font><font style="font-family:inherit;font-size:10pt;">4.75%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes due 2022 issued by Omnicare, its </font><font style="font-family:inherit;font-size:10pt;">4.875%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes due 2035 and its </font><font style="font-family:inherit;font-size:10pt;">3.875%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes due 2025 (collectively, the &#8220;Maximum Tender Offer Notes&#8221; and together with the Any and All Notes, the &#8220;Notes&#8221;). On May 31, 2016, the Company increased the aggregate principal amount of the tender offers for the Maximum Tender Offer Notes to </font><font style="font-family:inherit;font-size:10pt;">$2.25 billion</font><font style="font-family:inherit;font-size:10pt;">. The Company purchased approximately </font><font style="font-family:inherit;font-size:10pt;">$835 million</font><font style="font-family:inherit;font-size:10pt;"> aggregate principal amount of the Any and All Notes and </font><font style="font-family:inherit;font-size:10pt;">$2.25 billion</font><font style="font-family:inherit;font-size:10pt;"> aggregate principal amount of the Maximum Tender Offer Notes pursuant to the tender offers, which expired on June 13, 2016. The Company paid a premium of </font><font style="font-family:inherit;font-size:10pt;">$486 million</font><font style="font-family:inherit;font-size:10pt;"> in excess of the debt principal in connection with the purchase of the Notes, wrote off </font><font style="font-family:inherit;font-size:10pt;">$50 million</font><font style="font-family:inherit;font-size:10pt;"> of unamortized deferred financing costs and incurred </font><font style="font-family:inherit;font-size:10pt;">$6 million</font><font style="font-family:inherit;font-size:10pt;"> in fees, for a total loss on the early extinguishment of debt of </font><font style="font-family:inherit;font-size:10pt;">$542 million</font><font style="font-family:inherit;font-size:10pt;"> which was recorded in income from continuing operations in the condensed consolidated statements of income for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30,</font><font style="font-family:inherit;font-size:10pt;"> 2016. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 27, 2016, the Company notified the holders of the remaining Any and All Notes that the Company was exercising its option to redeem the outstanding Any and All Notes pursuant to the terms of the Any and All Notes and the Indenture dated as of August 15, 2006, between the Company and The Bank of New York Mellon Trust Company, N.A. Approximately </font><font style="font-family:inherit;font-size:10pt;">$1.1 billion</font><font style="font-family:inherit;font-size:10pt;"> aggregate principal amount of Any and All Notes was redeemed on July 27, 2016. The Company paid a premium of </font><font style="font-family:inherit;font-size:10pt;">$97 million</font><font style="font-family:inherit;font-size:10pt;"> in excess of the debt principal and wrote off </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> of unamortized deferred financing costs, for a total loss on early extinguishment of debt of </font><font style="font-family:inherit;font-size:10pt;">$101 million</font><font style="font-family:inherit;font-size:10pt;"> during the three months ended September 30, 2016.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recorded a total loss on the early extinguishment of debt of </font><font style="font-family:inherit;font-size:10pt;">$643 million</font><font style="font-family:inherit;font-size:10pt;"> which was recorded in the income from continuing operations in the condensed statements of income for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30,</font><font style="font-family:inherit;font-size:10pt;"> 2016.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:82.84600389863547%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;text-decoration:underline;">In millions</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">175</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the nine months ended September 30, 2016, the Company granted </font><font style="font-family:inherit;font-size:10pt;">4 million</font><font style="font-family:inherit;font-size:10pt;"> stock options with a weighted average fair value of </font><font style="font-family:inherit;font-size:10pt;">$13.02</font><font style="font-family:inherit;font-size:10pt;"> and a weighted average fair value exercise price of </font><font style="font-family:inherit;font-size:10pt;">$104.75</font><font style="font-family:inherit;font-size:10pt;">. The Company had </font><font style="font-family:inherit;font-size:10pt;">24 million</font><font style="font-family:inherit;font-size:10pt;"> stock options outstanding as of September 30, 2016 with a weighted average exercise price of </font><font style="font-family:inherit;font-size:10pt;">$68.31</font><font style="font-family:inherit;font-size:10pt;"> and a weighted average remaining contractual term of </font><font style="font-family:inherit;font-size:10pt;">3.94</font><font style="font-family:inherit;font-size:10pt;"> years. During the nine months ended September 30, 2016, the Company granted </font><font style="font-family:inherit;font-size:10pt;">2 million</font><font style="font-family:inherit;font-size:10pt;"> restricted stock units with a weighted average fair value of </font><font style="font-family:inherit;font-size:10pt;">$103.47</font><font style="font-family:inherit;font-size:10pt;">. The Company had </font><font style="font-family:inherit;font-size:10pt;">5 million</font><font style="font-family:inherit;font-size:10pt;"> unvested restricted stock units as of September 30, 2016 with a weighted average grant date fair value of </font><font style="font-family:inherit;font-size:10pt;">$56.20</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Earnings Per Share</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Earnings per share is computed using the two-class method. Options to purchase </font><font style="font-family:inherit;font-size:10pt;">7.7 million</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">and</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">6.4 million</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;text-decoration:line-through;">s</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">hares of common stock were outstanding, but were not included in the calculation of diluted earnings per share, for the thre</font><font style="font-family:inherit;font-size:10pt;">e and nine months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, because the options&#8217; exercise prices were greater than the average market price of the common shares and, therefore, the effect would be antidilutive. For the same reason, options to purchase approximately </font><font style="font-family:inherit;font-size:10pt;">3.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2.4 million</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock were outstanding, but were not included in the calculation of diluted earnings per share for the three and nine months ended September 30, 2015, respectively.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a reconciliation of basic and diluted net income per share from continuing operations for the respective periods:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:88.88888888888889%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended <br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended <br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;text-decoration:underline;">In millions, except per share amounts</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator for earnings per share calculations:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,542</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,237</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,613</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,730</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income allocated to participating securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income attributable to noncontrolling interest</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income from continuing operations attributable to CVS Health</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,534</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,230</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,593</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,711</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominators for earnings per share calculations:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares, basic</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,068</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,114</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,076</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,122</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of dilutive securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares, diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,073</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,121</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,082</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,130</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Earnings per share from continuing operations:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.44</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.10</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.34</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.43</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.10</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.32</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.28</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company utilizes the three-level valuation hierarchy for the recognition and disclosure of fair value measurements. The categorization of assets and liabilities within this hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy consist of the following:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 &#8211; Inputs to the valuation methodology are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 &#8211; Inputs to the valuation methodology are quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active or inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the instrument.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 &#8211; Inputs to the valuation methodology are unobservable inputs based upon management&#8217;s best estimate of inputs market participants could use in pricing the asset or liability at the measurement date, including assumptions about risk.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the carrying value of cash and cash equivalents, short-term investments, accounts receivable and accounts payable approximated their fair value due to the nature of these financial instruments. The Company invests in money market funds, commercial paper and time deposits that are classified as cash and cash equivalents within the accompanying condensed consolidated balance sheets, as these funds are highly liquid and readily convertible to known amounts of cash. These investments are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. The Company&#8217;s short-term investments of </font><font style="font-family:inherit;font-size:10pt;">$74 million</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> consist of certificates of deposit with initial maturities of greater than three months when purchased that mature within one year from the balance sheet date. These investments, which are classified within Level 1 of the fair value hierarchy, are carried at fair value, which approximated historical cost at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">. The carrying amount and estimated fair value of the Company&#8217;s total long-term debt was </font><font style="font-family:inherit;font-size:10pt;">$26.4 billion</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$28.7 billion</font><font style="font-family:inherit;font-size:10pt;">, respectively, as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">. The fair value of the Company&#8217;s long-term debt was estimated based on quoted prices currently offered in active markets for the Company&#8217;s debt, which is considered Level 1 of the fair value hierarchy.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Goodwill and Intangible Assets</font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill and indefinitely-lived trade names are not amortized, but are subject to annual impairment reviews, or more frequent reviews if events or circumstances indicate there may be impairment. During the three months ended September 30, 2016, the Company performed its required annual impairment tests and concluded there was no impairment of goodwill or trade names. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's total goodwill was </font><font style="font-family:inherit;font-size:10pt;">$38.2 billion</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$38.1 billion</font><font style="font-family:inherit;font-size:10pt;"> as of September 30, 2016 and December 31, 2015, respectively. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of the Company's intangible assets as of September 30, 2016 and December 31, 2015:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.66861598440545%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">September 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;text-decoration:underline;">In millions</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Gross</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Gross</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net Carrying Amount</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trademarks (indefinitely-lived)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,398</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,398</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,398</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,398</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer contracts and</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;relationships and covenants not </font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;to compete</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,340</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,624</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,716</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,594</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,092</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,502</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Favorable leases and other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,132</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(679</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">453</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,595</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(617</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">978</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,870</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5,303</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,567</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,587</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,709</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,878</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Interest Expense</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following are the components of net interest expense:&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:91.22807017543859%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September 30,</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;text-decoration:underline;">In millions</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">258</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">268</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">830</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">577</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest income</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">253</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">261</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">816</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">562</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">New Accounting Pronouncements</font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;"> (Topic 606). ASU 2014-09 outlines a single comprehensive model for companies to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. In March 2016, the FASB issued ASU 2016-08, &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Principal Versus Agent Considerations (Reporting Revenue Gross Versus Net)</font><font style="font-family:inherit;font-size:10pt;">,&#8221; which amends the principal-versus-agent implementation guidance and in April 2016 the FASB issued ASU 2016-10, "</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Identifying Performance Obligations and Licensing</font><font style="font-family:inherit;font-size:10pt;">," which amends the guidance in those areas in the new revenue recognition standard. Both ASU's were issued in response to feedback received from the FASB-International Accounting Standards Board joint revenue recognition transition resource group. This new revenue standard is effective for annual reporting periods (including interim reporting periods within those periods) beginning January 1, 2018; early adoption in 2017 is permitted. Companies have the option of using either a full retrospective or a modified retrospective approach to adopt the guidance. This standard could impact the timing and amounts of revenue recognized. The Company is currently evaluating the effect that implementation of this standard will have on its consolidated financial position and results of operations upon adoption, as well as the method of transition and required disclosures.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:17px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2015, the FASB issued ASU 2015-17, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes </font><font style="font-family:inherit;font-size:10pt;">(Topic 740). The new guidance simplifies the presentation of deferred income taxes by requiring that deferred tax assets and liabilities be classified as noncurrent in a classified statement of financial position. The updated standard is effective for the Company beginning on January 1, 2017 with early application permitted as of the beginning of any interim or annual reporting period. The Company elected to early adopt this standard as of January 1, 2016 and has, accordingly, reclassified the current deferred tax assets to noncurrent deferred tax liabilities for all periods presented. The following is a reconciliation of the effect of the reclassification on the Company's condensed consolidated balance sheet as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:17px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:77.19298245614034%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:43%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;text-decoration:underline;">In millions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As Previously Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As Revised</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets - current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,220</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,220</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,378</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,220</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,158</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,657</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,220</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92,437</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities - noncurrent</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,437</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,220</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,217</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities and shareholders&#8217; equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,657</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,220</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92,437</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;"> (Topic 842). Lessees will be required to recognize a right-of-use asset and a lease liability for virtually all of their leases (other than leases that meet the definition of a short-term lease). The liability will be equal to the present value of lease payments. The asset will be based on the liability, subject to adjustment, such as for initial direct costs. For income statement purposes, a dual model was retained, requiring leases to be classified as either operating or finance leases. Operating leases will result in straight-line expense (similar to current operating leases) while finance leases will result in a front-loaded expense pattern (similar to current capital leases). Lessor accounting is similar to the current model, but updated to align with certain changes to the lessee model (e.g., certain definitions, such as initial direct costs, have been updated) and the new revenue recognition standard. The standard is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The Company believes that the new standard will have a material impact on its consolidated balance sheet but it will not have a material impact on its liquidity. The Company is currently evaluating the effect that implementation of this standard will have on its consolidated results of operations upon adoption.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Improvements to Employee Share-Based Payment Accounting</font><font style="font-family:inherit;font-size:10pt;">, which amends Accounting Standard Codification Topic 718, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation - Stock Compensation</font><font style="font-family:inherit;font-size:10pt;">, in three areas. (1) The new guidance eliminates accounting for tax benefits and deficiencies through equity to the extent of previous windfalls, and then to the income statement. The new requirement is to record all tax benefits and deficiencies through the income statement. This amendment is required to be applied prospectively. The amendment also requires the presentation of excess tax benefits on the statements of cash flows as operating activities, a change which may be applied prospectively or retrospectively at the election of the Company. The amendment requires the presentation of employee taxes paid on the statement of cash flows when an employer withholds shares for tax withholding purposes as financing activities, a change which must be applied retrospectively. (2) The new guidance also permits companies to withhold an amount up to the employees' maximum individual tax rate in the relevant jurisdiction without resulting in liability classification of the award. (3) Finally, the new guidance provides companies with an accounting policy election for the impact of forfeitures on the recognition of expense for share-based payment awards. Forfeitures can be estimated, as required today, or recognized when they occur. If elected, the change to recognize forfeitures when they occur needs to be adopted using a modified retrospective approach, with a cumulative effect adjustment recorded to beginning retained earnings. The ASU is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that annual reporting period. The Company is currently evaluating the effect of adopting this new accounting guidance.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU No. 2016-15, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Classification of Certain Cash Receipts and Cash Payments. </font><font style="font-family:inherit;font-size:10pt;">ASU 2016-15 is intended to add or clarify guidance on the classification of certain cash receipts and payments in the statement of cash flows and to eliminate the diversity in practice related to such classifications. The guidance in ASU 2016-15 is required for annual reporting periods beginning after December 15, 2017, with early adoption permitted. The Company is currently evaluating the effect on its consolidated statement of cash flows of adopting this new accounting guidance.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Accounting Policies</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements of CVS Health Corporation and its subsidiaries (collectively, &#8220;CVS Health&#8221; or the &#8220;Company&#8221;) have been prepared in accordance with the rules&#160;and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) regarding interim financial reporting. In accordance with such rules&#160;and regulations, certain information and accompanying note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) have been condensed or omitted, although the Company believes the disclosures included herein are adequate to make the information presented not misleading. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto, which are included in Exhibit&#160;13 to the Company&#8217;s Annual Report on Form&#160;10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;2015 Form 10-K&#8221;).</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods presented. Because of the influence of various factors on the Company&#8217;s operations, including business combinations, certain holidays and other seasonal influences, net income for any interim period may not be comparable to the same interim period in previous years or necessarily indicative of income for the full year.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Principles of Consolidation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries and variable interest entities (&#8220;VIEs&#8221;) for which the Company is the primary beneficiary. All material intercompany balances and transactions have been eliminated.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company continually evaluates its investments to determine if they represent variable interests in a VIE. If the Company determines that it has a variable interest in a VIE, the Company then evaluates if it is the primary beneficiary of the VIE. The evaluation is a qualitative assessment as to whether the Company has the ability to direct the activities of a VIE that most significantly impact the entity&#8217;s economic performance. The Company consolidates a VIE if it is considered to be the primary beneficiary.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets and liabilities of VIEs for which the Company is the primary beneficiary were not significant to the Company&#8217;s condensed consolidated financial statements. VIE creditors do not have recourse against the general credit of the Company.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company utilizes the three-level valuation hierarchy for the recognition and disclosure of fair value measurements. The categorization of assets and liabilities within this hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy consist of the following:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 &#8211; Inputs to the valuation methodology are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 &#8211; Inputs to the valuation methodology are quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active or inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the instrument.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 &#8211; Inputs to the valuation methodology are unobservable inputs based upon management&#8217;s best estimate of inputs market participants could use in pricing the asset or liability at the measurement date, including assumptions about risk.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the carrying value of cash and cash equivalents, short-term investments, accounts receivable and accounts payable approximated their fair value due to the nature of these financial instruments. The Company invests in money market funds, commercial paper and time deposits that are classified as cash and cash equivalents within the accompanying condensed consolidated balance sheets, as these funds are highly liquid and readily convertible to known amounts of cash. These investments are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. The Company&#8217;s short-term investments of </font><font style="font-family:inherit;font-size:10pt;">$74 million</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> consist of certificates of deposit with initial maturities of greater than three months when purchased that mature within one year from the balance sheet date. These investments, which are classified within Level 1 of the fair value hierarchy, are carried at fair value, which approximated historical cost at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">. The carrying amount and estimated fair value of the Company&#8217;s total long-term debt was </font><font style="font-family:inherit;font-size:10pt;">$26.4 billion</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$28.7 billion</font><font style="font-family:inherit;font-size:10pt;">, respectively, as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">. The fair value of the Company&#8217;s long-term debt was estimated based on quoted prices currently offered in active markets for the Company&#8217;s debt, which is considered Level 1 of the fair value hierarchy.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Redeemable Noncontrolling Interest</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the acquisition of Omnicare, Inc. (&#8220;Omnicare&#8221;) in August 2015, the Company obtained a </font><font style="font-family:inherit;font-size:10pt;">73%</font><font style="font-family:inherit;font-size:10pt;"> ownership interest in a limited liability company (&#8220;LLC&#8221;). Due to the change in control in Omnicare, the noncontrolling member of the LLC had the contractual right to put its membership interest to the Company at fair value. Consequently, the noncontrolling interest in the LLC was recorded as a redeemable noncontrolling interest at fair value. During the first quarter of 2016, the noncontrolling shareholder of the LLC exercised its option to sell its ownership interest and the Company purchased the noncontrolling interest in the LLC for approximately </font><font style="font-family:inherit;font-size:10pt;">$39 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Below is a summary of the changes in the redeemable noncontrolling interest for the nine months ended September 30, 2016:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:79.92202729044834%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:89%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;text-decoration:underline;">In&#160;millions</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income attributable to noncontrolling interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Distributions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchase of noncontrolling interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(39</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reclassification to capital surplus in connection with purchase of noncontrolling interest</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Related Party Transactions</font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has an equity method investment in SureScripts, LLC (&#8220;SureScripts&#8221;), which operates a clinical health information network. The Pharmacy Services and Retail/LTC segments utilize this clinical health information network in providing services to its client plan members and retail customers. The Company expensed fees for the use of this network of approximately </font><font style="font-family:inherit;font-size:10pt;">$7 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$16 million</font><font style="font-family:inherit;font-size:10pt;"> in the three months ended September 30, 2016 and 2015, respectively, and expensed fees of </font><font style="font-family:inherit;font-size:10pt;">$29 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$37 million</font><font style="font-family:inherit;font-size:10pt;"> in the nine months ended September 30, 2016 and 2015, respectively. The Company&#8217;s investment in and equity in earnings of SureScripts for all periods presented is immaterial.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the acquisition of Omnicare in August 2015, the Company obtained an equity method investment in Heartland Healthcare Services, LLC (&#8220;Heartland&#8221;). Heartland operates several long-term care pharmacies in </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> states. Heartland paid the Company approximately </font><font style="font-family:inherit;font-size:10pt;">$46 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$116 million</font><font style="font-family:inherit;font-size:10pt;"> for pharmaceutical inventory purchases during the three and nine months ended September 30, 2016, respectively. Additionally, the Company performs certain collection functions for Heartland and then passes those customer cash collections to Heartland. The Company&#8217;s investment in Heartland as of December 31, 2015 and September 30, 2016 and equity in earnings of Heartland for the three and nine months ended September 30, 2016 is immaterial. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2016, the Company made a charitable contribution of </font><font style="font-family:inherit;font-size:10pt;">$32 million</font><font style="font-family:inherit;font-size:10pt;"> to the CVS Foundation (the &#8220;Foundation&#8221;) to fund future giving. The Foundation is a non-profit entity that focuses on health, education and community involvement programs. The charitable contribution was recorded as an operating expense in the condensed consolidated statement of income for the nine months ended September 30, 2016.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">New Accounting Pronouncements</font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;"> (Topic 606). ASU 2014-09 outlines a single comprehensive model for companies to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. In March 2016, the FASB issued ASU 2016-08, &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Principal Versus Agent Considerations (Reporting Revenue Gross Versus Net)</font><font style="font-family:inherit;font-size:10pt;">,&#8221; which amends the principal-versus-agent implementation guidance and in April 2016 the FASB issued ASU 2016-10, "</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Identifying Performance Obligations and Licensing</font><font style="font-family:inherit;font-size:10pt;">," which amends the guidance in those areas in the new revenue recognition standard. Both ASU's were issued in response to feedback received from the FASB-International Accounting Standards Board joint revenue recognition transition resource group. This new revenue standard is effective for annual reporting periods (including interim reporting periods within those periods) beginning January 1, 2018; early adoption in 2017 is permitted. Companies have the option of using either a full retrospective or a modified retrospective approach to adopt the guidance. This standard could impact the timing and amounts of revenue recognized. The Company is currently evaluating the effect that implementation of this standard will have on its consolidated financial position and results of operations upon adoption, as well as the method of transition and required disclosures.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:17px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2015, the FASB issued ASU 2015-17, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes </font><font style="font-family:inherit;font-size:10pt;">(Topic 740). The new guidance simplifies the presentation of deferred income taxes by requiring that deferred tax assets and liabilities be classified as noncurrent in a classified statement of financial position. The updated standard is effective for the Company beginning on January 1, 2017 with early application permitted as of the beginning of any interim or annual reporting period. The Company elected to early adopt this standard as of January 1, 2016 and has, accordingly, reclassified the current deferred tax assets to noncurrent deferred tax liabilities for all periods presented. The following is a reconciliation of the effect of the reclassification on the Company's condensed consolidated balance sheet as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:17px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:77.19298245614034%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:43%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;text-decoration:underline;">In millions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As Previously Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As Revised</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets - current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,220</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,220</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,378</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,220</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,158</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,657</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,220</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92,437</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities - noncurrent</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,437</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,220</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,217</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities and shareholders&#8217; equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,657</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,220</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92,437</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;"> (Topic 842). Lessees will be required to recognize a right-of-use asset and a lease liability for virtually all of their leases (other than leases that meet the definition of a short-term lease). The liability will be equal to the present value of lease payments. The asset will be based on the liability, subject to adjustment, such as for initial direct costs. For income statement purposes, a dual model was retained, requiring leases to be classified as either operating or finance leases. Operating leases will result in straight-line expense (similar to current operating leases) while finance leases will result in a front-loaded expense pattern (similar to current capital leases). Lessor accounting is similar to the current model, but updated to align with certain changes to the lessee model (e.g., certain definitions, such as initial direct costs, have been updated) and the new revenue recognition standard. The standard is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The Company believes that the new standard will have a material impact on its consolidated balance sheet but it will not have a material impact on its liquidity. The Company is currently evaluating the effect that implementation of this standard will have on its consolidated results of operations upon adoption.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Improvements to Employee Share-Based Payment Accounting</font><font style="font-family:inherit;font-size:10pt;">, which amends Accounting Standard Codification Topic 718, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation - Stock Compensation</font><font style="font-family:inherit;font-size:10pt;">, in three areas. (1) The new guidance eliminates accounting for tax benefits and deficiencies through equity to the extent of previous windfalls, and then to the income statement. The new requirement is to record all tax benefits and deficiencies through the income statement. This amendment is required to be applied prospectively. The amendment also requires the presentation of excess tax benefits on the statements of cash flows as operating activities, a change which may be applied prospectively or retrospectively at the election of the Company. The amendment requires the presentation of employee taxes paid on the statement of cash flows when an employer withholds shares for tax withholding purposes as financing activities, a change which must be applied retrospectively. (2) The new guidance also permits companies to withhold an amount up to the employees' maximum individual tax rate in the relevant jurisdiction without resulting in liability classification of the award. (3) Finally, the new guidance provides companies with an accounting policy election for the impact of forfeitures on the recognition of expense for share-based payment awards. Forfeitures can be estimated, as required today, or recognized when they occur. If elected, the change to recognize forfeitures when they occur needs to be adopted using a modified retrospective approach, with a cumulative effect adjustment recorded to beginning retained earnings. The ASU is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that annual reporting period. The Company is currently evaluating the effect of adopting this new accounting guidance.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU No. 2016-15, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Classification of Certain Cash Receipts and Cash Payments. </font><font style="font-family:inherit;font-size:10pt;">ASU 2016-15 is intended to add or clarify guidance on the classification of certain cash receipts and payments in the statement of cash flows and to eliminate the diversity in practice related to such classifications. The guidance in ASU 2016-15 is required for annual reporting periods beginning after December 15, 2017, with early adoption permitted. The Company is currently evaluating the effect on its consolidated statement of cash flows of adopting this new accounting guidance.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Below is a summary of the changes in the redeemable noncontrolling interest for the nine months ended September 30, 2016:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:79.92202729044834%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:89%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;text-decoration:underline;">In&#160;millions</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income attributable to noncontrolling interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Distributions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchase of noncontrolling interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(39</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reclassification to capital surplus in connection with purchase of noncontrolling interest</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Sale-Leaseback Transactions</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company finances a portion of its store development program through sale-leaseback transactions. The properties are</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">generally sold at net book value, which approximates fair value, and the resulting leases typically qualify and are accounted for</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">as operating leases. The Company does not have any retained or contingent interests in the stores and does not provide any</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">guarantees, other than a guarantee of lease payments, in connection with the sale-leaseback transactions. Proceeds from sale-leaseback transactions totaled </font><font style="font-family:inherit;font-size:10pt;">$230 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$34 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30,</font><font style="font-family:inherit;font-size:10pt;"> 2016 and 2015,</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the activity within the components of accumulated other comprehensive income. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in accumulated other comprehensive income (loss) by component is shown on the below:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:92.00779727095517%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">In millions</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign Currency</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Losses on Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pension and Other Postretirement Benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(125</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(186</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(317</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Other comprehensive income (loss) before <br clear="none"/> reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Amounts reclassified from accumulated <br clear="none"/> other comprehensive income</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(128</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(186</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(319</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign Currency</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Losses on Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pension and Other Postretirement Benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, June 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(104</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(143</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(255</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Other comprehensive income (loss) before <br clear="none"/> reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Amounts reclassified from accumulated <br clear="none"/> other comprehensive income</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net other comprehensive (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(165</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(143</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(316</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign Currency</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Losses on Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pension and Other Postretirement Benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(165</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(186</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(358</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Other comprehensive income (loss) before <br clear="none"/> reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Amounts reclassified from accumulated <br clear="none"/> other comprehensive income </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net other comprehensive income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(128</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(186</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(319</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign Currency</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Losses on Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pension and Other Postretirement Benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(65</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(143</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(217</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Other comprehensive income (loss) before <br clear="none"/> reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(100</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(99</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Amounts reclassified from accumulated <br clear="none"/> other comprehensive income </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(100</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(99</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(165</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(143</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(316</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">All amounts are net of tax. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The amounts reclassified from accumulated other comprehensive income for losses on cash flow hedges are recorded within interest expense, net on the condensed consolidated statement of income. The amounts reclassified from accumulated other comprehensive income for pension and other postretirement benefits are included in operating expenses on the condensed consolidated statement of income.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:82.84600389863547%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;text-decoration:underline;">In millions</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">175</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a reconciliation of basic and diluted net income per share from continuing operations for the respective periods:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:88.88888888888889%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended <br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended <br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;text-decoration:underline;">In millions, except per share amounts</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator for earnings per share calculations:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,542</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,237</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,613</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,730</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income allocated to participating securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income attributable to noncontrolling interest</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income from continuing operations attributable to CVS Health</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,534</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,230</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,593</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,711</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominators for earnings per share calculations:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares, basic</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,068</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,114</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,076</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,122</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of dilutive securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares, diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,073</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,121</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,082</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,130</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Earnings per share from continuing operations:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.44</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.10</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.34</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.43</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.10</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.32</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.28</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of the Company's intangible assets as of September 30, 2016 and December 31, 2015:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.66861598440545%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">September 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;text-decoration:underline;">In millions</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Gross</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Gross</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net Carrying Amount</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trademarks (indefinitely-lived)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,398</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,398</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,398</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,398</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer contracts and</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;relationships and covenants not </font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;to compete</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,340</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,624</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,716</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,594</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,092</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,502</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Favorable leases and other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,132</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(679</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">453</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,595</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(617</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">978</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,870</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5,303</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,567</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,587</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,709</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,878</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of the Company's intangible assets as of September 30, 2016 and December 31, 2015:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.66861598440545%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">September 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;text-decoration:underline;">In millions</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Gross</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Gross</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net Carrying Amount</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trademarks (indefinitely-lived)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,398</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,398</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,398</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,398</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer contracts and</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;relationships and covenants not </font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;to compete</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,340</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,624</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,716</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,594</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,092</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,502</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Favorable leases and other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,132</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(679</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">453</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,595</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(617</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">978</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,870</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5,303</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,567</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,587</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,709</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,878</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:17px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a reconciliation of the effect of the reclassification on the Company's condensed consolidated balance sheet as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:17px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:77.19298245614034%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:43%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;text-decoration:underline;">In millions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As Previously Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As Revised</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets - current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,220</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,220</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,378</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,220</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,158</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,657</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,220</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92,437</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities - noncurrent</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,437</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,220</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,217</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities and shareholders&#8217; equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,657</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,220</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92,437</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following are the components of net interest expense:&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:91.22807017543859%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September 30,</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;text-decoration:underline;">In millions</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">258</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">268</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">830</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">577</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest income</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">253</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">261</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">816</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">562</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;text-decoration:underline;">In millions</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmacy</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Services</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Segment</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Retail/LTC</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Segment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Segment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intersegment</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Eliminations</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Totals</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,429</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,143</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,957</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,615</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,797</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,893</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(198</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,492</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating profit (loss)</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)(5)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,458</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,773</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(229</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(185</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,817</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net revenues</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,528</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,912</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,796</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,644</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,468</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,373</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(180</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,661</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating profit (loss)</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)(5)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,162</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,643</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(309</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(165</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,331</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September 30, 2016:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net revenues</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,704</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,253</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,402</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">131,555</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,266</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,560</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(575</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,251</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating profit (loss)</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)(5)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,278</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,255</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(661</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(529</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,343</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September 30, 2015:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net revenues</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,849</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,105</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,810</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,144</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,735</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,990</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(498</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,227</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating profit (loss)</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)(5)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,837</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,050</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(712</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(450</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,725</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:48px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><font style="font-family:inherit;font-size:8pt;">(1)</font><font style="font-family:inherit;font-size:3pt;">&#160;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net revenues of the Pharmacy Services Segment include approximately </font><font style="font-family:inherit;font-size:8pt;">$2.5 billion</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">$2.1 billion</font><font style="font-family:inherit;font-size:8pt;"> of retail co-payments for the three months ended </font><font style="font-family:inherit;font-size:8pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:8pt;"> and 2015, respectively, as well as </font><font style="font-family:inherit;font-size:8pt;">$8.1 billion</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">$6.8 billion</font><font style="font-family:inherit;font-size:8pt;"> of retail co-payments for the </font><font style="font-family:inherit;font-size:8pt;">nine months ended September 30,</font><font style="font-family:inherit;font-size:8pt;"> 2016 and 2015, respectively.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Intersegment eliminations relate to&#160;intersegment revenue generating activities that occur between the Pharmacy Services Segment and the Retail/LTC Segment. These occur in the following ways: when members of Pharmacy Services Segment clients (&#8220;members&#8221;) fill prescriptions at the Company's retail stores to purchase covered products, when members enrolled in programs such as Maintenance Choice</font><font style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"> &#174;</sup></font><font style="font-family:inherit;font-size:8pt;"> elect to pick up maintenance prescriptions at one of the Company's retail stores instead of receiving them through the mail, or when members have prescriptions filled at the Company's long-term care pharmacies. When these occur, both the Pharmacy Services and Retail/LTC segments record the revenues, gross profit and operating profit on a standalone basis.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><font style="font-family:inherit;font-size:8pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The Retail/LTC Segment gross profit for the three and nine months ended September 30, 2016 includes </font><font style="font-family:inherit;font-size:8pt;">$5 million</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">$15 million</font><font style="font-family:inherit;font-size:8pt;">, respectively, of acquisition-related integration costs. The integration costs are related to the acquisitions of Omnicare and the pharmacies and clinics of Target. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><font style="font-family:inherit;font-size:8pt;">(4)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The Retail/LTC Segment operating profit for the three and nine months ended September 30, 2016 includes </font><font style="font-family:inherit;font-size:8pt;">$52 million</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">$194 million</font><font style="font-family:inherit;font-size:8pt;">, respectively, of acquisition-related integration costs. The Retail/LTC Segment operating profit for the three and nine months ended September 30, 2015 includes </font><font style="font-family:inherit;font-size:8pt;">$12 million</font><font style="font-family:inherit;font-size:8pt;"> of acquisition-related integration costs. The integration costs are related to the acquisitions of Omnicare and the pharmacies and clinics of Target. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><font style="font-family:inherit;font-size:8pt;">(5)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The Corporate Segment operating loss for the three and nine months ended September 30, 2016 includes </font><font style="font-family:inherit;font-size:8pt;">$13 million</font><font style="font-family:inherit;font-size:8pt;"> of integration costs. The Corporate Segment operating loss for the three and nine months ended September 30, 2015 includes </font><font style="font-family:inherit;font-size:8pt;">$115 million</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">$135 million</font><font style="font-family:inherit;font-size:8pt;">, respectively, of acquisition-related transaction and integration costs.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Segment Reporting</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> reportable segments: Pharmacy Services, Retail/LTC and Corporate. The Retail/LTC Segment includes the operating results of the Company's Retail Pharmacy and LTC/RxCrossroads operating segments as the operations and economic characteristics are similar. The Company&#8217;s </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> reportable segments maintain separate financial information by which operating results are evaluated on a regular basis by the Company&#8217;s chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company evaluates its Pharmacy Services and Retail/LTC segments&#8217; performance based on net revenue, gross profit and operating profit before the effect of nonrecurring charges and gains and certain intersegment activities. The Company evaluates the performance of its Corporate Segment based on operating expenses before the effect of nonrecurring charges and gains and certain intersegment activities. The chief operating decision maker does not use total assets by segment to make decisions regarding resources, therefore the total asset disclosure by segment has not been included.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Pharmacy Services Segment provides a full range of pharmacy benefit management (&#8220;PBM&#8221;) services including plan design and administration, formulary management, Medicare Part&#160;D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management services and medical spend management. The Company&#8217;s clients are primarily employers, insurance companies, unions, government employee groups, health plans, Managed Medicaid plans and other sponsors of health benefit plans, and individuals throughout the United States. A portion of covered lives primarily within the Managed Medicaid, health plan and employer markets have access to our services through public and private exchanges. Through the Company&#8217;s SilverScript Insurance Company subsidiary, the Company is a national provider of drug benefits to eligible beneficiaries under the federal government&#8217;s Medicare Part&#160;D program. The Pharmacy Services Segment operates under the CVS Caremark</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">TM</sup></font><font style="font-family:inherit;font-size:10pt;"> Pharmacy Services, Caremark</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, CVS Caremark</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">TM</sup></font><font style="font-family:inherit;font-size:10pt;">, CarePlus CVS Pharmacy</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, CVS Specialty</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">TM</sup></font><font style="font-family:inherit;font-size:10pt;">, RxAmerica</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, Accordant</font><font style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, SilverScript</font><font style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, NovoLogix</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, Coram</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, Navarro</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Health Services and Advanced Care Scripts</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">TM</sup></font><font style="font-family:inherit;font-size:10pt;"> names. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Pharmacy Services Segment operated </font><font style="font-family:inherit;font-size:10pt;">23</font><font style="font-family:inherit;font-size:10pt;"> retail specialty pharmacy stores, </font><font style="font-family:inherit;font-size:10pt;">13</font><font style="font-family:inherit;font-size:10pt;"> specialty mail order pharmacies, </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> mail service dispensing pharmacies, and </font><font style="font-family:inherit;font-size:10pt;">85</font><font style="font-family:inherit;font-size:10pt;"> branches for infusion and enteral services, including approximately </font><font style="font-family:inherit;font-size:10pt;">74</font><font style="font-family:inherit;font-size:10pt;"> ambulatory infusion suites and </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> centers of excellence, located in </font><font style="font-family:inherit;font-size:10pt;">41</font><font style="font-family:inherit;font-size:10pt;"> states, Puerto Rico and the District of Columbia. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Retail/LTC Segment sells prescription drugs and a wide assortment of general merchandise, including over-the-counter drugs, beauty products and cosmetics, personal care products, convenience foods, photo finishing, seasonal merchandise and greeting cards. With the acquisition of Omnicare, the Retail/LTC Segment now includes LTC operations, which is comprised of providing the distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings, as well as commercialization services which are provided under the name RxCrossroads</font><font style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">. We added approximately </font><font style="font-family:inherit;font-size:10pt;">1,670</font><font style="font-family:inherit;font-size:10pt;"> pharmacies through the acquisition of the pharmacies of Target Corporation ("Target") in December 2015, thereby expanding our presence in new and existing markets. The stores within Target sell only prescription drugs and over-the-counter drugs that are required to be behind the pharmacy counter. The Retail/LTC Segment also operates retail medical clinics under the MinuteClinic</font><font style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;name. MinuteClinics utilize nationally-recognized medical protocols to diagnose and treat minor health conditions, perform health screenings, monitor chronic conditions and deliver vaccinations. The clinics are staffed by board-certified nurse practitioners and physician assistants who provide access to affordable care without appointment. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, our Retail/LTC Segment included </font><font style="font-family:inherit;font-size:10pt;">9,694</font><font style="font-family:inherit;font-size:10pt;"> retail stores (of which </font><font style="font-family:inherit;font-size:10pt;">9,638</font><font style="font-family:inherit;font-size:10pt;"> were either the Company's retail stores that operated a pharmacy, or pharmacies located within Target stores) located in </font><font style="font-family:inherit;font-size:10pt;">49</font><font style="font-family:inherit;font-size:10pt;"> states, the District of Columbia, Puerto Rico and Brazil operating primarily under the CVS Pharmacy</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, CVS</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, Longs Drugs</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:inherit;font-size:7pt;"> </font><font style="font-family:inherit;font-size:10pt;">Navarro Discount Pharmacy</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> and Drogaria Onofre</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">TM</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;names, </font><font style="font-family:inherit;font-size:10pt;">34</font><font style="font-family:inherit;font-size:10pt;"> onsite pharmacies primarily operating under the CarePlus CVS Pharmacy</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, CarePlus</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> and CVS Pharmacy</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> names, </font><font style="font-family:inherit;font-size:10pt;">1,136</font><font style="font-family:inherit;font-size:10pt;"> retail health care clinics operating under the MinuteClinic</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;name (of which </font><font style="font-family:inherit;font-size:10pt;">1,129</font><font style="font-family:inherit;font-size:10pt;"> were located in CVS Pharmacy and Target stores), and our online retail websites, CVS.com</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, Navarro.com</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">TM</sup></font><font style="font-family:inherit;font-size:7pt;"> </font><font style="font-family:inherit;font-size:10pt;">and Onofre.com.br</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">TM</sup></font><font style="font-family:inherit;font-size:10pt;">. LTC operations are comprised of </font><font style="font-family:inherit;font-size:10pt;">151</font><font style="font-family:inherit;font-size:10pt;"> spoke pharmacies that primarily handle new prescription orders, of which </font><font style="font-family:inherit;font-size:10pt;">32</font><font style="font-family:inherit;font-size:10pt;"> are also hub pharmacies that use proprietary automation to support spoke pharmacies with refill prescriptions. LTC operates primarily under the Omnicare</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> and NeighborCare</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> names.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Corporate Segment provides management and administrative services to support the Company. The Corporate Segment consists of certain aspects of executive management, corporate relations, legal, compliance, human resources, information technology and finance departments.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;text-decoration:underline;">In millions</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmacy</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Services</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Segment</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Retail/LTC</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Segment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Segment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intersegment</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Eliminations</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Totals</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,429</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,143</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,957</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,615</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,797</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,893</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(198</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,492</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating profit (loss)</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)(5)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,458</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,773</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(229</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(185</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,817</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net revenues</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,528</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,912</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,796</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,644</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,468</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,373</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(180</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,661</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating profit (loss)</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)(5)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,162</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,643</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(309</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(165</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,331</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September 30, 2016:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net revenues</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,704</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,253</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,402</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">131,555</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,266</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,560</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(575</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,251</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating profit (loss)</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)(5)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,278</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,255</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(661</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(529</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,343</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September 30, 2015:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net revenues</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,849</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,105</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,810</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,144</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,735</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,990</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(498</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,227</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating profit (loss)</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)(5)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,837</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,050</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(712</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(450</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,725</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:48px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><font style="font-family:inherit;font-size:8pt;">(1)</font><font style="font-family:inherit;font-size:3pt;">&#160;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net revenues of the Pharmacy Services Segment include approximately </font><font style="font-family:inherit;font-size:8pt;">$2.5 billion</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">$2.1 billion</font><font style="font-family:inherit;font-size:8pt;"> of retail co-payments for the three months ended </font><font style="font-family:inherit;font-size:8pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:8pt;"> and 2015, respectively, as well as </font><font style="font-family:inherit;font-size:8pt;">$8.1 billion</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">$6.8 billion</font><font style="font-family:inherit;font-size:8pt;"> of retail co-payments for the </font><font style="font-family:inherit;font-size:8pt;">nine months ended September 30,</font><font style="font-family:inherit;font-size:8pt;"> 2016 and 2015, respectively.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Intersegment eliminations relate to&#160;intersegment revenue generating activities that occur between the Pharmacy Services Segment and the Retail/LTC Segment. These occur in the following ways: when members of Pharmacy Services Segment clients (&#8220;members&#8221;) fill prescriptions at the Company's retail stores to purchase covered products, when members enrolled in programs such as Maintenance Choice</font><font style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"> &#174;</sup></font><font style="font-family:inherit;font-size:8pt;"> elect to pick up maintenance prescriptions at one of the Company's retail stores instead of receiving them through the mail, or when members have prescriptions filled at the Company's long-term care pharmacies. When these occur, both the Pharmacy Services and Retail/LTC segments record the revenues, gross profit and operating profit on a standalone basis.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><font style="font-family:inherit;font-size:8pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The Retail/LTC Segment gross profit for the three and nine months ended September 30, 2016 includes </font><font style="font-family:inherit;font-size:8pt;">$5 million</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">$15 million</font><font style="font-family:inherit;font-size:8pt;">, respectively, of acquisition-related integration costs. The integration costs are related to the acquisitions of Omnicare and the pharmacies and clinics of Target. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><font style="font-family:inherit;font-size:8pt;">(4)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The Retail/LTC Segment operating profit for the three and nine months ended September 30, 2016 includes </font><font style="font-family:inherit;font-size:8pt;">$52 million</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">$194 million</font><font style="font-family:inherit;font-size:8pt;">, respectively, of acquisition-related integration costs. The Retail/LTC Segment operating profit for the three and nine months ended September 30, 2015 includes </font><font style="font-family:inherit;font-size:8pt;">$12 million</font><font style="font-family:inherit;font-size:8pt;"> of acquisition-related integration costs. The integration costs are related to the acquisitions of Omnicare and the pharmacies and clinics of Target. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><font style="font-family:inherit;font-size:8pt;">(5)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The Corporate Segment operating loss for the three and nine months ended September 30, 2016 includes </font><font style="font-family:inherit;font-size:8pt;">$13 million</font><font style="font-family:inherit;font-size:8pt;"> of integration costs. The Corporate Segment operating loss for the three and nine months ended September 30, 2015 includes </font><font style="font-family:inherit;font-size:8pt;">$115 million</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">$135 million</font><font style="font-family:inherit;font-size:8pt;">, respectively, of acquisition-related transaction and integration costs.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Accumulated Other Comprehensive Income</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive income consists of foreign currency translation adjustments, unrealized losses on cash flow hedges executed in previous years associated with the issuance of long-term debt, and changes in the net actuarial gains and losses associated with pension and other postretirement benefit plans. The following table summarizes the activity within the components of accumulated other comprehensive income. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in accumulated other comprehensive income (loss) by component is shown on the below:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:92.00779727095517%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">In millions</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign Currency</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Losses on Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pension and Other Postretirement Benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(125</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(186</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(317</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Other comprehensive income (loss) before <br clear="none"/> reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Amounts reclassified from accumulated <br clear="none"/> other comprehensive income</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(128</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(186</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(319</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign Currency</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Losses on Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pension and Other Postretirement Benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, June 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(104</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(143</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(255</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Other comprehensive income (loss) before <br clear="none"/> reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Amounts reclassified from accumulated <br clear="none"/> other comprehensive income</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net other comprehensive (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(165</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(143</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(316</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign Currency</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Losses on Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pension and Other Postretirement Benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(165</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(186</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(358</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Other comprehensive income (loss) before <br clear="none"/> reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Amounts reclassified from accumulated <br clear="none"/> other comprehensive income </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net other comprehensive income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(128</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(186</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(319</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign Currency</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Losses on Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pension and Other Postretirement Benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(65</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(143</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(217</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Other comprehensive income (loss) before <br clear="none"/> reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(100</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(99</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Amounts reclassified from accumulated <br clear="none"/> other comprehensive income </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(100</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(99</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(165</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(143</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(316</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">All amounts are net of tax. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The amounts reclassified from accumulated other comprehensive income for losses on cash flow hedges are recorded within interest expense, net on the condensed consolidated statement of income. The amounts reclassified from accumulated other comprehensive income for pension and other postretirement benefits are included in operating expenses on the condensed consolidated statement of income.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Share Repurchase Program</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30,</font><font style="font-family:inherit;font-size:10pt;"> 2016, the Company had the following outstanding share repurchase program that was authorized by the Company&#8217;s Board of Directors:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:69.78557504873294%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;text-decoration:underline;">In billions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-decoration:underline;">Authorization Date</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-decoration:underline;">Authorized</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-decoration:underline;">Remaining</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 15, 2014 (&#8220;2014 Repurchase Program&#8221;)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 2, 2016, the Company's Board of Directors authorized a new share repurchase program for up to </font><font style="font-family:inherit;font-size:10pt;">$15 billion</font><font style="font-family:inherit;font-size:10pt;"> of outstanding common stock (the &#8220;2016 Repurchase Program&#8221;). The 2014 and 2016 Repurchase Programs, which were effective immediately, permit the Company to effect repurchases from time to time through a combination of open market repurchases, privately negotiated transactions, accelerated share repurchase transactions, and/or other derivative transactions. The repurchase programs may be modified or terminated by the Board of Directors at any time. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company repurchased an aggregate of approximately </font><font style="font-family:inherit;font-size:10pt;">0.4 million</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock for approximately </font><font style="font-family:inherit;font-size:10pt;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;"> pursuant to the 2014 Repurchase Program. During the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30,</font><font style="font-family:inherit;font-size:10pt;"> 2016, the Company repurchased an aggregate of approximately </font><font style="font-family:inherit;font-size:10pt;text-align:right;">41.4 million</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock for approximately </font><font style="font-family:inherit;font-size:10pt;">$4.0 billion</font><font style="font-family:inherit;font-size:10pt;"> pursuant to the 2014 Repurchase Program. This activity includes the accelerated share repurchase agreement (&#8220;ASR&#8221;) described below. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the authorization under the 2014 Repurchase Program, effective December 11, 2015, the Company entered into a </font><font style="font-family:inherit;font-size:10pt;">$725 million</font><font style="font-family:inherit;font-size:10pt;"> fixed dollar ASR with Barclays Bank PLC (&#8220;Barclays&#8221;). Upon payment of the </font><font style="font-family:inherit;font-size:10pt;">$725 million</font><font style="font-family:inherit;font-size:10pt;"> purchase price on December 14, 2015, the Company received a number of shares of its common stock equal to </font><font style="font-family:inherit;font-size:10pt;">80%</font><font style="font-family:inherit;font-size:10pt;"> of the </font><font style="font-family:inherit;font-size:10pt;">$725 million</font><font style="font-family:inherit;font-size:10pt;"> notional amount of the ASR or approximately </font><font style="font-family:inherit;font-size:10pt;">6.2 million</font><font style="font-family:inherit;font-size:10pt;"> shares. The initial </font><font style="font-family:inherit;font-size:10pt;">6.2 million</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock delivered to the Company by Barclays were placed into treasury stock in December 2015. The ASR was accounted for as an initial treasury stock transaction for </font><font style="font-family:inherit;font-size:10pt;">$580 million</font><font style="font-family:inherit;font-size:10pt;"> and a forward contract for </font><font style="font-family:inherit;font-size:10pt;">$145 million</font><font style="font-family:inherit;font-size:10pt;">. The forward contract was classified as an equity instrument and was recorded within capital surplus on the condensed consolidated balance sheet as of December 31, 2015. On January 28, 2016, the Company received </font><font style="font-family:inherit;font-size:10pt;">1.4 million</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, representing the remaining </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;"> of the </font><font style="font-family:inherit;font-size:10pt;">$725 million</font><font style="font-family:inherit;font-size:10pt;"> notional amount of the ASR, thereby concluding the ASR. The remaining </font><font style="font-family:inherit;font-size:10pt;">1.4 million</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock delivered to the Company by Barclays were placed into treasury stock and the forward contract was reclassified from capital surplus to treasury stock in January 2016.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the time they were received, the initial and final receipt of shares resulted in an immediate reduction of the outstanding shares used to calculate the weighted average common shares outstanding for basic and diluted net income per share.</font></div></div> EX-101.SCH 8 cvs-20160930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2101100 - Disclosure - Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2401406 - Disclosure - Accounting Policies - Accounting Pronouncements (Details) link:presentationLink link:calculationLink link:definitionLink 2401403 - Disclosure - Accounting Policies - Fair Value of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2401404 - Disclosure - Accounting Policies - Redeemable Noncontrolling Interest (Details) link:presentationLink link:calculationLink link:definitionLink 2401405 - Disclosure - Accounting Policies - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 2301302 - Disclosure - Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Accumulated Other Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Accumulated Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - Accumulated Other Comprehensive Income (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Acquisition link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Acquisition - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Acquisition - Proforma (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Acquisition (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Borrowings link:presentationLink link:calculationLink link:definitionLink 2416401 - Disclosure - Borrowings (Details) link:presentationLink link:calculationLink link:definitionLink 2122100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2422401 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1003501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Statements of Income link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2120100 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 2420402 - Disclosure - Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2320301 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Goodwill and Intangible Assets link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - Goodwill and Intangible Assets - Schedule of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Goodwill and Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - Interest Expense link:presentationLink link:calculationLink link:definitionLink 2419402 - Disclosure - Interest Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2319301 - Disclosure - Interest Expense (Tables) link:presentationLink link:calculationLink link:definitionLink 2118100 - Disclosure - Sale-Leaseback Transactions link:presentationLink link:calculationLink link:definitionLink 2418401 - Disclosure - Sale-Leaseback Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 2121100 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 2421402 - Disclosure - Segment Reporting (Details) link:presentationLink link:calculationLink link:definitionLink 2321301 - Disclosure - Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Share Repurchase Program link:presentationLink link:calculationLink link:definitionLink 2413402 - Disclosure - Share Repurchase Program (Details) link:presentationLink link:calculationLink link:definitionLink 2313301 - Disclosure - Share Repurchase Program (Tables) link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2417402 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 2317301 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 cvs-20160930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 cvs-20160930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 cvs-20160930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Leases [Abstract] Proceeds from sale-leaseback transactions Sale Leaseback Transaction, Net Proceeds, Investing Activities Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Accumulated Translation Adjustment Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member] Defined Benefit Pension Items Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] AOCI AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Beginning balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Other comprehensive income (loss) before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Amounts reclassified from accumulated other comprehensive income(2) Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Net other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Ending balance Accounting Policies [Abstract] Short-term investments Short-term Investments Total long-term debt Long-term Debt, Gross Long-term debt, fair value Long-term Debt, Fair Value Interest Income (Expense), Net [Abstract] Interest expense Interest Expense Interest income Investment Income, Interest Interest expense, net Interest Income (Expense), Net Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block] Statement of Financial Position [Abstract] Assets: Assets [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Accounts receivable, net Accounts Receivable, Net, Current Inventories Inventory, Net Other current assets Other Assets, Current Total current assets Assets, Current Property and equipment, net Property, Plant and Equipment, Net Goodwill Goodwill Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Other assets Other Assets, Noncurrent Total assets Assets Liabilities: Liabilities [Abstract] Accounts payable Accounts Payable, Current Claims and discounts payable Claims and Discounts Payable Carrying value as of the balance sheet date of claims and discounts payable to clients in accordance with the terms of client contracts, which are normally based on fixed rebates per prescription for specific products dispensed or a percentage of manufacturer discounts received for specific products dispensed Accrued expenses Accrued Liabilities, Current Short-term debt Short-term Debt Current portion of long-term debt Long-term debt, current maturities (including capital leases) Amount of long-term debt, after unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans, capital leases and commercial paper. Total current liabilities Liabilities, Current Long-term debt Long-term debt, excluding current maturities (including capital leases) Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans, capital leases and commercial paper. Deferred income taxes Deferred Tax Liabilities, Net, Noncurrent Other long-term liabilities Other Liabilities, Noncurrent Commitments and contingencies (Note 12) Commitments and Contingencies Redeemable noncontrolling interest Redeemable Noncontrolling Interest, Equity, Carrying Amount Shareholders’ equity: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Preferred stock, par value $0.01: 0.1 share authorized; none issued or outstanding Preferred Stock, Value, Issued Common stock, par value $0.01: 3,200 shares authorized; 1,705 shares issued and 1,066 shares outstanding at September 30, 2016 and 1,699 shares issued and 1,101 shares outstanding at December 31, 2015 Common Stock, Value, Issued Treasury stock, at cost: 638 shares at September 30, 2016 and 597 shares at December 31, 2015 Treasury Stock, Value Shares held in trust: 1 share at September 30, 2016 and December 31, 2015 Common Stock, Shares Held in Employee Trust Capital surplus Additional Paid in Capital Retained earnings Retained Earnings (Accumulated Deficit) Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Total CVS Health shareholders’ equity Stockholders' Equity Attributable to Parent Noncontrolling interest Stockholders' Equity Attributable to Noncontrolling Interest Total shareholders’ equity Total liabilities and shareholders’ equity Liabilities and Equity Business Combinations [Abstract] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Omnicare, Inc. Omnicare, Inc. [Member] Omnicare, Inc. [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Pro Forma Information Business Acquisition, Pro Forma Information [Table Text Block] Redeemable Noncontrolling Interest Redeemable Noncontrolling Interest [Table Text Block] Schedule of New Accounting Pronouncements and Changes in Accounting Principles Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] Payments for Repurchase of Equity [Abstract] Share Repurchase Program Treasury Stock [Text Block] Acquisition Business Combination Disclosure [Text Block] Earnings Per Share [Abstract] Earnings Per Share Earnings Per Share [Text Block] Business Acquisition, Pro Forma Information, Nonrecurring Adjustments [Table] Business Acquisition, Pro Forma Information, Nonrecurring Adjustments [Table] Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items] Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items] Total revenues Business Acquisition, Pro Forma Revenue Income from continuing operations Business Acquisition, Pro Forma Income (Loss) from Continuing Operations before Changes in Accounting and Extraordinary Items, Net of Tax Earnings per share from continuing operations: Basic earnings per share (in dollars per share) Business Acquisition, Pro Forma Earnings Per Share, Basic Diluted earnings per share (in dollars per share) Business Acquisition, Pro Forma Earnings Per Share, Diluted Goodwill and Intangible Assets Disclosure [Abstract] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Customer Contracts Relationships and Covenants Not to Compete Customer Contracts Relationships and Covenants Not to Compete [Member] Represents customer contracts and relationships and covenants not to compete. Favorable Leases and Other Favorable Leases and Other [Member] Represents favorable leases and other. Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Indefinite-lived intangible assets (excluding goodwill) Indefinite-Lived Intangible Assets (Excluding Goodwill) Intangible assets, gross Intangible Assets, Gross (Excluding Goodwill) Intangible assets, accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Intangible assets, net Principles of Consolidation Consolidation, Policy [Policy Text Block] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Redeemable Noncontrolling Interest Redeemable Noncontrolling Interest [Policy Text Block] Disclosure of accounting policy for the redeemable noncontrolling interests included in the statement of financial position. New Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Stock-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Reconciliation of basic and diluted earnings per common share Earnings Per Share Reconciliation [Abstract] Numerator for earnings per share calculations: Net Income (Loss) Attributable to Parent [Abstract] Income from continuing operations Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest Income allocated to participating securities Undistributed Earnings (Loss) Allocated to Participating Securities, Basic Net income attributable to noncontrolling interest Net Income (Loss) Attributable to Noncontrolling Interest Income from continuing operations attributable to CVS Health Income (Loss) from Continuing Operations Attributable to Parent Denominators for earnings per share calculations: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Weighted averages shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Stock options (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Weighted averages shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Earnings per share from continuing operations: Earnings Per Share, Basic and Diluted [Abstract] Income from continuing operations attributable to CVS Health (in dollars per share) Income (Loss) from Continuing Operations, Per Basic Share Income from continuing operations attributable to CVS Health (in dollars per share) Income (Loss) from Continuing Operations, Per Diluted Share Noncontrolling Interest [Table] Noncontrolling Interest [Table] NCRX NCRX [Member] NCRX [Member] Noncontrolling Interest [Line Items] Noncontrolling Interest [Line Items] Outstanding common shares and voting interests acquired (percent) Business Acquisition, Percentage of Voting Interests Acquired Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward] Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward] Beginning balance Net income attributable to noncontrolling interest Net Income (Loss) Attributable to Redeemable Noncontrolling Interest Distributions Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Purchase of noncontrolling interest Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests Reclassification to capital surplus in connection with purchase of noncontrolling interest Noncontrolling Interest, Reclassification to Capital Surplus Noncontrolling Interest, Reclassification to Capital Surplus Ending balance Commitments and Contingencies Disclosure [Abstract] Loss Contingencies [Table] Loss Contingencies [Table] Litigation Case [Axis] Litigation Case [Axis] Litigation Case [Domain] Litigation Case [Domain] Lauriello Lawsuit Lauriello Lawsuit [Member] Represents putative class action lawsuit filed by John Lauriello in Alabama state court. North Jackson Pharmacy, Inc. and C&C, Inc. d/b/a Big C Discount Drugs, Inc. vs Caremark North Jackson Pharmacy, Inc. and C&C, Inc. d/b/a Big C Discount Drugs, Inc. vs Caremark Case [Member] North Jackson Pharmacy, Inc. and C&C, Inc. d/b/a Big C Discount Drugs, Inc. vs Caremark Case [Member] Wuotila Derivative Matter Wuotila Derivative Matter [Member] Wuotila Derivative Matter [Member] Banigan and Templin v. Organon USA, Inc., Omnicare, Inc. and PharMerica Corporation Banigan and Templin v. Organon USA, Inc., Omnicare, Inc. and PharMerica Corporation [Member] Banigan and Templin v. Organon USA, Inc., Omnicare, Inc. and PharMerica Corporation [Member] Darlene Ervin v. Omnicare, Inc. Darlene Ervin v. Omnicare, Inc. [Member] Darlene Ervin v. Omnicare, Inc. [Member] Pure Service Pharmacy Acquisition [Member] Pure Service Pharmacy Acquisition [Member] Pure Service Pharmacy Acquisition [Member] Omnicare Auto Label Verification System [Member] Omnicare Auto Label Verification System [Member] Omnicare Auto Label Verification System [Member] Spetter v. Abbott Laboratories, Inc., Omnicare, Inc., and PharMerica Corp. Spetter v. Abbott Laboratories, Inc., Omnicare, Inc., and PharMerica Corp. [Member] Spetter v. Abbott Laboratories, Inc., Omnicare, Inc., and PharMerica Corp. [Member] Sheet Metal Workers Local No. 20 Welfare and Benefit Fund v. CVS Health Corp. Sheet Metal Workers Local No. 20 Welfare and Benefit Fund v. CVS Health Corp. [Member] Sheet Metal Workers Local No. 20 Welfare and Benefit Fund v. CVS Health Corp. [Member] Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Loss contingencies Loss Contingencies [Line Items] Number of store leases guaranteed Guaranteed Store Leases Represents the number of store leases guaranteed by the reporting entity. Year the last lease expires Year the Last Lease Expires Year the Last Lease Expires Settlement agreement in principle medoff securities class action lawsuit Litigation Settlement, Amount Number of pharmacies filing putative action Number of Pharmacies Filing Putative Action Represents the number of independent pharmacies which have filed putative class action against the reporting entity. Number of competitors against whom putative actions are filed Loss Contingency, New Claims Filed, Number Number of Caremark entities named as defendants Loss Contingency, Number of Defendants Number of competitors against whom putative actions are filed Number of Competitors Against Whom Putative Actions are Filed Represents the number of competitors against whom putative class action has been filed by independent pharmacies. Number of officers named in lawsuit Loss Contingency, Number of Officers Named in Lawsuit Loss Contingency, Number of Officers Named in Lawsuit Number of directors named in lawsuit Loss Contingency, Number of Directors Named in Lawsuit Loss Contingency, Number of Directors Named in Lawsuit Number of states participating in multi-state investigation Number of States Participating in Multi State Investigations Represents the number of states participating in multi-state investigation under Federal Trade Commission Act. Number of former employees Litigation Settlement, Number of Former Employees Litigation Settlement, Number of Former Employees Corporate integrity agreement term (in years) Loss Contingency, Corporate Integrity Agreement Term Loss Contingency, Corporate Integrity Agreement Term Cases consolidated, number Loss Contingency, Cases Consolidated, Number Loss Contingency, Cases Consolidated, Number Number of states in which plaintiffs reside Loss Contingency, Number of States in which Plaintiffs Reside Loss Contingency, Number of States in which Plaintiffs Reside Number of pharmacies filing putative action Loss Contingency, Number of Plaintiffs Number of pharmacies indicated in subpoena Loss Contingency, Number of Pharmacies Indicated in Subpoena Loss Contingency, Number of Pharmacies Indicated in Subpoena Litigation settlement, expense Litigation Settlement, Expense Preferred Stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred Stock, shares authorized (in shares) Preferred Stock, Shares Authorized Preferred Stock, shares issued (in shares) Preferred Stock, Shares Issued Preferred Stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (in shares) Common Stock, Shares Authorized Common stock, shares issued (in shares) Common Stock, Shares, Issued Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Treasury stock, shares (in shares) Treasury Stock, Shares Shares held in trust, shares (in shares) Common Stock, Shares Held in Employee Trust, Shares Debt Disclosure [Abstract] Borrowings Debt Disclosure [Text Block] Statement of Cash Flows [Abstract] Cash flows from operating activities: Operating Cash Flows, Direct Method [Abstract] Cash receipts from customers Proceeds from Customers Cash paid for inventory and prescriptions dispensed by retail network pharmacies Payments to Suppliers Cash paid to other suppliers and employees Payments to Suppliers and Employees Interest received Proceeds from Interest Received Interest paid Interest Paid Income taxes paid Income Taxes Paid Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Proceeds from sale of property and equipment and other assets Proceeds from Sale of Property, Plant, and Equipment and Other Assets The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale and other assets. Acquisitions (net of cash acquired) and other investments Payments to Acquire Businesses, Net of Cash Acquired Purchase of available-for-sale investments Payments to Acquire Available-for-sale Securities Sales/maturities of available-for-sale investments Proceeds from Sale and Maturity of Available-for-sale Securities Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Increase in short-term debt Proceeds from (Repayments of) Short-term Debt Proceeds from issuance of long-term debt Proceeds from Issuance of Long-term Debt Repayments of long-term debt Repayments of Long-term Debt Purchase of noncontrolling interest in subsidiary Purchase of Noncontrolling Interest in Subsidiary The cash outflow for purchase of noncontrolling interest in subsidiary during the reporting period. Payment of contingent consideration Payment for Contingent Consideration Payment for Contingent Consideration Dividends paid Payments of Dividends Proceeds from exercise of stock options Proceeds from Stock Options Exercised Excess tax benefits from stock-based compensation Excess Tax Benefit from Share-based Compensation, Financing Activities Repurchase of common stock Payments for Repurchase of Common Stock Other Proceeds from (Payments for) Other Financing Activities Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash and Cash Equivalents Net increase (decrease) in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Reconciliation of net income to net cash provided by operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Stock-based compensation Share-based Compensation Loss on early extinguishment of debt Gains (Losses) on Extinguishment of Debt Deferred income taxes and other noncash items Deferred Income Tax (Expense) Benefit and Other Non Cash Items Represents deferred income tax expense / benefit and other non cash items for the applicable period. Change in operating assets and liabilities, net of effects from acquisitions: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable, net Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Other current assets Increase (Decrease) in Other Current Assets Other assets Increase (Decrease) in Other Operating Assets Accounts payable and claims and discounts payable Increase (Decrease) in Accounts Payable Accrued expenses Increase (Decrease) in Accrued Liabilities Other long-term liabilities Increase (Decrease) in Other Operating Liabilities Segment Reporting [Abstract] Segment Reporting Segment Reporting Disclosure [Text Block] Accumulated Other Comprehensive Income Stockholders' Equity Note Disclosure [Text Block] Schedule of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Schedule of Indefinite-Lived Intangible Assets Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Reconciliation of the Company's business segments to the consolidated financial statements Schedule of Segment Reporting Information, by Segment [Table Text Block] Goodwill and Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Income Statement [Abstract] Net revenues Revenues Cost of revenues Cost of Revenue Gross profit Gross Profit Operating expenses Operating Expenses Operating profit Operating Income (Loss) Interest expense, net Income before income tax provision Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest Income tax provision Income Tax Expense (Benefit) Income from continuing operations Income (loss) from discontinued operations, net of tax Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Net income Net income attributable to CVS Health Net Income (Loss) Available to Common Stockholders, Basic Basic earnings per share: Income from discontinued operations attributable to CVS Health (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Earnings per share, basic (in dollars per share) Earnings Per Share, Basic Diluted earnings per share: Income from discontinued operations attributable to CVS Health (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Earnings per share, diluted (in dollars per share) Earnings Per Share, Diluted Weighted averages shares outstanding, diluted (in shares) Dividends declared per share (in dollars per share) Common Stock, Dividends, Per Share, Declared New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Adjustments for New Accounting Principle, Early Adoption Adjustments for New Accounting Principle, Early Adoption [Member] Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Scenario, Previously Reported Scenario, Previously Reported [Member] Restatement Adjustment Restatement Adjustment [Member] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Deferred tax assets - current Deferred Tax Assets, Net, Current Total current assets Total assets Deferred tax liabilities - noncurrent Total liabilities and shareholders’ equity Sale-Leaseback Transactions Sale Leaseback Transaction Disclosure [Text Block] Reconciliation of basic and diluted earnings per common share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Components of net interest expense Schedule of Other Nonoperating Income (Expense) [Table Text Block] Class of Treasury Stock [Table] Class of Treasury Stock [Table] Share Repurchase Program [Axis] Share Repurchase Program [Domain] 2016 Repurchase Program Repurchase Program, 2016 [Member] Repurchase Program, 2016 [Member] Repurchase Program 2014 Repurchase Program 2014 [Member] Repurchase Program 2014 [Member] Repurchase Program 2013 Repurchase Program 2013 [Member] Repurchase Program 2013 [Member] Accelerated Share Repurchases, Date [Axis] Accelerated Share Repurchases, Date [Axis] Accelerated Share Repurchases, Date [Domain] Accelerated Share Repurchases, Date [Domain] December 11, 2015 December 11, 2015 [Member] December 11, 2015 [Member] Equity, Class of Treasury Stock [Line Items] Equity, Class of Treasury Stock [Line Items] Maximum authorization under share repurchase program Stock Repurchase Program, Authorized Amount Remaining authorized repurchase amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Repurchase of common stock (in shares) Stock Repurchased During Period, Shares Value of stock repurchased in the period Stock Repurchased During Period, Value Accelerated share repurchases agreement amount Accelerated Share Repurchases Agreement Amount Represents the agreement amount under the entity's fixed dollar accelerated share repurchase agreement with Barclays Bank PLC. Percent of notional amount received in shares Accelerated Share Repurchases, Percent of Notional Amount Received in Shares Accelerated Share Repurchases, Percent of Notional Amount Received in Shares Accelerated share repurchases number of shares repurchased (in shares) Accelerated Share Repurchases Number of Shares Repurchased Represents the number of shares of common stock repurchased under the entity's fixed dollar accelerated share repurchase agreement with Barclays Bank PLC. Accelerated share repurchases, settlement (payment) or receipt Accelerated Share Repurchases, Settlement (Payment) or Receipt Percent of notional amount in shares to be received at end of program Accelerated Share Repurchases, Percent of Notional Amount in Shares to be Received at End of Program Accelerated Share Repurchases, Percent of Notional Amount in Shares to be Received at End of Program Schedule of Activity Within the Components of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Heartland Healthcare Services Heartland Healthcare Services [Member] Heartland Healthcare Services [Member] Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] Equity Method Investee Equity Method Investee [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Amounts of transaction Related Party Transaction, Amounts of Transaction Number of states pharmacies operated Number of States in which Entity Operates Other revenues from transactions with related party Related Party Transaction, Other Revenues from Transactions with Related Party Charitable Contribution to the CVS Foundation Charitable Contribution to the CVS Foundation Charitable Contribution to the CVS Foundation Document and Entity Information -- None. No documentation exists for this element. -- Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Document Type Document Type Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Schedule of outstanding share repurchase programs Schedule of outstanding share repurchase programs [Table Text Block] [Table Text Block] for Schedule of outstanding share repurchase programs [Table] Business acquisition, share price (in dollars per share) Business Acquisition, Share Price Consideration transferred Business Combination, Consideration Transferred Consideration transferred, liabilities incurred Business Combination, Consideration Transferred, Liabilities Incurred Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Unsecured Debt Unsecured Debt [Member] Senior Notes Senior Notes [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Unsecured Senior Notes 2.125% Due in 2021 Unsecured Senior Notes 2.125% Due in 2021 [Member] Unsecured Senior Notes 2.125% Due in 2021 [Member] Unsecured Senior Notes 2.875% Due in 2026 Unsecured Senior Notes 2.875% Due in 2026 [Member] Unsecured Senior Notes 2.875% Due in 2026 [Member] 2016 Notes 2016 Notes [Member] 2016 Notes [Member] Unsecured Senior Notes 5.75% Due in 2017 Unsecured Senior Notes 5.75 Percent Due in 2017 [Member] Represents the unsecured senior notes bearing an interest rate of 5.75 percent and due in 2017. Unsecured Senior Notes 6.6% Due in 2019 Unsecured Senior Notes 6.6 Percent Due in 2019 [Member] Represents the unsecured senior notes bearing an interest rate of 6.6 percent and due in 2019. Unsecured Senior Notes 4.75% Due in 2020 Unsecured Senior Notes 4.75 Percent Due in 2020 [Member] Represents the unsecured senior notes bearing an interest rate of 4.75 percent and due in 2020. Maximum Tender Offer Notes Maximum Tender Offer Notes [Member] Maximum Tender Offer Notes [Member] The Notes [Member] The Notes [Member] The Notes [Member] Unsecured Senior Notes 6.25% Due in 2027 Unsecured Senior Notes 6.25 Percent Due in 2027 [Member] Represents the unsecured senior notes bearing an interest rate of 6.25 percent and due in 2027. Unsecured Senior Notes 6.125% Due in 2039 Unsecured Senior Notes 6.125 Percent Due in 2039 [Member] Represents the unsecured senior notes bearing an interest rate of 6.125 percent and due in 2039. Unsecured Senior Notes 5.75% Due in 2041 Unsecured Senior Notes 5.75 Percent Due in 2041 [Member] Represents the unsecured senior notes bearing an interest rate of 5.75 percent and due in 2041. Unsecured Senior Notes 5.00% Due in 2024 Unsecured Senior Notes 5.00 Percent Due in 2024 [Member] Unsecured Senior Notes 5.00 Percent Due in 2024 [Member] Unsecured Senior Notes 4.75% Due in 2022 Unsecured Senior Notes 4.75% Due in 2022 [Member] Unsecured Senior Notes 4.75% Due in 2022 [Member] Unsecured Senior Notes 4.875% Due in 2035 Unsecured Senior Notes 4.875% Due in 2035 [Member] Unsecured Senior Notes 4.875% Due in 2035 [Member] Unsecured Senior Notes 3.875% Due in 2025 Unsecured Senior Notes 3.875% Due in 2025 [Member] Unsecured Senior Notes 3.875% Due in 2025 [Member] Any and All Notes Any and All Notes [Member] Any and All Notes [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Aggregate principal amount Debt Instrument, Face Amount Interest rate, stated percentage Debt Instrument, Interest Rate, Stated Percentage Authorized face amount to be repurchased Debt Instrument, Authorized Face Amount to be Repurchased Debt Instrument, Authorized Face Amount to be Repurchased Repurchased face amount Debt Instrument, Repurchased Face Amount Payment of debt premium Debt Instrument, Redemption, Redemption Premium Debt Instrument, Redemption, Redemption Premium Write off of deferred debt issuance cost Write off of Deferred Debt Issuance Cost Payments of debt extinguishment costs Payments of Debt Extinguishment Costs Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Employee Stock Option Employee Stock Option [Member] Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock-based compensation expense Allocated Share-based Compensation Expense Options, grants in period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Options, grants in period, weighted average grant date fair value (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Options, grants in period, weighted average exercise price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Options, outstanding (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Options, outstanding, weighted average exercise price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Options, outstanding, weighted average remaining contractual term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Equity instruments other than options, grants in period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Equity instruments other than options, grants in period, weighted average grant date fair value (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Equity instruments other than options, nonvested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Equity instruments other than options, nonvested, weighted average grant date fair value (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Accounting Policies Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Segment Information by Services [Axis] Segment Information by Services [Axis] The information about types of services of business segments. Segment Information by Services [Domain] Segment Information by Services [Domain] Various types of services of business segments. Specialty stores Specialty Stores [Member] Represents the information about specialty stores of the entity. Specialty mail order Specialty Mail Order [Member] Represents the information about specialty mail order of the entity. Mail service Mail Service [Member] Represents the information about mail service of the entity. Infusion and Enteral Branches Infusion and Enteral Branches [Member] Infusion and Enteral Branches [Member] Ambulatory infusion suites Ambulatory infusion suites [Member] Ambulatory infusion suites [Member] Target Pharmacy Acquisition Target Pharmacy Acquisition [Member] Target Pharmacy Acquisition [Member] Products and Services [Axis] Products and Services [Axis] Products and Services [Domain] Products and Services [Domain] CarePlus and CVS Pharmacy CarePlus and CVS Pharmacy [Member] CarePlus and CVS Pharmacy [Member] MinuteClinic Minute Clinic [Member] Represents the MinuteClinic, a division of the entity. Major Customers [Axis] Customer [Axis] Name of Major Customer [Domain] Customer [Domain] MinuteClinic within CVS Pharmacy Stores Minute Clinic Within C V S Pharmacy Stores [Member] Represents the information about MinuteClinic within CVS Pharmacy Stores of the entity. Consolidation Items [Axis] Consolidation Items [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Operating Segments Operating Segments [Member] Intersegment Eliminations Intersegment Eliminations [Member] Statement, Business Segments [Axis] Segments [Axis] Segments [Domain] Segments [Domain] Pharmacy Services Segment Pharmacy Services Segment [Member] Represents the Pharmacy Services Segment of the entity. Retail/LTC Segment Retail/LTC Segment [Member] Represents the Retail/LTC Segment of the entity. Corporate Segment Corporate Segment [Member] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Gross Profit Gross Profit [Member] Gross Profit [Member] Operating Income (Loss) Operating Income (Loss) [Member] Segment reporting information Segment Reporting Information [Line Items] Number of segments Number of Reportable Segments Number of pharmacies Number of Pharmacies The number of pharmacies through which the reporting entity supplies pharmaceuticals. Number of infusion and enteral branches Number of Infusion and Enteral Branches Number of Infusion and Enteral Branches Number of centers of excellence for infusion and enteral services Centers of Excellence for Infusion and Enteral Services Centers of Excellence for Infusion and Enteral Services Number of pharmacies acquired Number of Pharmacies Acquired Number of Pharmacies Acquired Number of retail drugstores Number of Retail Drugstores The number of retail drugstores operated by the entity. Number of retail drugstores operating a pharmacy Number of retail drugstores operating a pharmacy Number of retail drugstores operating a pharmacy Number of clinics Number of clinics Number of clinics Number of clinics in retail drugstores Number of clinics in retail drugstores Number of clinics in retail drugstores Number of LTC spoke pharmacies Number of LTC spoke pharmacies Number of LTC spoke pharmacies Number of LTC hub pharmacies Number of LTC hub pharmacies Number of LTC hub pharmacies Net revenues Gross profit Operating profit (loss) Net revenues, retail co-payments Co Payment Revenue A fixed fee that subscribers to a medical plan must pay for use of entity medical services covered by the plan. Integration related costs Business Combination, Integration Related Costs Acquisition related costs Business Combination, Acquisition Related Costs Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Interest Expense Interest Income and Interest Expense Disclosure [Text Block] Statement of Comprehensive Income [Abstract] Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] Foreign currency translation adjustments, net of tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Cash flow hedges, net of tax Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax Comprehensive income Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive income attributable to noncontrolling interest Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Comprehensive income attributable to CVS Health Comprehensive Income (Loss), Net of Tax, Attributable to Parent EX-101.PRE 12 cvs-20160930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 13 a1282016cvslogoa02.gif begin 644 a1282016cvslogoa02.gif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end XML 14 R1.htm IDEA: XBRL DOCUMENT v3.5.0.2
Document and Entity Information - shares
 9 Months Ended
Sep. 30, 2016
Nov. 01, 2016
Document and Entity Information    
Entity Registrant Name CVS HEALTH CORPORATION  
Entity Central Index Key 0000064803  
Current Fiscal Year End Date --12-31  
Entity Filer Category Large Accelerated Filer  
Document Type 10-Q  
Document Period End Date Sep. 30, 2016  
Document Fiscal Year Focus 2016  
Document Fiscal Period Focus Q3  
Amendment Flag false  
Entity Common Stock, Shares Outstanding (in shares)   1,066,439,174
XML 15 R2.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements of Income - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Income Statement [Abstract]        
Net revenues $ 44,615 $ 38,644 $ 131,555 $ 112,144
Cost of revenues 37,123 31,983 110,304 92,917
Gross profit 7,492 6,661 21,251 19,227
Operating expenses 4,675 4,330 13,908 12,502
Operating profit 2,817 2,331 7,343 6,725
Interest expense, net 253 261 816 562
Loss on early extinguishment of debt 101 0 643 0
Income before income tax provision 2,463 2,070 5,884 6,163
Income tax provision 921 833 2,271 2,433
Income from continuing operations 1,542 1,237 3,613 3,730
Income (loss) from discontinued operations, net of tax (1) 10 (1) 10
Net income 1,541 1,247 3,612 3,740
Net income attributable to noncontrolling interest (1) (1) (2) (1)
Net income attributable to CVS Health $ 1,540 $ 1,246 $ 3,610 $ 3,739
Basic earnings per share:        
Income from continuing operations attributable to CVS Health (in dollars per share) $ 1.44 $ 1.10 $ 3.34 $ 3.31
Income from discontinued operations attributable to CVS Health (in dollars per share) 0.00 0.01 0.00 0.01
Earnings per share, basic (in dollars per share) $ 1.44 $ 1.11 $ 3.34 $ 3.32
Weighted averages shares outstanding, basic (in shares) 1,068 1,114 1,076 1,122
Diluted earnings per share:        
Income from continuing operations attributable to CVS Health (in dollars per share) $ 1.43 $ 1.10 $ 3.32 $ 3.28
Income from discontinued operations attributable to CVS Health (in dollars per share) 0.00 0.01 0.00 0.01
Earnings per share, diluted (in dollars per share) $ 1.43 $ 1.11 $ 3.32 $ 3.29
Weighted averages shares outstanding, diluted (in shares) 1,073 1,121 1,082 1,130
Dividends declared per share (in dollars per share) $ 0.425 $ 0.350 $ 1.275 $ 1.050
XML 16 R3.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements of Comprehensive Income - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Statement of Comprehensive Income [Abstract]        
Net income $ 1,541 $ 1,247 $ 3,612 $ 3,740
Other comprehensive income (loss):        
Foreign currency translation adjustments, net of tax (3) (61) 37 (100)
Cash flow hedges, net of tax 1 0 2 1
Net other comprehensive income (loss) (2) (61) 39 (99)
Comprehensive income 1,539 1,186 3,651 3,641
Comprehensive income attributable to noncontrolling interest (1) (1) (2) (1)
Comprehensive income attributable to CVS Health $ 1,538 $ 1,185 $ 3,649 $ 3,640
XML 17 R4.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2016
Dec. 31, 2015
Assets:    
Cash and cash equivalents $ 2,189 $ 2,459
Short-term investments 74 88
Accounts receivable, net 13,625 11,888
Inventories 14,348 14,001
Other current assets 703 722
Total current assets 30,939 29,158
Property and equipment, net 9,901 9,855
Goodwill 38,214 38,106
Intangible assets, net 13,567 13,878
Other assets 1,535 1,440
Total assets 94,156 92,437
Liabilities:    
Accounts payable 7,584 7,490
Claims and discounts payable 9,178 7,653
Accrued expenses 8,856 6,829
Short-term debt 340 0
Current portion of long-term debt 783 1,197
Total current liabilities 26,741 23,169
Long-term debt 25,610 26,267
Deferred income taxes 4,254 4,217
Other long-term liabilities 1,597 1,542
Commitments and contingencies (Note 12) 0 0
Redeemable noncontrolling interest 0 39
Shareholders’ equity:    
Preferred stock, par value $0.01: 0.1 share authorized; none issued or outstanding 0 0
Common stock, par value $0.01: 3,200 shares authorized; 1,705 shares issued and 1,066 shares outstanding at September 30, 2016 and 1,699 shares issued and 1,101 shares outstanding at December 31, 2015 17 17
Treasury stock, at cost: 638 shares at September 30, 2016 and 597 shares at December 31, 2015 (32,991) (28,886)
Shares held in trust: 1 share at September 30, 2016 and December 31, 2015 (31) (31)
Capital surplus 31,541 30,948
Retained earnings 37,732 35,506
Accumulated other comprehensive income (loss) (319) (358)
Total CVS Health shareholders’ equity 35,949 37,196
Noncontrolling interest 5 7
Total shareholders’ equity 35,954 37,203
Total liabilities and shareholders’ equity $ 94,156 $ 92,437
XML 18 R5.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2016
Dec. 31, 2015
Statement of Financial Position [Abstract]    
Preferred Stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred Stock, shares authorized (in shares) 100,000.0 100,000.0
Preferred Stock, shares issued (in shares) 0 0
Preferred Stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 3,200,000,000 3,200,000,000
Common stock, shares issued (in shares) 1,705,000,000 1,699,000,000
Common stock, shares outstanding (in shares) 1,066,000,000 1,101,000,000
Treasury stock, shares (in shares) 638,000,000 597,000,000
Shares held in trust, shares (in shares) 1,000,000 1,000,000
XML 19 R6.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Cash flows from operating activities:    
Cash receipts from customers $ 128,545 $ 108,324
Cash paid for inventory and prescriptions dispensed by retail network pharmacies (106,371) (89,530)
Cash paid to other suppliers and employees (11,092) (11,240)
Interest received 14 15
Interest paid (954) (423)
Income taxes paid (2,194) (2,305)
Net cash provided by operating activities 7,948 4,841
Cash flows from investing activities:    
Purchases of property and equipment (1,607) (1,490)
Proceeds from sale-leaseback transactions 230 34
Proceeds from sale of property and equipment and other assets 22 28
Acquisitions (net of cash acquired) and other investments (333) (9,503)
Purchase of available-for-sale investments (40) (184)
Sales/maturities of available-for-sale investments 76 115
Net cash used in investing activities (1,652) (11,000)
Cash flows from financing activities:    
Increase in short-term debt 340 (685)
Proceeds from issuance of long-term debt 3,455 14,808
Repayments of long-term debt (5,185) (2,898)
Purchase of noncontrolling interest in subsidiary (39) 0
Payment of contingent consideration 26 0
Dividends paid (1,384) (1,185)
Proceeds from exercise of stock options 205 277
Excess tax benefits from stock-based compensation 72 132
Repurchase of common stock (4,000) (3,871)
Other (6) (2)
Net cash provided by (used in) financing activities (6,568) 6,576
Effect of exchange rate changes on cash and cash equivalents 2 (8)
Net increase (decrease) in cash and cash equivalents (270) 409
Cash and cash equivalents at beginning of period 2,459 2,481
Cash and cash equivalents at end of period 2,189 2,890
Reconciliation of net income to net cash provided by operating activities:    
Net income 3,612 3,740
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 1,847 1,510
Stock-based compensation 166 175
Loss on early extinguishment of debt 643 0
Deferred income taxes and other noncash items 119 (184)
Change in operating assets and liabilities, net of effects from acquisitions:    
Accounts receivable, net (1,714) (2,530)
Inventories (337) (893)
Other current assets 2 591
Other assets (86) (13)
Accounts payable and claims and discounts payable 1,570 2,038
Accrued expenses 2,077 523
Other long-term liabilities 49 (116)
Net cash provided by operating activities $ 7,948 $ 4,841
XML 20 R7.htm IDEA: XBRL DOCUMENT v3.5.0.2
Accounting Policies
 9 Months Ended
Sep. 30, 2016
Accounting Policies [Abstract]  
Accounting Policies
Accounting Policies
 
Basis of Presentation
 
The accompanying unaudited condensed consolidated financial statements of CVS Health Corporation and its subsidiaries (collectively, “CVS Health” or the “Company”) have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. In accordance with such rules and regulations, certain information and accompanying note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted, although the Company believes the disclosures included herein are adequate to make the information presented not misleading. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto, which are included in Exhibit 13 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 (“2015 Form 10-K”).

In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods presented. Because of the influence of various factors on the Company’s operations, including business combinations, certain holidays and other seasonal influences, net income for any interim period may not be comparable to the same interim period in previous years or necessarily indicative of income for the full year.

Principles of Consolidation
 
The condensed consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries and variable interest entities (“VIEs”) for which the Company is the primary beneficiary. All material intercompany balances and transactions have been eliminated.

The Company continually evaluates its investments to determine if they represent variable interests in a VIE. If the Company determines that it has a variable interest in a VIE, the Company then evaluates if it is the primary beneficiary of the VIE. The evaluation is a qualitative assessment as to whether the Company has the ability to direct the activities of a VIE that most significantly impact the entity’s economic performance. The Company consolidates a VIE if it is considered to be the primary beneficiary.

Assets and liabilities of VIEs for which the Company is the primary beneficiary were not significant to the Company’s condensed consolidated financial statements. VIE creditors do not have recourse against the general credit of the Company.
 
Fair Value of Financial Instruments
 
The Company utilizes the three-level valuation hierarchy for the recognition and disclosure of fair value measurements. The categorization of assets and liabilities within this hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy consist of the following:
 
•
Level 1 – Inputs to the valuation methodology are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
 
•
Level 2 – Inputs to the valuation methodology are quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active or inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the instrument.

•
Level 3 – Inputs to the valuation methodology are unobservable inputs based upon management’s best estimate of inputs market participants could use in pricing the asset or liability at the measurement date, including assumptions about risk.
 

As of September 30, 2016, the carrying value of cash and cash equivalents, short-term investments, accounts receivable and accounts payable approximated their fair value due to the nature of these financial instruments. The Company invests in money market funds, commercial paper and time deposits that are classified as cash and cash equivalents within the accompanying condensed consolidated balance sheets, as these funds are highly liquid and readily convertible to known amounts of cash. These investments are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. The Company’s short-term investments of $74 million at September 30, 2016 consist of certificates of deposit with initial maturities of greater than three months when purchased that mature within one year from the balance sheet date. These investments, which are classified within Level 1 of the fair value hierarchy, are carried at fair value, which approximated historical cost at September 30, 2016. The carrying amount and estimated fair value of the Company’s total long-term debt was $26.4 billion and $28.7 billion, respectively, as of September 30, 2016. The fair value of the Company’s long-term debt was estimated based on quoted prices currently offered in active markets for the Company’s debt, which is considered Level 1 of the fair value hierarchy.

Redeemable Noncontrolling Interest

As a result of the acquisition of Omnicare, Inc. (“Omnicare”) in August 2015, the Company obtained a 73% ownership interest in a limited liability company (“LLC”). Due to the change in control in Omnicare, the noncontrolling member of the LLC had the contractual right to put its membership interest to the Company at fair value. Consequently, the noncontrolling interest in the LLC was recorded as a redeemable noncontrolling interest at fair value. During the first quarter of 2016, the noncontrolling shareholder of the LLC exercised its option to sell its ownership interest and the Company purchased the noncontrolling interest in the LLC for approximately $39 million.

Below is a summary of the changes in the redeemable noncontrolling interest for the nine months ended September 30, 2016:
In millions
 
 
Beginning balance
$
39

 
Net income attributable to noncontrolling interest
1

 
Distributions
(2
)
 
Purchase of noncontrolling interest
(39
)
 
Reclassification to capital surplus in connection with purchase of noncontrolling interest
1

 
Ending balance
$
—

 


Related Party Transactions

The Company has an equity method investment in SureScripts, LLC (“SureScripts”), which operates a clinical health information network. The Pharmacy Services and Retail/LTC segments utilize this clinical health information network in providing services to its client plan members and retail customers. The Company expensed fees for the use of this network of approximately $7 million and $16 million in the three months ended September 30, 2016 and 2015, respectively, and expensed fees of $29 million and $37 million in the nine months ended September 30, 2016 and 2015, respectively. The Company’s investment in and equity in earnings of SureScripts for all periods presented is immaterial.

In connection with the acquisition of Omnicare in August 2015, the Company obtained an equity method investment in Heartland Healthcare Services, LLC (“Heartland”). Heartland operates several long-term care pharmacies in four states. Heartland paid the Company approximately $46 million and $116 million for pharmaceutical inventory purchases during the three and nine months ended September 30, 2016, respectively. Additionally, the Company performs certain collection functions for Heartland and then passes those customer cash collections to Heartland. The Company’s investment in Heartland as of December 31, 2015 and September 30, 2016 and equity in earnings of Heartland for the three and nine months ended September 30, 2016 is immaterial.

In April 2016, the Company made a charitable contribution of $32 million to the CVS Foundation (the “Foundation”) to fund future giving. The Foundation is a non-profit entity that focuses on health, education and community involvement programs. The charitable contribution was recorded as an operating expense in the condensed consolidated statement of income for the nine months ended September 30, 2016.




New Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 outlines a single comprehensive model for companies to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. In March 2016, the FASB issued ASU 2016-08, “Principal Versus Agent Considerations (Reporting Revenue Gross Versus Net),” which amends the principal-versus-agent implementation guidance and in April 2016 the FASB issued ASU 2016-10, "Identifying Performance Obligations and Licensing," which amends the guidance in those areas in the new revenue recognition standard. Both ASU's were issued in response to feedback received from the FASB-International Accounting Standards Board joint revenue recognition transition resource group. This new revenue standard is effective for annual reporting periods (including interim reporting periods within those periods) beginning January 1, 2018; early adoption in 2017 is permitted. Companies have the option of using either a full retrospective or a modified retrospective approach to adopt the guidance. This standard could impact the timing and amounts of revenue recognized. The Company is currently evaluating the effect that implementation of this standard will have on its consolidated financial position and results of operations upon adoption, as well as the method of transition and required disclosures.
In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740). The new guidance simplifies the presentation of deferred income taxes by requiring that deferred tax assets and liabilities be classified as noncurrent in a classified statement of financial position. The updated standard is effective for the Company beginning on January 1, 2017 with early application permitted as of the beginning of any interim or annual reporting period. The Company elected to early adopt this standard as of January 1, 2016 and has, accordingly, reclassified the current deferred tax assets to noncurrent deferred tax liabilities for all periods presented. The following is a reconciliation of the effect of the reclassification on the Company's condensed consolidated balance sheet as of December 31, 2015:
In millions
 
As Previously Reported
 
Adjustments
 
As Revised
Deferred tax assets - current
 
$
1,220

 
$
(1,220
)
 
$
—

Total current assets
 
30,378

 
(1,220
)
 
29,158

Total assets
 
93,657

 
(1,220
)
 
92,437

Deferred tax liabilities - noncurrent
 
5,437

 
(1,220
)
 
4,217

Total liabilities and shareholders’ equity
 
93,657

 
(1,220
)
 
92,437



In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). Lessees will be required to recognize a right-of-use asset and a lease liability for virtually all of their leases (other than leases that meet the definition of a short-term lease). The liability will be equal to the present value of lease payments. The asset will be based on the liability, subject to adjustment, such as for initial direct costs. For income statement purposes, a dual model was retained, requiring leases to be classified as either operating or finance leases. Operating leases will result in straight-line expense (similar to current operating leases) while finance leases will result in a front-loaded expense pattern (similar to current capital leases). Lessor accounting is similar to the current model, but updated to align with certain changes to the lessee model (e.g., certain definitions, such as initial direct costs, have been updated) and the new revenue recognition standard. The standard is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The Company believes that the new standard will have a material impact on its consolidated balance sheet but it will not have a material impact on its liquidity. The Company is currently evaluating the effect that implementation of this standard will have on its consolidated results of operations upon adoption.

In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting, which amends Accounting Standard Codification Topic 718, Compensation - Stock Compensation, in three areas. (1) The new guidance eliminates accounting for tax benefits and deficiencies through equity to the extent of previous windfalls, and then to the income statement. The new requirement is to record all tax benefits and deficiencies through the income statement. This amendment is required to be applied prospectively. The amendment also requires the presentation of excess tax benefits on the statements of cash flows as operating activities, a change which may be applied prospectively or retrospectively at the election of the Company. The amendment requires the presentation of employee taxes paid on the statement of cash flows when an employer withholds shares for tax withholding purposes as financing activities, a change which must be applied retrospectively. (2) The new guidance also permits companies to withhold an amount up to the employees' maximum individual tax rate in the relevant jurisdiction without resulting in liability classification of the award. (3) Finally, the new guidance provides companies with an accounting policy election for the impact of forfeitures on the recognition of expense for share-based payment awards. Forfeitures can be estimated, as required today, or recognized when they occur. If elected, the change to recognize forfeitures when they occur needs to be adopted using a modified retrospective approach, with a cumulative effect adjustment recorded to beginning retained earnings. The ASU is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that annual reporting period. The Company is currently evaluating the effect of adopting this new accounting guidance.

In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 is intended to add or clarify guidance on the classification of certain cash receipts and payments in the statement of cash flows and to eliminate the diversity in practice related to such classifications. The guidance in ASU 2016-15 is required for annual reporting periods beginning after December 15, 2017, with early adoption permitted. The Company is currently evaluating the effect on its consolidated statement of cash flows of adopting this new accounting guidance.
XML 21 R8.htm IDEA: XBRL DOCUMENT v3.5.0.2
Acquisition
 9 Months Ended
Sep. 30, 2016
Business Combinations [Abstract]  
Acquisition
Acquisition

On August 18, 2015, the Company acquired 100% of the outstanding common shares and voting interests of Omnicare for $98 per share, for a total of $9.6 billion and assumed long-term debt with a fair value of approximately $3.1 billion. Omnicare is a leading health care services company that specializes in the management of complex pharmaceutical care. Omnicare’s long-term care (“LTC”) business is the nation’s largest provider of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings. In addition, Omnicare has a specialty pharmacy business operating primarily under the name of Advanced Care ScriptsTM, and provides commercialization services under the name of RxCrossroads®. The Company acquired Omnicare to expand its operations in dispensing prescription drugs to assisted-living and long-term care facilities, and to broaden its presence in the specialty pharmacy business as the Company seeks to serve a greater percentage of the growing senior patient population in the United States.

The following unaudited pro forma information presents a summary of the Company’s combined results of operations for the three and nine months ended September 30, 2015 as if the Omnicare acquisition and the related financing transactions had occurred on January 1, 2014. The following pro forma financial information is not necessarily indicative of the results of operations as they would have been had the transactions been effected on the assumed date, nor is it necessarily an indication of trends in future results for a number of reasons, including, but not limited to, differences between the assumptions used to prepare the pro forma information, basic shares outstanding and dilutive equivalents, cost savings from operating efficiencies, potential synergies, and the impact of incremental costs incurred in integrating the businesses.
In millions, except per share data
Three
Months Ended
September 30,
2015
 
Nine
Months Ended
September 30,
2015
Total revenues
$
39,374

 
$
115,652

Income from continuing operations
1,318

 
3,774

Earnings per share from continuing operations:
 
 
 
Basic
$
1.18

 
$
3.35

Diluted
$
1.17

 
$
3.32
XML 22 R9.htm IDEA: XBRL DOCUMENT v3.5.0.2
Goodwill and Intangible Assets
 9 Months Ended
Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets
Goodwill and Intangible Assets

Goodwill and indefinitely-lived trade names are not amortized, but are subject to annual impairment reviews, or more frequent reviews if events or circumstances indicate there may be impairment. During the three months ended September 30, 2016, the Company performed its required annual impairment tests and concluded there was no impairment of goodwill or trade names.

The Company's total goodwill was $38.2 billion and $38.1 billion as of September 30, 2016 and December 31, 2015, respectively.








The following is a summary of the Company's intangible assets as of September 30, 2016 and December 31, 2015:

 
September 30, 2016
 
December 31, 2015
In millions
Gross
Carrying Amount
 
Accumulated Amortization
 
Net Carrying Amount
 
Gross
Carrying Amount
 
Accumulated Amortization
 
Net Carrying Amount
Trademarks (indefinitely-lived)
$
6,398

 
$
—

 
$
6,398

 
$
6,398

 
$
—

 
$
6,398

Customer contracts and
  relationships and covenants not
  to compete
11,340

 
(4,624
)
 
6,716

 
10,594

 
(4,092
)
 
6,502

Favorable leases and other
1,132

 
(679
)
 
453

 
1,595

 
(617
)
 
978

 
$
18,870

 
$
(5,303
)
 
$
13,567

 
$
18,587

 
$
(4,709
)
 
$
13,878
XML 23 R10.htm IDEA: XBRL DOCUMENT v3.5.0.2
Share Repurchase Program
 9 Months Ended
Sep. 30, 2016
Payments for Repurchase of Equity [Abstract]  
Share Repurchase Program
Share Repurchase Program
 
During the nine months ended September 30, 2016, the Company had the following outstanding share repurchase program that was authorized by the Company’s Board of Directors:
In billions
 
 
 
 
 
 
Authorization Date
Authorized
Remaining
December 15, 2014 (“2014 Repurchase Program”)
 
$
10.0

 
 
$
3.7

 


On November 2, 2016, the Company's Board of Directors authorized a new share repurchase program for up to $15 billion of outstanding common stock (the “2016 Repurchase Program”). The 2014 and 2016 Repurchase Programs, which were effective immediately, permit the Company to effect repurchases from time to time through a combination of open market repurchases, privately negotiated transactions, accelerated share repurchase transactions, and/or other derivative transactions. The repurchase programs may be modified or terminated by the Board of Directors at any time.

During the three months ended September 30, 2016, the Company repurchased an aggregate of approximately 0.4 million shares of common stock for approximately $40.0 million pursuant to the 2014 Repurchase Program. During the nine months ended September 30, 2016, the Company repurchased an aggregate of approximately 41.4 million shares of common stock for approximately $4.0 billion pursuant to the 2014 Repurchase Program. This activity includes the accelerated share repurchase agreement (“ASR”) described below.

Pursuant to the authorization under the 2014 Repurchase Program, effective December 11, 2015, the Company entered into a $725 million fixed dollar ASR with Barclays Bank PLC (“Barclays”). Upon payment of the $725 million purchase price on December 14, 2015, the Company received a number of shares of its common stock equal to 80% of the $725 million notional amount of the ASR or approximately 6.2 million shares. The initial 6.2 million shares of common stock delivered to the Company by Barclays were placed into treasury stock in December 2015. The ASR was accounted for as an initial treasury stock transaction for $580 million and a forward contract for $145 million. The forward contract was classified as an equity instrument and was recorded within capital surplus on the condensed consolidated balance sheet as of December 31, 2015. On January 28, 2016, the Company received 1.4 million shares of common stock, representing the remaining 20% of the $725 million notional amount of the ASR, thereby concluding the ASR. The remaining 1.4 million shares of common stock delivered to the Company by Barclays were placed into treasury stock and the forward contract was reclassified from capital surplus to treasury stock in January 2016.

At the time they were received, the initial and final receipt of shares resulted in an immediate reduction of the outstanding shares used to calculate the weighted average common shares outstanding for basic and diluted net income per share.
XML 24 R11.htm IDEA: XBRL DOCUMENT v3.5.0.2
Accumulated Other Comprehensive Income
 9 Months Ended
Sep. 30, 2016
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income

Accumulated other comprehensive income consists of foreign currency translation adjustments, unrealized losses on cash flow hedges executed in previous years associated with the issuance of long-term debt, and changes in the net actuarial gains and losses associated with pension and other postretirement benefit plans. The following table summarizes the activity within the components of accumulated other comprehensive income.
Changes in accumulated other comprehensive income (loss) by component is shown on the below:
 
Three Months Ended September 30, 2016(1)
In millions
Foreign Currency
 
Losses on Cash Flow Hedges
 
Pension and Other Postretirement Benefits
 
Total
Balance, June 30, 2016
$
(125
)
 
$
(6
)
 
$
(186
)
 
$
(317
)
     Other comprehensive income (loss) before
reclassifications
(3
)
 
—

 
—

 
(3
)
     Amounts reclassified from accumulated
other comprehensive income(2)
—

 
1

 
—

 
1

Net other comprehensive income (loss)
(3
)
 
1

 
—

 
(2
)
Balance, September 30, 2016
$
(128
)
 
$
(5
)
 
$
(186
)
 
$
(319
)
 
 
 
 
 
 
 
 
 
Three Months Ended September 30, 2015(1)
 
Foreign Currency
 
Losses on Cash Flow Hedges
 
Pension and Other Postretirement Benefits
 
Total
Balance, June 30, 2015
$
(104
)
 
$
(8
)
 
$
(143
)
 
$
(255
)
     Other comprehensive income (loss) before
reclassifications
(61
)
 
—

 
—

 
(61
)
     Amounts reclassified from accumulated
other comprehensive income(2)
—

 
—

 
—

 
—

Net other comprehensive (loss)
(61
)
 
—

 
—

 
(61
)
Balance, September 30, 2015
$
(165
)
 
$
(8
)
 
$
(143
)
 
$
(316
)
 
 
 
 
 
 
 
 
 
Nine Months Ended September 30, 2016(1)
 
Foreign Currency
 
Losses on Cash Flow Hedges
 
Pension and Other Postretirement Benefits
 
Total
Balance, December 31, 2015
$
(165
)
 
$
(7
)
 
$
(186
)
 
$
(358
)
     Other comprehensive income (loss) before
reclassifications
37

 
—

 
—

 
37

     Amounts reclassified from accumulated
other comprehensive income (2)
—

 
2

 
—

 
2

Net other comprehensive income
37

 
2

 
—

 
39

Balance, September 30, 2016
$
(128
)
 
$
(5
)
 
$
(186
)
 
$
(319
)
 
 
 
 
 
 
 
 
 
Nine Months Ended September 30, 2015(1)
 
Foreign Currency
 
Losses on Cash Flow Hedges
 
Pension and Other Postretirement Benefits
 
Total
Balance, December 31, 2014
$
(65
)
 
$
(9
)
 
$
(143
)
 
$
(217
)
     Other comprehensive income (loss) before
reclassifications
(100
)
 
1

 
—

 
(99
)
     Amounts reclassified from accumulated
other comprehensive income (2)
—

 
—

 
—

 
—

Net other comprehensive income (loss)
(100
)
 
1

 
—

 
(99
)
Balance, September 30, 2015
$
(165
)
 
$
(8
)
 
$
(143
)
 
$
(316
)


(1)
All amounts are net of tax.
(2)
The amounts reclassified from accumulated other comprehensive income for losses on cash flow hedges are recorded within interest expense, net on the condensed consolidated statement of income. The amounts reclassified from accumulated other comprehensive income for pension and other postretirement benefits are included in operating expenses on the condensed consolidated statement of income.
XML 25 R12.htm IDEA: XBRL DOCUMENT v3.5.0.2
Borrowings
 9 Months Ended
Sep. 30, 2016
Debt Disclosure [Abstract]  
Borrowings
Borrowings

On May 16, 2016, the Company issued $1.75 billion aggregate principal amount of 2.125% unsecured senior notes due June 1, 2021 and $1.75 billion aggregate principal amount of 2.875% unsecured senior notes due June 1, 2026 (collectively, the "2016 Notes") for total proceeds of approximately $3.5 billion, net of discounts and underwriting fees. The 2016 Notes pay interest semi-annually and may be redeemed, in whole at any time, or in part from time to time, at the Company's option at a defined redemption price plus accrued and unpaid interest to the redemption date. The net proceeds of the 2016 Notes were used for general corporate purposes and to repay certain corporate debt.

On May 16, 2016, the Company announced tender offers for (1) any and all of its 5.75% Senior Notes due 2017, its 6.60% Senior Notes due 2019 and its 4.75% Senior Notes due 2020 (collectively, the “Any and All Notes”) and (2) up to $1.5 billion aggregate principal amount of its 6.25% Senior Notes due 2027, its 6.125% Senior Notes due 2039, its 5.75% Senior Notes due 2041, the 5.00% Senior Notes due 2024 issued by its wholly-owned subsidiary, Omnicare, Inc. (“Omnicare”), the 4.75% Senior Notes due 2022 issued by Omnicare, its 4.875% Senior Notes due 2035 and its 3.875% Senior Notes due 2025 (collectively, the “Maximum Tender Offer Notes” and together with the Any and All Notes, the “Notes”). On May 31, 2016, the Company increased the aggregate principal amount of the tender offers for the Maximum Tender Offer Notes to $2.25 billion. The Company purchased approximately $835 million aggregate principal amount of the Any and All Notes and $2.25 billion aggregate principal amount of the Maximum Tender Offer Notes pursuant to the tender offers, which expired on June 13, 2016. The Company paid a premium of $486 million in excess of the debt principal in connection with the purchase of the Notes, wrote off $50 million of unamortized deferred financing costs and incurred $6 million in fees, for a total loss on the early extinguishment of debt of $542 million which was recorded in income from continuing operations in the condensed consolidated statements of income for the nine months ended September 30, 2016.

On June 27, 2016, the Company notified the holders of the remaining Any and All Notes that the Company was exercising its option to redeem the outstanding Any and All Notes pursuant to the terms of the Any and All Notes and the Indenture dated as of August 15, 2006, between the Company and The Bank of New York Mellon Trust Company, N.A. Approximately $1.1 billion aggregate principal amount of Any and All Notes was redeemed on July 27, 2016. The Company paid a premium of $97 million in excess of the debt principal and wrote off $4.0 million of unamortized deferred financing costs, for a total loss on early extinguishment of debt of $101 million during the three months ended September 30, 2016.

The Company recorded a total loss on the early extinguishment of debt of $643 million which was recorded in the income from continuing operations in the condensed statements of income for the nine months ended September 30, 2016.
XML 26 R13.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stock-Based Compensation
 9 Months Ended
Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-Based Compensation
Stock-Based Compensation
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
In millions
2016
 
2015
 
2016
 
2015
Stock-based compensation:
 
 
 
 
 
 
 
Stock options
$
20

 
$
22

 
$
60

 
$
67

Restricted stock units
38

 
65

 
106

 
108

Total stock-based compensation
$
58

 
$
87

 
$
166

 
$
175



During the nine months ended September 30, 2016, the Company granted 4 million stock options with a weighted average fair value of $13.02 and a weighted average fair value exercise price of $104.75. The Company had 24 million stock options outstanding as of September 30, 2016 with a weighted average exercise price of $68.31 and a weighted average remaining contractual term of 3.94 years. During the nine months ended September 30, 2016, the Company granted 2 million restricted stock units with a weighted average fair value of $103.47. The Company had 5 million unvested restricted stock units as of September 30, 2016 with a weighted average grant date fair value of $56.20.
XML 27 R14.htm IDEA: XBRL DOCUMENT v3.5.0.2
Sale-Leaseback Transactions
 9 Months Ended
Sep. 30, 2016
Leases [Abstract]  
Sale-Leaseback Transactions
Sale-Leaseback Transactions

The Company finances a portion of its store development program through sale-leaseback transactions. The properties are
generally sold at net book value, which approximates fair value, and the resulting leases typically qualify and are accounted for
as operating leases. The Company does not have any retained or contingent interests in the stores and does not provide any
guarantees, other than a guarantee of lease payments, in connection with the sale-leaseback transactions. Proceeds from sale-leaseback transactions totaled $230 million and $34 million for the nine months ended September 30, 2016 and 2015,
respectively.
XML 28 R15.htm IDEA: XBRL DOCUMENT v3.5.0.2
Interest Expense
 9 Months Ended
Sep. 30, 2016
Interest Income (Expense), Net [Abstract]  
Interest Expense
Interest Expense
 
The following are the components of net interest expense: 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
In millions
2016
 
2015
 
2016
 
2015
Interest expense
$
258

 
$
268

 
$
830

 
$
577

Interest income
(5
)
 
(7
)
 
(14
)
 
(15
)
Interest expense, net
$
253

 
$
261

 
$
816

 
$
562
XML 29 R16.htm IDEA: XBRL DOCUMENT v3.5.0.2
Earnings Per Share
 9 Months Ended
Sep. 30, 2016
Earnings Per Share [Abstract]  
Earnings Per Share
Earnings Per Share
 
Earnings per share is computed using the two-class method. Options to purchase 7.7 million and 6.4 million shares of common stock were outstanding, but were not included in the calculation of diluted earnings per share, for the three and nine months ended September 30, 2016, respectively, because the options’ exercise prices were greater than the average market price of the common shares and, therefore, the effect would be antidilutive. For the same reason, options to purchase approximately 3.5 million and 2.4 million shares of common stock were outstanding, but were not included in the calculation of diluted earnings per share for the three and nine months ended September 30, 2015, respectively.

The following is a reconciliation of basic and diluted net income per share from continuing operations for the respective periods:
 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
In millions, except per share amounts
2016
 
2015
 
2016
 
2015
Numerator for earnings per share calculations:
 
 
 
 
 
 
 
Income from continuing operations
$
1,542

 
$
1,237

 
$
3,613

 
$
3,730

Income allocated to participating securities
(7
)
 
(6
)
 
(18
)
 
(18
)
Net income attributable to noncontrolling interest
(1
)
 
(1
)
 
(2
)
 
(1
)
Income from continuing operations attributable to CVS Health
$
1,534

 
$
1,230

 
$
3,593

 
$
3,711

 
 
 
 
 
 
 
 
Denominators for earnings per share calculations:
 

 
 

 
 

 
 
Weighted average shares, basic
1,068

 
1,114

 
1,076

 
1,122

Effect of dilutive securities
5

 
7

 
6

 
8

Weighted average shares, diluted
1,073

 
1,121

 
1,082

 
1,130

 
 
 
 
 
 
 
 
Earnings per share from continuing operations:
 

 
 

 
 

 
 

Basic
$
1.44

 
$
1.10

 
$
3.34

 
$
3.31

Diluted
$
1.43

 
$
1.10

 
$
3.32

 
$
3.28
XML 30 R17.htm IDEA: XBRL DOCUMENT v3.5.0.2
Segment Reporting
 9 Months Ended
Sep. 30, 2016
Segment Reporting [Abstract]  
Segment Reporting
Segment Reporting
 
The Company has three reportable segments: Pharmacy Services, Retail/LTC and Corporate. The Retail/LTC Segment includes the operating results of the Company's Retail Pharmacy and LTC/RxCrossroads operating segments as the operations and economic characteristics are similar. The Company’s three reportable segments maintain separate financial information by which operating results are evaluated on a regular basis by the Company’s chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company evaluates its Pharmacy Services and Retail/LTC segments’ performance based on net revenue, gross profit and operating profit before the effect of nonrecurring charges and gains and certain intersegment activities. The Company evaluates the performance of its Corporate Segment based on operating expenses before the effect of nonrecurring charges and gains and certain intersegment activities. The chief operating decision maker does not use total assets by segment to make decisions regarding resources, therefore the total asset disclosure by segment has not been included.
 
The Pharmacy Services Segment provides a full range of pharmacy benefit management (“PBM”) services including plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management services and medical spend management. The Company’s clients are primarily employers, insurance companies, unions, government employee groups, health plans, Managed Medicaid plans and other sponsors of health benefit plans, and individuals throughout the United States. A portion of covered lives primarily within the Managed Medicaid, health plan and employer markets have access to our services through public and private exchanges. Through the Company’s SilverScript Insurance Company subsidiary, the Company is a national provider of drug benefits to eligible beneficiaries under the federal government’s Medicare Part D program. The Pharmacy Services Segment operates under the CVS CaremarkTM Pharmacy Services, Caremark®, CVS CaremarkTM, CarePlus CVS Pharmacy®, CVS SpecialtyTM, RxAmerica®, Accordant®, SilverScript®, NovoLogix®, Coram®, Navarro® Health Services and Advanced Care ScriptsTM names. As of September 30, 2016, the Pharmacy Services Segment operated 23 retail specialty pharmacy stores, 13 specialty mail order pharmacies, four mail service dispensing pharmacies, and 85 branches for infusion and enteral services, including approximately 74 ambulatory infusion suites and five centers of excellence, located in 41 states, Puerto Rico and the District of Columbia.

The Retail/LTC Segment sells prescription drugs and a wide assortment of general merchandise, including over-the-counter drugs, beauty products and cosmetics, personal care products, convenience foods, photo finishing, seasonal merchandise and greeting cards. With the acquisition of Omnicare, the Retail/LTC Segment now includes LTC operations, which is comprised of providing the distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings, as well as commercialization services which are provided under the name RxCrossroads®. We added approximately 1,670 pharmacies through the acquisition of the pharmacies of Target Corporation ("Target") in December 2015, thereby expanding our presence in new and existing markets. The stores within Target sell only prescription drugs and over-the-counter drugs that are required to be behind the pharmacy counter. The Retail/LTC Segment also operates retail medical clinics under the MinuteClinic® name. MinuteClinics utilize nationally-recognized medical protocols to diagnose and treat minor health conditions, perform health screenings, monitor chronic conditions and deliver vaccinations. The clinics are staffed by board-certified nurse practitioners and physician assistants who provide access to affordable care without appointment. As of September 30, 2016, our Retail/LTC Segment included 9,694 retail stores (of which 9,638 were either the Company's retail stores that operated a pharmacy, or pharmacies located within Target stores) located in 49 states, the District of Columbia, Puerto Rico and Brazil operating primarily under the CVS Pharmacy®, CVS®, Longs Drugs®, Navarro Discount Pharmacy® and Drogaria OnofreTM names, 34 onsite pharmacies primarily operating under the CarePlus CVS Pharmacy®, CarePlus® and CVS Pharmacy® names, 1,136 retail health care clinics operating under the MinuteClinic® name (of which 1,129 were located in CVS Pharmacy and Target stores), and our online retail websites, CVS.com®, Navarro.comTM and Onofre.com.brTM. LTC operations are comprised of 151 spoke pharmacies that primarily handle new prescription orders, of which 32 are also hub pharmacies that use proprietary automation to support spoke pharmacies with refill prescriptions. LTC operates primarily under the Omnicare® and NeighborCare® names.

The Corporate Segment provides management and administrative services to support the Company. The Corporate Segment consists of certain aspects of executive management, corporate relations, legal, compliance, human resources, information technology and finance departments.

In millions
Pharmacy
Services
Segment(1)
 
Retail/LTC
Segment
 
Corporate
Segment
 
Intersegment
Eliminations(2)
 
Consolidated
Totals
Three Months Ended
 
 
 
 
 
 
 
 
 
September 30, 2016:
 
 
 
 
 
 
 
 
 
Net revenues
$
30,429

 
$
20,143

 
$
—

 
$
(5,957
)
 
$
44,615

Gross profit(3)
1,797

 
5,893

 
—

 
(198
)
 
7,492

Operating profit (loss)(4)(5)
1,458

 
1,773

 
(229
)
 
(185
)
 
2,817

September 30, 2015:
 

 
 

 
 

 
 

 
 

Net revenues
25,528

 
17,912

 
—

 
(4,796
)
 
38,644

Gross profit
1,468

 
5,373

 
—

 
(180
)
 
6,661

Operating profit (loss)(4)(5)
1,162

 
1,643

 
(309
)
 
(165
)
 
2,331

Nine Months Ended
 

 
 

 
 

 
 

 
 

September 30, 2016:
 

 
 

 
 

 
 

 
 

Net revenues
88,704

 
60,253

 
—

 
(17,402
)
 
131,555

Gross profit(3)
4,266

 
17,560

 
—

 
(575
)
 
21,251

Operating profit (loss)(4)(5)
3,278

 
5,255

 
(661
)
 
(529
)
 
7,343

September 30, 2015:
 

 
 

 
 

 
 

 
 

Net revenues
73,849

 
52,105

 
—

 
(13,810
)
 
112,144

Gross profit
3,735

 
15,990

 
—

 
(498
)
 
19,227

Operating profit (loss)(4)(5)
2,837

 
5,050

 
(712
)
 
(450
)
 
6,725


(1) 
Net revenues of the Pharmacy Services Segment include approximately $2.5 billion and $2.1 billion of retail co-payments for the three months ended September 30, 2016 and 2015, respectively, as well as $8.1 billion and $6.8 billion of retail co-payments for the nine months ended September 30, 2016 and 2015, respectively.
(2)
Intersegment eliminations relate to intersegment revenue generating activities that occur between the Pharmacy Services Segment and the Retail/LTC Segment. These occur in the following ways: when members of Pharmacy Services Segment clients (“members”) fill prescriptions at the Company's retail stores to purchase covered products, when members enrolled in programs such as Maintenance Choice ® elect to pick up maintenance prescriptions at one of the Company's retail stores instead of receiving them through the mail, or when members have prescriptions filled at the Company's long-term care pharmacies. When these occur, both the Pharmacy Services and Retail/LTC segments record the revenues, gross profit and operating profit on a standalone basis.
(3)
The Retail/LTC Segment gross profit for the three and nine months ended September 30, 2016 includes $5 million and $15 million, respectively, of acquisition-related integration costs. The integration costs are related to the acquisitions of Omnicare and the pharmacies and clinics of Target.
(4)
The Retail/LTC Segment operating profit for the three and nine months ended September 30, 2016 includes $52 million and $194 million, respectively, of acquisition-related integration costs. The Retail/LTC Segment operating profit for the three and nine months ended September 30, 2015 includes $12 million of acquisition-related integration costs. The integration costs are related to the acquisitions of Omnicare and the pharmacies and clinics of Target.
(5)
The Corporate Segment operating loss for the three and nine months ended September 30, 2016 includes $13 million of integration costs. The Corporate Segment operating loss for the three and nine months ended September 30, 2015 includes $115 million and $135 million, respectively, of acquisition-related transaction and integration costs.
XML 31 R18.htm IDEA: XBRL DOCUMENT v3.5.0.2
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
Commitments and Contingencies
 
Lease Guarantees
 
Between 1991 and 1997, the Company sold or spun off a number of subsidiaries, including Bob’s Stores, Linens ‘n Things, Marshalls, Kay-Bee Toys, Wilsons, This End Up and Footstar. In many cases, when a former subsidiary leased a store, the Company provided a guarantee of the store’s lease obligations. When the subsidiaries were disposed of, the Company’s guarantees remained in place, although each initial purchaser has agreed to indemnify the Company for any lease obligations the Company was required to satisfy. If any of the purchasers or any of the former subsidiaries were to become insolvent and failed to make the required payments under a store lease, the Company could be required to satisfy these obligations. As of September 30, 2016, the Company guaranteed approximately 87 such store leases (excluding the lease guarantees related to Linens ‘n Things, which have been recorded as a liability on the condensed consolidated balance sheet), with the maximum remaining lease term extending through 2047.


In April 2016, the parent entity of Bob’s Stores filed for Chapter 11 bankruptcy protection. As described above, the Company, through one or more of its affiliates, is alleged to have guaranteed certain of the Bob’s Stores’ leases (the “Bob’s Leases”). On June 20, 2016, the bankruptcy court approved the sale of substantially all of the assets of Bob’s Stores and certain other assets to a new entity (“Buyer”), which designated Buyer’s affiliate Bob’s Stores, LLC, a Delaware limited liability company (“New Bob’s”), to acquire substantially all of the assets of Bob’s Stores.

The Company, through its subsidiary, CVS Pharmacy, Inc., and New Bob’s have entered into an agreement dated October 14, 2016, pursuant to which, in exchange for an immaterial payment to be made by CVS Pharmacy, Inc., New Bob’s has agreed to accept the assignment of the Bob’s Leases and to be bound by certain restrictions regarding renewals, extensions and modifications to the Bob’s Leases. The Company believes these restrictions will potentially reduce the Company's exposure to liability under guarantees of the Bob's leases in the future. The assignment of the Bob’s Leases to New Bob’s will be subject to bankruptcy court approval. The Company will continue to monitor the bankruptcy proceedings.

Legal Matters
 
The Company is a party to legal proceedings, investigations and claims in the ordinary course of its business, including the matters described below. The Company records accruals for outstanding legal matters when it believes it is probable that a loss will be incurred and the amount can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in legal matters that could affect the amount of any accrual and developments that would make a loss contingency both probable and reasonably estimable. If a loss contingency is not both probable and estimable, the Company does not establish an accrued liability. None of the Company’s accruals for outstanding legal matters are material individually or in the aggregate to the Company’s financial position.

The Company’s contingencies are subject to significant uncertainties, including, among other factors: (i) the procedural status of pending matters; (ii) whether class action status is sought and certified; (iii) whether asserted claims or allegations will survive dispositive motion practice; (iv) the extent of potential damages, fines or penalties, which are often unspecified or indeterminate; (v) the impact of discovery on the legal process; (vi) whether novel or unsettled legal theories are at issue; (vii) the settlement posture of the parties, and/or (viii) in the case of certain government agency investigations, whether a sealed qui tam lawsuit (“whistleblower” action) has been filed and whether the government agency makes a decision to intervene in the lawsuit following investigation.

Except as otherwise noted, the Company cannot predict with certainty the timing or outcome of the legal matters described below, and is unable to reasonably estimate a possible loss or range of possible loss in excess of amounts already accrued for these matters.

•
Caremark (the term “Caremark” being used herein to generally refer to any one or more PBM subsidiaries of the Company, as applicable) was named in a putative class action lawsuit filed in October 2003 in Alabama state court by John Lauriello, purportedly on behalf of participants in the 1999 settlement of various securities class action and derivative lawsuits against Caremark and others. Other defendants include insurance companies that provided coverage to Caremark with respect to the settled lawsuits. A similar lawsuit was filed in November 2003 by Frank McArthur, also in Alabama state court, naming as defendants, among others, Caremark and several insurance companies involved in the 1999 settlement. This lawsuit was stayed as a later-filed class action, but McArthur was subsequently allowed to intervene in the Lauriello action. The parties have entered into an agreement to resolve the matter. In connection with this agreement, the Company contributed a total of $80 million to the settlement fund and agreed to forego its right to have its insurer continue to reimburse its related legal fees. The Company had established reserves related to this matter to fully cover such payments and the payment was made in the three months ended September 30, 2016. In August 2016, the court entered final judgment dismissing the matter and approving the settlement. The Company denies any wrongdoing, and agreed to a settlement to avoid the burden, uncertainty and distraction of litigation.

•
Beginning in August 2003, various lawsuits were filed by pharmacies alleging that various PBMs were violating certain antitrust laws. In October 2003, two independent pharmacies, North Jackson Pharmacy, Inc. and C&C, Inc. d/b/a Big C Discount Drugs, Inc., filed three separate putative class action complaints in the United States District Court for the Northern District of Alabama, all seeking treble damages and injunctive relief. One complaint named three Caremark entities as defendants, and the other two complaints named PBM competitors. The North Jackson Pharmacy case against two of the Caremark entities was transferred to the United States District Court for the Northern District of Illinois; the case against the third Caremark entity was sent to arbitration based on contract terms between the pharmacies and that entity. The arbitration was stayed at the parties’ request and later closed by the American Arbitration Association. In August 2006, the Judicial Panel on Multidistrict Litigation issued an order transferring all related PBM antitrust cases, including the North Jackson Pharmacy cases, to the United States District Court for the Eastern District of Pennsylvania for coordinated and consolidated proceedings with the cases originally filed in that court. The consolidated action is now known as In re Pharmacy Benefit Managers Antitrust Litigation. A motion for class certification filed by the North Jackson Pharmacy plaintiffs against the Caremark defendants in August 2015 is currently pending.

•
In February 2006, two substantially similar putative class action lawsuits were filed in the U.S. District Court for the Eastern District of Kentucky, and were consolidated and entitled Indiana State Dist. Council of Laborers & HOD Carriers Pension & Welfare Fund v. Omnicare, Inc. The consolidated complaint was filed against Omnicare, three of its officers and two of its directors and purported to be brought on behalf of all open-market purchasers of Omnicare common stock from August 3, 2005 through July 27, 2006, as well as all purchasers who bought shares of Omnicare common stock in Omnicare’s public offering in December 2005. The complaint alleged violations of the Securities Exchange Act of 1934 and Section 11 of the Securities Act of 1933 and sought, among other things, compensatory damages and injunctive relief. After dismissals and appeals to the United States Court of Appeals for the Sixth Circuit, the United States Supreme Court remanded the case to the district court. In October 2016, Omnicare filed an answer to plaintiffs’ third amended complaint, and discovery commenced.

•
In December 2007, the Company received a document subpoena from the Office of Inspector General (“OIG”) within the U.S. Department of Health and Human Services, requesting information relating to the processing of Medicaid and certain other government agency claims on behalf of its clients (which allegedly resulted in underpayments from our pharmacy benefit management clients to the applicable government agencies) on one of the Company’s adjudication platforms. In September 2014, the Company settled the OIG’s claims, as well as related claims by the Department of Justice and private plaintiffs, without any admission of liability. The Company is in discussions with the OIG concerning other claim processing issues.

•
In December 2009, a shareholder derivative lawsuit was filed by Mark Wuotila in the United States District Court for the District of Rhode Island against the directors and certain officers of the Company. The lawsuit includes allegations of, among other things, securities fraud, insider trading and breach of fiduciary duties and further alleges that the Company was damaged by the purchase of stock at allegedly inflated prices under its share repurchase program. The Company entered into an agreement to settle the matter, pursuant to which the Company agreed to maintain or implement certain corporate governance measures and pay the plaintiff’s legal fees of $270,000. In August 2016, the court entered final judgment dismissing the matter and approving the settlement. The Company denies any wrongdoing, and agreed to settle these matters to avoid the burden, uncertainty and distraction of litigation. The settlement was funded by insurance proceeds.

•
In March 2010, the Company learned that various State Attorneys General offices and certain other government agencies were conducting a multi-state investigation of certain of the Company’s business practices similar to those being investigated at that time by the U.S. Federal Trade Commission (“FTC”). Twenty-eight states, the District of Columbia and the County of Los Angeles are known to be participating in this investigation. The prior FTC investigation, which commenced in August 2009, was officially concluded in May 2012 when the consent order entered into between the FTC and the Company became final. The Company has cooperated with the multi-state investigation.

•
In March 2010, the Company received a subpoena from the OIG requesting information about programs under which the Company has offered customers remuneration conditioned upon the transfer of prescriptions for drugs or medications to the Company’s pharmacies in the form of gift cards, cash, non-prescription merchandise or discounts or coupons for non-prescription merchandise. In October 2016, the U.S. District Court for the Central District of California unsealed a qui tam complaint, filed in April 2009 against CVS Pharmacy and other retail pharmacies, alleging that the Company violated the federal False Claims Act, and the false claims acts of several states, by offering such programs. The federal government has declined intervention in the case.

•
On October 29, 2010, a qui tam complaint entitled United States et al., ex rel. Banigan and Templin v. Organon USA, Inc., Omnicare, Inc. and PharMerica Corporation that had been filed under seal with the U.S. District Court for the District of Massachusetts, was ordered unsealed by the court. The complaint was brought by two former employees of Organon, as private party qui tam relators on behalf of the federal government and several state and local governments. The action alleges civil violations of the federal False Claims Act based on allegations that Organon and its affiliates paid Omnicare and several other long-term care pharmacies rebates, post-purchase discounts and other forms of remuneration in return for purchasing pharmaceuticals from Organon and taking steps to increase the purchase of Organon’s drugs in violation of the Anti-Kickback Statute. The U.S. Department of Justice declined to intervene in this action. Discovery is closed in this matter. In August 2016, the Court granted in part and denied in part Omnicare’s motion for summary judgment. The Company has tentatively agreed with the Department of Justice to resolve this matter for $23 million plus interest. These financial terms are contingent on approval by authorized officials at the Department of Justice, negotiation of terms of a settlement agreement, approval and releases from the OIG, the National Association of Medicaid Fraud Control Units, and the Department of Justice. While the Company believes that a final settlement will be reached, there can be no assurance that any final settlement agreement will be reached or as to the final terms of such settlement.

•
In January 2012, the United States District Court for the Eastern District of Pennsylvania unsealed a first amended qui tam complaint filed in August 2011 by an individual relator, Anthony Spay, who is described in the complaint as having once been employed by a firm providing pharmacy prescription benefit audit and recovery services. The complaint seeks monetary damages and alleges that Caremark’s processing of Medicare claims on behalf of one of its clients violated the federal False Claims Act. The United States declined to intervene in the lawsuit. In September 2015, the Court granted Caremark's motion for summary judgment in its entirety, and entered judgment in favor of Caremark and against Spay. In October 2015, Spay filed a notice of appeal in the United States Court of Appeals for the Third Circuit.

•
In February 2012, the Attorney General of the State of Texas issued Civil Investigative Demands and other requests, and has issued a series of subsequent requests for documents and information in connection with its investigation concerning the Health Savings Pass program and other pricing practices with respect to claims for reimbursement from the Texas Medicaid program.

•
In November 2012, the Company received a subpoena from the OIG requesting information concerning automatic refill programs used by pharmacies to refill prescriptions for customers. The Company cooperated and provided documents and other information in response to this request for information.

•
In 2013, Omnicare received subpoenas seeking information regarding Omnicare’s nationwide billing practices with regard to National Drug Code overrides and Omnicare’s May 2008 acquisition of Pure Service Pharmacy. In 2014, Omnicare received subpoenas seeking information regarding Omnicare’s Auto Label Verification system and Omnicare’s per diem arrangements. Omnicare has produced documents and provided information in response to these subpoenas and continues to cooperate in the investigations. In October 2016, the Department of Justice intervened for purposes of settling a qui tam complaint Ervin v. Omnicare which related to the subpoena seeking information with regard to National Drug Code overrides. In October 2016, the Company, the Department of Justice, OIG, and National Association of Medicaid Fraud Control Units finalized and signed settlement agreements for approximately $2.2 million plus interest. The Court unsealed and dismissed the False Claim Act claims of the complaint.

Omnicare reached an agreement regarding financial terms to resolve, for $1.5 million plus interest, the subpoena regarding the acquisition of Pure Service Pharmacy. These financial terms are contingent on approval by authorized officials at the Department of Justice, negotiation of terms of a settlement agreement, approval and releases from the OIG, the National Association of Medicaid Fraud Control Units, and the Department of Justice. While the Company believes that a final settlement will be reached, there can be no assurance that any final settlement agreement will be reached or as to the final terms of such settlement.
Omnicare reached an agreement regarding financial terms to resolve, for $8 million plus interest, the subpoena regarding Omnicare’s Auto Label Verification system. These financial terms are contingent on approval by authorized officials at the Department of Justice, negotiation of terms of a settlement agreement, approval and releases from the OIG, the National Association of Medicaid Fraud Control Units, and the Department of Justice. While the Company believes that a final settlement will be reached, there can be no assurance that any final settlement agreement will be reached or as to the final terms of such settlement.
•
On March 22, 2013, a qui tam complaint entitled United States et al., ex rel. Susan Ruscher v. Omnicare, Inc., et al., which had been filed under seal in the U.S. District Court for the Southern District of Texas, was unsealed by the court. The complaint was brought by Susan Ruscher as a private party qui tam relator on behalf of the federal government and several state governments alleging violations of the federal False Claims Act and analogous state laws based upon allegations that Omnicare’s practices relating to customer collections violated the Anti-Kickback Statute. In September 2015, the court granted summary judgment dismissing all claims against Omnicare and denied relator’s motion for summary judgment related to Omnicare’s counterclaims and thereafter, in October 2015, the court entered a final judgment for Omnicare and stayed trial on the counterclaims pending an appeal from the relator. In October 2015, plaintiffs filed a notice of appeal in the United States Court of Appeals for the Fifth Circuit. In October 2016, the appellate court affirmed the district court’s grant of summary judgment dismissing all claims against Omnicare.

•
In March 2014, the Company received a subpoena from the United States Attorney’s Office for the District of Rhode Island, requesting documents and information concerning bona fide service fees and rebates received from pharmaceutical manufacturers in connection with certain drugs utilized under Part D of the Medicare Program, as well as the reporting of those fees and rebates to Part D plan sponsors. The Company has been cooperating with the government and providing documents and information in response to the subpoena.

•
The U.S. Department of Justice, through the U.S. Attorney’s Office for the Western District of Virginia, investigated whether Omnicare’s activities in connection with the agreements it had with the manufacturer of the pharmaceutical Depakote violated the False Claims Act or the Anti-Kickback Statute. Omnicare cooperated with this investigation and believes that it has complied with applicable laws and regulations with respect to this matter. In connection with this matter, on December 22, 2014, the U.S. Department of Justice filed a civil complaint-in-intervention in two qui tam complaints, entitled United States, et al., ex rel. Spetter v. Abbott Laboratories, Inc., Omnicare, Inc., and PharMerica Corp., and United States, et al., ex rel. McCoyd v. Abbott Laboratories, Omnicare, Inc., PharMerica Corp., and Miles White, alleging civil violations of the False Claims Act in connection with the manufacturer agreements described above. In July 2015, the parties filed a Joint Motion to Stay the Litigation stating that the parties have reached a proposed resolution of the monetary terms of a potential settlement agreement. In October 2016, the Company, the Department of Justice, OIG, and National Association of Medicaid Fraud Control Units finalized and signed a settlement agreement for approximately $28.1 million plus interest.

As part of Omnicare’s settlements with the Department of Justice, the Company entered into a corporate integrity agreement (“CIA”) with the OIG. The CIA has a term of five years commencing on October 11, 2016. The CIA imposes various compliance requirements relating to the provision of institutional pharmacy services. As part of entering into the CIA, OIG provided the Company with a release related to the previously described subpoena regarding Omnicare’s per diem arrangements. That release is more fully described in the CIA.
•
In May 2015, the Company received a subpoena from the OIG requesting information and documents concerning the Company’s automatic refill programs, adherence outreach programs, and pharmacy customer incentives, particularly in connection with claims for reimbursement made to the Minnesota Medicaid program. The Company has been cooperating with the investigation and providing information in response to the subpoena.

•
In July and September 2015, two related putative class actions, Corcoran, et al. v. CVS Health Corp., and Podgorny, et al. v. CVS Health Corp., were filed against the Company in the United States District Court in the Northern District of California and the Northern District of Illinois, respectively. The two cases have been consolidated in United States District Court in the Northern District of California. In March 2016, the Court granted in part and denied in part the Company’s first motion to dismiss. In July 2016, the Court granted in part and denied in part the Company's partial motion to dismiss the third amended complaint. Discovery is proceeding on the remaining allegations in the third amended complaint, which alleges that the plaintiffs overpaid for prescriptions for generic drugs filled at CVS pharmacies. The plaintiffs seek damages and injunctive relief under the consumer protection statutes and common laws of certain states and in October 2016 Plaintiffs moved for the certification of a class involving CVS customers from 11 states. In February 2016, two third-party payors filed a similar putative class action, Sheet Metal Workers Local No. 20 Welfare and Benefit Fund v. CVS Health Corp., against the Company in the United States District Court for the District of Rhode Island. The Company’s motion to dismiss remains pending. In August 2016, a similar complaint was filed by another third-party payor, Plumbers Welfare Fund, Local 130 v. CVS Health Corp., also in the United States District Court for the District of Rhode Island. The Company likewise intends to defend this action.

•
In September 2015, Omnicare was served with an administrative subpoena by the U.S. Drug Enforcement Agency (“DEA”). The subpoena seeks documents related to controlled substance policies, procedures, and practices at eight pharmacy locations from May 2012 to the present. The Company has been cooperating and providing documents in response to this administrative subpoena.

•
In October 2015, Omnicare received a Civil Investigative Demand from the United States Attorney’s Office for the Southern District of New York requesting information and documents concerning Omnicare’s cycle fill process for assisted living facilities. The Company has been cooperating with the government and providing documents and information in response to the Civil Investigative Demand.
•
In October 2015, the Company received from the U.S. Department of Justice a Civil Investigative Demand requesting documents and information in connection with a False Claims Act investigation concerning allegations that the Company submitted, or caused to be submitted, to the Medicare Part D program prescription drug event data that misrepresented true prices paid by the Company's PBM to pharmacies for drugs dispensed to Part D beneficiaries with prescription benefits administered by the Company’s PBM. The Company has been cooperating with the government and providing documents and information in response to the Civil Investigative Demand.

•
In November 2015, the United States District Court for the Eastern District of Pennsylvania unsealed a second amended qui tam complaint filed in September 2015, in an action captioned United States, et al., ex rel. Sally Schimelpfeinig and John Segura v. Dr. Reddy’s Laboratories Limited, et al. The U.S. Department of Justice declined to intervene in this action. The relators allege that the Company, Walgreens, Wal-Mart, and Dr. Reddy’s Laboratories violated the federal and various state False Claims Acts by dispensing prescriptions in unit dose packaging supplied by Dr. Reddy’s that was not compliant with the Consumer Product Safety Improvement Act and the Poison Preventive Packaging Act and thereby allegedly rendering the drugs misbranded under the Food, Drug & Cosmetic Act. The Company's motion to dismiss remains pending.

•
In February 2016, an ERISA class action lawsuit was filed against the Company, the Benefit Plans Committee of the Company, and Galliard Capital Management, Inc., in the United States District Court for the District of Rhode Island by Mary Barchock, Thomas Wasecko, and Stacy Weller, purportedly on behalf of the 401(k) Plan and the Employee Stock Ownership Plan of the Company (the “Plan”), and participants in the Plan. The complaint alleges that the defendants breached fiduciary duties owed to the plaintiffs and the Plan by investing too much of the Plan’s Stable Value Fund in short-term money market funds and cash management accounts. The Company has moved to dismiss the plaintiffs' amended complaint.

•
In April 2016, the Superior Court of the State of California (Sacramento) unsealed a first amended qui tam complaint filed in July 2013, in an action captioned State of California ex rel. Matthew Omlansky v. CVS Caremark Corporation, et al. The government has declined intervention in this case. The relator alleged that the Company submitted false claims for payment to California Medicaid in connection with reimbursement for drugs available through the Health Savings Pass program as well as certain other generic drugs. The Company's motion to dismiss the complaint was denied.

•
In June 2016, the Company entered into a settlement agreement with the U.S. Attorney’s Office for the District of Massachusetts, resolving alleged violations of the Controlled Substances Act (“CSA”). The Company paid a fine of $3.5 million in connection with the settlement in July 2016 which was previously fully reserved in the Company's financial statements. The Company is also undergoing several audits by the DEA Administrator and is in discussions with the DEA and the U.S. Attorney’s Office in several locations concerning allegations that the Company has violated certain requirements of the CSA.

•
In July 2016, the Company was served with a complaint filed on behalf of the State of Mississippi, in the Chancery Court of DeSoto County, Third Judicial District, alleging that CVS retail pharmacies in Mississippi submitted false claims for reimbursement to Mississippi Medicaid by not submitting as the pharmacy’s usual and customary price the price available to members of the CVS Health Savings Pass program. The Company has responded to the complaint, filed a counterclaim, and moved to transfer the case to circuit court.

The Company is also a party to other legal proceedings, government investigations, inquiries and audits, and has received and is cooperating with subpoenas or similar process from various governmental agencies requesting information, all arising in the normal course of its business, none of which is expected to be material to the Company. The Company can give no assurance, however, that its business, financial condition and results of operations will not be materially adversely affected, or that the Company will not be required to materially change its business practices, based on: (i) future enactment of new health care or other laws or regulations; (ii) the interpretation or application of existing laws or regulations as they may relate to the Company’s business, the pharmacy services, specialty pharmacy, retail pharmacy, long-term care pharmacy or retail clinic industries or to the health care industry generally; (iii) pending or future federal or state governmental investigations of the Company’s business or the pharmacy services, specialty pharmacy, retail pharmacy, long-term care pharmacy or retail clinic industry or of the health care industry generally; (iv) pending or future government enforcement actions against the Company; (v) adverse developments in any pending qui tam lawsuit against the Company, whether sealed or unsealed, or in any future qui tam lawsuit that may be filed against the Company; or (vi) adverse developments in pending or future legal proceedings against the Company or affecting the pharmacy services, specialty pharmacy, retail pharmacy, long-term care pharmacy or retail clinic industry or the health care industry generally.
XML 32 R19.htm IDEA: XBRL DOCUMENT v3.5.0.2
Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2016
Accounting Policies [Abstract]  
Principles of Consolidation
Principles of Consolidation
 
The condensed consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries and variable interest entities (“VIEs”) for which the Company is the primary beneficiary. All material intercompany balances and transactions have been eliminated.

The Company continually evaluates its investments to determine if they represent variable interests in a VIE. If the Company determines that it has a variable interest in a VIE, the Company then evaluates if it is the primary beneficiary of the VIE. The evaluation is a qualitative assessment as to whether the Company has the ability to direct the activities of a VIE that most significantly impact the entity’s economic performance. The Company consolidates a VIE if it is considered to be the primary beneficiary.

Assets and liabilities of VIEs for which the Company is the primary beneficiary were not significant to the Company’s condensed consolidated financial statements. VIE creditors do not have recourse against the general credit of the Company.
Fair Value of Financial Instruments
Fair Value of Financial Instruments
 
The Company utilizes the three-level valuation hierarchy for the recognition and disclosure of fair value measurements. The categorization of assets and liabilities within this hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy consist of the following:
 
•
Level 1 – Inputs to the valuation methodology are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
 
•
Level 2 – Inputs to the valuation methodology are quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active or inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the instrument.

•
Level 3 – Inputs to the valuation methodology are unobservable inputs based upon management’s best estimate of inputs market participants could use in pricing the asset or liability at the measurement date, including assumptions about risk.
 

As of September 30, 2016, the carrying value of cash and cash equivalents, short-term investments, accounts receivable and accounts payable approximated their fair value due to the nature of these financial instruments. The Company invests in money market funds, commercial paper and time deposits that are classified as cash and cash equivalents within the accompanying condensed consolidated balance sheets, as these funds are highly liquid and readily convertible to known amounts of cash. These investments are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. The Company’s short-term investments of $74 million at September 30, 2016 consist of certificates of deposit with initial maturities of greater than three months when purchased that mature within one year from the balance sheet date. These investments, which are classified within Level 1 of the fair value hierarchy, are carried at fair value, which approximated historical cost at September 30, 2016. The carrying amount and estimated fair value of the Company’s total long-term debt was $26.4 billion and $28.7 billion, respectively, as of September 30, 2016. The fair value of the Company’s long-term debt was estimated based on quoted prices currently offered in active markets for the Company’s debt, which is considered Level 1 of the fair value hierarchy.
Redeemable Noncontrolling Interest
Due to the change in control in Omnicare, the noncontrolling member of the LLC had the contractual right to put its membership interest to the Company at fair value. Consequently, the noncontrolling interest in the LLC was recorded as a redeemable noncontrolling interest at fair value.
New Accounting Pronouncements
New Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 outlines a single comprehensive model for companies to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. In March 2016, the FASB issued ASU 2016-08, “Principal Versus Agent Considerations (Reporting Revenue Gross Versus Net),” which amends the principal-versus-agent implementation guidance and in April 2016 the FASB issued ASU 2016-10, "Identifying Performance Obligations and Licensing," which amends the guidance in those areas in the new revenue recognition standard. Both ASU's were issued in response to feedback received from the FASB-International Accounting Standards Board joint revenue recognition transition resource group. This new revenue standard is effective for annual reporting periods (including interim reporting periods within those periods) beginning January 1, 2018; early adoption in 2017 is permitted. Companies have the option of using either a full retrospective or a modified retrospective approach to adopt the guidance. This standard could impact the timing and amounts of revenue recognized. The Company is currently evaluating the effect that implementation of this standard will have on its consolidated financial position and results of operations upon adoption, as well as the method of transition and required disclosures.
In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740). The new guidance simplifies the presentation of deferred income taxes by requiring that deferred tax assets and liabilities be classified as noncurrent in a classified statement of financial position. The updated standard is effective for the Company beginning on January 1, 2017 with early application permitted as of the beginning of any interim or annual reporting period. The Company elected to early adopt this standard as of January 1, 2016 and has, accordingly, reclassified the current deferred tax assets to noncurrent deferred tax liabilities for all periods presented. The following is a reconciliation of the effect of the reclassification on the Company's condensed consolidated balance sheet as of December 31, 2015:
In millions
 
As Previously Reported
 
Adjustments
 
As Revised
Deferred tax assets - current
 
$
1,220

 
$
(1,220
)
 
$
—

Total current assets
 
30,378

 
(1,220
)
 
29,158

Total assets
 
93,657

 
(1,220
)
 
92,437

Deferred tax liabilities - noncurrent
 
5,437

 
(1,220
)
 
4,217

Total liabilities and shareholders’ equity
 
93,657

 
(1,220
)
 
92,437



In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). Lessees will be required to recognize a right-of-use asset and a lease liability for virtually all of their leases (other than leases that meet the definition of a short-term lease). The liability will be equal to the present value of lease payments. The asset will be based on the liability, subject to adjustment, such as for initial direct costs. For income statement purposes, a dual model was retained, requiring leases to be classified as either operating or finance leases. Operating leases will result in straight-line expense (similar to current operating leases) while finance leases will result in a front-loaded expense pattern (similar to current capital leases). Lessor accounting is similar to the current model, but updated to align with certain changes to the lessee model (e.g., certain definitions, such as initial direct costs, have been updated) and the new revenue recognition standard. The standard is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The Company believes that the new standard will have a material impact on its consolidated balance sheet but it will not have a material impact on its liquidity. The Company is currently evaluating the effect that implementation of this standard will have on its consolidated results of operations upon adoption.

In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting, which amends Accounting Standard Codification Topic 718, Compensation - Stock Compensation, in three areas. (1) The new guidance eliminates accounting for tax benefits and deficiencies through equity to the extent of previous windfalls, and then to the income statement. The new requirement is to record all tax benefits and deficiencies through the income statement. This amendment is required to be applied prospectively. The amendment also requires the presentation of excess tax benefits on the statements of cash flows as operating activities, a change which may be applied prospectively or retrospectively at the election of the Company. The amendment requires the presentation of employee taxes paid on the statement of cash flows when an employer withholds shares for tax withholding purposes as financing activities, a change which must be applied retrospectively. (2) The new guidance also permits companies to withhold an amount up to the employees' maximum individual tax rate in the relevant jurisdiction without resulting in liability classification of the award. (3) Finally, the new guidance provides companies with an accounting policy election for the impact of forfeitures on the recognition of expense for share-based payment awards. Forfeitures can be estimated, as required today, or recognized when they occur. If elected, the change to recognize forfeitures when they occur needs to be adopted using a modified retrospective approach, with a cumulative effect adjustment recorded to beginning retained earnings. The ASU is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that annual reporting period. The Company is currently evaluating the effect of adopting this new accounting guidance.

In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 is intended to add or clarify guidance on the classification of certain cash receipts and payments in the statement of cash flows and to eliminate the diversity in practice related to such classifications. The guidance in ASU 2016-15 is required for annual reporting periods beginning after December 15, 2017, with early adoption permitted. The Company is currently evaluating the effect on its consolidated statement of cash flows of adopting this new accounting guidance.
XML 33 R20.htm IDEA: XBRL DOCUMENT v3.5.0.2
Accounting Policies (Tables)
 9 Months Ended
Sep. 30, 2016
Accounting Policies [Abstract]  
Redeemable Noncontrolling Interest
Below is a summary of the changes in the redeemable noncontrolling interest for the nine months ended September 30, 2016:
In millions
 
 
Beginning balance
$
39

 
Net income attributable to noncontrolling interest
1

 
Distributions
(2
)
 
Purchase of noncontrolling interest
(39
)
 
Reclassification to capital surplus in connection with purchase of noncontrolling interest
1

 
Ending balance
$
—

 
Schedule of New Accounting Pronouncements and Changes in Accounting Principles
The following is a reconciliation of the effect of the reclassification on the Company's condensed consolidated balance sheet as of December 31, 2015:
In millions
 
As Previously Reported
 
Adjustments
 
As Revised
Deferred tax assets - current
 
$
1,220

 
$
(1,220
)
 
$
—

Total current assets
 
30,378

 
(1,220
)
 
29,158

Total assets
 
93,657

 
(1,220
)
 
92,437

Deferred tax liabilities - noncurrent
 
5,437

 
(1,220
)
 
4,217

Total liabilities and shareholders’ equity
 
93,657

 
(1,220
)
 
92,437
XML 34 R21.htm IDEA: XBRL DOCUMENT v3.5.0.2
Acquisition (Tables)
 9 Months Ended
Sep. 30, 2016
Omnicare, Inc.  
Business Acquisition [Line Items]  
Pro Forma Information
The following pro forma financial information is not necessarily indicative of the results of operations as they would have been had the transactions been effected on the assumed date, nor is it necessarily an indication of trends in future results for a number of reasons, including, but not limited to, differences between the assumptions used to prepare the pro forma information, basic shares outstanding and dilutive equivalents, cost savings from operating efficiencies, potential synergies, and the impact of incremental costs incurred in integrating the businesses.
In millions, except per share data
Three
Months Ended
September 30,
2015
 
Nine
Months Ended
September 30,
2015
Total revenues
$
39,374

 
$
115,652

Income from continuing operations
1,318

 
3,774

Earnings per share from continuing operations:
 
 
 
Basic
$
1.18

 
$
3.35

Diluted
$
1.17

 
$
3.32
XML 35 R22.htm IDEA: XBRL DOCUMENT v3.5.0.2
Goodwill and Intangible Assets (Tables)
 9 Months Ended
Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Finite-Lived Intangible Assets
The following is a summary of the Company's intangible assets as of September 30, 2016 and December 31, 2015:

 
September 30, 2016
 
December 31, 2015
In millions
Gross
Carrying Amount
 
Accumulated Amortization
 
Net Carrying Amount
 
Gross
Carrying Amount
 
Accumulated Amortization
 
Net Carrying Amount
Trademarks (indefinitely-lived)
$
6,398

 
$
—

 
$
6,398

 
$
6,398

 
$
—

 
$
6,398

Customer contracts and
  relationships and covenants not
  to compete
11,340

 
(4,624
)
 
6,716

 
10,594

 
(4,092
)
 
6,502

Favorable leases and other
1,132

 
(679
)
 
453

 
1,595

 
(617
)
 
978

 
$
18,870

 
$
(5,303
)
 
$
13,567

 
$
18,587

 
$
(4,709
)
 
$
13,878
Schedule of Indefinite-Lived Intangible Assets
The following is a summary of the Company's intangible assets as of September 30, 2016 and December 31, 2015:

 
September 30, 2016
 
December 31, 2015
In millions
Gross
Carrying Amount
 
Accumulated Amortization
 
Net Carrying Amount
 
Gross
Carrying Amount
 
Accumulated Amortization
 
Net Carrying Amount
Trademarks (indefinitely-lived)
$
6,398

 
$
—

 
$
6,398

 
$
6,398

 
$
—

 
$
6,398

Customer contracts and
  relationships and covenants not
  to compete
11,340

 
(4,624
)
 
6,716

 
10,594

 
(4,092
)
 
6,502

Favorable leases and other
1,132

 
(679
)
 
453

 
1,595

 
(617
)
 
978

 
$
18,870

 
$
(5,303
)
 
$
13,567

 
$
18,587

 
$
(4,709
)
 
$
13,878
XML 36 R23.htm IDEA: XBRL DOCUMENT v3.5.0.2
Share Repurchase Program (Tables)
 9 Months Ended
Sep. 30, 2016
Payments for Repurchase of Equity [Abstract]  
Schedule of outstanding share repurchase programs
During the nine months ended September 30, 2016, the Company had the following outstanding share repurchase program that was authorized by the Company’s Board of Directors:
In billions
 
 
 
 
 
 
Authorization Date
Authorized
Remaining
December 15, 2014 (“2014 Repurchase Program”)
 
$
10.0

 
 
$
3.7

 
XML 37 R24.htm IDEA: XBRL DOCUMENT v3.5.0.2
Accumulated Other Comprehensive Income (Tables)
 9 Months Ended
Sep. 30, 2016
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Schedule of Activity Within the Components of Accumulated Other Comprehensive Income (Loss)
The following table summarizes the activity within the components of accumulated other comprehensive income.
Changes in accumulated other comprehensive income (loss) by component is shown on the below:
 
Three Months Ended September 30, 2016(1)
In millions
Foreign Currency
 
Losses on Cash Flow Hedges
 
Pension and Other Postretirement Benefits
 
Total
Balance, June 30, 2016
$
(125
)
 
$
(6
)
 
$
(186
)
 
$
(317
)
     Other comprehensive income (loss) before
reclassifications
(3
)
 
—

 
—

 
(3
)
     Amounts reclassified from accumulated
other comprehensive income(2)
—

 
1

 
—

 
1

Net other comprehensive income (loss)
(3
)
 
1

 
—

 
(2
)
Balance, September 30, 2016
$
(128
)
 
$
(5
)
 
$
(186
)
 
$
(319
)
 
 
 
 
 
 
 
 
 
Three Months Ended September 30, 2015(1)
 
Foreign Currency
 
Losses on Cash Flow Hedges
 
Pension and Other Postretirement Benefits
 
Total
Balance, June 30, 2015
$
(104
)
 
$
(8
)
 
$
(143
)
 
$
(255
)
     Other comprehensive income (loss) before
reclassifications
(61
)
 
—

 
—

 
(61
)
     Amounts reclassified from accumulated
other comprehensive income(2)
—

 
—

 
—

 
—

Net other comprehensive (loss)
(61
)
 
—

 
—

 
(61
)
Balance, September 30, 2015
$
(165
)
 
$
(8
)
 
$
(143
)
 
$
(316
)
 
 
 
 
 
 
 
 
 
Nine Months Ended September 30, 2016(1)
 
Foreign Currency
 
Losses on Cash Flow Hedges
 
Pension and Other Postretirement Benefits
 
Total
Balance, December 31, 2015
$
(165
)
 
$
(7
)
 
$
(186
)
 
$
(358
)
     Other comprehensive income (loss) before
reclassifications
37

 
—

 
—

 
37

     Amounts reclassified from accumulated
other comprehensive income (2)
—

 
2

 
—

 
2

Net other comprehensive income
37

 
2

 
—

 
39

Balance, September 30, 2016
$
(128
)
 
$
(5
)
 
$
(186
)
 
$
(319
)
 
 
 
 
 
 
 
 
 
Nine Months Ended September 30, 2015(1)
 
Foreign Currency
 
Losses on Cash Flow Hedges
 
Pension and Other Postretirement Benefits
 
Total
Balance, December 31, 2014
$
(65
)
 
$
(9
)
 
$
(143
)
 
$
(217
)
     Other comprehensive income (loss) before
reclassifications
(100
)
 
1

 
—

 
(99
)
     Amounts reclassified from accumulated
other comprehensive income (2)
—

 
—

 
—

 
—

Net other comprehensive income (loss)
(100
)
 
1

 
—

 
(99
)
Balance, September 30, 2015
$
(165
)
 
$
(8
)
 
$
(143
)
 
$
(316
)


(1)
All amounts are net of tax.
(2)
The amounts reclassified from accumulated other comprehensive income for losses on cash flow hedges are recorded within interest expense, net on the condensed consolidated statement of income. The amounts reclassified from accumulated other comprehensive income for pension and other postretirement benefits are included in operating expenses on the condensed consolidated statement of income.
XML 38 R25.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stock-Based Compensation (Tables)
 9 Months Ended
Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
In millions
2016
 
2015
 
2016
 
2015
Stock-based compensation:
 
 
 
 
 
 
 
Stock options
$
20

 
$
22

 
$
60

 
$
67

Restricted stock units
38

 
65

 
106

 
108

Total stock-based compensation
$
58

 
$
87

 
$
166

 
$
175
XML 39 R26.htm IDEA: XBRL DOCUMENT v3.5.0.2
Interest Expense (Tables)
 9 Months Ended
Sep. 30, 2016
Interest Income (Expense), Net [Abstract]  
Components of net interest expense
The following are the components of net interest expense: 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
In millions
2016
 
2015
 
2016
 
2015
Interest expense
$
258

 
$
268

 
$
830

 
$
577

Interest income
(5
)
 
(7
)
 
(14
)
 
(15
)
Interest expense, net
$
253

 
$
261

 
$
816

 
$
562
XML 40 R27.htm IDEA: XBRL DOCUMENT v3.5.0.2
Earnings Per Share (Tables)
 9 Months Ended
Sep. 30, 2016
Earnings Per Share [Abstract]  
Reconciliation of basic and diluted earnings per common share
The following is a reconciliation of basic and diluted net income per share from continuing operations for the respective periods:
 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
In millions, except per share amounts
2016
 
2015
 
2016
 
2015
Numerator for earnings per share calculations:
 
 
 
 
 
 
 
Income from continuing operations
$
1,542

 
$
1,237

 
$
3,613

 
$
3,730

Income allocated to participating securities
(7
)
 
(6
)
 
(18
)
 
(18
)
Net income attributable to noncontrolling interest
(1
)
 
(1
)
 
(2
)
 
(1
)
Income from continuing operations attributable to CVS Health
$
1,534

 
$
1,230

 
$
3,593

 
$
3,711

 
 
 
 
 
 
 
 
Denominators for earnings per share calculations:
 

 
 

 
 

 
 
Weighted average shares, basic
1,068

 
1,114

 
1,076

 
1,122

Effect of dilutive securities
5

 
7

 
6

 
8

Weighted average shares, diluted
1,073

 
1,121

 
1,082

 
1,130

 
 
 
 
 
 
 
 
Earnings per share from continuing operations:
 

 
 

 
 

 
 

Basic
$
1.44

 
$
1.10

 
$
3.34

 
$
3.31

Diluted
$
1.43

 
$
1.10

 
$
3.32

 
$
3.28
XML 41 R28.htm IDEA: XBRL DOCUMENT v3.5.0.2
Segment Reporting (Tables)
 9 Months Ended
Sep. 30, 2016
Segment Reporting [Abstract]  
Reconciliation of the Company's business segments to the consolidated financial statements
In millions
Pharmacy
Services
Segment(1)
 
Retail/LTC
Segment
 
Corporate
Segment
 
Intersegment
Eliminations(2)
 
Consolidated
Totals
Three Months Ended
 
 
 
 
 
 
 
 
 
September 30, 2016:
 
 
 
 
 
 
 
 
 
Net revenues
$
30,429

 
$
20,143

 
$
—

 
$
(5,957
)
 
$
44,615

Gross profit(3)
1,797

 
5,893

 
—

 
(198
)
 
7,492

Operating profit (loss)(4)(5)
1,458

 
1,773

 
(229
)
 
(185
)
 
2,817

September 30, 2015:
 

 
 

 
 

 
 

 
 

Net revenues
25,528

 
17,912

 
—

 
(4,796
)
 
38,644

Gross profit
1,468

 
5,373

 
—

 
(180
)
 
6,661

Operating profit (loss)(4)(5)
1,162

 
1,643

 
(309
)
 
(165
)
 
2,331

Nine Months Ended
 

 
 

 
 

 
 

 
 

September 30, 2016:
 

 
 

 
 

 
 

 
 

Net revenues
88,704

 
60,253

 
—

 
(17,402
)
 
131,555

Gross profit(3)
4,266

 
17,560

 
—

 
(575
)
 
21,251

Operating profit (loss)(4)(5)
3,278

 
5,255

 
(661
)
 
(529
)
 
7,343

September 30, 2015:
 

 
 

 
 

 
 

 
 

Net revenues
73,849

 
52,105

 
—

 
(13,810
)
 
112,144

Gross profit
3,735

 
15,990

 
—

 
(498
)
 
19,227

Operating profit (loss)(4)(5)
2,837

 
5,050

 
(712
)
 
(450
)
 
6,725


(1) 
Net revenues of the Pharmacy Services Segment include approximately $2.5 billion and $2.1 billion of retail co-payments for the three months ended September 30, 2016 and 2015, respectively, as well as $8.1 billion and $6.8 billion of retail co-payments for the nine months ended September 30, 2016 and 2015, respectively.
(2)
Intersegment eliminations relate to intersegment revenue generating activities that occur between the Pharmacy Services Segment and the Retail/LTC Segment. These occur in the following ways: when members of Pharmacy Services Segment clients (“members”) fill prescriptions at the Company's retail stores to purchase covered products, when members enrolled in programs such as Maintenance Choice ® elect to pick up maintenance prescriptions at one of the Company's retail stores instead of receiving them through the mail, or when members have prescriptions filled at the Company's long-term care pharmacies. When these occur, both the Pharmacy Services and Retail/LTC segments record the revenues, gross profit and operating profit on a standalone basis.
(3)
The Retail/LTC Segment gross profit for the three and nine months ended September 30, 2016 includes $5 million and $15 million, respectively, of acquisition-related integration costs. The integration costs are related to the acquisitions of Omnicare and the pharmacies and clinics of Target.
(4)
The Retail/LTC Segment operating profit for the three and nine months ended September 30, 2016 includes $52 million and $194 million, respectively, of acquisition-related integration costs. The Retail/LTC Segment operating profit for the three and nine months ended September 30, 2015 includes $12 million of acquisition-related integration costs. The integration costs are related to the acquisitions of Omnicare and the pharmacies and clinics of Target.
(5)
The Corporate Segment operating loss for the three and nine months ended September 30, 2016 includes $13 million of integration costs. The Corporate Segment operating loss for the three and nine months ended September 30, 2015 includes $115 million and $135 million, respectively, of acquisition-related transaction and integration costs.
XML 42 R29.htm IDEA: XBRL DOCUMENT v3.5.0.2
Accounting Policies - Fair Value of Financial Instruments (Details) - USD ($)
$ in Millions
Sep. 30, 2016
Dec. 31, 2015
Accounting Policies [Abstract]    
Short-term investments $ 74 $ 88
Total long-term debt 26,400  
Long-term debt, fair value $ 28,700  
XML 43 R30.htm IDEA: XBRL DOCUMENT v3.5.0.2
Accounting Policies - Redeemable Noncontrolling Interest (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2016
Sep. 30, 2016
Aug. 31, 2015
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]      
Beginning balance $ 7 $ 7  
Ending balance   5  
NCRX      
Noncontrolling Interest [Line Items]      
Outstanding common shares and voting interests acquired (percent)     73.00%
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]      
Beginning balance 39 39  
Net income attributable to noncontrolling interest   1  
Distributions   (2)  
Purchase of noncontrolling interest $ (39) (39)  
Reclassification to capital surplus in connection with purchase of noncontrolling interest   1  
Ending balance   $ 0  
XML 44 R31.htm IDEA: XBRL DOCUMENT v3.5.0.2
Accounting Policies - Related Party Transactions (Details)
$ in Millions
 1 Months Ended 3 Months Ended 9 Months Ended
Apr. 30, 2016
USD ($)
Sep. 30, 2016
USD ($)
state
Sep. 30, 2015
USD ($)
Sep. 30, 2016
USD ($)
state
Sep. 30, 2015
USD ($)
Related Party Transaction [Line Items]          
Amounts of transaction   $ 7 $ 16 $ 29 $ 37
Charitable Contribution to the CVS Foundation $ 32        
Equity Method Investee          
Related Party Transaction [Line Items]          
Other revenues from transactions with related party   $ 46   $ 116  
Heartland Healthcare Services          
Related Party Transaction [Line Items]          
Number of states pharmacies operated | state   4   4  
XML 45 R32.htm IDEA: XBRL DOCUMENT v3.5.0.2
Accounting Policies - Accounting Pronouncements (Details) - USD ($)
$ in Millions
Sep. 30, 2016
Dec. 31, 2015
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Total current assets $ 30,939 $ 29,158
Total assets 94,156 92,437
Deferred tax liabilities - noncurrent 4,254 4,217
Total liabilities and shareholders’ equity $ 94,156 92,437
Adjustments for New Accounting Principle, Early Adoption    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Deferred tax assets - current   0
Total current assets   29,158
Total assets   92,437
Deferred tax liabilities - noncurrent   4,217
Total liabilities and shareholders’ equity   92,437
Adjustments for New Accounting Principle, Early Adoption | Scenario, Previously Reported    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Deferred tax assets - current   1,220
Total current assets   30,378
Total assets   93,657
Deferred tax liabilities - noncurrent   5,437
Total liabilities and shareholders’ equity   93,657
Adjustments for New Accounting Principle, Early Adoption | Restatement Adjustment    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Deferred tax assets - current   (1,220)
Total current assets   (1,220)
Total assets   (1,220)
Deferred tax liabilities - noncurrent   (1,220)
Total liabilities and shareholders’ equity   $ (1,220)
XML 46 R33.htm IDEA: XBRL DOCUMENT v3.5.0.2
Acquisition - Additional Information (Details) - Omnicare, Inc.
$ / shares in Units, $ in Billions
Aug. 18, 2015
USD ($)
$ / shares
Business Acquisition [Line Items]  
Outstanding common shares and voting interests acquired (percent) 100.00%
Business acquisition, share price (in dollars per share) | $ / shares $ 98.00
Consideration transferred $ 9.6
Consideration transferred, liabilities incurred $ 3.1
XML 47 R34.htm IDEA: XBRL DOCUMENT v3.5.0.2
Acquisition - Proforma (Details) - Omnicare, Inc. - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2015
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]    
Total revenues $ 39,374 $ 115,652
Income from continuing operations $ 1,318 $ 3,774
Earnings per share from continuing operations:    
Basic earnings per share (in dollars per share) $ 1.18 $ 3.35
Diluted earnings per share (in dollars per share) $ 1.17 $ 3.32
XML 48 R35.htm IDEA: XBRL DOCUMENT v3.5.0.2
Goodwill and Intangible Assets - Additional Information (Details) - USD ($)
$ in Millions
Sep. 30, 2016
Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]    
Goodwill $ 38,214 $ 38,106
XML 49 R36.htm IDEA: XBRL DOCUMENT v3.5.0.2
Goodwill and Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)
$ in Millions
Sep. 30, 2016
Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]    
Indefinite-lived intangible assets (excluding goodwill) $ 6,398 $ 6,398
Intangible assets, gross 18,870 18,587
Intangible assets, accumulated amortization (5,303) (4,709)
Intangible assets, net 13,567 13,878
Customer Contracts Relationships and Covenants Not to Compete    
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, gross 11,340 10,594
Intangible assets, accumulated amortization (4,624) (4,092)
Intangible assets, net 6,716 6,502
Favorable Leases and Other    
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, gross 1,132 1,595
Intangible assets, accumulated amortization (679) (617)
Intangible assets, net $ 453 $ 978
XML 50 R37.htm IDEA: XBRL DOCUMENT v3.5.0.2
Share Repurchase Program (Details) - USD ($)
shares in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2016
Nov. 02, 2016
Jan. 28, 2016
Dec. 31, 2015
Dec. 11, 2015
Dec. 15, 2014
December 11, 2015              
Equity, Class of Treasury Stock [Line Items]              
Accelerated share repurchases agreement amount           $ 725,000,000.0  
Percent of notional amount received in shares           80.00%  
Accelerated share repurchases number of shares repurchased (in shares)       1.4   6.2  
Accelerated share repurchases, settlement (payment) or receipt       $ 145,000,000 $ 580,000,000    
Percent of notional amount in shares to be received at end of program           20.00%  
Repurchase Program 2014              
Equity, Class of Treasury Stock [Line Items]              
Maximum authorization under share repurchase program             $ 10,000,000,000
Remaining authorized repurchase amount $ 3,700,000,000 $ 3,700,000,000          
Repurchase of common stock (in shares)   41.4          
Value of stock repurchased in the period   $ 4,000,000,000          
Repurchase Program 2013              
Equity, Class of Treasury Stock [Line Items]              
Repurchase of common stock (in shares) 0.4            
Value of stock repurchased in the period $ 40,000,000            
Subsequent Event | 2016 Repurchase Program              
Equity, Class of Treasury Stock [Line Items]              
Maximum authorization under share repurchase program     $ 15,000,000,000        
XML 51 R38.htm IDEA: XBRL DOCUMENT v3.5.0.2
Accumulated Other Comprehensive Income (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Accumulated Other Comprehensive Income (Loss) [Roll Forward]        
Beginning balance     $ 37,203  
Other comprehensive income (loss) before reclassifications $ (3) $ (61) 37 $ (99)
Amounts reclassified from accumulated other comprehensive income(2) 1 0 2 0
Net other comprehensive income (loss) (2) (61) 39 (99)
Ending balance 35,954   35,954  
Accumulated Translation Adjustment        
Accumulated Other Comprehensive Income (Loss) [Roll Forward]        
Beginning balance (125) (104) (165) (65)
Other comprehensive income (loss) before reclassifications (3) (61) 37 (100)
Amounts reclassified from accumulated other comprehensive income(2) 0 0 0 0
Net other comprehensive income (loss) (3) (61) 37 (100)
Ending balance (128) (165) (128) (165)
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges        
Accumulated Other Comprehensive Income (Loss) [Roll Forward]        
Beginning balance (6) (8) (7) (9)
Other comprehensive income (loss) before reclassifications 0 0 0 1
Amounts reclassified from accumulated other comprehensive income(2) 1 0 2 0
Net other comprehensive income (loss) 1 0 2 1
Ending balance (5) (8) (5) (8)
Defined Benefit Pension Items        
Accumulated Other Comprehensive Income (Loss) [Roll Forward]        
Beginning balance (186) (143) (186) (143)
Other comprehensive income (loss) before reclassifications 0 0 0 0
Amounts reclassified from accumulated other comprehensive income(2) 0 0 0 0
Net other comprehensive income (loss) 0 0 0 0
Ending balance (186) (143) (186) (143)
AOCI        
Accumulated Other Comprehensive Income (Loss) [Roll Forward]        
Beginning balance (317) (255) (358) (217)
Ending balance $ (319) $ (316) $ (319) $ (316)
XML 52 R39.htm IDEA: XBRL DOCUMENT v3.5.0.2
Borrowings (Details) - USD ($)
 3 Months Ended 9 Months Ended
Jul. 27, 2016
May 31, 2016
May 16, 2016
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Debt Instrument [Line Items]              
Proceeds from issuance of long-term debt           $ 3,455,000,000 $ 14,808,000,000
Payment of debt premium $ 97,000,000   $ 486,000,000        
Write off of deferred debt issuance cost     50,000,000 $ 4,000,000      
Payments of debt extinguishment costs     6,000,000        
Loss on early extinguishment of debt       $ 101,000,000 $ 0 643,000,000 $ 0
The Notes [Member]              
Debt Instrument [Line Items]              
Loss on early extinguishment of debt           $ 542,000,000  
Unsecured Debt | Unsecured Senior Notes 2.125% Due in 2021              
Debt Instrument [Line Items]              
Aggregate principal amount     $ 1,750,000,000.00        
Interest rate, stated percentage     2.125%        
Unsecured Debt | Unsecured Senior Notes 2.875% Due in 2026              
Debt Instrument [Line Items]              
Aggregate principal amount     $ 1,750,000,000.00        
Interest rate, stated percentage     2.875%        
Unsecured Debt | 2016 Notes              
Debt Instrument [Line Items]              
Proceeds from issuance of long-term debt     $ 3,500,000,000        
Senior Notes | Unsecured Senior Notes 5.75% Due in 2017              
Debt Instrument [Line Items]              
Interest rate, stated percentage     5.75%        
Senior Notes | Unsecured Senior Notes 6.6% Due in 2019              
Debt Instrument [Line Items]              
Interest rate, stated percentage     6.60%        
Senior Notes | Unsecured Senior Notes 4.75% Due in 2020              
Debt Instrument [Line Items]              
Interest rate, stated percentage     4.75%        
Senior Notes | Maximum Tender Offer Notes              
Debt Instrument [Line Items]              
Authorized face amount to be repurchased   $ 2,250,000,000 $ 1,500,000,000.0        
Repurchased face amount   2,250,000,000          
Senior Notes | Unsecured Senior Notes 6.25% Due in 2027              
Debt Instrument [Line Items]              
Interest rate, stated percentage     6.25%        
Senior Notes | Unsecured Senior Notes 6.125% Due in 2039              
Debt Instrument [Line Items]              
Interest rate, stated percentage     6.125%        
Senior Notes | Unsecured Senior Notes 5.75% Due in 2041              
Debt Instrument [Line Items]              
Interest rate, stated percentage     5.75%        
Senior Notes | Unsecured Senior Notes 5.00% Due in 2024              
Debt Instrument [Line Items]              
Interest rate, stated percentage     5.00%        
Senior Notes | Unsecured Senior Notes 4.75% Due in 2022              
Debt Instrument [Line Items]              
Interest rate, stated percentage     4.75%        
Senior Notes | Unsecured Senior Notes 4.875% Due in 2035              
Debt Instrument [Line Items]              
Interest rate, stated percentage     4.875%        
Senior Notes | Unsecured Senior Notes 3.875% Due in 2025              
Debt Instrument [Line Items]              
Interest rate, stated percentage     3.875%        
Senior Notes | Any and All Notes              
Debt Instrument [Line Items]              
Repurchased face amount $ 1,100,000,000 $ 835,000,000          
XML 53 R40.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stock-Based Compensation (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense $ 58 $ 87 $ 166 $ 175
Options, grants in period (in shares)     4,000,000  
Options, grants in period, weighted average grant date fair value (in dollars per share)     $ 13.02  
Options, grants in period, weighted average exercise price (in dollars per share)     $ 104.75  
Options, outstanding (in shares) 24,000,000   24,000,000  
Options, outstanding, weighted average exercise price (in dollars per share) $ 68.31   $ 68.31  
Options, outstanding, weighted average remaining contractual term (in years)     3 years 11 months 9 days  
Employee Stock Option        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense $ 20 22 $ 60 67
Restricted Stock Units (RSUs)        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense $ 38 $ 65 $ 106 $ 108
Equity instruments other than options, grants in period (in shares)     2,000,000  
Equity instruments other than options, grants in period, weighted average grant date fair value (in dollars per share)     $ 103.47  
Equity instruments other than options, nonvested (in shares) 5,000,000   5,000,000  
Equity instruments other than options, nonvested, weighted average grant date fair value (in dollars per share) $ 56.20   $ 56.20  
XML 54 R41.htm IDEA: XBRL DOCUMENT v3.5.0.2
Sale-Leaseback Transactions (Details) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Leases [Abstract]    
Proceeds from sale-leaseback transactions $ 230 $ 34
XML 55 R42.htm IDEA: XBRL DOCUMENT v3.5.0.2
Interest Expense (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Interest Income (Expense), Net [Abstract]        
Interest expense $ 258 $ 268 $ 830 $ 577
Interest income (5) (7) (14) (15)
Interest expense, net $ 253 $ 261 $ 816 $ 562
XML 56 R43.htm IDEA: XBRL DOCUMENT v3.5.0.2
Earnings Per Share (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Earnings Per Share [Abstract]        
Antidilutive securities excluded from computation of earnings per share (in shares) 7.7 3.5 6.4 2.4
Numerator for earnings per share calculations:        
Income from continuing operations $ 1,542 $ 1,237 $ 3,613 $ 3,730
Income allocated to participating securities (7) (6) (18) (18)
Net income attributable to noncontrolling interest (1) (1) (2) (1)
Income from continuing operations attributable to CVS Health $ 1,534 $ 1,230 $ 3,593 $ 3,711
Denominators for earnings per share calculations:        
Weighted averages shares outstanding, basic (in shares) 1,068.0 1,114.0 1,076.0 1,122.0
Stock options (in shares) 5.0 7.0 6.0 8.0
Weighted averages shares outstanding, diluted (in shares) 1,073.0 1,121.0 1,082.0 1,130.0
Earnings per share from continuing operations:        
Income from continuing operations attributable to CVS Health (in dollars per share) $ 1.44 $ 1.10 $ 3.34 $ 3.31
Income from continuing operations attributable to CVS Health (in dollars per share) $ 1.43 $ 1.10 $ 3.32 $ 3.28
XML 57 R44.htm IDEA: XBRL DOCUMENT v3.5.0.2
Segment Reporting (Details)
$ in Millions
 1 Months Ended 3 Months Ended 9 Months Ended
Dec. 31, 2015
pharmacy
Sep. 30, 2016
USD ($)
Mail_Service_Pharmacy
state
Center
drugstore
pharmacy
Sep. 30, 2015
USD ($)
Sep. 30, 2016
USD ($)
Mail_Service_Pharmacy
state
Center
segment
drugstore
pharmacy
Sep. 30, 2015
USD ($)
Segment reporting information          
Number of segments | segment       3  
Net revenues   $ 44,615 $ 38,644 $ 131,555 $ 112,144
Gross profit   7,492 6,661 21,251 19,227
Operating profit (loss)   $ 2,817 2,331 $ 7,343 6,725
Pharmacy Services Segment          
Segment reporting information          
Number of centers of excellence for infusion and enteral services | Center   5   5  
Number of states pharmacies operated | state   41   41  
Net revenues, retail co-payments   $ 2,500 2,100 $ 8,100 6,800
Retail/LTC Segment          
Segment reporting information          
Number of states pharmacies operated | state   49   49  
Number of retail drugstores | drugstore   9,694   9,694  
Number of retail drugstores operating a pharmacy | drugstore   9,638   9,638  
Number of LTC spoke pharmacies | drugstore   151   151  
Number of LTC hub pharmacies | drugstore   32   32  
Retail/LTC Segment | Gross Profit          
Segment reporting information          
Acquisition related costs   $ 5   $ 15  
Retail/LTC Segment | Operating Income (Loss)          
Segment reporting information          
Integration related costs     12   12
Acquisition related costs   52   194  
Corporate Segment | Operating Income (Loss)          
Segment reporting information          
Integration related costs   13   13  
Acquisition related costs     115   135
Operating Segments | Pharmacy Services Segment          
Segment reporting information          
Net revenues   30,429 25,528 88,704 73,849
Gross profit   1,797 1,468 4,266 3,735
Operating profit (loss)   1,458 1,162 3,278 2,837
Operating Segments | Retail/LTC Segment          
Segment reporting information          
Net revenues   20,143 17,912 60,253 52,105
Gross profit   5,893 5,373 17,560 15,990
Operating profit (loss)   1,773 1,643 5,255 5,050
Operating Segments | Corporate Segment          
Segment reporting information          
Net revenues   0 0 0 0
Gross profit   0 0 0 0
Operating profit (loss)   (229) (309) (661) (712)
Intersegment Eliminations          
Segment reporting information          
Net revenues   (5,957) (4,796) (17,402) (13,810)
Gross profit   (198) (180) (575) (498)
Operating profit (loss)   $ (185) $ (165) $ (529) $ (450)
MinuteClinic within CVS Pharmacy Stores | Retail/LTC Segment          
Segment reporting information          
Number of clinics in retail drugstores | drugstore   1,129   1,129  
CarePlus and CVS Pharmacy | Retail/LTC Segment          
Segment reporting information          
Number of pharmacies | pharmacy   34   34  
MinuteClinic | Retail/LTC Segment          
Segment reporting information          
Number of clinics | drugstore   1,136   1,136  
Target Pharmacy Acquisition | Retail/LTC Segment          
Segment reporting information          
Number of pharmacies acquired | pharmacy 1,670        
Specialty stores | Pharmacy Services Segment          
Segment reporting information          
Number of pharmacies | pharmacy   23   23  
Specialty mail order | Pharmacy Services Segment          
Segment reporting information          
Number of pharmacies | pharmacy   13   13  
Mail service | Pharmacy Services Segment          
Segment reporting information          
Number of pharmacies | Mail_Service_Pharmacy   4   4  
Infusion and Enteral Branches | Pharmacy Services Segment          
Segment reporting information          
Number of infusion and enteral branches | Mail_Service_Pharmacy   85   85  
Ambulatory infusion suites | Pharmacy Services Segment          
Segment reporting information          
Number of infusion and enteral branches | Mail_Service_Pharmacy   74   74  
XML 58 R45.htm IDEA: XBRL DOCUMENT v3.5.0.2
Commitments and Contingencies (Details)
 1 Months Ended 3 Months Ended 9 Months Ended
Oct. 11, 2016
Dec. 22, 2014
qui_tam_complaint
Oct. 29, 2010
employee
Oct. 31, 2016
USD ($)
state
Aug. 31, 2016
USD ($)
Jul. 31, 2016
USD ($)
Feb. 29, 2016
plaintiff
Sep. 30, 2015
pharmacy
Mar. 31, 2010
state
Dec. 31, 2009
USD ($)
Feb. 28, 2006
class_action_complaint
officer
director
Oct. 31, 2003
class_action_complaint
competitor
defendant
pharmacy
Sep. 30, 2015
class_action_complaint
Sep. 30, 2016
USD ($)
store_lease
Loss contingencies                            
Number of store leases guaranteed | store_lease                           87
Year the last lease expires                           2047
Number of competitors against whom putative actions are filed | class_action_complaint                       3 2  
Number of Caremark entities named as defendants | defendant                       2    
Number of states participating in multi-state investigation | state                 28          
Cases consolidated, number | class_action_complaint                         2  
Litigation settlement, expense           $ 3,500,000                
Subsequent Event                            
Loss contingencies                            
Corporate integrity agreement term (in years) 5 years                          
Number of states in which plaintiffs reside | state       11                    
Omnicare, Inc.                            
Loss contingencies                            
Number of competitors against whom putative actions are filed   2                 2      
Number of officers named in lawsuit | officer                     3      
Number of directors named in lawsuit | director                     2      
Number of pharmacies indicated in subpoena | pharmacy               8            
Lauriello Lawsuit                            
Loss contingencies                            
Settlement agreement in principle medoff securities class action lawsuit                           $ 80,000,000
North Jackson Pharmacy, Inc. and C&C, Inc. d/b/a Big C Discount Drugs, Inc. vs Caremark                            
Loss contingencies                            
Number of pharmacies filing putative action | pharmacy                       2    
Number of competitors against whom putative actions are filed | class_action_complaint                       1    
Number of Caremark entities named as defendants | defendant                       3    
Number of competitors against whom putative actions are filed | competitor                       2    
Wuotila Derivative Matter                            
Loss contingencies                            
Settlement agreement in principle medoff securities class action lawsuit                   $ 270,000        
Banigan and Templin v. Organon USA, Inc., Omnicare, Inc. and PharMerica Corporation                            
Loss contingencies                            
Settlement agreement in principle medoff securities class action lawsuit         $ 23,000,000                  
Number of former employees | employee     2                      
Darlene Ervin v. Omnicare, Inc. | Subsequent Event                            
Loss contingencies                            
Settlement agreement in principle medoff securities class action lawsuit       $ 2,200,000.0                    
Pure Service Pharmacy Acquisition [Member]                            
Loss contingencies                            
Settlement agreement in principle medoff securities class action lawsuit                           1,500,000.0
Omnicare Auto Label Verification System [Member]                            
Loss contingencies                            
Settlement agreement in principle medoff securities class action lawsuit                           $ 8,000,000
Spetter v. Abbott Laboratories, Inc., Omnicare, Inc., and PharMerica Corp. | Omnicare, Inc. | Subsequent Event                            
Loss contingencies                            
Settlement agreement in principle medoff securities class action lawsuit       $ 28,100,000                    
Sheet Metal Workers Local No. 20 Welfare and Benefit Fund v. CVS Health Corp.                            
Loss contingencies                            
Number of pharmacies filing putative action | plaintiff             2              
EXCEL 59 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 61 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 63 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 163 234 1 false 64 0 false 19 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.cvshealth.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Condensed Consolidated Statements of Income Sheet http://www.cvshealth.com/role/CondensedConsolidatedStatementsOfIncome Condensed Consolidated Statements of Income Statements 2 false false R3.htm 1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income Sheet http://www.cvshealth.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome Condensed Consolidated Statements of Comprehensive Income Statements 3 false false R4.htm 1003000 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.cvshealth.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 4 false false R5.htm 1003501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.cvshealth.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 5 false false R6.htm 1004000 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.cvshealth.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 2101100 - Disclosure - Accounting Policies Sheet http://www.cvshealth.com/role/AccountingPolicies Accounting Policies Notes 7 false false R8.htm 2105100 - Disclosure - Acquisition Sheet http://www.cvshealth.com/role/Acquisition Acquisition Notes 8 false false R9.htm 2112100 - Disclosure - Goodwill and Intangible Assets Sheet http://www.cvshealth.com/role/GoodwillAndIntangibleAssets Goodwill and Intangible Assets Notes 9 false false R10.htm 2113100 - Disclosure - Share Repurchase Program Sheet http://www.cvshealth.com/role/ShareRepurchaseProgram Share Repurchase Program Notes 10 false false R11.htm 2115100 - Disclosure - Accumulated Other Comprehensive Income Sheet http://www.cvshealth.com/role/AccumulatedOtherComprehensiveIncome Accumulated Other Comprehensive Income Notes 11 false false R12.htm 2116100 - Disclosure - Borrowings Sheet http://www.cvshealth.com/role/Borrowings Borrowings Notes 12 false false R13.htm 2117100 - Disclosure - Stock-Based Compensation Sheet http://www.cvshealth.com/role/StockBasedCompensation Stock-Based Compensation Notes 13 false false R14.htm 2118100 - Disclosure - Sale-Leaseback Transactions Sheet http://www.cvshealth.com/role/SaleLeasebackTransactions Sale-Leaseback Transactions Notes 14 false false R15.htm 2119100 - Disclosure - Interest Expense Sheet http://www.cvshealth.com/role/InterestExpense Interest Expense Notes 15 false false R16.htm 2120100 - Disclosure - Earnings Per Share Sheet http://www.cvshealth.com/role/EarningsPerShare Earnings Per Share Notes 16 false false R17.htm 2121100 - Disclosure - Segment Reporting Sheet http://www.cvshealth.com/role/SegmentReporting Segment Reporting Notes 17 false false R18.htm 2122100 - Disclosure - Commitments and Contingencies Sheet http://www.cvshealth.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 18 false false R19.htm 2201201 - Disclosure - Accounting Policies (Policies) Sheet http://www.cvshealth.com/role/AccountingPoliciesPolicies Accounting Policies (Policies) Policies http://www.cvshealth.com/role/AccountingPolicies 19 false false R20.htm 2301302 - Disclosure - Accounting Policies (Tables) Sheet http://www.cvshealth.com/role/AccountingPoliciesTables Accounting Policies (Tables) Tables http://www.cvshealth.com/role/AccountingPolicies 20 false false R21.htm 2305301 - Disclosure - Acquisition (Tables) Sheet http://www.cvshealth.com/role/AcquisitionTables Acquisition (Tables) Tables http://www.cvshealth.com/role/Acquisition 21 false false R22.htm 2312301 - Disclosure - Goodwill and Intangible Assets (Tables) Sheet http://www.cvshealth.com/role/GoodwillAndIntangibleAssetsTables Goodwill and Intangible Assets (Tables) Tables http://www.cvshealth.com/role/GoodwillAndIntangibleAssets 22 false false R23.htm 2313301 - Disclosure - Share Repurchase Program (Tables) Sheet http://www.cvshealth.com/role/ShareRepurchaseProgramTables Share Repurchase Program (Tables) Tables http://www.cvshealth.com/role/ShareRepurchaseProgram 23 false false R24.htm 2315301 - Disclosure - Accumulated Other Comprehensive Income (Tables) Sheet http://www.cvshealth.com/role/AccumulatedOtherComprehensiveIncomeTables Accumulated Other Comprehensive Income (Tables) Tables http://www.cvshealth.com/role/AccumulatedOtherComprehensiveIncome 24 false false R25.htm 2317301 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.cvshealth.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.cvshealth.com/role/StockBasedCompensation 25 false false R26.htm 2319301 - Disclosure - Interest Expense (Tables) Sheet http://www.cvshealth.com/role/InterestExpenseTables Interest Expense (Tables) Tables http://www.cvshealth.com/role/InterestExpense 26 false false R27.htm 2320301 - Disclosure - Earnings Per Share (Tables) Sheet http://www.cvshealth.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://www.cvshealth.com/role/EarningsPerShare 27 false false R28.htm 2321301 - Disclosure - Segment Reporting (Tables) Sheet http://www.cvshealth.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://www.cvshealth.com/role/SegmentReporting 28 false false R29.htm 2401403 - Disclosure - Accounting Policies - Fair Value of Financial Instruments (Details) Sheet http://www.cvshealth.com/role/AccountingPoliciesFairValueOfFinancialInstrumentsDetails Accounting Policies - Fair Value of Financial Instruments (Details) Details 29 false false R30.htm 2401404 - Disclosure - Accounting Policies - Redeemable Noncontrolling Interest (Details) Sheet http://www.cvshealth.com/role/AccountingPoliciesRedeemableNoncontrollingInterestDetails Accounting Policies - Redeemable Noncontrolling Interest (Details) Details 30 false false R31.htm 2401405 - Disclosure - Accounting Policies - Related Party Transactions (Details) Sheet http://www.cvshealth.com/role/AccountingPoliciesRelatedPartyTransactionsDetails Accounting Policies - Related Party Transactions (Details) Details 31 false false R32.htm 2401406 - Disclosure - Accounting Policies - Accounting Pronouncements (Details) Sheet http://www.cvshealth.com/role/AccountingPoliciesAccountingPronouncementsDetails Accounting Policies - Accounting Pronouncements (Details) Details 32 false false R33.htm 2405402 - Disclosure - Acquisition - Additional Information (Details) Sheet http://www.cvshealth.com/role/AcquisitionAdditionalInformationDetails Acquisition - Additional Information (Details) Details 33 false false R34.htm 2405403 - Disclosure - Acquisition - Proforma (Details) Sheet http://www.cvshealth.com/role/AcquisitionProformaDetails Acquisition - Proforma (Details) Details 34 false false R35.htm 2412402 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details) Sheet http://www.cvshealth.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails Goodwill and Intangible Assets - Additional Information (Details) Details 35 false false R36.htm 2412403 - Disclosure - Goodwill and Intangible Assets - Schedule of Intangible Assets (Details) Sheet http://www.cvshealth.com/role/GoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails Goodwill and Intangible Assets - Schedule of Intangible Assets (Details) Details 36 false false R37.htm 2413402 - Disclosure - Share Repurchase Program (Details) Sheet http://www.cvshealth.com/role/ShareRepurchaseProgramDetails Share Repurchase Program (Details) Details http://www.cvshealth.com/role/ShareRepurchaseProgramTables 37 false false R38.htm 2415402 - Disclosure - Accumulated Other Comprehensive Income (Details) Sheet http://www.cvshealth.com/role/AccumulatedOtherComprehensiveIncomeDetails Accumulated Other Comprehensive Income (Details) Details http://www.cvshealth.com/role/AccumulatedOtherComprehensiveIncomeTables 38 false false R39.htm 2416401 - Disclosure - Borrowings (Details) Sheet http://www.cvshealth.com/role/BorrowingsDetails Borrowings (Details) Details http://www.cvshealth.com/role/Borrowings 39 false false R40.htm 2417402 - Disclosure - Stock-Based Compensation (Details) Sheet http://www.cvshealth.com/role/StockBasedCompensationDetails Stock-Based Compensation (Details) Details http://www.cvshealth.com/role/StockBasedCompensationTables 40 false false R41.htm 2418401 - Disclosure - Sale-Leaseback Transactions (Details) Sheet http://www.cvshealth.com/role/SaleLeasebackTransactionsDetails Sale-Leaseback Transactions (Details) Details http://www.cvshealth.com/role/SaleLeasebackTransactions 41 false false R42.htm 2419402 - Disclosure - Interest Expense (Details) Sheet http://www.cvshealth.com/role/InterestExpenseDetails Interest Expense (Details) Details http://www.cvshealth.com/role/InterestExpenseTables 42 false false R43.htm 2420402 - Disclosure - Earnings Per Share (Details) Sheet http://www.cvshealth.com/role/EarningsPerShareDetails Earnings Per Share (Details) Details http://www.cvshealth.com/role/EarningsPerShareTables 43 false false R44.htm 2421402 - Disclosure - Segment Reporting (Details) Sheet http://www.cvshealth.com/role/SegmentReportingDetails Segment Reporting (Details) Details http://www.cvshealth.com/role/SegmentReportingTables 44 false false R45.htm 2422401 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.cvshealth.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://www.cvshealth.com/role/CommitmentsAndContingencies 45 false false All Reports Book All Reports cvs-20160930.xml cvs-20160930.xsd cvs-20160930_cal.xml cvs-20160930_def.xml cvs-20160930_lab.xml cvs-20160930_pre.xml true true ZIP 65 0000064803-16-000097-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000064803-16-000097-xbrl.zip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�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�S)![2[!*B;&/,);2KJYI"]4!MVG96? M-X[[B\7W0+T-SJ\OJS\GU3$.-FH?_']@H&6>,BSBMBX!]10!:S0V<;E?]S:7 M3KDN4!Y*89ZA)S,MH'%,:&!DM""HI,$$P 9C* @&KE&$HJVMZM.!&H"MLZ== M69]0FF="W%]X>+5]=>)E&3;:U:HJ/JQ7T5IX7YZ*TAV-%%_<:R:5-L)PZH05 MU B@../$:4*%!0KZ%"J.<0OKE(3]R6&H3<[FTRJ6+/B#9 MC('=<<'>??KFW8 SR?NHA\QJ[T58SL@(3+5@2@5361E/B#%$TY1:E6_P/P:+N83]/KRSSZ:\?R\^_S?(BLI'$/T02DDXV3U(>2#[8\U4F@I'%#.-684@EXB)L<%HAA0$@BK*4"^PC)$S'TBW;PKD; MAFR'-?3 -TWR75Y^+:;X\FC9PLEV&#'84&F,]Q-1A)@S63!KI.(10DRLI MEGBYU,KNP.ROH%V3#?!$&EOS3C)-A+=$V8"&IYY(*8%B%NBPRK"T,"7R-\(8 M=C^*IG,Q#$'&D]EO3S_.B*>"!Y=,*8FIID1Z#J*'1C#3A(N42QTCVJ^Z%/<1 M1EV$<5_,V1;'^#U?W9:S[27[/#]9EO-PHRS PC&Q8;]F.F@ *"DG88H<:"HY M$2E%P$;.I'/%7':$Z< *\&6#G+I333/@L $86F>0HP(2[00F6@&IE#&&7]DE MLU$HNTO!'YANVUH.R]?\BK^\%CBRNG6 5L6 M?)KH+'-+#1,:OWC=N=O>V=UGQGG#2%6JG@!@%HJB.&0RF#J!'N'-*O!\7R4RN# ^9FXG5;')[3+QK/@^#V95AI&:?[SS8?^>30[HVW.:9\I;:6(-6R8Y M52(LQ 4UM%1KH42T08VVAJ+ J$9' MY!WM34\J2+\J5[DMEM-YN5Q7C91BXSXR)C '*!AXDA.*+%.:(::]UU9BC]3U MZ<-NV?+DU<9NY#":G60$:8HCV5 LQ, 1A(SEV@-@8*QB$-01Y0X KQO5#1H4 MHU-YC>=TDRD*""*4<>\4T"8L$Z9J-#BVUU> O%O.?/^D2G>BZ,T"KY\ W&Z+ M<0;E(K]_#?RH9CO2+F/,0(NYTH 2@,.,H73U7"&7O5[]'0WMSJ3!H8>'6P"\ MW]R"W5!/)J;L_3Z+Q=@)Q!"J>.L^S,P;7<_-NZ1K92,D4TMRWIM2:"] M@+%>(";.4EYCH(!/2?\;X8%P9W1K%>41,2UNYR\;I)F>VU4&"8[IW0()$H#7 MWB "[A&!P?1.N; U0JW;B]_:L0SZR\_ZMC)"M"8:3.W^D>8WFXO]9T0_N_AU M&0C.HX?"&,6IV#QXIFN3!DI%KZPV=G?$>W(2/[BL^HL6?G^.$N8R7\\V1\/5 MAA/?% 0[N\A;.[\@LRRJ3,9YD*A75B@!V$Z4 J9D*HZV]."P-#QYX-:#'/M: M!<>V$YW?E%7^O2QV1PY'J)_0:T:(EUI*#*CQWD/FB4(U3D(G584;H=TR*J;W M)[;G:.KT9.)D#'GO@LZ&1FBH.( <[:0'(.DG-;WOTG.C6@<#BG,,^W[B!K^; M.;?8:X$U9EAIH!GAX&%+P#S% ST_\E&N)O,?A\$=R.>_[/)O[3D-L#/$4N:< M1]H@RS"LT3-2IN3-GEV]L9]B>Z-B^"!2'$V.W/!W2D:2(A=\*":)\0HK2C5" MVGI,F =2"V>Q&$4-P'-BD^== +BHYX 9U\(SC)C!U%"OK0$.*@:T)A)>VWM@ MG3/KX'6 /J33UXZT>V%FL#VG?NTFH/BA6&R]SP8;R[%FF>9>( *P ,$ "K9Y M4$%D^QPL8I2 1E'DWF9[7KI^LPXR)AB5DO"8BV4E@D H52/ PX^N:R]HAPP' MGF%J%>G>U[6:S3;_CB_ WY35W78> Z?B=['FB0@^CP.$6V0H9T0Z Y$W"@&N M0,.3HZXMACTO>RWUUT?_U;Q@<+.N,FX0AQ(J*[FD6E%!H34$2LH,%;;958,K MV0<:$^2@XN\$\[[\[_;>+\8>*Q>\*8\MI X#):UV7.!@V "@U95QJCOQ-WS: M^#RXAZ13>T\;$R6],UX YAE%V,I@(R/#D 2":F>NK,1YLN3/?MKX/'PO+,WR M^FY1Q%*YP27Z]6BMXJN?!;KM1^;4%@98NP M#KB7O&R0.G>L668LQHI#12@+;KX7$CH".-0*.$?"QGQ=Q\U#*JE+,1^078,\ MBVR 0CCLX)(K2:D"84$'*Q0#ARS@PEV_3KN *.V\C'P>\@/R\MUMP/9-54R/ M^8!'VV7$(:14, \05E0YI06GDAEEG(-*Z"O;]_IBV<4 ]TVF1YZO"3M_,8L5 M)>.N'V_ ;44'&W"K23>9),AQ(AF$%E$HC68< B4\)@X"H!I5#'L^%VXZI5H' M>(^0>2^+R8=B'J"+U9*F\?BXB9J]K.,, JJI@LQZ3BG72D.,N QK5KM@_X(K M*]@X-#O3)=![9/Q-56X"XM<8#!?!,0S06^:40=)RJ9 BT$!.N4?"-[HWWI\U M7I4^"N+1 <6K8J'H 2!QS M=#= ::]4M[4@L!-!];-@'3+LV733O3#Z?G[_F1*<6W/UK%><1^?O6F4=&!6\6.J\!M8C&^Q7UO"VW5_;, M4L]<.<'Q>D5\ *-8K -RVS=_-J=TFYN8>ZJ)J\7,?0DN62!, M\-&JKQMX&USF&F(X6=!\3%@5'WBQQ,9GE>.YXE8R7M"4Y* KV]"[72DC$7!O M93PGU2(,??DFKS9G-0T":(>:Q <#I-806(B$PHXP2G8SI,ZEU+5['N<:/5*X M)2&,P*C^?B9ZLBRFE]G/>[O*E'/"80IQD+'7B&M%[[T5 21U5^:^IQ.CN0'< M!MXC9* MYNO5V9DLQSO+- /4("(5E\S)\&=)6(V*XOS*]/N0++P,\=Z/T0:^ MLMK%Z1EDDBN,I9-44A%?=H4< P%58)#3L%&FUO5=)8DQ,JE=X+HGU!BN)?1> M2>5)^!&[MJ>&VR%(ZE62\S!_AN=@&F((,&16"6J44$8JC+0*_\>X0U>6YMV= M^)N>>IT%]W6<>B%A/;<&.L@H548(S8@'-OY(@J##KXMBR9(_^]3K/'P'./4B M4#EO.=;,42J=418#!KRA7'DNZ97Y32T*[/BIUWFP/N>K))8+;)3F'(2I LQ1&_#[_Y1(QJW^>9(A@IB" 7%GN@H6!TAY+#Y@IW\(ME6[8.YU!$ M.1EUVM\@(P( PPS$PA+D& 355?%Q/<>P,I*@>D[4P!22C##NU#))4N'LBR+?JMP3)LK3 MC[-8Y-T0K$GXGV%8> EVZAD(DG+->80D:=- 209S&(J\FMR=-E .-R1@EQ9:<=TF9:=8]PJ803?C89=0)BGS3,C!<). MJ&#F:Q]6$ ">WT]&@@#>-:N?3@B3C/&%A%'Q)\*I !E""J M'-+UX! !*;&T$2;+MTJ 1"Q;W!GHKYS>%U(+Y'L1R ?YV?O#X4XR9J& A$JH MF?064B9WWIDT7J9$T498BZ?S7:(UI%ND$/N5?33:##O:160:(=QIRA !1 M'&%,9#TM*)+*F)_]*-,5$*@MH%OD#WG":03.)M#A3C(6=E:GF9:"2&@MA\K8 M>F)$H)0MB/V #&H-Z0LI]/OD2W&WOGL?CU6KUSW^6D"?/M11@FSTCC$G=0,^N"*H6!P A\PW7PYUDA 5?G0F('910$HJU-S5W@P^?XMW( M*Z=(ITBW2B'X_:#P):;KP5XR 8%VB# N.$8JYEK;G5L'K4X)T4/P0[*H+:P[ M=:')^3'9PYUDW!,GA?$,2D=DV%VMQ#NK"O&D6PP_8FBV-:A;Y1 #V/:Q #) M!1PZU$EFD(-AES5A67!,B09:N]WB@" INO\C1FM;@[IE/[H>#+K(@?ZN=<:% M5]9Q@#%TGD,A#7H(/TN4=/7@VD.\W6#<*ET>#APPO8 O3YMGRN&@<[V)]PUA MH#X0>A>#M$HFO4/\(X9[6P"Y1<;@QT=4YS-F7_-,8XF-# O 4.(EYYQ!L-.X MAB6EP_V(\=T60+[T&''Q=;*8J?F\P5'BGD\S0X S1 1GD&"./"5"[=Q C4C2 MWG'M<=H6 !TFI>EE@QNZ!UID858"Q2FQAA 8;;U#*465WC_)TG.1WES,:S# M$*=^'.[M9)6_"]++9P\/R#6FTK%.,F($04@ CH)BQ Q;QG:P2F%37L4:O8_= M-KE:!+HONKVIRFF>SS955U\LE^O)8IJ_OHG)[>_OD]N/T.QTX\P2)"@!DB%@ MC$:,6+X[H,?"I23KV[+JOAW/GO835?EA_QM_FE= M36\GR[U%'"_J)\.,20V%PQY(IZ"()0WJZ0GO4A+ 1^^;7\Z?/K >1B$^&N\% M1M7>UAE@BA'%O;; 0(\)TKR.32BJ4,I9Q>B]^;958!L(M[))O/;%Z?^.BD6R_B@1KY\O?AVV-NI'.'4R;:9 M$-!0X+$SB$ %+06JCN(%?9Y4W;]YIIG<ZG%;/M*R\=\,2T&K*A^9$QG%98ZJY_,"22,M8@;AZDC3&L")83L%I4MK@^+1,1VPI>Q3! MX%O&T+7G!MHYG)#6.@@@EYIY*!6GV%-(PP;O)6N4U=8-'E$=?3/Z4\7J]C?( MK$?!:>-*.(&-8-P 0NH9,H?9#[T3-)7^DX)3+4#=E^GYLE@5'S>B,Y/ER3IV M3S[.I ;(2&R54Q03B#UZ ,D%F^BZ")0JVN^9DHKG,"QI5LCN0)-,AM6#F>00 M$8)DC M:6,]0>'!M!F'(]N5D717Y?%Z^G/RY7!>'B],=_CCS M6"C,/9=< .\,!]3O9AXOY5RSZ"^15]DRHA>*_E59K6[_]V3ZQ[)3 MZ=?X7,,DZ% 3_S#[,-'%1Q-U:#Q#L-7ZXS+^_//2!*3N)M4?$8&CC&GU=V0( M*(ABVA)2FB(:LYYKA+T$+L6L&6&F1*M$&U(0%_+SG^MR5(>TML-(30PBGK!XVERKE78X1ID*TRI\V@;V0#WJR"/-9 M!,:^S^\^A:\___JZ"C\H%W]_IR)5'[\Y$[Z*-/\]C''2<^])-<\7N:L^;\;:].FI M4\TR;( @7GKE H#QMCR1M1G@F4M*.QUA6D2K'&H9VPN)\69=Y>_R,(9I7BO= M1X_)'"5'DZ89U!@SZPE70 A#-7([#]4;85,4V@C3(%HE2 ?X7DB2FIQJO2HW M^/TC[&4WX4=Q(.^^+E?Y7:,7[$ZVSZ"%S(2Y!$\5ALEHR+&JIZ.@2;G..\+< MAE;ITA7(%W+FW:<\FE^??U4?/I2K51A15'ME\"67)Q7D<:740L^98TH!KS4F MV!C/F%0.UQ!8B5*VI1&F.[3*L_[AOY2!MWF^^CU?3>;_+*L_ L@O@QCGK\I? M$?AG/K\)8PSCTT$%WQ0KOU[,/O]J_O'N;YNCJ08D;*7S#%!-N/&66 \)AD)X MHFL@PL),.1 =83&>=GDXA 3.BWLO\^FO'\O/O\WR(H:\2?Q#Y"EY%.D./\I> MYA\G<[=8%:NO!PY"]GR5$0B%]8@[C2B&P8LU4&Q'#H&EYNK>4FCE!"0=R&XH ML!W.P<.-[S_)L$*<8QD< 6,T1A!Q).LQ!W"O)),B25IE*] EFLP7O>XL)!5( M>BD]030H2 M)/4##TZJ3C$NVE\GEQ"/.9Z'7UT'FN_6'9?ZO=<##?8[7G$^_ MW7:@14:\DUPQZ#4$V@BAC'8[F*2]LMOA+1]\MP/J@*0Y>?Q]L$W&PTR85TH* MK618(Q@'Q^]^CECS*SL$39;T:>9^[[/@C@F&@T6..?7:6!;3 MV.O-U((K2]-J0<;'67,1JKWEVGR_U;YL4,/D<*-,"$!%4+BQRKJ5L48<4_4L M'=0I&5IC/%]J.4.K+5POM%__NIY4D\4JSV?O@E3REWEPV/?QX."W&>;,.(^) MHMY2A0'#?K=DB(=7]BQ7&_(JVX7T0LG_GWQ2K6X#6LO5YM>Z+Y^*ZJ#L#WR= MJ<#N8,UCK25S'F*"O-Y-6M"4NS_/(3B1)OUV0.T_1_-=OEK-\TTI@5-W[@\W MRJ TV#@E$&?<"^& !#O$ /;].#C?7AM[_YP8U#K$EV;OK:.Q\_KF_O RS,D7 MH/8#J7E-6J<622X0U03S[C4'!CH'F(&&%];#DN[VTPG& ]C MK7Y]E?]IYI/B+DXAGVUGUMALW=LZ8U!*K* 2@-FP2A@SGM7SALA?V0--76Q MK8,\%+GN%TJL&+"8!;NLN4>TIVVF#7#2*(\HY %80BTRNP5%=8J"&V-.3/?$ M2H4X4<&9\NY3OBJ"D);J8[RSO?KG;7GW[2ZZ5%6^X?T)?7=67V%KUHY ";B' MA@EH#86VGJ8W22F<8TR7Z4;]=0GYI7=>]A&\O'E]0NLBJ>35&)-9>N%0.U@G*KA-G=+EFTFU*J;%ITD MU"'B&,,I%6;'^-)4VUM39TBWH]SJ.S5YK*W\L8J)0A^K?#/,6 *WF7([T4E& M55@'P&M#C-:88FYT'06!D,HD"EU_1+M3L%MB43QB"?^]+.?%+ 9]#P:1FC?. M8G$W ;"A% 7$N%+Q&%M/;-_/@ M/JZ*FYOEV_"SV;ZR.)=VE0'LO%364H.L$H!X1NN< 0BL33\_:KHUUEGELN%!2<&0T Q%#OXF10&9'T,.=U1[E[ M@GS(] #WY5.^6!XM&W>X5<8U1,((IA"DC-B KGS8E\.>G4*MZPY[MX_N XNZ M+1"YF,7!S1Y;?WHRCR6[-_? ABL0N3$AMB5Y?;$( RHF\S?E]HYV@[J039IG M1&(#B11>"F"\Z^#R9;VIAKLRDJKZ& MC>T?D_GZF#IHU#Z#AEMLM#%6:0$T10JQ>N[$VY1#K!&RZE+!?U\_N -H>[OD M<%M6FXC1-H2]*;!Z;+/=\WD&@>*"!WT'D:>8>HV#EKN?F>3RRC)56R)-"TCV MQ1$UW92+"T[]- _L_C#/7^4KLZXB6L<4UI%FF;>,^& <$46=,\P8&';LW5[- M4F[?CC"JUQ)G6D2T+^Y$=B^"Z+Z&D1[ARN//LH %,XI0QSE$5"/CS4Z/ R%2 M(B@CC-.UQ(T$!/OBPNO5;5YMIWMZ]WCZ<0:"!ZX@H5)IJHUTUL)[:!R@4*<$ M<$<86&N)%\DX]J9E&A+CV[D8&UQK2R1TR$K*O$6.U7.1/LD-.C]&5JXF\^? MB10(^Z+#FZK\E%>KKV_FD\4J6-?1LOZT.3<_JDB.-E5(XQZM426%A'MBSM_+)Y4?.S_4 M^KPLUS/!Z^^<=O*AF!>K(F]RGK/GZ\P%BYMH"0AGR"FND#6[>06;/.4-V1%& M4CL]U$F'M^_PZIO)UQC2:QY8_;9!1I'3%E"EO*-(J_A**JYGA\&UG=TDR?= M7#4)T NSC+87>H-?5;_*4H_B0"K1P>\S0$ 8KM( T."4<0L0J_UXZ$G238\1 M;AYMR+]-/'O<+:IUD,+#]!MM&/O;9,@K 312G@9/GB.'A7 [Q(!**3$TPF.8 MEO>,5C#M_:!7EU55_ADR"GC*@ M>7PFV5J'G?0^UG$3]10%)RG6[ C/:]I22-TC/8 _=%I'[=E(M9'!ZE+&"NXP MP8Y@6<\*(4>N[&RGS0TG&!:"DF ,)!B;X5C@-2S)-A?W1,V[1&H M-5![R^(N[^Z*;;)GS!A^?"?E6.[VX5:9=?'M.JR\$#:XG=:!W6D9 D9?VXE2 MF^QI#]:^Z/,VG^7YW2;Q,S ]##@@-]_4(@G(Y\M5S,U8?:WSSD^6D+VDN\PQ M2X5U5'B*O!8"(.UWR#"<='?LRN/,/>#=6SAI54[_N"WG06[+[;!?U/;@F[+: MR'6UJHH/ZU6<[OMR_X0;7>]J\Q=ES%BKK90$(@4!D>HAV0UYC%.VRQ$&/#L] M81M4,OVE(=Y+=#/;4Y>L]GR=>1/F(FQ8Q=@@H40LK[&;ES2]5O'_G%?9L%(H<0R;0,L,1>&8K:SLKJ[#._'XA< MB7+HBUGOJWRR7%=?&W'KZ<<9L\H% Q@SSH/-:RADGG,M&O2/$/">X0P-9Q:(( EE.W,7\-8RANM MS4\=?SP.=B";WC(D9K.-@1M,W4D1QFRV\>EC^1'[6V1:%80$4?PI@"T11_=80UH$9"P=;ETF-R6#W036@\%N:O\MM\ ML2P^QQ=^R[L\UD)ZE:]>W[R??#F>,G9.3QFUV$BN!<("":PY4'AW4@,L2JD! M,<*3UI'PM%LA#1=*/"L9G,AHE9* -,*#V9$P M*U$*S^L I/.#CPP"8!FA0CA-++3(([4[R(2T[QN'/^[VV(/PAKCGMIB=I;Y/ M-WYGXD>A:\MB>2#BL"5-WVQD<)NOBNE#_.,=(X10 >L;_KM.5R0R.MJ,Z/9)K#])J\VX<7& M9ZJ'.L@4048:ISU FF(#E6><"NFMX] J<66/I;=+BJ-'IRTA/LR!_39VK=:K MVV!3_GOOVY'-&F;>,!#\96Z !E0)*1DWU!.-A?#.)14?&^'MRA[YE8CTD+QZ ML5RNS^;4ME$67&6B+;(2,D-Q?'%.01I@) 12*V0*GYYK(E*;?+H(Y2&Y]'J] M6JXFBVCYG4FH1RTS"TRT] 0*.%)!F0QKB# !&+6(@J1\D!'>T>R=59=#/<"1 M_ 6V5H/6F9<(*P6-$BRJ?:,%5< QCH75/"RO:SL4[9!B[<,]6.9'(Q/K2*O, M$6D ,@A90*F"0B)N. +4*B5%V*RO[:"S'UHEPCP8G4Y:5@=:9%I*3J$U3!-% M+F)KZ>J:C#3%DB+,.: M00VX3'K*;80W._LET^4X#Y(]NQUTT_39[=<9$UAY Z#2$E##N+(:*T*T(@([ M %/X,\KSPP[YDP[OF))B3[*I>2<9E]I(Q)CRFS=#K!"**0:(E HSII,*28[P M FB_NU1;L ]X(K(#;/GZ)CY1Y.?EGZ-X[&TWF/,.09XTRY#BT$L'@EVK&/)> M\2!L9'FLV@9!LQ70S6Q??\JK2;Q5O!NT+:I\NOH]#P;YK,&\FW60.65]T)M< M8XZ8Y5!ALT- *YRT!XQZ"T@@P_>E!+I NK^ 8CG-\]G2!ZQ,V*/*NR"$HV'$ M/=]GGEF/PAYF@R5F"%$!,%C/C3.;DL,Y0A:U+?"GSR8D0]P;?29?-PKB??EN M_>G3O#A!GJ=?9YAHPCB5V@5]B)B0,D9'M_-R!J;4!FQ^.M;C+9VNR9,,\8#4 MB6^$W!M,9]+H<F^.%4/,UXO.\*A MQY]EB%AAG2=2>4:ALEAR6\^$>95B&C4_]+J>S2@!V_Y8$J_/O)]\R9RG@]B/*5 4O.3K&OB2@J\?=$E/L0:IA^VP\_%+)_I MKW]?YK,7BQTV:KHJ/F\2;(\PJ7DGF>$&0*:4YTAC)XP*.VV- C8\):W__'.N MSM.D.Z989[@/S+[MT]+?3*!!S.G\SC(K--90>FV9@BH8CT;M?!.$;,KA_;B3 M(]N+/W6.>O\>H9K^:QV6Z<$')!LYAZ8T !EEH1[]W.+W9)-X^; M1ZUZ5+==$N6@S]BR%'J[I#>9YR]C7>H/D^D?[ZO)8AG@"#(.&-:.RQ[X*WN:IT>&]B*/TVS=6PR_'D $*(ZSO/EF M^4P>+9_PYT=O'.[A7U)_F:%4<^\T,- S!!@R:*>3J, IT=D1YIKW0+\^Q3&8 MWM;K9;'(PY"W!20BIO=_% RU^4 ]1F?; _U M(=3XV_S3O5GR^F;W2*?-/QP-339IGV&"J1=6!*0E5-(+L3N*$)Q3=%VY=%V2 MXXB*;@O^0;)9ELMUK%3S^B8^MW*%=_+_[67N%4DZ> MGT^8L6O2M8)]7XQ[O$(:\NQ0DTQ#1YF$R <;@RK-PN*J30LI95(E]E$FY/7( MKY8POS10O:ZFMY-E8/3^\F(O%N_6'Y;%K)A4^VJ[G=M%!AC55"(-K+<@F+T" MX]VDE.+]%*FX+B)U+(-+B;4E]4U9[1[76\6K20&%:B.Y0VPZU2XS"EL0=E4G M531F)=$QA+YY@"VLEJ1J 2,L0M$7@5J&O>\X\>L;6T2 %K,F\>!'7V=.6*_" M@B".6X4P8#S6V;Q?#52E')"-,F6O3],I&>Y!XKOQ"NCK3U&62_.2%4T+9L&:\QO41BT1$IQQUC; PQ4"V>1O0]T4W]V6:+Y?O)U]T MOLAOBM5F_/%NL9YL;O#>?NH8Q8@HPQT17-?) MMM(KDQ)$:UX_X[K5[I#&) M"4\J33["0AL#J?#V)3&^0ZY6#KK%)^5K,XK]B:N+GR3PNM&.FY!G= M9 @YB85!2%D--!; *E8CX61/4;WG?<;:(=Z]5;_:.]@W>564805-8Q6OW.;; M?Q]AWCG=9,989HP!%#"MO:!0N1IN20 !O08#>W@RI /F=8CWL,Q382>OJJ]A MTS[YMGJ3]F'5*4HIYIIY!YR*IS)F%TO0U/29>O=I(Y[ AVIU+8Q+@_NZJ$8$ M1MP)"1&6'E$+(*R1523 TF?$<$LUM^CZ[>O!B'8>V..[57YYWMR1SC*H!>#2 M"$:-5(X[ W"=U*"0IRG5E$<8#>PS;ZX]U'L,O-P4J_B>[/&8ROU'F2&:& P% M\L$AP@$P#7:S %C]&!EPK8CY:;3D,HS[8HJ:_=_U;@WJ$TG')]MF0%C#$&,6(*RQY$SBNNR7LAJF M;'VCS#X>%0_;%L^%^:3V7DB[DG#N2UP4^7U*A;HOL_"JW,3,7P1G[E MC0MZ MRC1CD!@@*8,246N)PKZ>HB8- MO)WFG63>.Q <0X*%]@0PC@P"-0I"HI0#XA$F28^"L)U+:3BNJNFT7 =PM]5] MXSWXLUCZM'E&C;,&,T0U@= )*NFC50J3+A2-LG);%Z0XR;MDW(=C7+S?O@@B M/YXQ<[1=)H@41B-EH0/2(VC\0UQ?>-=/9J/18-95!/5@V;5S MFF?<,BFIL5#$7$E%&7[ $W.2XB>/TD,9A&K)N _,N =CXT+.?==!6&^.0Q'+ M$'.@,2&(Z=UF+BU).24>Y67*X5B7AOSPAMN;R=>+K;;[MAE'UEH(D8($^N#M M2[8K+Z.U!"D7Y4;H4@QJL%T&^: TJ]9!=,7D0S$_E>;P_/7 S[NFUY%[J_#=\4G_-MU._;<0[S MSNUV)#$%\>GXSGOZMDE/F1,>4T>,P!0:H3PRA*)X(AW7IB6-]JUQ9) 1R"AR MV&H,J27(2B]Q/9/@Y25=N!O?#MR9G ^GCYT'<%^J?NOB/YUY'/*F=/7[R9?] M-Q.:/*BY#?TZOC[(H Y+_Z=SV+N29SZZX4->'\.T_L<;.&J6 :+U:ZK M\,^M'!)6QN6_+).0 261]5QQ%DO56V]K5(/X4Y)"1J@,1K@J>I/=T"OB,<:) M!DZFO9/.0HJ4I$;$& \3]S/'"B:E,HW0Q1XA:Q.DT=LEQZ>CKD<<_FN^GL4% M%9.@@_A7JZKXL%[%>/7[1[C M_$2]:V;WL((;P4+HCOB-\&($ ^ UUMQS1E0PXQ[PTFD!DE$^5S1.JG<@JA%0 M^S+:9AXC+A@EB #*+?'.([[39=3U>V;W@^Z]9PIA)-'[@0/VVU^_&U"S3.Q] M+3)N/#?!P39!9V$"K8NG-$@Z8(*SH6"C7;F;.;[-/^>+]=$3TOJ3S+E8'YQ2 M#163&CJS23O8S,(H8E/*.8TPW),LRR<%_2^"L;]]?QFVBOM!'MWI'WV7>8\8 M!4YRI(+/'.PQ0_']7)QV*L6N'F&LHVU*I VQ6^*BBN[0'1$58\^BH#W@D' M/=?,( ^X@0&!^WEX*5&*OA]A)*%M3ER.9&_1J#HYX/[6U3'=\>3;S!#,+, 0LU$@ M4,_+JJ3+O2.LX-<93RY&M+\LOOHIFCC0>UH'M^6HE;V_2<8MUH)RQKFP2$J% M@AJM9PA\TIN.HWRSHVW6M 3L=507$)!3XR100B#ID1(>TNV<-<$ P2+D4 M?GY)OV>G:L5:G;LMYT&Z M2SU9%M/&3#S94Z: 9-Y8P8QU D(OH,4U'IPF5T6<&+3$&, F18))9PI'<8F0!T Q9D)1QY&A,I"(>.K5<318QMGB*5V?UDVEGC80R .PM]3Y6JE$[7\LF M:=T1)CEUS;#P4T%K% M4=&X2T$-Y1'=#_D,G^B^11:].A-L)<04$X!"1"6L,<7 I.1] MC= K&IB([0AA8'/U\?)XC-GY=NFAGC+(X\T6!9FBCFFF"'DXIL(XZ6FY$;I. M Y.R6^'T>&6]/G*R1:QCNI@]++-\.@__.K8]-FF>.<>\M8!![HRR '%%ZGPB MRH!**8\SPM.;@6G9@43ZN=%NR^EZXT4N9BZ8&3'#]Z:L[KYY9?.,:^S[7[QK M\#L>L?Q4D\PHCB'2$-(8G$&$$4BU$U1@3376C?+#CJWK93[]]6/Y^;=97L0E M3>(?XJS(HY4.M2;I&.R /I<,M(@;,;0M03?1]^QP$F//XDTX(+*F6\ M4L61%)Q"[NLQ(\-3BA2,R-KOA ().'8K^VW1K>.:8N^WF8FWZRC$E"*&PPR4 M5+LM#3*=DCTPHD>'.F5#"J#=TN)!@_GPDWTW)(Y\G7D(E41 !@ <$4!9BG<$ MI]*D6! C>A&H4VJD0=H'.;;D;4Z/1]]GBBDEI$2(&PYI/#E0N]D$GRHER_S\ MN]7/F2"7@]H-1508VFPSO/ED7_S[R3<9\23X1RK6Z!'< ,^4 ?6H QPIYWXC MNMS<"152@.PT,O$0J&QR)M*L86:!)('0!''D+!/8 XEW"$F>5&?Q_!O%SXLI MKI'1?8F6(?+;-4+O[M-Y*]/7-DQG>Q?>3CT#22O^9 -(2QS&R MEG(BN4!$U?AQ(JXL03&=1N7P0A@J:^MM/BT7TV)>; 5]_J+=WT'FA 7 6F88 MM YBB6&P;NYG+T!2K&I$YUV=4; 3E(>Y2W^:4GN_S["@'@K,+0D30]0J&LSP M>FXTJ1K<,]C$4@5^]);\91"/)[G_>13D$HX!@C0V !"/B*8(U6M?(L:3;MJ/ MC\")#.NG&M=Y(NF+\']?S&+"2QQ]/JLW@@V,\PTK\MG[\LTDS'):?-H44WXP M2DY=%TSM.E-8($^ -4 Q:1W EKD:,8:3RD4TU^-]%\EIE\L]R^#'J-Y$5)R_ MEM!#9ZBE6DM=8P)!TF-.XRW>U"XONP9]//9"DN[/@ _SY9"R,$>CXOM55M2S M5L:F>-,CK,_4MQX_$][_NB?];6H[=$$E2!%3&(*2L-@)8&KTG*0I^^ S\+-; M]I(&DKH9_;?V25W>(Y^]F7S=G-M6U63Q,6_PFD%BYT%=24DU9Y)K@KWF M0+(=:@CRE$2:$6ZX Q.Z=WE=_[U6ZHTE5&"'$!'0<0Q,K1NE-,VN63V?5_'& MN2&W))Q!:Y]U4YP42PL%05(+()W7PF):SY]3E9+O?C8Y^RCZT[$]VPWLX_'K MNRI6RJCE4"FH.5'0>R*\W^D,(6W24P7CT_&MLR2Q6.EYZ(^*C9V5G.(:!"L= MQ$0"QB$/EHS98<(E3LGO'Z'5.0I&)N _3 ;8^V@.7T<"F)':"H,%E@Q1 YF, MUW,,"$:1A)SYY%H E\_RW?0VGZWG^=.TG^](NI%&DWS."WO,5+S660EG2KE$+#WLQ/\M2QG?Q;S^>;]ON!+?"S"D-5RF:^& MVPZ.C.G!RVJP1YS53]BG(44R6 U22V05H@C:X/=CSR&PB#1:% /BT62_.*^C MS'C#!284&1+0,!HR%9\U)0B[X,A>VS;1$5N^?U*V2Q$,OF6HV:R(/<9B&[M+ M,$.GEP^SG5@CD/ L.!W4&QS^B)!PR/)8,( !-V B>CV/!E/-F %>(T$TA\&C M_1;06,('MH SP1U\<3^8/4_ ^2%7..#"\?BB/ .6 M41(L.8*W\G?0(=$HOZUK3\,7BV*5ORP^YT]FM#%.&SD7ISK)(-,0808PPMPP MH[T2J$:"*Y]TV_.Y[Q*-67+0R6@9_KZB7D>&K;_^/OF_967FD^52?2F.';N> MT4MFXE%'?)W(*!BV8^JL(34.A.DKN\38!4'*OL ? 0D?QA]K!=KR;E+L*SYY M84\9#>:!9U@Z@86$5$K+_&[="WME>V(G3&G.QA8D<)J1>TN9FO5R5=[E58P$ MQ_U^^3:?;^/ M\6G95 1IOR<+R:+U?)5N=H\+?DI7^6_Y_$T=P_;4KO,I(1< M6HQI,$%U6/!0$%I/FD)Y93='.J-$.8@X+N2@GWPNJ[C1O\PGRSP.Z?7J-J^. MDNQHFXQ@I@'@7DH K(:*!*51#]MXG9*W/,(SHSY8U";>(U">P:ON9>J92KFB-DVK VVZ6H]W=./LMO#@]_>XN^6'QL M$, ZMZN,<^-! (,9Y"562@#A:D2P37O2?7P\;)D1YX2#2$NFPL*W'IIZ]]/3*LH([9EX'B(] VZKI='VWGL>;@NHN MWEG^]Z&G$B[O+ MH>&,H#TO/.XN")0,?3%5B^LGN_?9:Y/-E8N?X#[4+OLI7 M*7O@ON99O/^I@^N/"!)8FQ@>A0\@XW[?2^H\K[S7'; %O <_=QHX.6V8PR7I MD;"&( 2EI2!XFUK6QP8< ]?(*ACZ<.F\%+;&O65!6W,EE09>21 6B*76WF,C M+!$I&:TCM-4[XLW%QTV7RJ$OC?7XF/JH(W(!1\_J,;. *NX;B:9>RZ$?GU<4QW)=/^6(Y7,'<>AS;W/;[T03+H8%2.]4T,TA; MQYGFA )*"%7&"Q8+V%'E(2 #ID%]._0M:Q^+X[S4R@MZRW18 E#&BPC<4HZQ MTE8C*G3\$=,FY96>$>JQ]JCRU.;M&/I!MH.ADZJZW!6@LH9*K+4&##&(".$4 ML%@71F&.2:-H:[>S_FY//C+)^R\S Y%G,+AK!#$.L"+<^7I.PI K>;RQ?1$? M6,V7P=I?6.1S&&,L$[ %H%&IR/U-,A-<<(L]88IRIX5E!/'M##7&X2>]F(D] M!MXZI$XK"/<86MN+PP4;:^8ADIPY&VQGJ#QU1,O=#"5&0P1OWW<>2>M\#TJ$ M>1"S8>!H69=6@^:4,B$<@EY0894DW 1UH"R'!)!FA<&[CCELLCI>E8MR>Q\X M5D!\-)L+0@[G=)@A(AGS3@*""(48"X4"7C08U;$DB+FRZOWM$>9@D*%#]/O9 M'=Y-[E../DRF?[RO)HME .9Q8=XC[!*C3^\&W'V:<0V24U338@=Q1!PT& M#A.$)$-2T2%7_P&,SXL@G-%+YCUR1BDO-!,:"LI0 3XCE4@">]V3C"=7XI M$;Y?U9T!//!2'CI2@^&+-5P .J@7-Y4Y33/ M9\NMLQ$T@@I_\WE3C1J"-[)%N_;*OQ_\ MH^H4^NO]7S:_#]VXM^" FCJ#X7T_S0A>8FS<+@G<6.*RVI8Y:PX-'L!F\\OC;UT*5XR\Y@[X S M!V\?-VN8"174IC$(*:BX4XI+CNH)<.^NI$Q+N[)L2)"+$+Z4(I_R:1$LAZ_O M@GCRY=$+G'N_S9#T+#A-A!GA*634:N3NARD,,5?R\F';,BO;A355^K\'V_!U M!+T9 ;[[/*-:4([B07D8GR#8$*WKP0;%FY*(,**TPSXXD(;LA32(O_1^$D?E M_^2[#%%GG<) ,:X5HTPBA>OA::E[+8'^+ 6?"NF%$@_36"]CU;S%S,4CKS7/D0\L(7T@/=?:>,MBC6ZO2$!4EG/&2%Q92FUR9)OP*04?"]4 M7^\GU<=\]>9V$M;)].NCP1S57R=:900#$F]+,R1$+*,>M"VKATZ1OQ)'MP-1 MEEUAW->6\Z8J9^OIZG5UK\5/:+!]GV>8Q%>P(62$!LLM*&@G=TL*&7PEGM(0 MZJL%N'LF4JS%=3(.>[)-Y@0Q\7EU"(''L8 7T/;!%=!7%KI/$_-^SB2#>FD) MQS#C-_/U,GAYYA_OZNWP>(G&(TV"[2^$H((Y1(RG%B#'_&[07%U9$FX+PBL[ M ?;2\%NQ6*]R$SXKIL?C;T\^S&A,_PTS%<'I$U9R(\,@[P=H.6QTV?7Y>$7M M2CX9SK[4QK8DY'U1T%/EJY]^'*,- 1IEA)'!7M-&ZK [WL]*(IZB*$84E1O" M]D@&NR\*Q5JBKV^^&>Y)R^-@F\Q:RB#1S$O&@8">4[];)M*21HGQST??I BY M[ ;2%C3-/XO5;;%XI/(:G W;I^%L>/@P"&%I%3Q%4*H8#T=B/"5/4K:@E@/ MZ*4V4>YKKS'E8EG.B]E&<-NGJ8^KK/T-,N29$L@*S*A"5EMC>+W()/8V)18W MHA.#(=16*X /1Z>3FNM0DPP[90WV3FM@@0!*Q)G>S]"[I/I((]R64L5\DC47 MH=H7;U[7%RCOE\QAU7:B109(F" 6VE@4%#T1G)$Z"4,2K*XDUZT],9==P-IK MC83E=J1N7MP5B\G1HX-&[3(/-:3Q%44'J&/4$&-,/5=HK^U)[-8IU":XO54% M#)+*XX#KHY2:_B>LH:/MPN8M VC!MD-0.0"8$:P^(9%4D)32+>Q<(GW.JP_E M%9E%;2+?&\NV0SQI$GWS7281TA"1>+H6H.&8<[6;BV'JRIZ*:DFN^V^&783H MA?[[S@F\#W[>#^&HSWZT3<:#XG4FC%!#;)!76HHZG4S&P_XK(\)E(BN[0?-" M$KS=W.1[^=XTD?[^CS,-H7 (8(]]L+D(]=SM-"9R*J7^^0C-D72QMP)C?PYS M%53DY,B;;P>^#(K3""@-=A##T+<1EN^@$1ZD.#IC3%)(HD4[&#[EQ#,Z:&D% MO^=HVF]+,NW,BI=Q(9S.;#W2*L/026&1Y\)1"YF$Q-0'S5)KDW*BPD?(G!Z- M^O90'YA=)TW\H^TRZ91DC%NL&?! 8V>"T7L_5\; E64+M2+U9DRZ"-\+;;_- M\U)OJO*F.&[V/?DNL\0AZ*QB'CA+PM@$JP^B)-!)B2+/1_SGBJIL#]'>H]Y; M"%Z&43>/>W_?)B,TO@CEHI$+M&58(+*+UZF@X*_+3VB7-6VCVW-$:9]*?MG@ M#=8FS3,0;$.#.+<">L2$" #69IUB J4H(S$^7O4:PVP?_MYRE-9Q5;R^V8X] MHE#'Z8XE*1ULE 7%J0RF8=DB;9"3SLCZ@H*"ZEI*5'0C^._SEMI"^4*[I_[] M]^&W_94/]W^8X9BVB[@"T ,LJ5#,UL?=89,U_12[?]XT: 79)-&7-X=O1A^E MPK&&&8*<*&JPHM!([(328C>%=7U&@1Z4NO5>2;6%)YX[Y,\_D\ M7TSS,,.GHZJ#]P>(S7+UNV9,>VI);8ZF[+ M@P")$3>[R5.'Q6*QBM4^C4Z,>]=FS&H?,?]I\L?-^/(F=WV\^/ZP%=AY;6^# MULF9#*$6DCMBC)2!N[B93"1 B?4\Q,#(+@R;]N N7.:>EM?'=-NK/>PNF^6LH0.0SQ;.#4="O$M),-L]?6KS=UIDE^]3(XU-) M.TZI]]%S&ZE77M75;->;/($E%PK;#TB&XV!M1^+CR4LJ-N/ ZW9)*2DZ%B'?C0':3F^QQ[F3'\=?7\8UTJ= M;3NL>?%8TLBCYD9: ?7&"NNZC>O.H>%%YL9'\GX6 MN5MEBG=.'T[N(Q=+R. M*+^>K7[\7-W6A<%Q.M\91-+\)8EQH@ ("D(CBHRGVYPY8>VZ*:'71_&FGASV M'LGW[$[3X\FWY24IU/>L,J3!!$\"80KL.B@,C2^SDS^*9_;DL#^1K\OZ?JNH MP?,H[T?J]$F@(1@B9!#@T&@''#%"O0+U6:3WL$#.)A4\CWMCBK4_4"&QV6B7 M2FOC% =F U= \T0K"+B^@ M=[UI@D>K<1ZGLZ=.??H:LFI=?&^@%AJU3R8()$(@LRBBH(YQJX*0MO9T.&QF MAIUF_%]FU6B^G-47M5W^V40%O-T@&1'-RF43&5AM!,I@UR,TV*QF\?N9X2U+ M?7H"B/NKM%,D;+0,'5UVE%$[@@$M;C"XZ?V0+1@IQ?VH"MX-HC M;_;?^;2M34*G)1)-0HB.:]22@%N/,8__S H&%$MZ/W..PK4G[NS-!W[S^92W M/((SS;DPBMML(7%IUV.3QM"SY\RA,M[-FJ-0[8PQ;UJA^Q:JK8V25\X3[P,H M9H $$3@GZU$RKTKT#7M'*TY; /5+@_WKSHYF"31E""2B]ERBCP3((^$UL3P4 M7L%\(F70@N :<>$HC(X\8'WU\?J)/9?);6V1ZG-?2U54Z#!;\C(XB.LN,W1% M,1H#7!U:D=[T%-"VR 9Q,!L>6R2P>?"4 ")8RPSQ8-D& BW/[7[!+MAP'+0M MLH$?S :^KJJ4C261C222+1Q#(**Q8MUE:8KBMX:89MT%&XZ#MBN[ 2XOJ]M5 M]N35"S3F/O_G'CNR0>M$O*/2!R\E#QA)/2"+?V M&J>-VB?&F'#4,A3HG*,@P<2\C .'K\0MO.RU=WT5Z3:N<>%4DY!28]\NY MSU6MR^O JLTPGIXYEH9-7IJ\% %,[=^0D?O(% UAC9(7YU:_N'M>GD (/5'U MRB]G>1R_5K/Q],$@V5U$:5_C%*@)PD6EO$<7A4;K-HX4+;#$FAO@%K)#ZI6# M/02*_7MT^V;24>.V23FIZ\,!2F4PX#D'I!LXRXI-#M"RZXM@QV!]Y/YQQXX( MKF?5ZM+H!YVZ95?9_ 4I,A(QSY@CPG!;Q] M!F4V7^;>3+_^,JWE-;I]Z-?GO%<>?ZNNQI.M:UX[+\X[>0F"9,],.XT@FB?B9L[$5?=>:9V#^?>UE+2*.>V(4\R+ MS?;(@"PQ_ >81MD#V]J"?@!^_=^JQ>)VI:L?8XD_S5:3YGY7R/E1[TO"9:V/ M=0: LIHCC<8_AB%K"KY("39/L+0/M)Q4UW7OWQTQNY1 9^OP6CLOIA?56F./ M%F%R-?WZ(N.J>&7>_ZED+(U>,$DIL\$AM9&K-4B1FI*MQ0 OY1O.6MVZ:/I, M*NHY9;B;G")T+*]OA GIF0R9%Y%P1:6W%"*/IE'L22.5LDXIG7Z=+A?SQ6B2 M#;KK>0W\;-.[^P?@YROD=^4&EKTP&:*5$UXHQ;2D1ENBC T:)0A1!3=@3(\ M]= R$:8]B* C-5"K3%?;@#B]NZ\F\]5+>E, ?CR_O)UF79Z%];Q#S^]>6&FN MB[K+:RDWT QE+TY:"Z\5.LF,EV"M%40*X@A#ZWQTC=+S>D;,/1]8DR3DPC>G MC(SF40&M;Q'3+#KI%487&)'21']FX;]=$6S:IY#ZU$E]YSL/53492K7S(4N0 M6DFD-48$$;*Y"58$2GM43<]NU-@P\/D 838;3:Y76[ZY^_Z*I?#?T>QJ7T9U M:]](,6*-HPA$.QFE!R=LMMF!U2?S'L\LEZTKTFV_9*53<77FL5IU<'\"]P_/ M)40O0(>L>QV3@BK(ZM<&!.F"MZC/++*T!PZ\]$(5H-]IGMU1V#R-;G+UZ^UH M\LOHKD%>^ D^EU &=#I0;C65+O_##')!01&:E04_LP+31[+JK23 ?@7162#M MW?WM]'M5K>R]3_?U./?FH6]MDZ1!&ATHKKVK:[TY*GADH*TRGI*BT_$!DJU? MFKR,MVU)*%T1[W.5S9CQ9>WCK7O\^V2\F'_^[?>]Y-O9+ME@I2?.6$\SD%& M)[3.O(HACY\5$7" <8N#(F";@AG, K\-OY\;9!F4OSQ9$24JB(;+_(<%ZTAP M>3H[I0 =.3O]D+DO%H@R>:.RVE M$,&(.FU(NRBEM85%A@9(V [I\G+[= IY#%[M/M@U\W_E!Q?SGR8/D::KTAFG MT,/;OY;4RD$,/()D4DOCA.3@04<7("AS;L7K^^-Y_\)[GY/BCVI\?9/5 WRK M9J/K:O7+.CTTCL:SO2'TW?8D16) ,1=B'1#B.;%,.&Z4S[8B"(\E+HH!9GR< MS61J6["#F6A;CI&,B6"$Y52"EY%%@P3 2>HB M*,6PT06^[R?C9<@3K#>A#F9R[0'@TU- ST.D] G7J5??2G7=7[26,T6E#&B M* WUR3P!35&4A$L,,+MGR!/EQ*)[A]/A5.M,.SU( (8RE#8O['FMCP&(L=IR MHYF6H&S)^>D TY3.8^JT*-!.)]3%_M%?'#SZ34H^3B>K (OEZ/9+-;MC^R97 MM[W)=!ZDP"C3$"5.2'S_ #*V^)]J@A3OX5>PAUONGR7PQ M6Z[,WT^+FVKVY68T>=/>/<4R=F 7DB:& 8*,'*GD/)J\5P7'B7$L($#)O4]# M+.7W#M>QTTKTW.94+X[ MON85.!$6F>I!RNC898#P+/BB6D;D M[WGW#F1Z1O-JF"MA\^XESIT61' %&SU\Q^ M=G[U&'>4G]X6I;="Q7VOHTKWYM/WVI\4!4,'P- X)[,\K+6HT&HE?0BRR),V M0'7:%9FW9IL-5[0-=.?C+^J_:GS^^8__ U!+ 0(4 Q0 ( !TX:$GK8S/Y M)"H! -@A$@ 0 " 0 !C=G,M,C Q-C Y,S N>&UL4$L! M A0#% @ '3AH299#[KH*$ T*L ! ( !4BH! &-V M7W!R92YX;6Q02P4& 8 !@"$ 0 D)4" end